id,nct_id,sampling_method,gender,minimum_age,maximum_age,healthy_volunteers,population,criteria,gender_description,gender_based,adult,child,older_adult
6260055,NCT05050916,,FEMALE,19 Years,40 Years,f,,"* INCLUSION CRITERIA:~In order to be eligible to participate in this study, an individual must meet all of the following criteria:~* Provision of signed and dated informed consent form~* Stated willingness to comply with all study procedures and availability for the duration of the study~* Having natural, spontaneous menstrual cycles (no hormonal therapy) less than 50 days in length.~* Aged 19-40 years~* Ability to take a vitamin D capsule and willing to adhere to the weekly regimen~* If sexually active, use of a non-hormonal contraceptive method.~EXCLUSION CRITERIA:~An individual who meets any of the following criteria will be excluded from participation in this study:~* No menstrual period in the last 50 days, or, a typical menstrual cycle length \<16 or \>49 days.~* Use of a vitamin D supplement for more than one month and on more than 15 days out of each month. Volunteers will be asked to check their supplement label for vitamin D content.~* Unwilling to abstain from taking non-study vitamin D supplements during the study or if already taking a medically-advised vitamin D supplement.~* Use of a calcium supplement (including certain antacids) and unwilling to abstain from taking a calcium supplement during the study.~* Known polycystic ovarian syndrome~* Depo-provera use in the previous 12 months~* Current use of any hormones, including birth control~* Current use of a hormonal intrauterine device (IUD)~* Current pregnancy or lactation, trying to become pregnant, or planning to try in the next four menstrual cycles or 5 months.~* History of seizure disorders~* Celiac disease~* Crohn s Disease~* Body mass index \>35~* Aged \<19 or \> 40 years~* Presence of known contraindications for vitamin D supplementation, history of any of the following: calcium disorder or hypercalcemia, tuberculosis or granulomatous disease, metastatic bone disease, sarcoidosis, Williams syndrome, kidney disease (kidney stones, renal failure or dialysis, lupus nephritis)~* Known liver disease (cirrhosis)~* History of cancer other than skin cancer.~* History of anorexia nervosa, bulimia or an eating disorder~* Use within the past 60 days, of exogenous hormones~* Type 1 or Type 2 diabetes~* Known heart disease~* Gastric bypass surgery~* Unwilling or unable to complete study activities, e.g. collect daily urine specimens, have blood drawn, complete daily diaries, attend in person study visits~  25. Non-English speaking~* Due to the complexity of daily/weekly diaries, testing and procedurerequirements, all consents, instructions and questionnaires are provided in English. Therefore, all participants must be able to able to read and speak English.",,,t,f,f
6260056,NCT01092156,,FEMALE,18 Years,,t,,Inclusion Criteria:~* Pregnant women who intend to breastfeed their infants~* Single infant~* Resides in catchment area~* Has phone~* Speaks English,,,t,f,t
6260057,NCT01218256,,ALL,30 Years,80 Years,f,,Inclusion Criteria:~* type 2 diabetes mellitus~Exclusion Criteria:~* myocardial infarction within the last 6 months~* unstable angina pectoris~* left ventricular ejection fraction less than 40%~* orthopedic limitations that eliminate to perform resistance training,,,t,f,t
6260058,NCT03240432,,ALL,60 Years,,t,,"Inclusion Criteria:~To be eligible for the study, all participants must meet the following criteria:~1. Clinical diagnosis of insulin dependent presumed autoimmune type 1 diabetes by the investigator and meeting at least one of the following criteria:~   i. Age \> 6 months and \< 10 years old at diagnosis OR ii. Positive pancreatic autoantibodies at any time (GAD-65, IA-2, ICA or ZnT8) or positive anti-insulin autoantibody at diagnosis only (within 10 days of starting insulin) OR iii. Presence of 2 or more of the following clinical indicators suggestive of type 1 diabetes:~  1. Age at diagnosis \< 40 years~  2. Non-obese at diagnosis according to BMI (\< 95th percentile pediatric and \< 30 kg/m2 adult)~  3. Diabetic ketoacidosis (DKA) at any time,~  4. Plasma C-peptide level \< 0.8 ng/ml (with blood glucose \> 80 mg/dL if available) at any time~  5. Family history of type 1 diabetes in a first degree relative (parent, sibling, or child).~2. Age ≥60 years~3. HbA1c \<10.0% at screening or within 30 days prior to screening visit (the upper limit was selected as a surrogate measure of likelihood of adherence to the protocol with the belief that those with higher HbA1c levels are generally noncompliant with diabetes management and thus not good candidates for the trial)~4. Insulin regimen involves either use of an insulin pump (a minimum of 40% of study population) or multiple daily injections of insulin (minimum of 40% of study population).~5. Participant is able to manage his/her diabetes with respect to insulin administration and glucose monitoring (which may include assistance from spouse or other caregiver)~6. Participant understands the study protocol and agrees to comply with it~7. Participant comprehends written and spoken English~8. At least 240 hours (10 out of 14 days) of sensor glucose data with appropriate number of calibrations from the blinded CGM pre-randomization phase~Exclusion Criteria:~Individuals meeting any of the following exclusion criteria at baseline will be excluded from study participation.~1. Use of unblinded CGM, outside of a research study, as part of real-time diabetes management in the last 3 months~2. At least 10% of time spent with sensor glucose levels \< 54 mg/dl during the blinded CGM screening period AND a severe hypoglycemic event in the past 6 months (a severe hypoglycemic event that required assistance of another person due to altered consciousness, and required another person to actively administer carbohydrate, glucagon, or other resuscitative actions (see section 8.1).~3. Extreme visual or hearing impairment that would impair ability to use real-time CGM assessed at screening visit~4. Known adhesive allergy or skin reaction during the blinded CGM pre-randomization phase that would preclude participation in the randomized trial~5. Plans to begin non-insulin medication for blood glucose lowering during the course of the study~6. Stage 4 or 5 renal disease or most recent GFR \< 30 ml/min/m2 from local lab within the past 6 months~7. The presence of a significant medical or psychiatric condition or use of a medication that in the judgment of the investigator may affect completion of any aspect of the protocol, or is likely to be associated with life expectancy of \<1 year.~8. Clinical diagnosis of dementia (cognitive impairment that is mild and not considered sufficient for diagnosis of dementia is acceptable)~9. Need for use of acetaminophen or acetaminophen-containing products on a regular basis during the 6 months of the trial (unless stipulation no longer required with use of newer generation sensors)~10. Inpatient psychiatric treatment in the past 6 months~11. Participation in an intervention study (including psychological studies) in past 6 weeks.~12. Expectation that participant will be moving out of the area of the clinical center during the next 6 months, unless the move will be to an area served by another study center.",,,t,f,t
6260059,NCT04348578,,ALL,18 Years,65 Years,t,,"Inclusion Criteria:~* necrotic, single root teeth with a periapical lesion (2\>PAI\>5)~Exclusion Criteria:~* pregnant~* had used antibiotics within the previous week~* allergy to local anesthetic agents~* history of intolerance to non-steroidal anti-inflammatory drugs~* had uncontrolled hypertension, uncontrolled diabetes mellitus, chronic renal failure, hematological disease, or had received or were receiving radiotherapy and periodontal bone loss (visualized radiographically)~* open tooth apex",,,t,f,t
6260060,NCT04469283,NON_PROBABILITY_SAMPLE,ALL,,,f,patients with genetically proven ADCY5-related dyskinesia,"Inclusion criteria~* Proven genetic diagnosis of ADCY5-related dyskinesia~* Adults or children without age limits~* Past or present caffeine intake~* Non-opposition by the patient (adults) or the legal representatives (minors) in France, and patient information according to each country's legislation in other countries.~4.2. Exclusion criteria None.",,,t,t,t
6260061,NCT02605616,,ALL,21 Years,75 Years,f,,"Inclusion Criteria:~* Age: 21-75~* Body Mass Index (BMI) \>19 kg/m\^2~* Subjects with biopsy/MRE proven NASH \[MRE liver fat ≥ 5%, with elevated liver enzymes ALT \<5x upper limit normal (ULN)\].~* Subjects with NAFLD and MRE shows F0 or greater fibrosis~* Subjects with history suggestive of NAFLD/NASH~* Total bilirubin must be \< 1.5 x ULN and INR must be \< 1.3 at baseline screening.~* TSH and CPK will be within normal limits (WNL) at screening.~* Subjects with type 2 diabetes who are on stable doses of medications (except pioglitazone) to control hyperglycemia and have baseline HbA1c of 10% or lower.~* Hemoglobin must be greater than or equal to 12.0 in males and 11.0 in females.~Exclusion Criteria:~* Medications that may affect glucose metabolism such as corticosteroids, opiates, barbiturates, and anticoagulants.~* Subjects with anemia, and symptoms suggestive of undiagnosed illness, overt hepatic disease, stroke, Alzheimer's disease, autoimmune hepatitis, alcoholism or increased alcohol consumption over the American Diabetes Association (ADA) guidelines.~* Any disorder that may potentially impact the outcome measures.~* Pregnant women and children.~* Subjects planning weight loss or in any weight loss program.~* Subjects taking TZD's, Atazanavir, Indinavir, Ketoconazole, Valproic acid, Silybum marianum and Valeriana officinalis.",,,t,f,t
6057061,NCT02111174,,ALL,18 Years,,f,,"Inclusion Criteria:~* Men and women, 18 years of age or older with cancer~* English speakers~* Lower extremity CIPN neuropathy: Received neurotoxic chemotherapy (including taxanes-such as paclitaxel or docetaxel, or platinum-based compounds such as carboplatin or cis-platinum or oxaliplatin, or vinca alkaloids such as vincristine, vinblastine, or vinorelbine, or proteosome inhibitors such as bortezimib).~* Pain or symptoms of lower extremity peripheral neuropathy of \>3 month's duration attributed to chemotherapy-induced peripheral neuropathy~* An average daily pain rating of \> 4 out of 10~* Life expectancy \>3 months~* ECOG Performance Status 0, 1, 2, or 3~* Patient understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form~Exclusion Criteria:~* Any of the following: pregnant women, nursing women, women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device \[IUD\], surgical sterilization, subcutaneous implants, abstinence, etc.).~* Use of an investigational agent for pain control concurrently or within the past 30 days~* History of an allergic reaction or previous intolerance to transcutaneous electronic nerve stimulation~* Patients with implantable drug delivery systems, e.g. Medtronic Synchromed~* Patients with heart stents or metal implants such as pacemakers, automatic defibrillators, cochlear implants, aneurysm clips, vena cava clips and skull plates. (Metal implants for orthopedic repair, e.g. pins, clips, plates, cages, joint replacements are allowed)~* Patients with a history of myocardial infarction or ischemic heart disease within the past six months~* Patients with history of epilepsy, brain damage, or symptomatic brain metastases~* Prior celiac plexus block, or other neurolytic pain control treatment~* Other identified causes of painful parasthesias existing prior to chemotherapy (e.g., radiation or malignant plexopathy, lumbar or cervical radiculopathy, pre-existing peripheral neuropathy of another etiology: e.g., carpal tunnel syndrome, B12 deficiency, AIDS, monoclonal gammopathy, diabetes, heavy metal poisoning amyloidosis, syphilis, hyperthyroidism or hypothyroidism, inherited neuropathy, etc.) that might be responsible for the patient's current neuropathic symptoms~* Skin conditions such as open sores that would prevent proper application of the electrodes~* Other medical or other condition(s) that in the opinion of the investigators might compromise the objectives of the study~* Currently receiving anti-convulsants (such as gabapentinoids, e.g. gabapentin (Neurontin) or pregabalin (Lyrica). Because of data that support that patients do not do as well when on gabapentin or pregabalin, all patients on these medications will be weaned off them prior to study initiation. The study team will provide instructions on how to do this",,,t,f,t
6260062,NCT05266365,,ALL,40 Years,65 Years,f,,"Inclusion Criteria:~* Being aged between 40 and 65 years~* Having the degenerative meniscus tear in at least one knee~* Having body mass index in the range of 18-30 kg/m2~* Feeling the pain that lasts for at least 2 months~* Having grade 1 or grade 2 degenerative meniscal tear diagnosed by an orthopedic specialist according to the MRI results~* Having the activity level is between 1 and 5 according to the Tegner Activity Scale~* Having the ability to read and write Turkish~Exclusion Criteria:~* Having undergone arthroscopic partial meniscectomy surgery due to degenerative meniscal tear~* Participating in a physiotherapy program for degenerative meniscal tear in the last 12 weeks~* Have received steroid injections in the last 6 months~* Accompanying conditions such as injury to the surrounding ligaments, congenital anomaly in the affected knee, coxarthrosis and spinal stenosis~* Presence of any systemic disorder that may affect assessment parameters~* Failure to cooperate with assessments~* Any vision or hearing problem that would prevent them from adapting to the assessment",,,t,f,t
6260063,NCT01395537,,ALL,18 Years,,f,,"Inclusion Criteria:~* Patients must have a histologic diagnosis of adenocarcinoma of the esophagus, or gastroesophageal junction based on biopsy material or adequate cytologic exam.~* Patients must have incurable metastatic or recurrent adenocarcinoma of esophagus or gastroesophageal junction.~* Patients must have an ECOG performance status of 0-1.~* Patients must have adequate bone marrow function as evidence by: absolute neutrophil count \> 1500/uL, and platelet count \> 100,000/uL~* Patients must have adequate renal function as evidenced by a Cockcroft-Gault calculated creatinine clearance \> 30 mL/min.~* Patient must have adequate hepatic function as evidenced by: serum total bilirubin \< 2.0 mg/dl, and AST/ALT \< 3 X the institutional upper limit of normal. Patients with an elevated unconjugated bilirubin (Gilbert's syndrome) will be eligible if hepatic enzymes and function are otherwise completely normal (AST/ALT/Alk Phos within normal limits), and there is no evidence of hemolysis.~* Patients must have cardiac ejection fraction \> 50% as measured by echocardiogram or MUGA scan.~* Patient must agree to stop medications or substances known to affect, or with the potential to affect the activity or pharmacokinetics of lapatinib. (See Appendix I).~* Patients must be able to adhere to the study visit schedule and other protocol requirements.~* Patients must have measurable/evaluable disease as per RECIST 1.1 criteria.~* Tumor must be tested for HER2 and EGFR before patient registration.~* Patients of childbearing potential must agree to use an effective form of contraception during the study and for 90 days following the last dose of study medication (an effective form of contraception is an oral contraceptive or a double barrier method).~* Patients must be \>18 years old.~* Women of childbearing potential must have a negative pregnancy test prior to enrollment.~* Patients must have a life expectancy \>12 weeks.~* Patients must be able to tolerate oral (or feeding-tube administered) medications.~Exclusion Criteria:~* Patients with any other diagnosis except for adenocarcinoma (squamous cell carcinoma, small cell carcinoma, lymphoma, etc) will be ineligible.~* Patients with another active malignancy within the last 5 years will not be eligible except for curatively treated basal cell carcinoma of the skin, cervical intra-epithelial neoplasia, or localized prostate cancer with PSA \<1.0 mg/dL on 2 successive evaluations at least 3 months apart, with the most recent evaluation within 4 weeks of entry.~* Patients may not have had any previous chemotherapy for recurrent or metastatic disease and no chemotherapy or radiation therapy within the past 4 weeks.~* Patients may not have received any previous treatment with carboplatin, paclitaxel, or a HER2 or EGFR inhibitor prior to enrollment.~* Patients may not be receiving any other investigational agents or other concurrent anticancer therapy.~* Patients with brain metastases are excluded.~* Patients with \> grade 2 peripheral neuropathy per NCI's Common Toxicity Criteria Version 4.0 will be ineligible.~* Males with QTc \> 450 or females with QTc \> 470msec will be ineligible.~* Patients with active cardiac disease are excluded including current uncontrolled or symptomatic angina, history of clinically significant arrhythmias requiring medications, (with the exception of asymptomatic atrial tachycardias requiring anticoagulation and/or beta-blockade), myocardial infarction \< 6 months from study entry, uncontrolled or symptomatic congestive heart failure, or any other cardiac condition, which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient~* Women who are currently pregnant or lactating will be ineligible.~* Any other uncontrolled inter-current medical or psychiatric illness.~* Known HIV-positive patients will be excluded.~* Patients with any gastrointestinal disease resulting in an inability to take oral )or feeding-tube administered medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, or uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).~* Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors.",,,t,f,t
6260064,NCT01504997,,ALL,20 Years,80 Years,f,,"Inclusion Criteria:~1. Biopsy specimen from the primary lesion shows adenocarcinoma~2. Diagnosed as Stage IA early gastric cancer according to the preoperative esophagogastroduodenoscopy and computer tomography~3. Endoscopic submucosal dissection is not indicated~4. Tumor was located within lower two thirds of stomach~5. Not having duodenal invasion~6. Eastern clinical oncology group performance status is 0 or 1~7. Body mass index is lower than 30~8. No prior laparotomy~9. No prior chemotherapy or radiation including those for other cancers~10. Fulfil all following conditions WBC \> 3,000/mm3 Plt \> 100,000/mm3 AST \< 100 IU/L ALT \< 100IU/L T.Bil \< 2.0 g/dl Cre \< 1.5mg/dl~Exclusion Criteria:~1. Having other active cancers~2. Possibly pregnant, or breast feeding woman~3. with psychiatric disorder~4. Receiving steroids~5. With Acute myocardial infarction in 6 months or with unstable angina~6. With uncontrolled hypertension~7. With uncontrolled diabetes mellitus~8. With pulmonary disease which require continuous oxygen therapy",,,t,f,t
6260065,NCT01652183,,ALL,18 Years,65 Years,f,,"Inclusion Criteria:~* ≥ 18 years of age,~* American Society of Anesthesiologists (ASA) Physical Status of I-II,~* undergoing PNL with urinary bladder catheter.~Exclusion Criteria:~* obesity (BMI \> 30),~* chronic opioid use,~* bladder outflow obstruction,~* benign prostatic hyperplasia, and~* overactive bladder (OAB) (frequency \> 3 times at night or \> 8 times within 24h).",,,t,f,t
6260066,NCT01660932,,ALL,25 Years,80 Years,f,,"Inclusion Criteria:~* hypertriglyceridemia~Exclusion Criteria:~* overt liver disease, chronic renal failure, hypothyroidism, myopathy, uncontrolled diabetes (HbA1c \> 9%), severe hypertension, stroke, acute coronary events, coronary revascularization within the preceding 3 months, or alcohol abuse",,,t,f,t
6260067,NCT06144983,,ALL,18 Years,,t,,"Inclusion Criteria:~1. Absence of any history of systemic diseases that can impede wound healing or surgical operation.~2. No history of recently using anti-inflammatory drugs.~3. Patients aged ≥18 years who were indicated for surgical extraction of mesioangular, class I or II, and position A or B impacted mandibular third molar.~4. Well-educated patients who had no objection to take part in the study and likely to comply with all study procedures.~Exclusion Criteria:~1. Medical conditions that forbid surgical involvement, such as those in patients with bleeding-related conditions, recent myocardial infarctions, psychological issues, uncontrolled systemic diseases, immune-compromised patients, and patients who were on corticosteroid anti-inflammatory drugs.~2. Recent history of head and neck radiotherapy.~3. Pregnancy, and female patients taking contraceptives.~4. Patients with severe localized infections in relation to the third molar, such as Pericoronitis, or those with severe periodontal disease and/or poor oral hygiene.~5. Patients who were unable to come back for follow-up and recall appointments.~6. Impacted third molar that interferes with the inferior alveolar nerve.~7. Periapical pathology or cystic lesions related to the impacted tooth.~8. Heavy smokers (more than 20 cigarettes/day).",,t,t,f,t
6260068,NCT03324997,,FEMALE,25 Years,55 Years,t,,"Inclusion Criteria:~* Female patients between the ages of 25-55 years.~* Moderate photodamaged skin of the chest/décolletage, as per the Fabi-Bolton chest wrinkle scale~* Subject is willing and able to participate in the study as an outpatient, making frequent visits to the study center during the treatment and follow-up periods and able to comply with all study requirements including daily applications of the study product, and restrictions regarding concomitant medication and other treatments.~* Female subject of childbearing potential must have a negative urine pregnancy test at screening and must be practicing an adequate, medically acceptable method of birth control for at least 30 days before Day 0 and at least 6 months after the last study product administration. Acceptable methods of birth control include intrauterine device (IUD); oral, transdermal, implanted or injected hormonal contraceptives (must have been initiated at least 1 month before entering the study); tubal ligation; abstinence and barrier methods with spermicide. Otherwise, if not of childbearing potential, subjects must: have a sterile or vasectomized partner; have had a hysterectomy, a bilateral oophorectomy or be clinically diagnosed infertile; or be in a menopausal state for at least a year.~Exclusion Criteria:~* History of keloid or hypertrophic scarring~* History of allergy or hypersensitivity to injectable hyaluronic acid gel, lidocaine, local topical anesthetics or nerve blocking agents~* Presence of any of the following at treatment sites: active inflammation/dermatitis, infection, psoriasis, herpes zoster, acanthosis, cancer, precancer, actinic keratosis~* History of the use of any other rejuvenate treatment in the preceding eight months or plans to use these substances or have these procedures during the study (including but not limited to neuromodulators, soft tissue augmentation, fractional resurfacing, chemical peel, ultrasound)~* The use of daily platelet inhibiting agents (i.e. Aspirin), anti-inflammatory medications, anticoagulants, Vitamin E, ginkgo biloba and other herbs / homeopathic remedies within 7 days of before or after treatment.~* History of severe allergies or multiple allergies manifested by Premarket Approval (PMA) P040024/s072: FDA Summary of Safety and Effectiveness Data page 10 anaphylaxis or a history of a hypotensive crisis in response to radio-contrast media or other osmotic agent~* Presence of any condition, which in the opinion of the investigator, would make the subject unable to complete the study per protocol~* Current use of immunosuppressive therapy~* History of connective tissue diseases such as rheumatoid arthritis, systemic lupus erythematous, polymyositis, dermatomyositis, or scleroderma;~* Participation in any interventional clinical research study within 30 days prior to randomization.~* Current smoker (or has quit smoking for less than 1 year)~* Current active malignancy",,t,t,f,f
6361029,NCT03191318,,ALL,18 Years,65 Years,f,,Inclusion Criteria:~* All patients undergoing laparoscopic sleeve gastrectomy during this study period~Exclusion Criteria:~* 1. Redo procedures 2. ASA III and above status 3. Previous major upper abdominal surgeries 4. Not willing to participate,,,t,f,t
6361030,NCT05173818,,ALL,18 Years,,f,,"Inclusion Criteria:~* Volunteers must have a history of mild traumatic brain injury, specifically, persistent post-concussive symptoms after examination by a neuropsychologist or neurologist.~* Volunteers time from concussive incident (Mild traumatic brain injury) must be between 3 months - 5 years following head trauma incident~* TBI was caused by non-penetrating trauma~* Volunteers must have current complaints of TBI symptoms such as headache, dizziness, or cognitive or affective problems~* Volunteers must be 18-year-old or more~* Willing and able to provide informed consent~* Able to speak and read English, as primary language~* Agrees to provide blood samples for clinical lab tests~* Willing and committed to comply with research protocol and complete all outcome measures~* Able to equalize middle ear pressures or willing to undergo needle myringotomies if needed~* Willingness and committed to comply with study protocol outlined reproductive plan based on baseline reproductive status~Exclusion Criteria:~* Prior treatment with hyperbaric oxygen treatment~* Hyperbaric chamber inside attendant, professional, SCUBA diver (technical, commercial, operational/military or recreational)~* The investigators will exclude pregnant women from this study because potential fetal adverse reactions triggered by high oxygen partial pressures such as retrolenticular fibroplasia though careful review of human data are generally reassuring such as the use of hyperbaric oxygen to treat acute carbon monoxide poison in the pregnant patient.13~* Prisoners~* Minors~* Unable to protect airway or requires frequent suctioning~* Known or suspected peri-lymphatic fistula~* Presence of tracheostomy (due to limitations in auto-inflating the middle ear)~* Unable to participate fully in outcome assessments~* Unable to cooperate with hyperbaric oxygen treatments~* Unable to speak and read English, as primary language~* Not cooperating with instructions during hyperbaric oxygen treatments such as bringing contraband items into the chamber (such as fire lighter)~* Not competent to sign their own consent. Such potential participants will not have the capacity to participate in a full range of neurocognitive testing~* Pre-existing diagnosis of a psychotic disorder(s): schizophrenia, bipolar, dissociative disorder~* History of moderate or severe traumatic brain injury~* History of brain injury not of traumatic etiology such as stroke or drug-induced coma~* Verifiable diagnosis of learning disability. Other pre-existing cognitive issues may make it difficult for potential participants to fill out certain outcome assessments such as neurobehavioral symptomatic inventory. This could lead to measurement bias or confound the result.~* Claustrophobia and unwilling to enter hyperbaric chamber~* Untreated pneumothorax~* Presence of implanted device with un-verifiable test to pressure by manufacturer~* Concurrent enrollment in an alternate interventional trial for post concussive symptoms",,,t,f,t
6361031,NCT05138718,NON_PROBABILITY_SAMPLE,ALL,18 Years,80 Years,f,* Patients 18-80 years of age~* Patients with documented myocardial infarction \> 90 days before study inclusion~* Clinically stable at the time of screening and able to tolerate the study procedure,"Inclusion Criteria:~* Willing and able to provide written informed consent~* Patients 18-80 years of age~* Patients with documented myocardial infarction \> 90 days before study inclusion~* Clinically stable at the time of screening and able to tolerate the study procedure~* Female patients must not be pregnant at the time of FDG PET/CT imaging~* Patients included in other clinical trials could be included, provided this complies with specific local and research center requirements~* If after 6 months of patient recruitment it is foreseeable that the target number of patients will not be reached, patients who undergo FDG PET/CT imaging for cancer screening or surveillance can be included, provided that they have no evidence of an active malignancy on the scan or other exclusion criteria as listed below at study entry, including recent radio- and / or chemotherapy (≥ 12 months before the FDG PET/CT)~Exclusion Criteria:~* Severe congestive heart failure (class III or IV according to NYHA, or pulmonary edema)~* Extra-cardiac illness that is expected to limit survival to less than 4-5 years; e. g. oxygen-dependent chronic obstructive pulmonary disease, active hepatitis or severe hepatic dysfunction, severe renal disease, active cancer~* Patients with chronic use of anti-inflammatory medication (except NSAIDs and inhaled corticosteroids)~* Patients with Diabetes Type I~* Insulin-dependent or uncontrolled Diabetes Type II (as HbA1C\>7.5)~* Withdrawal of Informed consent",,,t,f,t
6361032,NCT06167460,PROBABILITY_SAMPLE,ALL,18 Years,80 Years,f,"This study population will include female and male, aged 18 and older, who are diagnosed with stage IIIB-IV Non-small cell lung cancer and indicated for TKI or TKI combined with chemotherapy. Eligible participants will meet all of the inclusion and exclusion criteria to be recruited into this study.",Inclusion Criteria:~* Patients are diagnosed with advanced non-small cell lung cancer and indicated for TKI (first or second line). TKI combined with chemotherapy is allowed.~* FFPE/FNA sample is available.~* Compliant with treatment protocol.~* Patients consented to participate in the study.~Exclusion Criteria:~* Patients already started TKI before enrollment.~* Patients already started chemotherapy before enrollment.~* Medical or psychiatric conditions or occupational responsibilities that may preclude compliance with the protocol.~* Patients did not agree to participate in the studies.,,,t,f,t
6260069,NCT01212016,,ALL,18 Years,65 Years,t,,"* INCLUSION CRITERIA:~Subjects must meet all of the inclusion criteria:~All Subjects must:~1. Be willing to have samples collected and stored for future research.~2. Have a documented clinical history compatible with EGID, peanut allergy, or other allergic and inflammatory diseases or be healthy without known allergic conditions.~In addition to the above inclusion criteria for all subjects, the subjects in the following groups must meet additional group-specific inclusion criteria.~Subjects with EGID must:~1. Be greater than or equal to 18 years of age~2. Maintain a primary non-NIH physician for routine care~3. Have one of the types of EGID below:~   * Eosinophilic gastroenteritis: Have a clinical history of eosinophilic gastroenteritis -including gastrointestinal symptoms-, and histological evidence of stomach or duodenal eosinophilia with no other known etiology for the eosinophilia despite careful clinical evaluation.~OR~-Eosinophilic esophagitis: Have a diagnosis of eosinophilic esophagitis, including evidence of esophageal dysfunction with a peak count of greater than or equal to 25 eosinophils per high powered field, for which the biopsy was obtained while under proton pump inhibitor treatment.~OR~-Probable eosinophilic esophagitis: Have a likely diagnosis of eosinophilic esophagitis, based on evidence of esophageal dysfunction and a peak count of greater than or equal to 15 eosinophils per high powered field, but for which the biopsy was not obtained under proton pump inhibitors (per section 6.3). To confirm~a diagnosis of EoE, these subjects may be treated with proton pump inhibitor therapy at recommended doses for gastroesophageal reflux disease for at least 84 weeks prior to EGD and biopsy. The decision to recommend diagnostic biopsy will be according to concensus guidelines \[7\] and current standards of care: based on the severity of symptoms, history of food impactions, and evidence of remodeling (strictures).~Subjects with Peanut Allergy:~1. Be greater than or equal to 18 years of age and less than or equal to 65 years of age.~2. Have a history of immediate hypersensitivity to peanuts with involvement of at least one extracutaneous site, including wheezing, laryngeal edema, angioedema, vomiting, diarrhea, hypotension and circulatory collapse.~3. Have peanut specific IgE of greater than or equal to 5 kIU/L.~Subjects with Other Allergic and Inflammatory Diseases:~1. Be greater than or equal to 18 years of age and less than or equal to 65 years of age.~2. These subjects must be diagnosed with an allergic or an inflammatory disease, including anaphylaxis, asthma, or hay fever. Diagnosis will be based on established criteria for each clinical entity.~Healthy, Non-Atopic Subjects:~1. Be greater than or equal to 18 years of age and less than or equal to 65 years of age.~2. Have no history of allergies, asthma or food allergy~3. Have a negative ImmunoCAP fx5 in vitro food allergy screen for allergen specific IgE to egg white, milk, cod, wheat, peanut, and soy~4. Have a negative Phadiatop allergy screen~EXCLUSION CRITERIA:~Subjects with any of the following criteria will be excluded:~1. Any other condition that, in the investigator s opinion, places the subject at undue risk by participating in the study~Subjects with Peanut Allergy with any of the following will be excluded:~1. Chronic upper GI symptoms that are consistent with EGID (dysphagia, nausea, vomiting, abdominal pain/cramps, early satiety)~PROCEDURAL INCLUSIONS:~Subjects with EoE and EG undergoing research EGD or lymphapheresis must:~1. Be greater than or equal to 18 years of age and less than or equal to 65 years of age.~Subjects with EG undergoing EGD or lymphapheresis must have:~1. Histological evidence of stomach or duodenal eosinophilia with a peak count greater than or equal to 40 eosinophils per high powered field~2. Greater than two positive allergen skin tests or antigen specific IgE tests out of the following panel (peanut, wheat, soy, shrimp, egg white, milk, walnut, cod, corn)~Subjects with either EG or EoE undergoing lymphapheresis must have:~1. An absolute eosinophil count of \>750 eos/microL at least once in the last 2 years~Subjects with EoE undergoing EGD must have:~1. Diagnosed EoE per section 5.1 with a previous biopsy showing greater than or equal to 25 eosinophils per high powered field, OR~2. Probable eosinophilic esophagitis per section 5.1 with a previous biopsy showing greater than or equal to 25 eosinophils per high powered field~PROCEDURAL EXCLUSIONS:~Subjects with any of following will not undergo EGD:~1. Uncontrolled asthma or Grade 3 or higher by the American Society of Anesthesiologist s (ASA) Physical Status Classification System.~2. History of adverse reaction to conscious sedation required for EGD.~Subjects with any of following will not undergo EGD or lymphapheresis:~1. Hemoglobin \<12 g/dL~2. Viral screens positive for HIV or hepatitis B or C~3. Pregnant or breast-feeding women~Control Subjects (Healthy, Non-Atopic) Undergoing EGD with any of the following will be excluded:~1. History of reflux or use of acid suppression medication within the last 6 months.~2. Chronic gastrointestinal disease or immunological disease.~3. Clinically indicated EGD in the past 12 months.~4. Use of systemic corticosteroids in the past 6 months.~EGID subjects who are pregnant or breast-feeding may be followed without research phlebotomy.",,,t,f,t
6058731,NCT03445312,NON_PROBABILITY_SAMPLE,ALL,,,f,All inpatients on medical and surgical units who have a mid-stream urine culture ordered,Inclusion Criteria:~* inpatients on medical or surgical units at Mount Sinai Hospital~Exclusion Criteria:~* none,,,t,t,t
6260070,NCT01469858,,ALL,18 Years,80 Years,t,,Inclusion Criteria:~* diagnosis of the investigated neuronal disease~Exclusion Criteria:~* contraindication for MRI scan~* pregnancy~* refusal to participate in the study,,,t,f,t
6260071,NCT04096807,NON_PROBABILITY_SAMPLE,ALL,18 Years,,f,Patient admitted to the Montpellier University Hospital for cardiac surgery requiring perioperative TEE and pulmonary arterial catheter monitoring.,"Inclusion Criteria:~* Patients aged of 18 years or more,~* Scheduled for an elective cardiac surgery at the Montpellier University Hospital,~* Requiring a pulmonary arterial catheter monitoring due to the complexity of cardiac surgery or severe cardiopulmonary comorbidities.~Exclusion Criteria:~* Failure of the pulmonary artery catheterization,~* Failure of PCWP measurement,~* Failure of TEE measure of the left upper pulmonary vein diameter and collapsibility,~* Refusal to participate expressed secondarily.~Non-inclusion criteria :~* Cardiac transplantation,~* Left ventricule assist device,~* Pulmonary vein stenosis,~* Contraindications to TEE or PAC,~* Refusal to participate,~* Patient under juridical protection",,,t,f,t
6260072,NCT06144658,,ALL,18 Years,66 Years,t,,"Inclusion Criteria:~Healthy male or female volunteers.~* Aged between 18 and 66.~* Not currently pregnant.~* Affiliated to a social security system or, for non-Europeans, holders of a European Health Insurance Card (EHIC).~* Have signed written consent for the study.~* Have passed a standard JAR FCL3 Class 2 (Private Pilot Aptitude) medical examination less than 1 year old.~Exclusion Criteria:~On the day of the flight, before the volunteer boards the plane:~* Flu, digestive symptoms (nausea, vomiting), fever.~* Pregnancy: a urine pregnancy test will be performed on the morning of the flight before boarding.~* Altered mental state (flight anxiety, phobia).~* Failure to attend the safety briefing.~During the flight :~* Non-compliance with basic safety instructions.~* Flight-related side effects: fatigue, motion sickness.",,,t,f,t
6260073,NCT02288507,,ALL,18 Years,,f,,"Inclusion Criteria:~* Histologically or cytologically confirmed HCC or clinical diagnosis by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic subjects is required. m)~* Barcelona Clinic Liver Cancer Stage B or C. Segmental and subsegmental portal vein thrombosis is allowed.~* Metastatic disease is allowed if investigator feels liver directed therapy could offer palliative benefit (i.e., minimal extrahepatic tumor burden)~* No evidence of cirrhosis or cirrhosis grade of Child-Pugh class A or B7. Eligibility~* Have at least one tumor lesion that can be accurately measured according to Response Evaluation Criteria in Solid Tumor (RECIST v1.1).~* Consultation with interventional radiologist and deemed an appropriate candidate for TARE.~* Prior local therapy, such as surgery, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation is allowed if the index lesion(s) remains outside of the treatment field or has progressed since prior treatment. Local therapy must have been completed at least 4 weeks prior to the baseline scan.~* Prior yittrium-90 transarterial radioembolization (TARE) or sorafenib not allowed~* Patient must be informed of the investigational nature of this study, sign and give written informed consent in accordance with institutional and federal guidelines.~* Age ≥ 18 years.~* Eastern Cooperative Group (ECOG) performance status ≤ 1.~* Have adequate hematologic function as documented by an absolute neutrophil count (ANC) ≥ 1000/ul, platelet count ≥ 60,000/ul, and hemoglobin ≥ 8.5 mg/dl obtained within 28 days prior to registration.~* Have adequate hepatic function, as determined by the following tests measured within 28 days prior to registration: serum bilirubin ≤ 2 x upper limit of normal (ULN); serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) ≤ 5 x the institutional upper limit of normal (IULN).~* Have adequate renal function, as determined by the following tests measured within 28 days prior to registration: serum creatinine ≤ 1.5 x ULN OR a measured creatinine clearance or calculated creatinine clearance ≥ 50 mL/min.~* Have a life expectancy of ≥12 weeks~* Must be able to swallow oral medications.~* Negative pregnancy test done ≤7 days prior to registration, for women of childbearing potential only.~Exclusion Criteria:~* Known or suspected allergy or hypersensitivity to sorafenib.~* Any malabsorption condition.~* Must not have known brain metastases.~* No concurrent anticancer chemotherapy or local therapy.~* No concurrent herbal or unconventional therapy (e.g., St. John's Wort)~* Pregnant or nursing women~* No prior radiation therapy to the liver~* Inability to perform y90 TARE due to: (1) inability to catheterize the hepatic artery, (2) portal vein thrombosis/occlusion without the ability to perform selective infusion, (3) Tecnetium-99m macro-aggregated albumin hepatic artery perfusion scintigraphy shows unfavorable shunt fraction between the liver and the pulmonary parenchyma as determined by the interventional radiologist, or (4) other contraindication to TARE identified by interventional radiologist.~* Women/men of reproductive potential unwilling or unable to use an effective contraceptive method~* No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 3 years.~* History of myocardial infarction, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within 6 months.~* Concurrent severe or uncontrolled medical disease (i.e., active systemic infection, diabetes, coronary artery disease, congestive heart failure) that, in the opinion of the Investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study.",,,t,f,t
6260074,NCT05889143,PROBABILITY_SAMPLE,ALL,19 Years,,f,"The number of test subjects was calculated using the confidence interval of the rate of change, noting that the primary purpose of this observation study was to evaluate the rate of change in a single group.~Recruitment of 14,151 people, which is 1.5%, was expected by referring to the minimum number of subjects required and the estimated patients taking two components of single drug and ezetimib compound.~However, this study was a non-intervention observation study conducted under daily treatment, and it was confirmed that the number of subjects who applied 10% of the dropout rate was about 15,000 Therefore, this study will be conducted with study population of 15,000 subjects.","Inclusion Criteria:~1. an adult male and female over 19 years of age~2. A patient with dyslipidemia who is scheduled to administer Crezet tablets according to the medical judgment of the investigator based on permission~3. A person who voluntarily participates in the observational study and agrees in writing to comply with the subject's precautions during the study period after hearing and understanding the detailed explanation of the characteristics of the observational study and the drug to be studied~Exclusion Criteria:~1. A person who is prohibited from administering according to the permission of the Crezet definition~   * Patients who overreact to the principal or component of the Crezet definition~  * Patients with active liver disease or patients with persistent high symptoms of serum aminotransferase levels~  * a patient with a muscle disease~  * a patient administered in combination with a cyclosporine-med~  * Patients with severe renal failure (Creatinine Clearance (CLcr) \< 30 mL/min)~  * Women and lactating women who may be pregnant or pregnant~  * Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption~2. A person who has a history of taking Crezet tablets within three months of the date of registration~3. A person who is deemed inappropriate to participate in this observational study based on the judgment of investigator.",,,t,f,t
6260075,NCT01311011,NON_PROBABILITY_SAMPLE,ALL,14 Years,85 Years,f,Patients with Critical Limb Ischemia,Inclusion Criteria:~* Patients with Critical Limb Ischemia~Exclusion Criteria:~* Patients with other than Critical Limb Ischemia,,,t,t,t
6260076,NCT01287000,NON_PROBABILITY_SAMPLE,ALL,21 Years,,f,Workers and volunteers engaged or potentially engaged in oil spill clean-up operations in the Gulf of Mexico,"* INCLUSION CRITERIA:~We anticipate screening as many as 90,000 individuals in order to recruit approximately 55,000 volunteers primarily from the four most affected Gulf States\* (LA, MS, AL, and FL) into the cohort, which will include a randomly sampled Active Follow-up Sub-cohort of approximately 24,000 individuals nested within it. Eligibility criteria for the cohort include:~* 21 years of age or older~* Fall into one of two oil-related exposure categories:~  * Potentially exposed subjects must have completed at least one day of oil-spill clean-up-related work (other than safety training), either paid or volunteer.~ * Unexposed subjects will be individuals who were not directly involved in oil spill clean-up activities, but who worked near the oil spill or completed some oil spill worker training.~* Unexposed subjects will be individuals who were not directly involved in oil spill clean-up activities, but who worked near the oil spill or completed some oil spill worker training.~* pregnant women will be allowed to enroll in the study, and women who become pregnant during the study will not be withdrawn.~EXCLUSION CRITERIA:~* Children will not be enrolled because they were not allowed to participate in clean-up activities.~* Those who were deemed medically ineligible to participate in clean-up activities because of pre-existing conditions are excluded because they won t be representative of those individuals who were engaged in clean-up activities.",,,t,f,t
6260077,NCT01427907,,ALL,18 Years,,f,,"Inclusion Criteria:~* Male or female subjects ≥18 years of age able to give written informed consent to the study~* Hemodialysis dependent chronic kidney disease stage 5D patients~* Taking sevelamer carbonate tablets or sevelamer hydrochloride as phosphate binder monotherapy~* Taking 3 or more sevelamer carbonate or sevelamer hydrochloride tablets per day~Exclusion Criteria:~* Estimated life expectancy of less than 6 months and for cancer patients, an Eastern Cooperative Oncology Group (ECOG) Performance Status \>1~* Active malignancy within the past 5 years. Basal or squamous cell skin cancer is not exclusionary. History of malignancy is not an exclusion~* Known hypersensitivity reaction to calcium-based phosphate binders~* Anticipated renal transplantation during the study~* Pregnant or sexually active female subjects who are of childbearing potential and who are not willing to use an acceptable form of contraception.",,,t,f,t
6260078,NCT06372132,,ALL,18 Years,,f,,Inclusion Criteria:~* Patients with GP~* 13C octanoic acid test or gastric scintigraphy (minimal 4-hour measurement) within the past twelve months~* 18 years old~Exclusion Criteria:~* \< 18 years old~* Medical history of stomach surgery in which resection of antrum and/ or pylorus took place~* Medical history of surgical or laparoscopic pyloromyotomy~* Gastric bypass~* Current opioid use~* Pregnancy,,,t,f,t
6260079,NCT02544932,,ALL,40 Years,85 Years,t,,Inclusion Criteria:~* CHA2DS2-VASc score above 2~Exclusion Criteria:~* severe peripheral arterial disease (greater than a Fontaine IIb category)~* grade 4 or higher cerebral infarction on the Modified Rankin Scale~* proven coronary artery disease by coronary angiogram~* severe hepatic or renal dysfunction~* uncontrolled congestive heart failure~* uncontrolled hypertension or diabetes mellitus~* hematologic disorders~* allergy or hypersensitivity to the investigational drugs~* pregnant or lactating women or women wishing to become pregnant,,,t,f,t
6263714,NCT01878578,,ALL,18 Years,65 Years,f,,"Inclusion Criteria:~* Male or female subjects aged between 18 and 65 years, inclusive.~* Subjects who were on an established regimen of phenytoin monotherapy, which had been stable for at least 3 months.~* Subjects who had clinical laboratory tests acceptable to the Investigator.~* Subjects who were negative for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody (Ab) and human immunodeficiency viruses (HIV-1 and HIV-2) Ab tests at screening.~* Subjects who were negative for alcohol and drugs of abuse at screening.~* Subjects who were non-smokers or who smoked less than 10 cigarettes or equivalent per day.~* Subjects who were able and willing to gave written informed consent.~* (If female) She was not of childbearing potential by reason of surgery or, if of childbearing potential, she used one of the following methods of contraception: double barrier or intrauterine device.~* (If female) She had a negative pregnancy test at screening.~Exclusion Criteria:~* Subjects who did not conform to the above inclusion criteria.~* Subjects who had a clinically relevant history or presence of any disease that may interfere with the pharmacokinetics or pharmacodynamics of the Investigational Products, or may affect its safety.~* Subjects who had a history of relevant drug hypersensitivity.~* Subjects who had a history of alcoholism or drug abuse in the last 2 years.~* Subjects who consumed more than 21 units of alcohol a week.~* Subjects who had one of the following findings on the electrocardiogram (ECG): sinus bradycardia, sinoatrial block, atrioventricular block of any degree.~* Subjects who had a significant infection or known inflammatory process on screening and/or admission.~* Subjects who had acute gastrointestinal symptoms at the time of screening and/or admission (e.g., nausea, vomiting, diarrhoea, heartburn).~* Subjects who had used any drugs (other than phenytoin) that may affect the pharmacokinetic profile of the investigational products within 2 weeks of first dosing.~* Subjects who had used any investigational drug and/or participated in any clinical trial within 3 months of their first admission to this study.~* Subjects who had previously received ESL.~* Subjects who had donated and/or received any blood or blood products within the previous 3 months prior to screening.~* Subjects who were vegetarians, vegans and/or have medical dietary restrictions.~* Subjects who cannot communicate reliably with the investigator.~* Subjects who were unlikely to co-operate with the requirements of the study.~* Subjects who were unwilling or unable to gave written informed consent.~* (If female) She was pregnant or breast-feeding.~* (If female) She was of childbearing potential and she did not use an approved effective contraceptive method.",,,t,f,t
6361033,NCT01306773,,ALL,18 Years,,f,,Inclusion Criteria:~* adult patients ≥ 18 years old with written informed consent given by patient or next-of-kin~* laboratory confirmatory diagnosis of 2009 H1N1 infection by positive RT-PCR from respiratory specimens~* required intensive care within 7 days of onset of symptoms~Exclusion Criteria:~* age 18 years old or below~* known hypersensitivity to immune globulin~* known IgA deficiency,,,t,f,t
6260080,NCT03418532,,ALL,18 Years,,f,,"Inclusion Criteria:~1. Histologically confirmed metastatic or unresectable locally advanced non-squamous NSCLC with documented EGFR mutation-positive disease~2. Radiologically documented disease progression on previous osimertinib treatment.~3. Radiologically documented disease progression on or after most recent antitumor therapy.~4. Measurable disease according to RECIST 1.1.~5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 2.~6. Men and women ≥18 years old on the day of signing informed consent.~7. Adequate hematological, hepatic and renal function prior to first dose~8. Serum albumin concentration ≥30 g/L~9. Potassium and magnesium within normal range~Exclusion Criteria:~1. Necrotic tumors or tumors close to large blood vessels that may impose an increased bleeding risk when treated with anti-VEGF agents.~2. Second malignancy that is currently clinically significant or required active intervention during the period of 12 months prior to Screening, except early stage non-melanoma skin cancer treated with curative intent.~3. Known pre-existing interstitial or inflammatory lung disease.~4. Clinical signs of or documented leptomeningeal carcinomatosis. Features such as headache, nuchal rigidity, and photophobia may indicate meningeal involvement.~5. Known brain metastases who are clinically unstable~6. Prohibited anti-NSCLC therapies and not having recovered from related AEs to Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤1~7. Any investigational drug within 28 days prior to study treatment.~8. Current participation in any other interventional clinical study (except survival follow up).~9. Neuropathy as residual toxicity after prior antitumor therapy Grade \>2~10. Patients taking medications that have the potential to prolong the QT interval~11. Significant cardiac abnormalities~12. Uncontrolled hypertension~13. Significant risk for bleeding~14. Active or recent thrombolic events",,,t,f,t
6260081,NCT00618332,,ALL,18 Years,60 Years,f,,"Inclusion Criteria~1. Males and females between 18 and 60 years of age.~2. History of grass and/or ragweed allergic rhinitis.~3. Positive skin or RAST test to grass, trees and/or ragweed antigen.~4. Symptomatic at time of entry into study.~Exclusion Criteria~1. Women of childbearing potential not using the contraception method(s) (Birth control pills, depo Provera, double barrier) as well as women who are pregnant or breastfeeding.~2. Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (heart, lung, kidney, neurological, oncologic or liver disease).~3. Use of any other investigational agent in the last 30 days.~4. Absence of nasal symptoms.~5. Smoking.~6. URI at the time of screening.",,,t,f,f
6260082,NCT06219811,,MALE,50 Years,70 Years,t,,"Inclusion Criteria:~* Age range between 50-70 years old.~* Completely edentulous patients~* Systemically free from any disease that contraindicates implant placement.~* A minimum of 12 -15 millimeters of bone height and 6 mm bone width at canine areas diagnosed from the pre-operative cone beam CT.~* Sufficient inter-arch space (15mm) to accommodate the mandibular implant-retained overdentures.~Exclusion Criteria:~* Patients with bone or mucosal diseases.~* Heavy smokers.~* Patients with uncontrolled metabolic disorders such as diabetes mellitus.~* Patients with parafunctional habits.~* Patients with conditions that might complicate the treatment, such as: severe gag reflex, limited mouth opening.",,,t,f,t
6260083,NCT04760496,,FEMALE,18 Years,,f,,"Inclusion criteria~Inclusion criteria are the following:~* Age ≥ 18 years~* Nulliparous (no previous childbirth beyond 22 SA)~* BMI ≥ 30 kg/m² at the beginning of pregnancy~* Singleton pregnancy~* Spontaneous or induced onset of labour~* Cephalic presentation~* Term ≥ 37 weeks of gestation and \< 42 weeks of gestation~* Medical Indication and absence of medical contraindication for oxytocin during labour: inadequate and/or ineffective uterine contraction and/or delayed cervical dilation~* Written consent~* Affiliation to a french social security system~Exclusion criteria~Exclusion criteria are the following:~* Hypersensitivity to the active substance (oxytocin), to any of its excipients or to latex (risk of cross allergy)~* Medical contraindication for oxytocin~* Coagulation disorders~* Foetal growth restriction (inferior to 5th percentile)~* Foetal malformation (major)~* Foetal heart rate anomalies before use of oxytocin (at the time of inclusion)~* History of uterine surgery (scarred uterus of gynaecological origin)~* Patient with a disease requiring caesarean section prior to labour (planned caesarean section before labour)~* Severe renal failure~* Patient deprived of their liberty (under curatorship or guardianship)~* Participation in another interventional trial of category 1. Patients included in interventional research with minimal risk and constraints may participate in the study after the investigator's assessment.",pregnant women,t,t,f,t
6260084,NCT00222183,,ALL,18 Years,65 Years,f,,"Inclusion Criteria:~Subjects may be included only if they fulfil the following inclusion criteria on the pre-treatment days (between Day -14 and Day -2) and on Day 1 (before first application of study medication):~1. Female and male patients aged 18-65 years (females of childbearing potential may be enrolled provided they are routinely using adequate contraception in the assessment of the investigator).~2. Patients with histologically defined dLE or scLE.~3. The test sites (lupus erythematosus plaques) must be on the face only, and have a total sign score of 4 or more (sum of erythema, induration and scaling scores) and must be the same within a given patient (ie not differing in the sum for erythema, induration or scaling). Each of the 2 test sites must be at least 3 cm apart.~4. The patients must receive a baseline medication with chloroquine.~5. Patients must have been informed about the study procedures and medication and must have given their written Informed Consent.~6. Patients expected to be available for the duration of the study and able to comply with the study visits.~Exclusion Criteria:~Any of the following criteria will disqualify a patient from participating in this study:~1. Systemic therapy for lupus erythematosus within one month prior to first application of study medication in this study (steroids, retinoids, herbal medicines, etc) except chloroquine.~2. Patients with systemic lupus erythematosus or patients whose chronic discoid lupus erythematosus appears to be spontaneously flaring or improving based on the experience of the investigator.~3. Patients who are receiving oral medication, known to precipitate lupus lesions (e.g. procainamide, diuretics, piroxicam, beta blockers, griseofulvin, lithium and other psychotropic drugs).~4. Topical therapy \[i.e. corticosteroids, etc.\] within 2 weeks prior to first application of study medication.~5. Patients with clinically significant medical conditions which could interfere with the conduct of the study. This includes:~   * Renal impairment (creatinine \> 2.0 mg/dl)~  * Hepatic impairment (liver function test values above notable abnormalities; g-GT, ALAT, ASAT: 2x the upper limit)~  * Haematologic disorders (haemoglobin, platelet, erythrocyte and leukocyte counts above notable abnormalities)~  * Neurologic disorders (significant impairment of sensory and motor function as judged by the investigator)~  * Patients known to be previously immunocompromised (e.g. lymphoma, AIDS, myelodysplastic disorders) or treated recently with immunosuppressive drugs or treatment (e.g. radiation therapy or chemotherapy). HIV tests are not necessary.~  * Patients with clinically relevant cardio-vascular diseases (New York Heart Association \[NYHA\] III or IV)~6. Patients who suffer from systemic or generalized infections (bacterial, fungal, viral)~7. Patients with malignancy or history of malignancy.~8. Patients who suffer from acute or chronic bacterial, viral, or fungal skin diseases. However, patients with tinea pedum and/or onychomycosis can be included. Likewise, only patients with acute herpes lesions are excluded.~9. Patients with a history of drug or alcohol abuse during the past 1 year.~10. Patients with known hypersensitivity to any of the ingredients of the study medication or to tacrolimus (the investigator will be provided with a list of ingredients of the study medication).~11. Patients who have received an investigational drug within 4 weeks prior to the first application of the study medication.~12. Patients who are unwilling or unable to provide Informed Consent or to participate satisfactorily for the entire trial period.~13. Any other condition which, in the opinion of the investigator, would render the patient ineligible for the study.",,,t,f,t
6361034,NCT05484973,,FEMALE,21 Years,,f,,"Inclusion Criteria:~1. Female patients ≥ 21 years of age~2. Documented diagnosis of breast cancer, stage I, II, or III~3. A planned taxane-containing CT regimen in the adjuvant or neoadjuvant setting with curative intent~4. Concomitant agents may include trastuzumab, pertuzumab, or other CT agents such as cyclophosphamide, or carboplatin Note: Targeted and/or hormonal therapies intended for use after completion of the taxane-containing CT regimen will not be considered part of the study treatment period, and the AMMA PSCS will not be used during the post-CT targeted and/or hormonal therapy period~5. Plan to complete the current CT regimen within six months~6. At least two years out from the last CT causing hair loss with complete recovery of hair~7. Karnofsky17 performance status 80% or greater~8. Willing and able to sign informed consent for this study~9. Willing and able to complete all required study procedures~Exclusion Criteria:~1. Patients with female pattern baldness resembling picture I-3 or higher on the Savin scale~2. Autoimmune disease affecting hair; e.g. alopecia areata, systemic lupus with associated hair loss, others~3. A history of whole brain radiation~4. Plans to use a CT regimen other than those specified in the inclusion criteria; specifically, a regimen not including paclitaxel or docetaxel or a regimen including an anthracycline (AC/T, EC/T, TAC, etc.)~5. Hormone therapy concurrent with CT. Hormone therapy after CT is permitted~6. Current and/or prior use of hair growth products, such as Nutrafol, minoxidil, and Keranique~7. A serious concurrent infection or medical illness which would jeopardize the ability of the patient to complete the planned therapy and follow-up~8. History of persistent grade 2 (or higher) alopecia induced by prior chemotherapeutic regimens~9. History of and/or current exposure to other agents, drugs, device, or procedure that may cause hair loss~10. Cold sensitivity~11. Intercurrent life-threatening malignancy~12. Evidence of untreated or poorly controlled hyperthyroidism or hypothyroidism~13. History or current diagnosis of any of the following: Cold agglutinin disease, cryoglobulinemia, or cryofibrinogenemia~14. Concurrent hematologic malignancy~15. Participation in any other clinical investigation~16. Concurrent treatment with any investigational agent~17. Any reason the investigator does not believe the patient is a good candidate for the study",Breast cancer,t,t,f,t
6263715,NCT04535388,,ALL,20 Years,69 Years,t,,"Inclusion Criteria:~* Age between 20 to 69 years~* Intractable ocular surface disease~* Uncorrected visual acuity better than count finger and ≥ 0.3 logMAR (log of the Minimum Angle of Resolution)~* Best-corrected visual acuity ≥ 0.3 logMAR (log of the Minimum Angle of Resolution)~Exclusion Criteria:~* Currently under treatment for infectious keratitis~* Difficulty of scleral lens application due to severe allergic conjunctivitis, low compliance, and other potential contraindications~* Diabetes mellitus and/or hypertension~* Pregnant or planning pregnancy E. Unwilling to follow study schedule F. Enrolled in another clinical study G. Determined inappropriate under investigators' discretion",,,t,f,t
6260085,NCT06020937,NON_PROBABILITY_SAMPLE,FEMALE,18 Years,55 Years,t,"Number of participants: 400, 200 healthy controls, and 200 patients diagnosed with multiple sclerosis divided as follow: 100 with manifest trigeminal pain 100 without known trigeminal pathology.","Inclusion Criteria:~Adult women (age 18 to 55) diagnosed with multiple sclerosis using the 2017 McDonald Criteria under treatment with Disease Modifying Therapy (DMTs) with or without trigeminal concerns, or newly diagnosed with MS~Exclusion Criteria:~* Chronic rhinosinusitis with and without nasal polyposis; current allergic rhinitis; other nasal issues that lead to olfactory dysfunction~* anamnestic COVID with incomplete recovery~* Neurodegenerative disorders (Parkinson, Alzheimer, Fronto-temporal Dementia, cognitive impairment and brain vascular diseases)~* History of stroke in the last three years~* Depression or any psychiatric condition~* intake of drugs with sedating side effects~* major health issues that might affect olfactory function (e.g., significant renal insufficiency, uncontrolled diabetes)~* Chronic alcoholism / drug abuse~* Severe head trauma~* Severe facial injuries~* Smoker over 20 cigarettes day or smoking from more than 15 years",,,t,f,f
6260086,NCT04991207,,ALL,18 Years,45 Years,t,,"Inclusion Criteria:~Subjects who met the following criteria were considered eligible to participate/continue in the study:~* Provided signed and dated informed consent before any study specific procedures were conducted.~* Male and female subjects aged 18 to 45 years (both inclusive) at the Screening Visit.~* Healthy as determined by the Principal Investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs and digital 12 lead electrocardiogram (ECG). If a vital sign or ECG assessment was outside of the reference range at the Screening Visit or baseline, the assessment could have been repeated once as soon as possible and in any cases before enrollment to rule out any error.~* Non-smoker or ex-smoker for at least 3 months prior to the Screening Visit.~* Body mass index (BMI) between 18.5 and 29.9 kg/m2 (both inclusive) at the Screening Visit and on admission to each treatment period.~* Negative test results for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti HBc), immunoglobulin M (IgM) anti-HBc, hepatitis C virus antibody (anti HCV) and human immunodeficiency virus (HIV) (Types 1 and 2) antibodies at the Screening Visit.~* Negative screen for alcohol and drugs of abuse at the Screening Visit and on admission to each treatment period.~* Subject had to be willing and able to be confined to the clinical unit and had to adhere to the study and lifestyle restrictions.~* Male subjects had to use together with his female partner/spouse a highly effective contraception form of birth control in combination with a barrier method throughout the clinical study period. And agreed not to father a child or to donate sperm starting at the Screening Visit and throughout the clinical study.~* Female subjects had to either be of non childbearing potential or had to use highly effective methods of contraception from at least 3 months before the Screening Visit and throughout the clinical study in combination with a barrier method.~Exclusion Criteria:~1. Clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue disease or disorders within 5 years before the first IMP administration.~2. Documented coronary artery disease (any of prior myocardial infarction, positive stress test, positive nuclear perfusion study, prior coronary artery bypass graft \[CABG\] surgery or percutaneous coronary intervention, angiogram showing at least 75% stenosis in a major coronary artery), acute coronary syndrome or current symptoms of myocardial ischemia and angina.~3. Clinically relevant surgical history involving the stomach and/or intestinal system, potentially affecting absorption of IMPs.~4. Any clinically relevant findings in the laboratory tests, particularly any abnormality in the coagulation tests or the liver function tests, as judged by the Principal Investigator, at the Screening Visit and on admission to each treatment period. If a laboratory assessment was outside of the reference range at the local laboratory at the Screening Visit or baseline, the assessment could have been repeated once as soon as possible and in any cases before enrollment to rule out laboratory error.~5. Subjects with alanine aminotransferase (ALT) \> 1.0 x the upper limit of normal (ULN) and/or aspartate aminotransferase (AST) \> 1.0 x ULN and/or total bilirubin \> 1.0 x ULN (isolated bilirubin \> 1.0 x ULN and 1.5 x ULN was acceptable if bilirubin was fractionated and direct bilirubin \< 35%), as confirmed by subsequent repeat assessment, at the Screening Visit and on admission to each treatment period.~6. History of relevant atopy or drug hypersensitivity.~7. History of alcoholism or drug abuse.~8. History of drinking \> 24 g (males) and \> 12 g (females) of pure alcohol per day (10 g pure alcohol = 250 mL of beer \[5%\] or 35 mL of spirits \[35%\] or 100 mL of wine \[12%\]) within 3 months before first admission to the clinical unit.~9. Use of alcohol within 72 hours before the Screening Visit and from 48 hours before dosing until completion of the Follow-up Visit.~10. Significant infection or known inflammatory process at the Screening Visit or upon admission to all treatment periods, as judged by the Principal Investigator.~11. Acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea, heartburn) at the time of the Screening Visit or upon admission to all treatment periods.~12. Subjects with blood pressure (BP) measurements (mean of triplicate) outside the ranges, at the Screening Visit or admission to the first treatment period:~    * Systolic BP (SBP) \< 100 mmHg or \> 140 mmHg~   * Diastolic BP (DBP) \< 60 mmHg or \> 90 mmHg~13. Symptomatic orthostatic hypotension (drop of \> 20 mmHg in SBP and/or \> 10 mmHg in DBP when moving from supine to standing position), together with other symptoms, e.g., dizziness, at the Screening Visit or admission to the first treatment period.~14. Abnormal fundoscopy.~15. Electrocardiogram (mean of triplicate) with corrected QT interval using the Fridericia's formula (QTcF) \> 450 ms at the Screening Visit or admission to the first treatment period.~16. Having an estimated glomerular filtration rate (eGFR) \< 90 mL/min, based on creatinine clearance calculation by the Cockcroft Gault formula and normalized to an average surface area of 1.73m2.~17. Previous use of BIA 5 1058.~18. Use of any investigational drug or participation in any clinical study within 60 days or 5 half life times, whichever was longer, before first administration of IMP.~19. Having received IMP in more than 3 studies within 12 months before the Screening Visit.~20. Donated or received blood within 56 days before first administration of IMP.~21. Donated or received plasma within 30 days before first administration of IMP.~22. History of any significant bleeding within the last 56 days prior to first administration of IMP.~23. Vegetarians, vegans or other medical dietary restrictions.~24. Not able to communicate reliably with the Principal Investigator.~25. Unlikely to comply with the requirements of the study.~26. Use of over the counter (OTC) medications (including oral natural health products, vitamin and herbal supplements) within 7 days before the first IMP administration until the Follow up Visit.~    Use of prescription medications that could have affected the safety or other study assessments, in the Principal Investigator's opinion, within 14 days before the first IMP administration until the Follow-up Visit. By exception, acetaminophen/paracetamol 1000 mg/day was permitted.~    CYP2B6, CYP2C8, CYP2D6, CYP3A4 (BIA 5-1058 metabolism) and CYP2C9, CYP2C19, CYP3A4 (bosentan metabolism): Use of inhibitors taken within 7 days before the first IMP administration and inducers taken within 28 days before first IMP administration.~27. Any known allergy or contra-indication to any of the IMPs or their content.~28. The subject was an employee or the close relative of an employee of the Sponsor or the Contract Research Organization (CRO) involved in the clinical study.~29. Vulnerable subjects, e.g., subjects kept in detention, protected adults under guardianship, trusteeship and soldiers or subjects committed to an institution by governmental or juridical order.~    If female:~30. Pregnant or breast-feeding.",,,t,f,f
6260087,NCT01269437,,ALL,12 Years,70 Years,f,,"Inclusion Criteria:~* Provision of informed consent by the subject and his/her legal guardian if the subject is under 18 years old.~* Male or females aged more than 12 and under 70~* Had a definite diagnosis of asthma with symptoms of cough/expectoration/chest tightness/wheeze/breathlessness within the last one month~* Inhaled corticosteroid (ICS) naïve or no regular use of ICS within the last one month (It is suggested that ICS average daily dose with no more than 100mg budesonide or equal within the last month as No-regular-use)~* FEV1 between 60% and 85% of predicted normal values~* Reversibility test of airway obstruction is positive, i.e. degree of reversibility in FEV1 as over 12%(included) and 200ml(included). Or average diurnal PEFR variability is not less than 20% in two weeks.~* Are able to use Peak Flow Meter and record it on patient diary card~Exclusion Criteria:~* Asthma exacerbation leading to hospitalization for more than 2 days within the last 6 months or emergency room visit due to asthma exacerbation in the last 3 months prior to screening~* Infection of respiratory system in the last 4 weeks prior to screening visit~* Use of oral, injectable, rectal or transdermal glucocorticoid in the last 4 weeks prior to screening visit~* Use of Leukotriene receptor antagonist (LTRAs), oral b2 agonist, methylxanthines or use of inhaled long acting b2 agonist, inhaled anticholinergic receptor in the last 1 week, or inhaled Tiotropium Bromide within 45 days prior to screening visit~* Patients with chronic obstructive pulmonary disease (COPD)or COPD with asthma~* Patients with severe persistent asthma (Based on definition in GINA 2006)~* Patients with specific immunity treatment (including monoclonal antibody treatment) due to asthma within the 6 months prior to screening visit~* Patients with eye disorders including cataract, glaucoma and herpes virus infection~* Smoking history of 10 pack-year (1 pack-year refers to 20 cigarette per day for 1 year)~* History of drug or alcohol abuse~* History of adrenal disease~* History of malignancy disease in the last 5 years, with the exception of basal cell carcinoma~* Heart function failure or any severe systematic disease, at the investigator's discretion, which will make it undesirable for the patient to participate in the trial or which could jeopardize compliance with the trial protocol~* ALT or AST \> 2 times of upper limit of reference range~* Creatinine (Cr) \> 159µmol/L for males or \> 141µmol/L for females~* Patients with hypersensitivity to budesonide and/or lactose~* Participation in a clinical study or treatment with a non-approved experimental medication in the last 1 month~* Pregnant or breast-feeding women, or women of childbearing age without appropriate contraception measures~Limitations:~The following medications are prohibited from screening onward:~* Use of oral, injectable, rectal or transdermal glucocorticoid~* Inhaled nedocromil sodium/Inhaled cromoglycate sodium~* Leukotriene receptor antagonist~* Methylxanthines~* Inhaled long acting b2 agonist~* Oral b2 agonist~* Inhaled anticholinergic receptor~* Any b2 receptor blocker (Including eye drops)",,,t,t,t
6260088,NCT00502996,,ALL,18 Years,,f,,"Inclusion Criteria:~* adult patients, \>=18 years of age;~* rheumatoid arthritis \>=6 months;~* lack of response to 1-5 DMARDs or biological agents;~* rheumatoid factor positive.~Exclusion Criteria:~* other chronic inflammatory articular disease or systemic rheumatic disease;~* joint or bone surgery during 8 weeks prior to randomization;~* previous treatment with any cell-depleting therapy.",,,t,f,t
6260089,NCT04129632,,ALL,18 Years,80 Years,t,,"Inclusion Criteria:~* DO's, MD's, MA's, NP's, PA's, RN's, PharmD's~Exclusion Criteria:~* any one not in the above professional categories",,,t,f,t
6260090,NCT05007158,NON_PROBABILITY_SAMPLE,ALL,18 Years,,,Consecutive patients presenting with cardiac device infection CDI,Inclusion Criteria:~• device associated infections~Exclusion Criteria:~* malignancy~* cytostatic or immunomodulating therapy,,,t,f,t
6260091,NCT04074837,,ALL,50 Years,72 Years,t,,"Inclusion Criteria:~* Healthy aged volunteers of either sex between the ages of 50 and 72 inclusive at time of screening.~  * Subjects must be in reasonably good health as determined by investigator based on medical history, vital signs measurements, physical examination, screening laboratory results and ECG.~ * Normal age-related findings as well as well-controlled, chronic and stable medical conditions (e.g., hypertension, osteoarthritis, non-insulin dependent diabetes mellitus, osteoporosis, gout, Paget's disease, hypothyroidism) will not be exclusionary if they are not expected to compromise subject safety, study conduct, or study objectives.~ * Non-interacting medications for stable allowable medical conditions will be allowed following review and approval by the medical monitor.~ * An adequate understanding of the requirements of the study, provision of written informed consent, and agreement to abide by the study restrictions.~ * Negative urine screen for drugs of abuse within 24 h before the administration of the first dose of study drug and in the multiple dose study upon readmission to the clinical unit from outpatient status.~ * Body Mass Index (BMI) of between 18 and 30 kg/m2 inclusive, and a total body weight greater than 48kg at screening.~Exclusion Criteria:~* • Women of child-bearing potential, defined as premenopausal (unless the potential research subject has previously undergone hysterectomy and/or bilateral salpingo-oophorectomy)~  * Pregnant or breastfeeding~ * Any clinically significant hematology, chemistry, coagulation, or urinalysis value at screening and day -1 Abnormal liver enzymes (ALT and/or AST \>1.5X ULN) at screening and day -1~ * Serum creatinine \> ULN at screening and day -1~ * Hemoglobin \<13 g/dL for males or \<11.5 g/dL for females, leukocytes \<3.0 X 103/uL, absolute neutrophil count \<1000/uL, or platelets \<150 X 103/uL at screening and day -1~ * Any significant medical illness that could compromise the interpretability of study data or affect subject safety including, but not necessarily limited to:~    * Chronic pulmonary disease or sleep apnea~   * Clinically significant cardiac arrhythmia (either at screening or based on history)~   * Congestive heart failure, valvular heart disease or ischemic heart disease~   * Pulmonary hypertension~   * Any disorder of the kidney or urinary tract~   * Active peptic ulcer disease, gastrointestinal bleeding, inflammatory bowel disease, chronic pancreatitis~   * Liver disease (excluding Gilbert's syndrome)~   * Any neurologic disorder other than chronic Bell's Palsy~   * History of malignancy that has not been cured or in complete remission for at least 10 years (excluding resected non-metastatic basal cell carcinoma)~   * History of seizure activity other than early childhood~   * Any traumatic brain injury in adulthood~ * Current smoker or nicotine user (quit less than 2 months)~ * Active substance abuse.~ * Glomerular filtration rate \<50 mL/min based on Cockcroft-Gault calculation using ideal (lean) body weight or present weight.~ * Difficulty swallowing",,t,t,f,t
6260092,NCT04172883,,ALL,18 Years,100 Years,f,,"Inclusion Criteria:~1 Subject is implanted with a Medtronic cardiac implantable device with an atrial lead equipped with atrial ATP therapies (rATP) enabled no longer than 18 months and at the minimum 6 weeks has passed since the implant; 2. Age \> 55 years; 3. Subject provides informed consent; 4. Subject is willing and able to comply with the study procedures; 5. Subject has documented history of atrial fibrillation or atrial flutter, or one or more of the risk factors for developing AF as per AHA/HRS (American heart Association/Heart rhythm Society) guidelines.~* Age \> 60 years;~* Stroke/TIA (Transient ischemic Attack);~* Diabetes;~* High Blood Pressure;~* Coronary artery disease;~* Cardiomyopathy;~* Pericardial inflammation;~* Prior heart attacks;~* Congestive heart failure;~* Structural heart disease (valve problems or congenital defects);~* Prior open-heart surgery;~* Untreated atrial flutter (another type of abnormal heart rhythm);~* Thyroid disease;~* Chronic lung disease;~* Sleep apnea;~* Excessive alcohol use;~* Serious illness or infection.~Exclusion criteria:~Patients are not eligible to be enrolled in the study if any of the following criteria is met:~1. Subject has been implanted with a Medtronic cardiac implantable device with an atrial lead equipped with atrial ATP therapies (rATP) enabled for more than 18 months;~2. Subject is in permanent AF or persistent AF at the baseline visit:~   1. The definition of permanent AF will be based on the physicians' decision that nothing further can be done to cardiovert the patient or, in historical cases, the investigators will refer to the Cardiac Compass reports:~  2. The definition of persistent AF at baseline will refer to the Cardiac Compass reports (\>7 consecutive days in AF with the last day being the day of enrollment)~3. Participation in other studies which could potentially conflict with this study;~4. Legal incapacity or evidence that a subject cannot understand the purpose and risks of the study or inability to comply fully with study procedures and follow up.",,,t,f,t
6260093,NCT03082183,,MALE,18 Years,55 Years,t,,"Inclusion Criteria:~* Healthy male subjects according to the assessment of the investigator, based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests~* Age of 18 to 55 years (incl.)~* BMI of 18.5 to 29.9 kg/m2 (incl.)~* Signed and dated written informed consent prior to admission to the study in accordance with GCP and local legislation~Exclusion Criteria:~* Any finding in the medical examination (including BP, PR or ECG) is deviating from normal and judged as clinically relevant by the investigator~* Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 bpm~* Any laboratory value outside the reference range that the investigator considers to be of clinical relevance~* Any evidence of a concomitant disease judged as clinically relevant by the investigator~* Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders~* Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)~* Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders~* History of relevant orthostatic hypotension, fainting spells, or blackouts~* Chronic or relevant acute infections~* History of relevant allergy or hypersensitivity (including allergy to the trial medication or its excipients)~* Use of drugs within 30 days prior to administration of trial medication if that might reasonably influence the results of the trial (incl. QT/QTc interval prolongation)~* Participation in another trial where an investigational drug has been administered within 60 days prior to planned administration of trial medication, or current participation in another trial involving administration of investigational drug~* Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)~* Inability to refrain from smoking on specified trial days~* Alcohol abuse (consumption of more than 20 g per day)~* Drug abuse or positive drug screening~* Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial~* Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial~* Inability to comply with dietary regimen of trial site~* Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study~In addition, the following trial-specific exclusion criteria apply:~* History of relevant liver diseases such as disturbance of liver function, jaundice, drug induced liver injury, Dubin-Johnson syndrome, Rotor syndrome, or liver tumours~* Thrombocytes below lower limit of normal or liver enzymes (ALT, AST, GGT, AP) above upper limit of normal at the screening examination",,,t,f,f
6260094,NCT05465356,NON_PROBABILITY_SAMPLE,ALL,18 Years,,f,All new patients referred to rheumatology outpatients + patients with inflammatory arthritis under follow up in rheumatology outpatients,"Inclusion Criteria: quantitative phase:~* Aged 18 years and above~* Able to complete the questionnaire in English~  1. New patient pre-appointment questionnaires~* Referred as a new patient to the rheumatology outpatient department at Guys and St Thomas' Trust between 01/01/2019 to 01/10/2023 and sent a digital pre-appointment questionnaire~* Electronic patient notes recorded between 01/01/2019 to 01/10/2024~  2. Follow up patients PROM questionnaires~* Patients under followup of the rheumatology department at Guys and St Thomas' Trust with a diagnosis of rheumatoid arthritis, psoriatic arthritis or axial spondyloarthropathy who have been added to the remote monitoring program between 01/01/2019 to 01/10/2023~* Electronic patient notes recorded between 01/01/2019 to 01/10/2024~Inclusion criteria: qualitative phase:~* Aged 18 years and above~  1. New patient pre-appointment questionnaires~* Referred as a new patient to the rheumatology outpatient department at Guys and St Thomas' Trust between 01/01/2019 to 01/10/2023 and sent a digital pre-appointment questionnaire~* Able to communicate in English or any language offered for audio interpreting by the LanguageLine service~  2. Follow up patients PROM questionnaires~* Patients under followup of the rheumatology department at Guys and St Thomas' Trust with a diagnosis of rheumatoid arthritis, psoriatic arthritis or axial spondyloarthropathy who have been added to the remote monitoring program between 01/01/2019 to 01/10/2023~* Able to communicate in English or any language offered for audio interpreting by the LanguageLine service~Exclusion Criteria: quantitative phase:~* Under 18 years of age~* Unable to complete study questionnaires~Exclusion criteria: qualitative phase:~* Under 18 years of age~* Patients lacking the capacity to consent for themselves for the semi-structured interview",,,t,f,t
6260095,NCT05237232,NON_PROBABILITY_SAMPLE,ALL,,17 Years,f,"Newborns, infants and children having been treated with jugulocarotid ECMO and weaned alive off ECMO and newborns treated for hypoxic-ischemic encephalopathy, hospitalized in pediatric intensive care unit (PICU) at Trousseau Hospital.","Inclusion Criteria:~For everyone :~1. Information and non-opposition of holders of parental authority~2. Newborn, infant and child \<20kg~3. Hospitalization in pediatric and neonatal intensive care unit (PICU) of Trousseau Hospital~4. Performing a Magnetic Resonance Angiography (MRA) as part of the treatment~   For patients treated with ECMO: study population~5. Hemodynamic or respiratory failure~6. Requiring the use of extracorporeal circulation with jugulo-carotid cannulation~7. Weaned alive off Extra corporeal membrane oxygenation (ECMO)~   For patients with hypoxic-ischemic encephalopathy: control population~8. hypoxic-ischemic encephalopathy diagnosed at birth~Exclusion Criteria:~1. Contraindication to gadolinium contrast medium injection (study population)~2. Contraindication to MRA~3. Opposition of holders of parental authority",,,f,t,f
6260096,NCT06454656,,ALL,6 Years,17 Years,f,,Inclusion Criteria:~* Primary diagnosis of Cerebral Palsy (GMFCS Levels I-III)~* Has a specific walking related goal~* Has capacity to follow instruction~* Has a primary caregiver who can support a home program~Exclusion Criteria:~* Has had surgery within 6 months of intervention start date~* Has had botox/ baclofen within 3 months of intervention start date~* Has a dual diagnosis that impacts ability to follow instruction~* Has a significant cognitive impairment,,,f,t,f
6260097,NCT04687696,,ALL,13 Years,40 Years,t,,"Inclusion Criteria:~* Being overhead athlete~* Glenohumeral internal rotation range of motion of the affected shoulder should be less than other shoulder and bilateral shoulder internal rotation range of motion difference should be ≥15 º~Exclusion Criteria:~* Shoulder pain required medical attention for the last year.~* Current shoulder pain~* Cervical pain during upper extremity movement~* History of fracture to the shoulder girdle~* Systemic musculoskeletal disease~* History of shoulder surgery,~* Glenohumeral instability (positive apprehension, relocation, or positive sulcus test) or positive findings for a full thickness rotator cuff tear (positive lag sign, positive drop arm test, or marked weakness with shoulder external rotation)",,,t,t,f
6260098,NCT03734796,NON_PROBABILITY_SAMPLE,ALL,18 Years,75 Years,f,"In primary phase of the present study, 400 patients with acute chest pain, who suspected NSTEMI, will be enrolled when visiting emergency department of Fuwai hospital. In subsequent study, multi center emergency department in China plan to recruit 2000 patients suspected NSTEMI. Patients aged 18-75 years old and highly suspected NSTEMI without Left bundle branch block (LBBB) will be included. Patients will be excluded if who is STEMI, underwent surgical operation within four weeks, medium and several kidney dysfunction (Ccr\<30ml/min), anemia, acute myocarditis, chronic cardiac dysfunction (NYHA III-IV), serious cardiac arrhythmias, with history of intravenous drug, oncosis and recent thrombolysis treatment, or pregnant.",Inclusion Criteria:~* 18-75y;~* highly suspected NSTEMI;~* ECG results without ST-segment elevation;~* without new Left bundle branch block (LBBB) ;~Exclusion Criteria:~* STEMI;~* underwent major surgical operation or injury within four weeks;~* medium and several kidney dysfunction (Ccr\<30ml/min);~* anemia(Hb\<90g/L);~* acute myocarditis;~* chronic cardiac dysfunction (NYHA III-IV);~* serious cardiac arrhythmias;~* Have had similar symptoms and treatment with thrombolysis before one month;~* history of intravenous drug;~* history of oncosis;~* pregnant;~* even recruited;,,,t,f,t
6260099,NCT05358483,NON_PROBABILITY_SAMPLE,FEMALE,18 Years,44 Years,t,The PROMISE Study is enrolling women undergoing IVF for the first time without use of a gestational carrier or donor oocytes.,Inclusion Criteria:~* Women ages 18-44 seeking pregnancy at Northwestern Fertility and Reproductive Medicine (FRM) who agree to~  1. Be followed for a period for up to 25 years~ 2. Share information regarding their child's health~* No prior IVF cycles~Exclusion Criteria:~* Women using donor oocytes or gestational carriers~* Inability or unwillingness to provide informed consent for any aspects of the study,,,t,f,f
6260100,NCT01284088,,MALE,21 Years,54 Years,t,,"Inclusion Criteria:~* Ages 21 - 54 years~* Subject wants to be circumcised~* Uncircumcised~* Agrees to be circumcised by any of the study methods, PrePex™ or Surgical as will be determined randomly~* Able to understand the study procedures and requirements~* Agrees to abstain sexual intercourse and to keep caution not directly rub the cut area if masturbating, for 8 weeks post removal (9 weeks total).~* Agrees to return to the health care facility for follow-up visits (or as instructed) after his circumcision that may take up to 8 weeks~* Subject able to comprehend and freely give informed consent for participation in this study and is considered by the investigator to have good compliance for the study~Exclusion Criteria:~* Active genital infection, anatomic abnormality or other condition, which in the opinion of the investigator prevents the subject from undergoing a circumcision~* Subject with the following diseases/conditions: phimosis, paraphimosis, warts under the prepuce, torn or tight frenulum, narrow prepuce, hypospadias,epispadias~* Known bleeding/coagulation abnormality, uncontrolled diabetes~* Subject who have an abnormal penile anatomy or any penile diseases~* Subject that to the opinion of the investigator is not a good candidate~* Subject that refuse to have an HIV test~* Subject does not agree to anonymous video and photographs of the procedure and follow up.",,,t,f,f
6260101,NCT03362632,NON_PROBABILITY_SAMPLE,ALL,,,f,Patients with chronic liver disease,"Inclusion Criteria:~1. Meet the end-stage liver disease part of the type of standard (including slow plus acute liver failure, chronic liver failure, cirrhosis decompensation);~2. age\> 18 years old~3. ascites nucleated cell count\> 250 × 106 / L;~4. Unable to obtain ascites specimens or ascites nucleated cells count does not meet the conditions of 3) are required abdominal examination tenderness (+), rebound tenderness (+), abdominal ultrasound can detect ascites, and procalcitonin (PCT) \> 0.5ng / ml, hs-CRP\> 10ng / ml~Exclusion Criteria:~1. history of abdominal surgery within 4 weeks;~2. secondary peritonitis;~3. tuberculous peritonitis;~4. Malignant tumor;~5. patients who use hormones or immunosuppressants;~6. AIDS patients;~7. heart failure or respiratory failure;~8. merge other parts of the infection;~9. died within 48h;~10. liver transplantation during observation;~11. Diagnosis of spontaneous bacterial peritonitis is the use of carbapenems or third-generation cephalosporins / enzyme inhibitors, piperacillin / enzyme inhibitor antibiotics",,,t,t,t
6260102,NCT02794116,,ALL,6 Years,10 Years,t,,"Inclusion Criteria:~* The inclusion criteria were children born and living in Araraquara/SP (Brazil), 6 to 8-year-aged, presenting FPM with MIH or sound, fully erupted, with sealant treatment indication.~Exclusion Criteria:~* It was excluded teeth with enamel breakdown, enamel tooth malformation linked to syndromes, dental fluorosis, amelogenesis imperfect, fixed orthodontic appliances and patients with bruxism.",,,f,t,f
6260103,NCT05066256,,ALL,18 Years,,f,,Inclusion Criteria:~* Age more than 18 years~* Diagnosis of shock defined by systolic blood pressure \< 90 mmHg or mean arterial blood pressure \< 65 mmHg and/or clinical hypoperfusion~* Mechanically ventilated without ventilator dyssynchrony and no ventilator triggering~* Present of central venous cather or arterial catheter~Exclusion Criteria:~* Age \< 18 years~* Frankly hypovolemic shock or hemorrhagic shock~* Suspicious of cardiogenic shock~* Suspicious of acute decompensated heart failure~* Suspicious of acute coronary syndrome~* Denied participation or denied inform consent,,,t,f,t
6057062,NCT03625674,,ALL,18 Years,70 Years,f,,"Inclusion Criteria:~* 18-70 years old;~* met the ROME IV criteria for FD;~* absence of abnormalities in physical examination, laboratory tests (including a routine blood test, blood glucose, and liver function examination), abdominal ultrasonography and upper GI endoscopy within 6 months;~* absence of H. pylori infection;~* Generalized Anxiety Disorder Scale (GAD-7) ≥ 1 or Patient Health Questionnaire Depression Scale (PHQ-9) ≥ 5~Exclusion Criteria:~* any evidence of organic digestive diseases;~* other FGIDs such as IBS;~* severe psychological symptoms with GAD-7 ≥ 11 or PHQ-9 ≥15;~* pregnancy or breastfeeding; recent myocardial infarction or cardiac arrhythmias;~* previous gastric surgery;~* use of PPIs, psychoactive drugs or other drugs that might affect gastric function within 6 months",,,t,f,t
6260104,NCT02266732,,ALL,18 Years,70 Years,f,,Inclusion Criteria:~* ASA 1 to 3 patients for any shoulder surgery or unilateral ACL knee surgery~Exclusion Criteria:~* Refusal to consent~* Allergy to Chirocaine local anaesthetic~* Pace maker in situ~* Sepsis at site of regional block,,,t,f,t
6260105,NCT01078558,PROBABILITY_SAMPLE,ALL,18 Years,99 Years,f,Rheumatologists,Inclusion Criteria:~* Patients with ongoing HUMIRA (adalimumab) treatment who have been prescribed HUMIRA (adalimumab) within local reimbursement guidelines.~* Patients must be willing to consent to data being collected and provided to Abbott Laboratories.~Exclusion Criteria:~* Contraindications according to the summary of product characteristics.~* Patients who are actually followed in the ReAlise registry (M03-634 NCT00234884).,,,t,f,t
6260106,NCT03703271,,FEMALE,12 Years,60 Years,f,,"Inclusion Criteria:~* low-risk postmolar gestational trophoblastic neoplasia (GTN)~* World Health Organization(WHO) risk score≤4~* Age≤60 years; female, Chinese women~* Initial treatment~* Performance status: Karnofsky score≥60~* Laboratory tests: WBC≥3.5×10(9)/L, ANC≥1.5×10(9)/L, PLT≥80×10(9)/L, serum bilirubin≤ 1.5 times the upper limit of normal, transaminase≤ 1.5 times the upper limit of normal,blood urea nitrogen, Cr≤ normal~* Provide written informed consent.~Exclusion Criteria:~* Patients with unconfirmed diagnosis of GTN~* Patients with placental-site trophoblastic tumor (PSTT) or epithelioid trophoblastic tumor (ETT)~* WHO risk score ≥5分~* The diameter of a single metastatic lesion in the lung was ≥2cm~* The number of lung CT metastases was≥ 5~* With severe or uncontrolled internal disease, unable to receive chemotherapy~* Concurrently participating in other clinical trials~* Unable or unwilling to sign informed consents~* Unable or unwilling to abide by protocol",,,t,t,f
6260107,NCT00399178,,ALL,18 Years,,,,"Inclusion Criteria:~* OA diagnosis~* BS11 greater than or equal to 4 at base line~* Not adequately pain relieved with 4,000 mg paracetamol daily~Exclusion Criteria:~* Treated with high potent opioids for their OA pain~* Treated with a regular dose for greater than one week of Tramadol, Codeine or dextropropoxifene during the last three months~* Other chronic conditions requiring frequent analgesic therapy",,,t,f,t
6260108,NCT05304507,,ALL,13 Years,,t,,"Stakeholders (players, coaches, caregivers, club administrators) of all youth teams (13-17 years) in two community handball clubs will be eligible for participation.~Inclusion Criteria:~* Players: ages 13-17 years and training ≥2 times/week in a team~* Coaches: leading ≥1 training session/week~* Caregivers: directly associated with the eligible players~* Club administrators: engagement in the issues of sports injury, coach education or policy development for youth players~Exclusion Criteria:~* Employed/paid players~* Stakeholder other than the groups listed in inclusion criteria",,,t,t,t
6260109,NCT01750697,,ALL,2 Years,17 Years,f,,"Inclusion Criteria:~* Diagnosis of GPA (EULAR/PRINTO/PRES 2008, Ankara criteria for childhood Wegener's granulomatosis) or diagnosis of MPA (according to the Chapel Hill Consensus Conference)~* Newly diagnosed participants or participants with relapsing disease according to the following definition:~The recurrence or new onset of potentially organ- or life-threatening disease (i.e. one or more major Birmingham Vasculitis Activity Score for Wegener's Granulomatosis \[BVAS/WG\] items or disease severe enough to require treatment with cyclophosphamide)~* For participants of reproductive potential (males and females), use of reliable means of contraception throughout the study participation~* For all eligible participants mandatory prophylactic treatment for Pneumocystis jirovecii infection~Exclusion Criteria:~* Diagnosis of Churg-Strauss syndrome, as defined by the Chapel Hill Consensus Conference~* Limited disease that would not normally be treated with cyclophosphamide~* Severe disease requiring mechanical ventilation due to alveolar hemorrhage~* Requirement for plasmapheresis or dialysis at screening~* Incomplete recovery from recent surgery or less than (\<) 12 weeks since surgery prior to baseline or planned within 24 weeks of baseline~* Lack of peripheral venous access~* Pregnancy or breast-feeding~* Evidence of other significant uncontrolled concomitant disease, or of disorder or condition that, in the investigator's opinion, would preclude or interfere with participation of participant~* Primary or secondary immunodeficiency (history of or currently active), including known history of human immunodeficiency virus (HIV) infection~* Evidence of active tuberculosis (participants receiving chemoprophylaxis for latent tuberculosis infection are eligible for the study)~* Known active infection of any kind (excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with IV anti-infective agents within 4 weeks of baseline or completion of oral anti-infective agents within 2 weeks prior to baseline. Entry into this study may be reconsidered once the infection has fully resolved~* History of deep space/tissue infection within 24 weeks prior to baseline~* History of serious recurrent or chronic infection~* History of cancer (except for basal cell and squamous cell carcinoma of the skin that have been excised and cured)~* Currently active alcohol or drug abuse or history of alcohol or drug abuse~* History of severe allergic or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of rituximab or to murine proteins~* Treatment with rituximab or other biologic B cell-targeted therapy (e.g., anti- Cluster of Differentiation \[CD\] 19, anti-CD20, anti-CD22, or anti-B-lymphocyte stimulator \[BLys\]/B-cell activating factor \[BAFF\]) within 6 months prior to baseline visit~* Previous treatment with an anti-alpha 4 integrin antibody or co-stimulation modulator~* Previous treatment with other cell-depleting therapies, including, but not limited to, investigational agents (e.g., alemtuzumab, anti-CD4, anti-CD5, anti-CD3, and anti-CD11a)~* Receipt of oral or IV cyclophosphamide within the previous 4 months prior to the baseline visit~* Receipt of infliximab within 3 months, adalimumab within 2 months or etanercept within 1 month prior to the baseline visit~* Treatment with any investigational agent within 28 days of baseline or 5 half-lives of the investigational drug (whichever is longer)~* Receipt of any live attenuated vaccine within 28 days prior to baseline~* Intolerance or contraindications to IV glucocorticoids~* Positive serum human chorionic gonadotropin measured at screening or a positive pregnancy test prior to the first rituximab infusion for participants of childbearing potential~* Positive tests for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis B virus (HBV), or hepatitis C serology~* Level of Immunoglobulin (Ig) M below lower limit of normal of age-specific reference range~* Level of IgG below 5.65 milligram per milliliter~* Absolute neutrophil count \< 1.5 × 10\^3 per microliter and platelet count \< 130 × 10\^3 per microliter~* Estimated Glomerular Filtration Rate \< 15 milliliter per minute per 1.73 m\^2~* Alanine aminotransferase or aspartate aminotransferase levels greater than 2.5 times the upper limit of normal (for age and sex) that cannot be attributed to underlying granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)",,,f,t,f
6260110,NCT04024397,NON_PROBABILITY_SAMPLE,ALL,18 Years,,t,Any individual that receives an opioid prescription.,"Inclusion Criteria:~* Age ≥ 18 years~* No use of opioids for 6 months prior to the issuance of the initial opioid prescription~* Willingness to participate in all aspects of the study including use of the Hugo platform on their personal smartphone~Exclusion Criteria:~* Cancer-associated pain~* Concurrent treatment for cancer (e.g., chemotherapy, radiation therapy)~* Residence in an extended care facility~* Any operation or hospitalization within the past 6 months~* Mental health disorders that could impede functioning in an ambulatory care setting (e.g., schizophrenia, dementia)~* Non-English speaking individuals~* No smartphone~* Use of a pharmacy that is not compatible with the Hugo platform.",,,t,f,t
6260111,NCT03906032,,ALL,60 Years,,t,,"Inclusion Criteria:~* OTA Hip fracture grade A1 and A2~* Greater than 60 years old~Exclusion Criteria:~* Polytrauma, high-energy hip fractures, pathological fractures,~* Reverse oblique and sub-trochanteric femoral fractures~* less than 60 years old",,,t,f,t
6361035,NCT00283231,,FEMALE,40 Years,65 Years,t,,"Inclusion Criteria:~1. Self-report \>4 hot flashes per day or ≥ 30 hot flashes per week.~2. Successful completion of a Hot Flash Diary.~3. Willingness to attend all visits, fast before blood draws, complete all questionnaires, complete the hot flash diary, wear an ambulatory monitor, collect a 24-hour urine and wear the RESPeRATE for 15 minutes per day.~4. Agree not to use therapies that may affect hot flashes during the trial (estrogens, progestins, raloxifene, tamoxifen, clonidine, selective serotonin reuptake inhibitors, relaxation techniques or acupuncture). -~Exclusion Criteria:~1. Inability to sign an informed consent or fill out questionnaires.~2. Use of therapies that may affect hot flashes within 4 weeks of entering the trial (estrogens, progestins, raloxifene, tamoxifen, clonidine, selective serotonin reuptake inhibitors, relaxation techniques or acupuncture).~3. History of pulmonary disease including emphysema, chronic bronchitis, or chronic obstructive pulmonary disease (COPD).~4. Pregnant or breast feeding.~5. Any condition that, in the investigator's opinion, would preclude the participant from being able to understand and use the RESPeRATE device or complete the trial, including severe illness, (e.g., active ischemic heart disease/unstable angina, severe congestive heart failure, chronic atrial fibrillation, stroke resulting in permanent impairment, chronic renal failure or sleep paralysis), plans to move, substance abuse, significant psychiatric problems, or dementia.~6. Blood pressure during screening of ≤ 100/60 mmHg.~7. Current use of any medication prescribed to lower blood pressure.~   -",,,t,f,t
6260112,NCT01622816,PROBABILITY_SAMPLE,ALL,18 Years,,f,Patients enrolled in clinical trials for various retinal diseases at the Wills Eye Institute,"Inclusion Criteria:~1. Ability to provide written informed consent and comply with study assessments for the full duration of the study (one visit per patient).~2. Age greater than 18 years.~3. Clinical diagnosis of retinal disease (including age-related macular degeneration, macular degeneration, retinal vessel occlusion, among others).~Exclusion Criteria:~1. Presence of a significant cataract as determined by your doctor.~2. Presence of a significant posterior capsular opacity (haziness in your eyes) as determined by your doctor.~3. Diagnosis of uveitis (inflammation in part of the eye).",,,t,f,t
6260113,NCT02131558,,FEMALE,18 Years,90 Years,f,,"Inclusion Criteria:~* Adult women patients (\>18 years of age and \<90 years of age)~* Research authorization (consent)~* Pre-operative diagnosis of clinical Stage 1 endometrial cancer~* Pre-operative indications of grade 3 tumor, and/or tumor size greater than 2 cm in size~* Scheduled and consented to undergo robotic hysterectomy and surgical staging, including bilateral pelvic and para-aortic lymphadenectomy~Exclusion Criteria:~* Severe coagulopathy or severe thrombocytopenia~* Severe anemia~* Severe cardio-pulmonary comorbidities demanding minimization of operative time~* History of liver disease~* Iodide allergy~* Emergent operation~* Additional surgical risk as determined during surgery at the discretion of the attending~* Impaired capacity to make informed medical decisions",,,t,f,t
6260114,NCT04899232,,ALL,18 Years,,f,,"INCLUSION CRITERIA:~1. \>18y of age,~2. Subject or proxy who can provide informed consent~3. Positive SARS-COV-2 by Polymerase Chain Reaction (PCR) or as determined by clinical team~EXCLUSION CRITERIA:~1. Adults or Proxy unable to consent~2. Individuals who are not yet adults (infants, children, teenagers)~3. Pregnant women~4. Prisoners~5. Patients expected to die within 24 hours or with a do not resuscitate order,~6. Multi-organ failure,~7. History of hypersensitivity or allergy to any component of the study drug,~8. Ongoing massive surgical or unexplained bleeding,~9. History of bleeding or clotting disorder,~10. Severe traumatic brain injury (Glasgow Coma Scale \<6),~11. Spinal or multiple-trauma,~12. Cancer (incurable/terminal phase) and/or patients receiving palliative care,~13. Enrollment in another concurrent clinical interventional study if considered interfering with this study objectives~14. Per study team discretion, any condition(s) that may prevent safe treatment, preclude adequate evaluation or adding further risk to their underlying illness.",,,t,f,t
6260115,NCT06221332,,FEMALE,18 Years,42 Years,f,,Inclusion Criteria:~* 36-42. Pregnant women who are their gestational age and request epidural anesthesia~* Pregnant women aged 18-42 with ASA II~* Pregnant women who will stay in the hospital for at least 24 hours~* Primiparous pregnant women who will have a planned normal birth~* Singleton births with vertex presentation~Exclusion Criteria:~* Pregnant women who do not want to give consent~* Regional anesthesia is contraindicated~* Pregnant women who use anticoagulants and have an abnormal bleeding profile~* Pregnant women with infection in the area to be treated~* Emergency cases and pregnant women who had a birth with instruments (forceps and vacuum),Pregnant women who will have normal birth,t,t,f,f
6260116,NCT02548832,,ALL,30 Years,60 Years,f,,"Inclusion Criteria:~A. Men and women~B. Accomplished age 30 to 60 years~C. Diagnosis of mixed dyslipidemia established to meet the following criteria:~* Total cholesterol \> 5,17 mmol/l.~* Triglycerides \> 1,7 mmol/l.~D. BMI of 25 kg / m\^2 to 39.9 kg / m\^2, weight stable over the past three months, defined as a variability in the lower body weight of 5%.~E. No drug treatment for lipid profile 3 months prior to baseline.~F. Women must ensure a non-hormonal method to avoid pregnancy during the study period.~G. Written information consent~Exclusion Criteria:~A. Removal for informed consent letter~B. Loss of monitoring~C. Presence of serious adverse event~D. Adherence to treatment \<80%~E. Consumption of drugs known about lipid profile, glucose metabolism, blood pressure and body weight during the intervention period influence~F. Intolerance or not tolerability or hypersensitivity to the compounds used in the study",,,t,f,f
6260117,NCT00993356,,ALL,18 Years,80 Years,f,,"Inclusion Criteria:~* patients with newly diagnosed acromegaly due to GH-secreting macro-adenomas.~* newly diagnosed, previously untreated patients with GH nadir more than 2.5 μg/L during a standard 75-g, 2-h oral glucose tolerance test (OGTT)~* pituitary macroadenomas (maximum diameter \>1 cm) verified by a pituitary magnetic resonance imaging (MRI) scan~* age between 18 and 80 yr.~Exclusion Criteria:~* immediate surgery indicated by clinical criteria~* pregnancy~* contraindications to MRI scan~* patients judged not suitable to participate in the study for other reasons such as personality disorders and alcohol abuse.",,,t,f,t
6260118,NCT03589378,,ALL,18 Years,75 Years,f,,"Inclusion Criteria:~1. Age, gender: 18-75 years old, male or female;~2. basic conditions: 20 ≤ APACHE II score ≤ 35 points and 10 ≤ Sequential Organ Failure Assessment(SOFA)≤ 18 points;~3. septic shock : On the basis of sepsis, after adequate fluid resuscitation, sustained hypotension requires maintenance of vasoactive drugs, mean arterial pressure（MAP）≥ 60 mmHg and Lactate ≥ 2.0 mmol/L; MODS: if the patient's SOFA score is ≥2 points, it means there is organ dysfunction. When the patient has two or more organ dysfunctions, it is MODS.~Exclusion Criteria:~1. can not remove the cause (surgical patients refused surgery, pan drug resistant infection without drug use)~2. Allergic to AMPLYA™ series~3. Presence of relative or absolute contraindications to PFA~4. MODS caused by severe liver disease~5. malignant tumors~6. Chronic end-stage disease (predicted to survive no more than one month)~7. Maternal and possibly pregnant women~8. participated in drug clinical trials within three months~9. Admission from an other ICU where the patient remained for more than 24 hours",,,t,f,t
6260119,NCT04525937,NON_PROBABILITY_SAMPLE,ALL,18 Years,,f,"Patients:~- Over 18 years of age with echocardiographic diagnosis of severe, symptomatic AS and intermediate to high surgical risk per Society of Thoracic Surgeons (STS) mortality risk-score who have a disparate condition~Providers:~- Referring primary care providers, cardiologists and cardiovascular surgeons at the study sites.","Inclusion Criteria:~* Disparity/Diversity background (either race/ethnicity, low SES (adults with incomes at or below the federal poverty level (family income to poverty ratio, ≤1), language (non-English speaker) or education (≤9 years of education))~* Patient scheduled for transcatheter aortic valve replacement using the Edwards Sapien valve, OR recently implanted with Edwards Sapien valve (up to 1 year post-TAVR)~* Echocardiographic diagnosis of severe, symptomatic AS and intermediate to high surgical risk per Society of Thoracic Surgeons (STS) mortality risk-score~Exclusion Criteria:~* Age \< 18~* Patients who do not allow their records to be used for research",,,t,f,t
6260120,NCT00052637,,ALL,18 Years,,f,,DISEASE CHARACTERISTICS:~* Indication for cystoscopy for suspected or confirmed bladder cancer~* Meets at least one of the following criteria:~  * Multiple bladder lesions~ * Bladder lesion greater than 3 cm~ * Bladder tumor of at least stage T1~ * Grade 2 or 3 bladder tumor~ * Recurrent bladder cancer~* No positive cytology obtained in the last 4 weeks~* No prior G3 tumor with one set of positive random biopsies~* No porphyria~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* No gross hematuria~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 1 month after study~* No known allergy to reconstituted hexyl 5-aminolevulinate or a similar compound~* No concurrent condition that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 3 months since prior BCG~Chemotherapy~* More than 3 months since prior chemotherapy~  * Single prior dose of chemotherapy for prevention of seeding after resection allowed~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* More than 30 days since prior participation in another clinical trial~* No concurrent participation in another clinical trial,,,t,f,t
6361036,NCT02713373,,ALL,18 Years,,f,,"Inclusion Criteria:~* Have a pathologically confirmed diagnosis of colorectal cancer, which is metastatic or otherwise unresectable~* Have received at least 1 prior systemic therapy in the metastatic or unresectable disease setting; patients who have recurred within six months of adjuvant chemotherapy are not required to have received an additional line of chemotherapy~* Retrovirus-associated deoxyribonucleic acid (DNA) sequence (RAS) wild-type; v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) testing must be completed, with full KRAS and neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) testing strongly advised; the presence of known mutations in KRAS or NRAS is exclusionary; primary tumor or metastatic tumor may be tested; (note: in the case of multiple genomic evaluations with conflicting results - e.g. KRAS mutant in one sample, but wild-type in another - the patient may be included as RAS wild-type, if clinically justified, after review with the principal investigator \[PI\])~* Appropriate for anti-EGFR therapy: Naive to anti-EGFR therapy (cetuximab or panitumumab) or a candidate for rechallenge by virtue of the following:~  1. the investigator deems anti-EGFR retreatment with cetuximab to be a reasonable standard of care option AND~ 2. outcome of prior anti-EGFR therapy was not rapid progression (i.e. \<= 3 months on therapy) AND~ 3. prior anti-EGFR therapy was administered \> 6 months prior to the start of protocol therapy~* Have an Eastern Cooperative Oncology Group (ECOG) performance status =\< 2~* Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present~* Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion; newly-obtained is defined as a specimen obtained up to 30 days prior to initiation of treatment on day 1~* Hemoglobin \>= 8 g/dL (performed within 14 days of treatment initiation)~* Absolute neutrophil count \>= 1000/mm3 (performed within 14 days of treatment initiation)~* Platelet count \>= 100,000/mm3 (performed within 14 days of treatment initiation)~* Serum creatinine =\< 2 upper limit of normal (ULN) or, \>= 15 mL/min for participants with creatinine levels \> 2 ULN (performed within 14 days of treatment initiation)~* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 ULN or, =\< 5 ULN for participants with liver metastases (performed within 14 days of treatment initiation)~* Female participants of childbearing potential are to have a negative serum pregnancy test~* Female participants of child-bearing potential must agree to use an acceptable method of birth control, be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication; participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \> 1 year; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately~* Male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy~* Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure~Exclusion Criteria:~* Participants who have had chemotherapy, targeted therapies, radiotherapy, or used an investigational device within 2 weeks prior to the first dose of treatment or those who have not recovered from adverse events (i.e., =\< grade 1 or at baseline) due to agents administered more than 2 weeks earlier; note: participants with =\< grade 2 neuropathy are an exception to this criterion and may qualify for the study~* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment~* Has a known history of active TB (Bacillus Tuberculosis)~* Hypersensitivity to pembrolizumab or any of its excipients~* Prior severe infusion reaction to cetuximab~* Has a known additional malignancy that requires active treatment; exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer~* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis; participants with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment; this exception does not include carcinomatous meningitis which is excluded regardless of clinical stability~* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment~* Has known history of, or any evidence of active, non-infectious pneumonitis~* Uncontrolled clinically significant intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, or psychiatric illness, substance abuse disorders or social situations that would limit compliance with study requirements~* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment~* Has a known history of human immunodeficiency virus (HIV or HIV 1/2 antibodies); testing not required~* Has known active hepatitis B (e.g., hepatitis B surface antigen \[HBsAg\] reactive) or hepatitis C (e.g., hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] \[qualitative\] is detected); testing not required~* Has received a live vaccine within 30 days of planned start of study therapy (note: seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and shingles are not allowed)~* Received an investigational agent within 30 days prior to starting study treatment~* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator~* Unwilling or unable to follow protocol requirements",,,t,f,t
5955908,NCT02128256,,ALL,18 Years,90 Years,f,,"Inclusion Criteria:~* Patients with a long bone infection in femur, tibia, humerus or radius~* Candidate for one stage procedure~* Patients above the age of 18~* Written informed consent obtained before any study-related activities~* Patients with communicative ability to understand the procedure and participate in the study and comply with the follow up program~Exclusion Criteria:~* Clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation~* Hypersensitivity to aminoglycoside antibiotics~* Myasthenia gravis~* Severe renal impairment~* Pre existing calcium metabolism disorder.~* Women who are pregnant or breastfeeding (a pregnancy test will be done in women of childbearing potential)~* History of hypersensitivity to the investigational device or any of its ingredients",,,t,f,t
6260121,NCT03833778,,ALL,8 Years,21 Years,f,,"Inclusion Criteria:~* Female and male children and young adults between 8-21 years~* Diagnosis Morbus Crohn, Colitis ulcerosa or Colitis indeterminate~* Clarification and signed Informed Consent Form~* Patients must know how to write and read in German~* Patients must be able to play independently on the tablet~Exclusion Criteria:~* Age \< 8 years or \> 21 years~* Illiteracy~* Mental or psychomotor disability",,,t,t,f
6260122,NCT03721458,PROBABILITY_SAMPLE,ALL,1 Day,,f,"Patient is admitted to the NICU, evaluated by the clinical staff, recommended for participation in this study and consented.","Child:Inclusion Criteria:~1. Age: ≤ 180 days~2. Sex: male or female~3. Admitted to the Hershey Medical Center NICU with a clinical presentation consistent with a genetic disease, e.g. congenital malformations, metabolic disorder, uncontrolled seizures or unexplained abnormal neurological findings.~4. Both Biological Parents are involved in the study~Child:Exclusion Criteria:~1. Age: \> 180 days~2. Known genetic mutation.~Biological Parents : Inclusion Criteria~1. Age: ≥18 years~2. Both biological parents must be willing to participate in the research.~3. Fluent in written and spoken English.~Biological Parents: Exclusion Criteria~1. Age: \<18 years~2. Prisoner~3. Cognitive impairment",,,t,t,t
6260123,NCT03721978,,FEMALE,18 Years,,f,,"Inclusion Criteria:~* Women aged 18 years and above~* Confirmed cervical infection with HPV types 16 and/or 18 at screening~* Cervical tissue specimen/slides provided to Study Pathology Adjudication Committee for diagnosis scheduled to be collected within 10 weeks prior to anticipated date of first dose of study drug~* Confirmed histologic evidence of cervical HSIL at screening~* Must be judged by Investigator to be an appropriate candidate for the protocol-specified procedure required at Week 36~* With respect to their reproductive capacity must be post-menopausal or surgically sterile or willing to use a contraceptive method with failure rate of less than 1% per year when used consistently and correctly from screening until Week 36~* Normal screening electrocardiogram (ECG)~Exclusion Criteria:~* Microscopic or gross evidence of adenocarcinoma-in-situ (AIS), high grade vulvar, vaginal, or anal intraepithelial neoplasia or invasive cancer in any histopathologic specimen at screening~* Cervical lesion(s) that cannot be fully visualized on colposcopy~* History of endocervical curettage (ECC) which showed cervical HSIL indeterminate, or insufficient for diagnosis~* Treatment for cervical HSIL within 4 weeks prior to screening~* Pregnant, breastfeeding or considering becoming pregnant during the study~* History of previous therapeutic HPV vaccination~* Immunosuppression as a result of underlying illness or treatment~* Receipt of any non-study, non-live vaccine within 2 weeks of Day 0~* Receipt of any non-study, live vaccine within 4 weeks of Day 0~* Current or history of clinically significant, medically unstable disease or condition which, in the judgment of the investigator, would jeopardize the safety of the participant, interfere with study assessments or endpoint evaluation, or otherwise impact the validity of the study results~* Presence of acute or chronic bleeding or clotting disorder that would contraindicate IM injections, or use of blood thinners within 2 weeks of Day 0~* Participation in an interventional study with an investigational compound or device within 30 days of signing informed consent~* Less than two acceptable sites available for IM injection",,t,t,f,t
6260124,NCT01473407,,ALL,18 Years,80 Years,f,,"Inclusion Criteria:~1. Patient is able to provide written informed consent after risks and benefits of the study have been explained prior to any study related activities~2. Hemodialysis patients with chronic renal failure and renal anemia currently on stable Epogen (Amgen) treatment for at least 4 weeks prior to randomization, for whom the following apply (during this period):~   * Epogen (Amgen) dose has been administered intravenously 1 to 3 times per week with no more than a 10% dose change from the mean for at least 4 weeks prior to randomization~  * Stable hemoglobin, defined as meeting all of the following:~     * Mean hemoglobin during the 4 weeks prior to randomization between 9.0 and 11.0 g/dL~    * No more than one hemoglobin outside of range from 9.0-11.0 g/dL during the 4 weeks prior to randomization~    * No hemoglobin result more than ±1 g/dL from the mean hemoglobin level during the 4 week period prior to randomization~3. Patients on stable, adequate dialysis for at least 12 weeks prior to randomization, defined as no clinically relevant changes of dialysis regimen and/or dialyzer~4. Patients with adequate iron stores, defined as ferritin \>100 μg/L and TSAT \>20%, prior to randomization~5. Male or female patients aged 18 to 80 years (both inclusive)~6. If female, patient must be either postmenopausal for at least 1 year prior to randomization, surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or practicing at least 1 of the following methods of birth control:~   * hormonal contraceptives (oral, parenteral, or transdermal) for at least 3 months prior to randomization~  * intrauterine device (IUD)~  * double-barrier method (condoms, contraceptive sponge, diaphragm, or vaginal ring with spermicidal jellies or cream)~If hormonal contraceptives are used, the specific contraceptive must have been used for at least 3 months prior to randomization. If the patient is currently using a hormonal contraceptive, she should also use a barrier method during this study and for at least 30 days following the administration of the patient's last dose~Exclusion Criteria:~1. Maintenance Epoetin dosage \>600 U/kg per week (1-3 times per week)~2. Treatment with long-acting epoetin analogues such as Aranesp ® within 3 months prior to randomization~3. Any of the following within 3 months prior to randomization:~   * Myocardial infarction~  * Stroke (cerebrovascular accident)/cerebrovascular insult (minor stroke) or transient ischemic attack/intracerebral bleeding/cerebral infarction~  * Severe/unstable angina~  * Coronary angioplasty, bypass surgery, or peripheral artery bypass graft~  * Decompensated congestive heart failure (New York Heart Association \[NYHA\] class IV)~  * Pulmonary embolism~  * Deep vein thrombosis or other thromboembolic event~  * Received live or attenuated vaccination (except flu vaccination)~4. Uncontrolled Hypertension within the 4 weeks prior to randomization, defined as more than 10% of post-dialysis blood pressures \>170 mmHg systolic and/or \>110 mmHg diastolic, based on blood pressure readings obtained when the patient's post-dialysis body weight was not more than 0.5 kg above their listed dry weight~5. Known, clinically manifested deficiency of folic acid and/or vitamin B12 (irrespective of whether currently treated or not)~6. A patient with any active, uncontrolled systemic, inflammatory or malignant disease (including demyelinating diseases such as multiple sclerosis) that in the Investigator's opinion may be significant to exclude participation in the study, including but not limited to microbial, viral, or fungal infection or mental disease~7. Contraindication for the test drug or have been previously treated with Epoetin Hospira~8. Relative or absolute iron deficiency prior to randomization~9. Platelet count below 100 x 10\^9/L~10. Clinically relevant increase of CRP (\>10 mg/dL) for at least 2 weeks~11. Significant drug sensitivity or a significant allergic reaction to any drug, as well as known hypersensitivity or idiosyncratic reaction to epoetin (or its excipients, including albumin) or any other related drugs that in the judgment of the Investigator is exclusionary for the study participation~12. History of any of the following:~    * Detectable anti- rhEPO antibodies~   * Clinically relevant malnutrition~   * Confirmed aluminum intoxication~   * Myelodysplastic syndrome~   * Known bone marrow fibrosis (osteitis fibrosa cystica)~   * Known seizure disorder~   * Liver cirrhosis with clinical evidence of complications (portal hypertension, splenomegaly, ascites)~13. A female patient who is pregnant, lactating or planning a pregnancy during the study~14. History of drug abuse or alcohol abuse within 2 years prior to randomization as determined by the Investigator~15. Current participation or participation in a drug or other investigational research study within 30 days prior to randomization~16. May not be able to comply with the requirements of this clinical study, communicate effectively with study personnel, or is considered by the Investigator, for any reason, to be an unsuitable candidate for the study~17. Donated or lost \>475 mL (i.e., 1 pint) blood volume (including plasmapheresis) or had a transfusion of any blood product within 3 months prior to randomization~18. A patient who in the Investigator's opinion, has any clinically significant abnormal laboratory evaluations, including liver function taken at Screening Visit~19. Positive laboratory test for human immunodeficiency virus (HIV) or hepatitis B surface antigen (HBsAg)",,,t,f,t
6260125,NCT00304837,,ALL,21 Years,,,,"Inclusion Criteria:~* Be at least 21 years old~* Have critical limb ischemia~* Have severe blockages in at least one artery in the affected leg as demonstrated by an angiogram~* Have nonhealing leg ulcers and/ or have severe rest pain secondary to a severely decreased blood flow~* Agree to participate in follow-up.~Exclusion Criteria:~* Have any evidence of malignant neoplasms (other than non-melanoma skin cancer or in situ carcinoma) within the last 5 years~* Be pregnant or lactating~* Have a history of alcohol or drug abuse within 3 months of screening~* Have advanced (Rutherford Category 6) critical limb ischemia, characterized by extensive tissue loss or gangrene~* Have osteomyelitis~* Have undergone successful aortic or lower extremity surgery, angioplasty, or lumbar sympathectomy within the 2 months preceding screening~* Be a suitable candidate for surgical or endovascular revascularization in the limb in which treatment is proposed~* Subjects in whom arterial insufficiency in the lower extremity is the result of a non-atherosclerotic disorder",,,t,f,t
6260126,NCT05696158,,ALL,18 Years,,f,,"Inclusion Criteria:~* Participant scores ≥ 25 on the Tinnitus Functional Index.~* Participant has experienced symptoms of tinnitus for at least 3 months.~* Participant is at least 18 years of age at the time of consent.~* Participant resides in the United States.~* Participant is able to speak, read, and understand English.~* Participant has access to an iOS or Android smartphone with the ability to complete study tasks.~* Participant is able to commit the time required to complete therapy modules and study assessments.~Exclusion Criteria:~* Participant scores ≥2 on item 9 (suicidal thoughts) of the Beck's Depression Index (BDI).~* Participant has been hospitalized for psychiatric reasons within 12 months of screening.~* Participant is currently enrolled in or plans to enroll in another clinical study that could impact outcomes of this trial.",,,t,f,t
6260127,NCT01829607,,ALL,18 Years,,f,,"Inclusion Criteria:~(i) symptoms \[New York Heart Association (NYHA) class II or III\] and signs typical of heart failure~(ii) left ventricular (LV) ejection fraction (LVEF) \>50% and LV end-diastolic volume index \<97 mL/m2~(iii) findings of left atrial (LA) dilatation (LA volume index \>40mL/m2), LV hypertrophy and/or LV diastolic dysfunction \[ie, mitral E/A ratio \<1 or \>2, mitral E/e' ratio \>15 or 8-15, (A pulmonary - A mitral) duration difference \>30 ms etc)~(iv) no alterations in medical therapy during the previous 4 weeks~(v) no myocardial infarction within 3 months prior to enrollment~Exclusion Criteria:~recent (≤4 weeks) heart failure decompensation~* acute coronary syndrome~* chronic inflammatory diseases and malignancies",,,t,f,t
6260128,NCT02811432,,ALL,1 Hour,48 Hours,f,,"Inclusion criteria~* Liveborn at Jinja Hospital, Masaka Hospital, Entebbe Hospital, or Iganga Hospital~* Singleton or twin pregnancy~* Birthweight ≥700g and ≤2000g~* Chronological age 1-48 hours at time of screening~* Alive at time of recruitment~* Parent/caregiver able and willing to provide KMC~* Parent/caregiver willing to attend follow-up visit~* Indication for KMC uncertain according to WHO guideline concerning clinical stability: pragmatically defined as receiving ≥1 therapy: oxygen, CPAP, IV fluids, therapeutic antibiotics, phenobarbital~Exclusion criteria~* Outborn~* Result of triplet or higher order multifetal pregnancy~* Indication for KMC certain according to WHO guidelines: pragmatically defined as clinically well neonates receiving none of the above therapy-based criteria~* Severely life-threatening instability defined as SpO2 \<88% in oxygen AND ≥1 of:~  * Respiratory rate \<20 or \>100 breaths/min~ * Apnoea requiring bag-mask ventilation~ * HR \<100 or \>200 bpm~* Severe jaundice requiring immediate management~* Active neonatal seizures~* Major congenital malformation~* Parent does not provide written informed consent to participate in trial~* Mother or neonate enrolled in another MRC/UVRI research project",,,f,t,f
6058732,NCT01720940,,ALL,21 Years,80 Years,f,,Inclusion Criteria:~* Adults aged 21-80 years~* Documented infection requiring prolonged (\> 10 days) of vancomycin therapy~* Creatinine clearance \> 50 ml/min (using Cockroft-Gault equation)~Exclusion Criteria:~* Patient already received 7 days or more of vancomycin therapy~* Pregnancy~* Severe burns \> 40% body surface area~* Spinal cord injuries~* Participation in another interventional trial in previous 30 days~* Inability to obtain informed consent,,,t,f,t
6159061,NCT01131624,,FEMALE,18 Years,,f,,"Inclusion Criteria:~* Pregnant women aged ≥18, gestational week ≥20, ≤33 at baseline visit with normal antenatal screening test results.~* Iron deficiency anaemia defined as Hb concentration ≥8 g/dl and ≤10.4 g/dL and serum ferritin ≤20 mcg/L at screening.~* Demonstrated the ability to understand the requirements of the study, abide by the study restrictions, and agree to return for the required assessments. Patients (or their representative) must provide written informed consent for their participation in the study.~Exclusion Criteria:~* Blood transfusion, erythropoietin treatment, parenteral iron or oral iron treatment (1 month prior to screening) or anticipated need for a blood transfusion during the study.~* Anaemia not caused by iron deficiency (e.g., aplastic, megaloblastic or haemolytic anaemia) or related to acute or ongoing, haemoglobinopathies, rheumatic and other chronic diseases, autoimmune diseases, malignancies, bone marrow diseases, enzyme defects and drug induced anaemia.~* Acute or chronic infection, clinically relevant active inflammatory disease (C-reactive protein \>10 mg/dl or outside reference range), any acute infection at screening.~* Pre-eclampsia.~* Multiple pregnancy.~* Evidence on any significant abnormalities on anomaly ultrasound.~* Haemochromatosis or other iron storage disorders.~* Folate deficiency (S-folate \<4.5 nmol/L) at screening.~* Vitamin B12 deficiency (S-cobalamin \<145 pmol/L) at screening.~* Serious medical condition, uncontrolled systemic disease or any other medical condition that, in the judgment of the Investigator, prohibits the patient from entering or potentially completing the study.~* Known chronic renal failure (defined as creatinine clearance \<30 mL/min calculated by Cockcroft-Gault or modification of diet in renal disease formula).~* Severe cardiovascular diseases.~* Known human immunodeficiency virus/acquired immunodeficiency syndrome, hepatitis B virus or hepatitis C virus infection.~* Inability to fully comprehend and/or perform study procedures in the Investigator's opinion~* History of endocrine disorders~* Ongoing significant neurological or psychiatric disorders including psychotic disorders or dementia~* Recent significant bleeding/surgery (within the 3 months prior to screening).~* Chronic/acute hepatic disorder or elevating of liver enzymes (aspartate aminotransferase, alanine aminotransferase) over 2 times above the upper normal limit at screening.~* Participation in any other interventional study since estimated conception and throughout study participation.~* Known hypersensitivity to FCM or other IV iron preparations.",,,t,f,t
6159062,NCT05680324,,FEMALE,20 Years,45 Years,t,,Inclusion Criteria:~* Any adult married woman from 20 to 45 years old candidate for abdominoplasty with stable weight in last 6 months~Exclusion Criteria:~* patients less than 20 years old and more than 45 years old~* patients with medical conditions affecting wound healing~* patients with skin infection in lower abdomen and pubic area,,t,t,f,f
6263716,NCT01910688,,ALL,18 Years,70 Years,t,,"Inclusion Criteria:~1. History of RGB surgery at least 1 year prior to enrollment~2. Achievement of \> 40% EBWL after RGB~3. Weight regain of \> 25% of the lost weight at the time of enrollment. For example, if excess body weight was 50 kg prior to RGB, patient must have lost at least 20 kg after RGB, then regained at least 5 kg to be eligible for the present study~4. Age 18-70 inclusive~5. Subject is able to tolerate endoscopy and sedation~6. Subject agrees to participate, fully understands content of the informed consent, and signs the informed consent form (ICF)~Exclusion Criteria:~1. History of any bariatric surgery other than RGB, including lap band~2. History or presence of a gastrogastric fistula or gastric pouch / jejunal ulceration~3. Gastrojejunostomy \> 4 cm in diameter (size estimated at time of endoscopy)~4. Perceived inability of the patient by the Investigator to comply with a post-treatment diet or medication regimen~5. History of alcohol, tobacco and/or controlled substance dependency that would impair the patient from complying with protocol requirements~6. Pregnancy~7. Subject is unable to provide informed consent for this study",,,t,f,t
6361037,NCT00788073,,ALL,6 Years,40 Years,f,,"Inclusion Criteria:~* Male or female subjects 12 to 40 years of age eventually expanding to 6 years of age~* Molecular documentation of the fragile X mutation.~* Clinical Global Impression - Severity (CGI-S) rating for problem behavior of moderate or higher at screening and at Visit 1~* An Aberrant Behavior Checklist (ABC-C) Irritability Subscale score \>12 and at least 3 items on the Irritability Subscale rated at least moderate or above.~* Current treatment with no more than three psychoactive medications, including anti-epileptics.~* Current pharmacological treatment regimen has been stable for at least 4 weeks.~Exclusion Criteria:~* Subjects with a history of seizure disorder who are not currently receiving treatment with antiepileptics.~* Subjects with any condition, including alcohol and drug abuse, which might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being. This includes, but is not limited to impairment of renal function, evidence or history of malignancy or any significant hematological, endocrine, cardiovascular, respiratory, hepatic, or gastrointestinal disease.~* Subjects who plan to initiate or change pharmacologic or non-pharmacologic interventions during the course of the study.~* Subjects who are currently receiving treatment with racemic baclofen.~* Subjects currently treated with vigabatrin or tiagabine.~* Subjects taking another investigational drug currently or within the last 30 days.",,,t,t,f
6159063,NCT01526018,NON_PROBABILITY_SAMPLE,ALL,1 Month,6 Months,t,Bottle-fed infants aged 1-6 months,"Inclusion Criteria:~* healthy, exclusively formula-fed infants aged 1-6 months at enrollment;~* parent must be at least 19 years of age, able to understand written and verbal English, and provide daytime care for the infant at least 4 days per week.~Exclusion Criteria:~* born \< 37 weeks;~* birth weight \< 2500g or \> 4000g;~* current weight \< 10th percentile for age;~* hospitalization \> 72 hours following birth or any hospital admission since birth;~* any health issue that could interfere with feeding and/or growth;~* use of complementary foods;~* inability or unwillingness to comply with study-related procedures.",,,f,t,f
6159064,NCT01464528,,FEMALE,18 Years,,t,,Inclusion Criteria:~* age 18 year old and over~* need of hysteroscopic surgery~Exclusion Criteria:~* preoperative fever or infection~* malignancy~* previous PID~* contraindications for anesthesia~* pregnancy~* under 18 year old~* not able to read and/or understand informed consent~* taking any medicine other than oral contraceptives,,,t,f,t
6263717,NCT00902707,,ALL,18 Years,50 Years,t,,Inclusion Criteria:~* Healthy~* Non smoker~* BMI 19-29~* Normal lung function~Exclusion Criteria:~* Pregnant~* Smokers~* Any illness,,,t,f,f
6159065,NCT01588418,,MALE,18 Years,65 Years,f,,"Inclusion Criteria:~1. Males age 18-65 years old~2. Patients must have Body Mass Index (BMI) between 25 and 40 kg/m2~3. 2-hour glucose concentration above 140mg/dl after 75g glucose load, ie, having impaired glucose tolerance or newly diagnosed type 2 diabetes.~4. Patients must have BMI of 25-40 kg/m2~5. Patients must have no known severe liver or kidney disease, cancer, neurologic, psychiatric or systemic disease, ability to understand the study.~6. Only patients whose body weight has been stable (±3-4 pounds) over the three months prior to study will be included.~7. Patients must have the following laboratory values:~   * Hematocrit ≥ 34 vol%~  * Serum creatinine\* ≤ 1.5 mg/dl in males and~  * Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT): ≤ 2.5 times upper limit of normal~  * Alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT): ≤ 2.5 times upper limit of normal~  * Alkaline phosphatase ≤ 2.5 times upper limit of normal~  * If serum creatinine is ≤ 1.5 mg/dl in males, the PI can grant an exception and not exclude the patient if the Glomerular filtration rate (GFR) is \>70 ml/min~Exclusion Criteria:~Patients are excluded from participation in the study if they meet any of the following criteria:~1. Patients with major chronic illness (cancer, liver, kidney, cardiovascular disease)~2. Patients with BMI over 40 and under 25~3. Patient with age below 18 yrs and over 65 yrs~4. Female subjects~5. Patients with type 1 diabetes~6. Patients treated for type 2 diabetes~7. Subjects with normal glucose tolerance (NGT)",,,t,f,t
6159066,NCT02634918,NON_PROBABILITY_SAMPLE,MALE,6 Months,18 Years,f,Boys with hemophilia and inherited bleeding disorders with and without a history of hemarthroses,"Inclusion Criteria:~1. All children ages 6 months - 18 years with hemophilia A or B~2. Hemophilia subjects with and without a history of hemarthroses including target joints ( joint of interest) and joints without documented bleeds( control joints)~3. Hemophilia subjects with a history of inhibitor to FVIII or FIX and documented hemarthroses~4. History of hemarthroses more than 4 weeks prior to study enrolment to allow for resolution of hemarthroses which could affect detection of synovial and cartilage changes~Exclusion Criteria:~1. Bleeding disorder subjects without a diagnosis of hemophilia~2. Hemophilia subjects with any underlying illness such as liver or renal disease or any systemic illness such as diabetes or any other chronic illness apart from the hemophilia~3. Hemophilia subjects on medications which could increase bleeding risk such as non steroidal anti inflammatory agents, anti seizure medications apart from factor concentrates~4. History of hemarthroses within the 4 weeks prior to study enrolment",,,t,t,f
6260129,NCT03719937,,ALL,18 Years,,f,,"Inclusion Criteria:~1. Patients with ARDS and moderate to severe oxygenation impairment (PaO2/FiO2≤150 mmHg while receiving controlled mechanical ventilation with PEEP=5 cmH2O) will be the studied population.~   Acute respiratory failure within 1 week of a known clinical insult or new or worsening respiratory symptoms;~  * Bilateral infiltrates at the chest x-ray or CT scan, not fully explained by effusions, lobar/lung collapse, or nodules;~  * Respiratory failure not fully explained by cardiac failure or fluid overload; objective assessment required to exclude hydrostatic edema if no risk factor present.~  * PaO2/FiO2 ratio\<150 mmHg after 30 mins - 1 hour of mechanical ventilation with PEEP=5 cmH2O(14).~  * Written informed consent.~2. Prone positioning deemed non-feasible by the attending clinician, or presence of at least one of the following absolute contraindications for prone positioning(5)~   * Serious facial trauma or facial surgery during the previous 15 days~  * Deep venous thrombosis treated for less than 2 days~  * Unstable spine, femur, or pelvic fractures~  * Pregnant women~  * Intracranial pressure \>30 mm Hg or cerebral perfusion pressure \<60 mm~Exclusion Criteria:~* Chest trauma~* Cardiothoracic surgery in the last 4/6 weeks~* Cardiac PM inserted the last 2 days~* Haemodynamic instability (MAP \< 65 mmHg despite vasoactive/inotrope support)~* Chest tube with air leaks~* Presence of intrinsic PEEP \> 1 cmH2O~* BMI \< 18~* Height \< 150 cm~* More than 48 hours from endotracheal intubation to the time of randomization",,,t,f,t
6260130,NCT04217356,NON_PROBABILITY_SAMPLE,ALL,18 Years,70 Years,f,"Patients with high-risk myelofibrosis including pre-fibrotic primary myelofibrosis (pre-fibrotic primary myelofibrosis), overt primary myelofibrosis, post-polycythemia myelofibrosis or post-essential thrombocythemia myelofibrosis.","Inclusion Criteria:~Recruitment Part:~* Documented diagnosis of pre-fibrotic primary myelofibrosis (pre-fibrotic PMF), overt PMF, post-polycythemia MF (PPV-MF) or post-essential thrombocythemia MF (PET-MF) confirmed by bone marrow biopsy~* Have been tested or have results available for phenotypic driver mutations (JAK2/CALR/MPL) and high molecular risk (HMR) mutations using a broad myeloid malignancies targeted gene panel.~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Able to provide informed consent~* Adequate organ function~* Donor search initiated or patient is agreeable to donor search~* Meet the definition/criteria for high-risk myelofibrosis~Study Arm Allocation:~* Grade of fibrosis on bone marrow biopsy available according to World Health Organization (WHO) criteria~* Results available for phenotypic driver mutations (JAK2/CALR/MPL) and targeted sequencing results using a broad myeloid malignancy panel with a minimal requirement to include results on High molecular risk (HMR) mutations such as ASXL1/EZH2/IDH1/IDH2/SRSF2/U2AF1/TP53~* ECOG performance status 0-2~* Adequate organ function~* Information on donor search and donor type available~Exclusion Criteria:~Recruitment Part:~* Blasts in peripheral blood or bone marrow ≥10%~* For patients already on ruxolitinib at study entry, and meet the criteria of ruxolitinib failure~* Previous history of transformation to blast phase or acute myeloid leukemia~* Received allogeneic stem cell transplant for myeloproliferative neoplasm~* Presence of an active uncontrolled infection~* Myocardial infarction in the preceding 3 months~* Active hepatitis A, B or C~* Known human immunodeficiency virus (HIV) positive~* History of active malignancy in the previous 2 years, except basal cell carcinoma or squamous cell carcinoma of skin or stage 0 cervical cancer~* Any psychiatric illness or social circumstances or significant co-morbid conditions that will prevent patient from proceeding to allogeneic hematopoietic cell transplantation.~* Pregnant or breastfeeding women~Study Arm Allocation:~* Blasts in peripheral blood or bone marrow ≥10%~* Meet the criteria of ruxolitinib failure~* Presence of an active uncontrolled infection~* Myocardial infarction in the preceding 3 months~* Active hepatitis A, B or C~* Known HIV positive~* History of active malignancy in the previous 2 years, except basal cell carcinoma or squamous cell carcinoma of skin or stage 0 cervical cancer~* Pregnant or breastfeeding women~* Any psychiatric illness or social circumstances or significant co-morbid conditions that will prevent patient from proceeding to allogeneic hematopoietic cell transplantation.~* Time between registration and allocation of study arm \>24 weeks",,,t,f,t
6058733,NCT05858190,,ALL,18 Years,45 Years,f,,"Inclusion Criteria:~* age between 18y and 45y.~* with ≥ 60% stenosis in at least one renal artery.~* with hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg).~* patients with no severe renal insufficiency (eGFR\>30 ml/min, length of the kidney ≥ 7cm).~* Good compliance.~* with informed consent.~Exclusion Criteria:~* With apparent atherosclerotic risk factors.~* With renal intervention or surgery history.~* With congenital anatomical anomaly.~* With severe renal insufficiency (length of the target kidney \< 7cm, total~* eGFR\<30ml/min, divided eGFR of the target kidney\<8 ml/min)~* With contraindication for antiplatelet therapy.~* With severe cardiopulmonary insufficiency.~* Allergic to contrast medium~* Being pregnant or preparing for pregnancy~* With active cancer.~* Life expectancy \< 12 month~* Without informed consent",,,t,f,f
6057063,NCT00951574,,ALL,18 Years,,f,,"INCLUSION CRITERIA:~* both sexes;aged\>18 years;~* suffering from different types of malignancies(lung, breast,gastric,colon- rectum,pancreatic,ovarian,head and neck cancer)undergoing systemic chemotherapy,~* having signed Informed Consent prior to initiation of any study procedure.~EXCLUSION CRITERIA:~* adjuvant and neo-adjuvant chemotherapy;~* objectively confirmed venous or arterial thromboembolism in the last three months;~* antithrombotic treatment for other indications;~* life expectancy of less than 3 months;~* Performance Status\>2(ECOG);~* active bleeding or bleedings in the last four weeks requiring hospitalization,transfusion or surgical intervention;~* bleeding diathesis(prothrombin time\<70% or activated partial thromboplastin time ratio\>1.3),or platelet count\<50x10\^9/L;~* cerebrovascular hemorrhage in the last six months;~* known active gastric or duodenal ulcer;~* known cerebral metastasis;~* cerebral aneurysm;~* III-IV grade diabetic retinopathy;~* severe and uncontrolled hypertension(systolic blood pressure\>180 mmHg or diastolic blood pressure\>110 mmHg);~* chronic atrial fibrillation;~* acute endocarditis;~* acute pancreatitis;~* known hypersensitivity to unfractionated heparin or LMWH;~* previous occurrence of heparin-induced thrombocytopenia;~* renal impairment (dependent on dialysis or creatinine higher than 2.5mg%);~* liver insufficiency (alanine aminotransferase,aspartate aminotransferase,alkaline phosphatase levels\>3 times the upper limit of the normal ranges and/or total bilirubin \>3.0 mg/ml);~* pregnancy or childbearing potential without adequate contraception;~* treatment with other investigational drugs or patient inclusion in other clinical trials;~* patients who are unable to fulfill the study requirements in terms of visits/compliance to treatment.",,,t,f,t
6057064,NCT01532310,NON_PROBABILITY_SAMPLE,FEMALE,,,f,Women with SLE who have been exposed to commercially supplied belimumab within the 4 months prior to and/or during pregnancy will be eligible to participate in the registry as well as their infants.,"Inclusion Criteria:~* Pregnant women containing sufficient evidence to confirm that exposure to commercially supplied belimumab occurred within the 4 months prior to and/or during pregnancy~* Pregnant women with sufficient information to classify the pregnancy as prospective or retrospective (ie,whether the outcome of pregnancy was known at the time of first contact with the registry)~* Pregnant women with full contact information to allow for follow-up (name, address, telephone number/email address) and contact information for applicable HCPs if initial reporter is the pregnant woman~* Consent provided by the pregnant woman for her participation and assent for participation of her infant.~Exclusion Criteria:~* Reported cases that do not meet the minimum inclusion criteria for registry enrollment will be ineligible for inclusion in the registry",,,t,t,t
6057065,NCT05541510,,ALL,18 Years,65 Years,f,,"Inclusion Criteria:~1. Aged ≥ 18 and ≤65 years old.~2. Laboratory confirmed SARS-CoV-2 infection, with first positive PCR test results within the past 48 hours of randomization.~3. Participants with COVID-19 symptoms within 5 days prior to the day of randomization, based on the following criteria: At least TWO of the following symptoms: Stuffy/runny nose, sore throat, shortness of breath, cough, low energy/tiredness, muscle/body aches, headache, chill/shivering, Fever (≥ 38ºC), nausea, vomiting, diarrhea, and loss of taste or smell.~4. Have a mild or moderate form of COVID-19 defined as:~   respiratory rate ≤30 breaths per minute, heart rate ≤125 beats per minute; with saturation of oxygen (SpO2) ≥93% on room air at sea level No clinical signs listed in Inclusion Criteria #3 indicative of Severe Severity~5. Have a negative pregnancy test at Screening (for female participants of childbearing potential).~6. Participant or the participant's legal representative understands the study procedures, alternative treatments available, risks involved with the study, and voluntarily agrees to participate by giving written informed consent.~7. Provide written informed consent for the study and willing to adhere to dose regimen and visit schedules.~Exclusion Criteria:~1. Participant has clinical signs suggestive of severe illnesses with SPO2≤94.~2. Sign of severe pneumonia as determined by treating physician on X-ray or SPO2~3. Participant has CT≥25 at screening~4. Participation in any other clinical study of an investigational agent treatment for SARS-CoV-2 infection within 30 days prior to the first IMP dosing.~5. Concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS-CoV-2 prior to PCR screening.~6. Participant with breakthrough SARS-CoV-2 infection within 2 weeks of SARS-CoV-2 vaccination.~7. History of severe renal disease (treatment with dialysis or phosphate binders) or clinically apparent hepatic impairment (e.g., jaundice, cholestasis, hepatic synthetic impairment, active hepatitis).~8. Impaired cardiac function or clinically significant cardiac diseases as judged by the Investigator.~9. History of anaphylaxis reaction to any known or unknown cause.~10. Immunosuppressed persons as result of illness (e.g., HIV infection) or treatment.~11. Documented history of Bell's palsy.~12. History of allergic reaction to kanamycin.~13. Immunosuppressive treatment within 3 months prior to the Screening Visit.~14. Intranasal medication or nasal topical treatment at the time of screen and study.~15. Assessed by the Investigator to be ineligible to participate in the study.",,,t,f,t
6057066,NCT02598310,,FEMALE,20 Years,70 Years,f,,"Inclusion Criteria:~1. Histologically confirmed invasive breast cancer~2. Tumor size of 3cm or less and N0~3. Hormone receptors have been identified as negative~4. HER2 positive confirmed by IHC 3+ or FISH+~5. LVEF \> 50% by echocardiogram or MUGA~6. Adequate EKG~7. No prior treatment for breast cancer~8. PS 0-1~9. Required baseline laboratory data WBC \> 4,000/mm3 and Neut \> 2,000/mm3 PLT \> 100,000/mm3 Hb \> 9.0g/dl AST and ALT \< ULNx2.5 T-Bil \< 1.5mg/dl Serum creatinin \< 1.5mg/dl~10. Written informed consent~Exclusion Criteria:~1. With history of hypersensitivity reaction for important drug in this study~2. With history of invasive breast cancer~3. Bilateral invasive breast cancer~4. Patients with medical conditions that renders them intolerant to primary chemotherapy and related treatment, including infection, diarrhea, intestinal paralysis, severe Diabetes Mellitus~5. Positive for HBs antigen or HCV antibody~6. With history of congestive heart failure, uncontrolled or symptomatic angina pectoris, arrhythmia or myocardial infarction, poorly controlled hypertension~7. With severe edema~8. With severe peripheral neuropathy~9. With severe psychiatric disorder~10. Pregnant or nursing women~11. The case that is judged to be unsuitable for this study by physician",,,t,f,t
6260131,NCT00576407,,ALL,,,f,,"Inclusion Criteria:~* The subject's parent(s) signed the ICF.~* For a diagnosis of DiGeorge Syndrome (DGS), the subject had one of the following:~  * Heart defect~ * Hypoparathyroidism~ * 22q11 hemizygosity~ * 10p13 hemizygosity~ * Coloboma, heart defect, choanal atresia, growth and development retardation, genital hypoplasia, ear anomalies/ deafness CHARGE association mutation (CHD7 deletion);~ * PHA proliferative responses less than 20-fold above background.~* Subjects with typical Complete DiGeorge Anomaly (cDGA) had to have one of the following on 2 separate occasions:~* Circulating CD3+ T cells by flow cytometry \< 50/mm3 or PHA \< 20-fold over background~  * If CD3+ were \> 50/mm3, then CD45RA+ (cluster of differentiation 45RA) CD62L+ had to be \< 50/mm3~ * Or T cell receptor rearrangement excision circles (TRECs) by PCR had to be \< 100 per 100,000 CD3+ cells.~* Subjects with atypical cDGA had to have both of the following with 2 studies each:~  * Circulating CD3+ T cells by flow cytometry \> 500/mm3 and CD45RA+ CD62L+ CD3+ T cells \< 50/mm3 and TRECs less than 100 per 100,000 CD3+ cells.~ * T cell proliferative response to PHA more than 20-fold over background. Circulating CD3+ T cells by flow cytometry \> 500/mm3 and CD45RA+ CD62L+ CD3+ T cells \< 50/mm3 and TRECs less than 100 per 100,000 CD3+ cells.~ * T cell proliferative response to PHA more than 20-fold over background. While T cell response to PHA might have been seen, eligible subjects were to have no T cell proliferative response to antigens (less than 20-fold response) and were to have serious clinical problems related to immunodeficiency, such as opportunistic infection or failure to thrive.~Exclusion Criteria:~* Subjects on ventilators, with tracheostomies, with cytomegalovirus (CMV) infections, or requiring ongoing steroids could still be enrolled, but their data were to be analyzed separately~* Subjects who had heart surgery \< 4 weeks prior to transplant~* Heart surgery anticipated within 3 months of the proposed time of transplantation~* Ongoing parenteral steroid therapy between enrollment and transplantation~* Present or past lymphadenopathy~* Rash associated with T cell infiltration of the dermis and epidermis~* Rejection by the surgeon or anesthesiologist as surgical candidates~* Lack of sufficient muscle tissue to accept a transplant of 4 g/m2 body surface area (BSA) of the recipient~* Prior attempts at immune reconstitution, such as bone marrow transplantation or previous thymus transplantation~* Human immunodeficiency virus (HIV) infection",,,t,t,t
6260132,NCT06124937,,ALL,18 Years,80 Years,f,,"Inclusion criteria~* Adult patients (≥18 years) who are candidates for isolated CABG~* Patients who provided written informed consent and are willing to participate in the study~Exclusion criteria~* History of type Ⅰ or Ⅱ diabetes mellitus~* History of ketoacidosis~* History of atrial fibrillation or flutter~* History of recurrent UTI~* SGLT2I or any other oral hypoglycemic medications used due to other indications~* Patients with acute kidney injury (45)~* Severe hepatic disease (Child-Pugh score C)~* Patients with Estimated Glomerular Filtration Rate (eGFR) \< 30 mL/min/1.73m2~* Patients who are candidates for emergent CABG~* Patients with unstable hemodynamic state~* Patients with positive urine culture, urinary symptoms (frequency, dysuria, hesitancy), and asymptomatic bacteriuria~* Patients who are enrolled in other clinical trials~* Patients with a history of drug-sensitive reactions to SGLT2I~* Pregnancy or lactation",,,t,f,t
6159067,NCT02224118,,MALE,20 Years,64 Years,t,,"Inclusion Criteria:~Part 1~* Weighs greater than or equal to (\>=) 50 kilogram (kg) and less than (\<) 100 kg and has a body mass index (BMI) of \>= 18.5 and \<25.0 at the time of screening tests~* Is a non-smoker, or is able to refrain from smoking from 2 days before screening tests until completion of post-treatment examinations or follow-up investigations~* Is able to refrain from consuming alcohol from 2 days before screening tests until completion of screening tests, from 2 days before hospitalization (Day -4) until after discharge (Day 8), from 2 days before clinic visits (Days 13 and 20) until completion of tests at clinic visits (Days 15 and 22), and from 2 days before post-treatment examinations or follow-up investigations until completion of post-treatment examinations or follow-up investigations~* Has agreed to use a medically acceptable form of contraception (example \[eg\], condoms) from the day of hospitalization (Day -2) until completion of post-treatment examinations or follow-up investigations~* Has no clinically problematic abnormalities in medical examinations and tests before study treatment~Part 2~* Weighs \>= 50 kg and \<100 kg and has a BMI of \>=18.5 and \<37.0 at the time of screening tests~* Was diagnosed with type 2 diabetes mellitus at least 3 months before screening tests and this is being stably managed with dietary modification, exercise therapy, or sulfonylureas or biguanides If sulfonylureas or biguanides are being used, these have been used at a fixed dosage to stably manage the disease since at least 3 months before screening tests~* If the participant has hyperlipidemia, this has been stably managed with antihyperlipidemic drugs at a fixed dosage since at least 3 months before screening tests~* If the participant has hypertension, this has been stably managed with antihypertensive drugs at a fixed dosage since at least 3 months before screening tests~* Is a non-smoker, or is able to refrain from smoking during the hospitalization period and from 1 day before clinic visit days until completion of tests~Exclusion Criteria:~Part 1~* Has or has had hepatic, renal, central nervous system (including psychiatric), cardiovascular, respiratory, gastrointestinal, hematopoietic, ophthalmic, infectious, or endocrine disease that would make the participant unsuitable as a study participant~* Has had a malignant tumor within 5 years before study treatment~* Has undergone surgery that would make the participant unsuitable as a study participant within 12 weeks before screening tests~* Has or had acute disease that occurred within 7 days before study treatment~* Has or has had an eating disorder (pathological anorexia or bulimia)~Part 2~* If only dietary modification and exercise therapy are being used, fasting blood glucose is \<130 milligram per deciliters (mg/dL) or \>= 270 mg/dL in screening tests and at hospitalization (Day -1). If oral antihyperglycemic drugs are being used, fasting blood glucose is \<100 mg/dL or \>= 240 mg/dL at the time of screening tests and \<120 mg/dL or \>= 270 mg/dL at hospitalization (Day -1)~* If only dietary modification and exercise therapy are being used, HbA 1C at the time of Screening tests is \<6% or \>= 10 percent (%). If oral antihyperglycemic drugs are being used, HbA 1C at the time of screening tests is \<6% or \>=9%~* Has blood pressure or a pulse rate that is outside of the following ranges, or has hypertension and blood pressure or a pulse rate that is outside of the following ranges despite taking an antihypertensive drug at the same dosage since at least 3 months before screening tests~* Has or has had type 1 diabetes mellitus~* Has or has had autoimmune diabetes mellitus",,,t,f,f
6260133,NCT00927771,,ALL,18 Years,89 Years,f,,"Inclusion Criteria:~* must have stable moderate-severe epidermal or mixed melasma involving the face~* all races~* males and females~* persons taking birth control medication, hormone replacement therapy or any other hormone altering medication may participate only if they have not started or stopped the medication within the last 3 months~Exclusion Criteria:~* if the person has only dermal melasma~* pregnancy, breastfeeding, a positive pregnancy test in the office or plans to become pregnant~* a known allergy or sensitivity ot azelaic acid or hydroquinone~* the use of photosensitizing medications (ex. tetracycline) within 3 months of the study.~* starting or stopping hormonal medication within 3 months~* chemical peels, microdermabrasion, or laser treatment within 6 months~* worsening or improving melasma",,,t,f,t
6159068,NCT04288518,,ALL,18 Years,70 Years,f,,"Inclusion Criteria:~* Subject is \> 18 years of age~* Clinical and radiological diagnosis of a primary brain tumor or recurrence of a brain tumor with immunohistological verification.~* Clinical and radiological diagnosis of a benign intracranial lesions.~* White blood cell count: \> 2.0 x 10\^9/L~* Haemoglobin: \> 80 g/L~* Platelets: \> 50.0 x 10\^9/L~* alanine amino transferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST): =\< 5.0 times Upper Limit of Normal~* Bilirubin =\< 2.0 times Upper Limit of Normal~* Serum creatinine: Within Normal Limits~* Blood glucose level not more than 5.9 mmol/L~* A negative pregnancy test (serum beta-human chorionic gonadotropin, beta-HCG) at screening for all patients of childbearing potential. Sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception for at least 30 days after study termination~* Subject is capable to undergo the diagnostic investigations to be performed in the study~* Informed consent~Exclusion Criteria:~* Second, non-brain malignancy~* Active current autoimmune disease or history of autoimmune disease~* Active infection or history of severe infection within the previous 3 months (if clinically relevant at screening)~* Known HIV positive or chronically active hepatitis B or C~* Administration of other investigational medicinal product within 30 days of screening~* Ongoing toxicity \> grade 2 from previous standard or investigational therapies, according to US National Cancer Institute's",,,t,f,t
6260134,NCT06290037,,ALL,65 Years,,t,,Inclusion Criteria:~* Individuals over the age of 65 who are currently driving.~* Individuals capable of understanding and following the researcher's instructions.~* Individuals who can understand the purpose of the research and have consented to participate~Exclusion Criteria:~* Those who have not signed the consent form.~* Individuals with a history of severe dizziness or epilepsy.~* Patients with restrictions on sitting in a wheelchair or chair for more than 30 minutes.~* Patients with severe shoulder pain.~* Patients whose range of motion in major joints is restricted by more than 50%.~* Pregnant women.~* Patients with pressure sores.~* Patients with limitations on simulator use due to heterotopic ossification.~* Patients with acute fractures.~* Other patients for whom participation in the study is expected difficult.,,,f,f,t
6260135,NCT05299437,,ALL,18 Years,,f,,"Inclusion Criteria:~* Histo-pathological diagnosis of DTC~* At least one documented non surgically-curable soft-tissue metastasis previously untreated~* ECOG performance status = 0 - 1~* Life expectancy \> 6 months~* Females of childbearing age must have negative serum pregnancy test prior to registration and agree to use birth control throughout the study and for 6 months after completion of therapy~* Preserved hematologic and renal function (hemoglobin \> 10 g/dL; WBC \> 3500/uL; neutrophils \> 50%; PLT \> 100000/uL; albumin ≥ 2.5 g/dL; creatinine ≤ 2 mg/dL)~* Signed informed consent~Exclusion Criteria:~* All lesions surgically resectable~* Minimal lymph nodal disease (diameter \< 1 cm, up to 2 nodes)~* Patient with skeletal metastases only~* Lung diffuse miliary micro-metastases~* Ongoing pregnancy~* Breast-feeding (enrollment could be considered after suspension)~* Refusal of male and female patients to use an effective contraception method during the study and for 6 months after completion of protocol therapy~* Impossibility to undergo follow-up procedures~* Presence of medical, psychiatric or surgical condition, not adequately controlled by treatment, which would likely affect subjects' ability to complete the protocol~* Assumption of any anti-tumor therapy including chemotherapy, biological or investigational drug treatments~* Assumption of any myelotoxic drugs~* Previous or concomitant assumption of Amiodarone~* Any other oncologic disease that required treatment in the last 5 years.~* Participation in a clinical trial in which an investigational drug was administered within 30 days or 5 half-lives prior to the study drug.",,,t,f,t
6260136,NCT06175858,,ALL,,,f,,"Inclusion Criteria:~* Red flags include any one of the following:~Clinical Red flags:~* Bilateral carpal tunnel syndrome (30).~* Popeye sign, rupture of long head of the biceps tendon.~* Lumbar spinal canal stenosis in association with unilateral carpal tunnel syndrome (31).~Echocardiographic/imaging Red Flags~* LV wall thickness ≥ 12 mm and heart failure in men \> 60 y/ women \> 70y.~* LV wall thickness ≥ 12 mm and AV-Block or pacemaker.~* Infiltrative phenotype (biventricular hypertrophy, thickening of cardiac valves, pericardial effusion, thickening of the interatrial septum).~* LV wall thickness ≥ 12 mm and low voltage on ECG.~* Paradoxical low flow/low gradient aortic stenosis.~Exclusion Criteria:~- 1. Patient who refuse to give a consent to the following investigations. 2. Patient with any contra-indication to undergo CMR, or bone scintigraphy will be excluded e.g., non compatible implantable cardiac devices, claustrophobic, severe kidney function impairment.~3. Patient with established diagnosis of other infiltrative cardiac disease.",,,t,t,t
6159069,NCT02836418,,ALL,16 Years,25 Years,f,,"Inclusion Criteria:~1. Enrolled in and completed the treatment period in the parent study.~2. Demonstrated, in the Sponsor's and Investigator's opinions, acceptable tolerability of ATYR1940.~3. In the Investigator's opinion, participant has shown acceptable compliance with ATYR1940 and the study procedures in the parent study and is willing and able to comply with all procedures in the current study.~4. Is, in the opinion of the Investigator and Sponsor, a suitable candidate for continued ATYR1940 treatment.~5. Provide written informed consent or assent after the nature of the study has been explained and prior to the performance of any research-related procedures.~Exclusion Criteria:~1. Is expected to require treatment with curcumin or systemic albuterol (intermittent inhaled albuterol is permissible) during study participation; or use of a product that putatively enhances muscle growth (for example, insulin-like growth factor, growth hormone) or activity (for example, Coenzyme Q, Coenzyme A, creatine, L-carnitine) on a chronic basis; or statin treatment initiation or significant adjustment to statin regimen (stable, chronic statin use is permissible).~2. Planned to receive any vaccination during study participation.~3. Abnormal baseline findings, medical condition(s), or laboratory findings that, in the Investigator's opinion, might jeopardize the participant's safety or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.~4. Evidence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, metabolic, dermatological, or gastrointestinal disease, or has a condition that requires immediate surgical intervention, other treatment, or may not allow safe participation.~5. If female and of childbearing potential (premenopausal and not surgically sterile), has a positive pregnancy test at entry or is unwilling to use contraception from the time of entry through the 3-month Follow-up visit. Acceptable methods of birth control include abstinence, barrier methods, hormones, or intra-uterine device.~6. If male, is unwilling to use a condom plus spermicide during sexual intercourse from the time of entry through the 1 month Follow-up visit.",,,t,t,f
6260137,NCT05077488,,ALL,18 Years,,f,,"Inclusion Criteria:~1. Male or female, 18 years of age or older.~2. Signed the Independent Ethics Committee (IEC)-approved informed consent form prior to any studyrelated procedures being performed.~3. Eligible for treatment in at least one of the following treatment areas:~   1. Juvéderm VOLIFT treatment of skin depressions in the marionette lines:~      * Grade 1, 2, 3 or 4 on both sides at baseline in the Allergan Marionette Line Scale~     * Juvéderm VOLIFT is permitted in the oral commissures, at the discretion of the subject and investigator~  2. Juvéderm VOLIFT treatment for irregularities of forehead contouring as assessed by the investigator and is likely to see improvement~4. Accept the obligation not to receive any other facial procedures or treatments anywhere in the face during the study that are not related to the study.~5. Women of childbearing potential must have a negative urine pregnancy test before each injectable treatment and practice a reliable method of contraception throughout the study.~6. Ability to follow study instructions and likely to complete all required visits and assessments, as assessed by the Investigator.~7. Affiliated to a health social security system.~Exclusion Criteria:~In terms of population~1. Females who are pregnant, nursing, or planning a pregnancy.~2. Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.~3. Subject in a social or sanitary establishment (socially or mentally vulnerable).~4. Current enrolment in an investigational drug or device study, participation in such a study within 6 weeks before enrollment, or be planning to participate in another investigation during the course of this study.~5. Is an employee (or immediate relative of an employee) of the Investigator, study staff, Allergan, or a representative of Allergan.~6. In France: subject having received 4500 euros indemnities for participation in researches involving human beings in the 12 previous months, including participation in the present study.~   In terms of associated pathology~7. Has a history of multiple or severe allergies, anaphylaxis, atopy, or allergy to lidocaine, HA products, or Streptococcal protein, or is planning to undergo desensitization therapy during the study.~8. Has an active inflammation or infection (acne, herpes,...), cancerous or precancerous lesion, or unhealed wound.~9. Subject with history of hypertrophic scarring~10. Has porphyria.~11. Has epilepsy.~12. Has impaired cardiac conduction, severely impaired hepatic function, or severe renal dysfunction.~13. History of, or currently suffering from, autoimmune disease or autoimmune deficiency or being under immunosuppressive therapy.~14. History of streptococcal disease (recurrent sore throats, acute rheumatic fever).~15. Has any uncontrolled disease.~16. Has any condition or is in a situation that, in the Investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study. Relating to previous or ongoing treatment~17. Has ever undergone facial plastic surgery or received permanent facial implants (e.g., polymethylmethacrylate, silicone, polytetrafluoroethylene, threads) anywhere in the face, or is planning to be implanted with any of these products during the study.~18. Has undergone semi-permanent dermal filler treatment (e.g., hyaluronic acid, calcium hydroxyapatite, poly-L-lactic acid) in the face within 12 months before enrolment or is planning to undergo such treatment during the study.~19. Has undergone mesotherapy or cosmetic resurfacing (laser, photo-modulation, intense pulsed light, radiofrequency, dermabrasion, chemical peel, or other ablative or non-ablative procedures) anywhere in the face or neck, or Botulinum toxin injections in the face within 6 months before enrolment or is planning to undergo any of these procedures during the study.~20. Has begun using any over-the-counter or prescription, oral or topical, anti-wrinkle products within 90 days before enrolment or is planning to begin using such products during the study (subjects who have been on a regimen of such products for at least 90 days are eligible for the study if they intend to continue their regimen throughout the study).~21. Is on an ongoing regimen of anti-coagulation therapy (e.g., warfarin) or non-steroidal antiinflammatory drugs (NSAIDs) (e.g., aspirin, ibuprofen) or other substances known to increase coagulation time (e.g., herbal supplements with garlic or gingko) within 10 days of undergoing study device treatment (study treatment may be delayed as necessary to accommodate this 10- day washout period).~22. Is on a concurrent regimen of lidocaine or structurally related local anaesthetics (e.g., bupivacaine).~23. Is on an ongoing treatment that reduce or inhibit hepatic metabolism (cimetidine, beta-blockers, etc.).",,,t,f,t
6260138,NCT04833907,,ALL,3 Months,60 Months,f,,"Inclusion Criteria:~* Definitive diagnosis of typical CD by a board certified neurologist.~* Written informed consent from parent(s)/guardian(s). Consent to enroll into the study will include a written agreement to comply with all the conditions of the study, including attendance at follow-up visits.~* For cohort 1: age more than 36 months and up to 60 months.~* For cohort 2: age between 15 months and 36 months.~* For cohort 3: age less than 15 months.~Exclusion Criteria:~* At the discretion of the PI, any significant chronic medical condition, including, but not limited to neurological, cardiac, hepatic, renal, hematological, gastrointestinal, endocrine, pulmonary, or infectious disease, which would put the subject at increased risk during surgery or which would interfere with participation in the study, interpretation of safety monitoring, or the integrity of the study data.~* History of severe allergic reaction or anaphylaxis.~* Past participation in gene therapy trials or receipt of any other investigational product within 6 months prior to enrollment.~* Prior intracranial surgery.~* Any absolute contraindication to immunosuppression.~* Any absolute contraindication to MRI.~* Any vaccination less than 1 month prior to gene therapy.~* Anticipated life expectancy of less than 12 months for any reason.~* GMFM-88 total raw score \>35%.~* Clinically significant out-of-range lab values, at the discretion of clinical PI.",,,f,t,f
6260139,NCT05722171,,ALL,18 Years,,f,,"Inclusion Criteria:~* (1) Age≥ 18 years old, gender is not limited;~* (2) expected survival time≥ 3 months;~* (3) ECOG score 0-1 points;~* (4) Acute myeloid leukemia was clearly diagnosed during screening, and tumor cells were positive for B7-H3 expression;~* (5) Subjects with relapsed/refractory acute myeloid leukemia who have failed standard treatment or lack effective treatment methods.~* (6) Coagulation function, liver and kidney function, cardiopulmonary function meet requirements.~* (7) Be able to understand the trial and have signed the informed consent form.~Exclusion Criteria:~* (1) Malignant tumors other than acute myeloid leukemia within 5 years before screening;~* (2) Those who test positive for virus and syphilis;~* (3) Severe heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association \[NYHA\] classification≥ grade III), severe arrhythmia;~* (4) Unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment;~* (5) Active infection or uncontrollable infection requiring systemic treatment within 7 days prior to screening;~* (6) pregnant or lactating women, female subjects who planned to become pregnant within 2 years after cell reinfusion or male subjects whose partners planned to become pregnant within 2 years after their cell reinfusion;~* (7) Subjects who were receiving systemic steroid therapy within 7 days prior to the year or who were judged by the investigator to require long-term systemic steroid therapy during treatment (other than inhalation or topical use);~* (8) Have participated in other clinical studies within 1 month before screening;~* (9) There was evidence of central nervous system invasion during subject screening, such as tumor cells detected in cerebrospinal fluid or imaging showing central infiltration;~* (10) Those who have graft-versus-host response and need to use immunosuppressants;~* (11) Those with a history of epilepsy or other central nervous system diseases;~* (12) Patients with primary immunodeficiency diseases;~* (13) situations that other investigators consider unsuitable for enrollment.",,,t,f,t
6260140,NCT03098407,,FEMALE,18 Years,,t,,"Inclusion Criteria:~* Pregnant women 18+ years old, with a singleton pregnancy ≤ 28 weeks gestation confirmed by ultrasound, who meet Diagnostic and Statistical Manual-IV criteria for opioid dependence confirmed by urine drug screen (UDS), who are interested in opioid maintenance treatment and plan to receive prenatal care and deliver at Magee Womens Hospital (MWH) will be recruited.~Exclusion Criteria:~* (1) active, current dependence on benzodiazepines or alcohol~* (2) acute severe psychiatric condition in need of immediate treatment (e.g. suicidal ideations)~* (3) pending or legal action that could prohibit or interfere with participation (e.g. incarceration)~* (4) current, established treatment with methadone or buprenorphine. Exclusion criteria are based on the Substance Abuse and Mental Health Services Administration (SAMHSA) recommendations for office-based buprenorphine use.",,,t,f,t
6260141,NCT05708378,,ALL,40 Years,60 Years,f,,"Inclusion Criteria:~* Both genders~* Age: between 40-60 years.~* Unilateral hemiplegia.~* ACA and MCA lesions only.~* Subacute and chronic stroke patients.~* First time affected.~* No visual and sensory deficits.~* Ambulatory stroke patients scoring 21 to 40 on Berg Balance Scale.~* Scoring \> 21 on MMSE.~Exclusion Criteria:~* ● Any other neurological deficits as multiple sclerosis, Parkinsons disease etc.~  * Any musculoskeletal disorders like OA, ligament injury etc.~ * Non-ambulatory patients",,,t,f,f
6159070,NCT06450119,,ALL,50 Years,100 Years,f,,"Inclusion Criteria:~1. age more than 50 years;~2. with physical frailty identified as The FRAIL Scale ≥1~3. subjective cognitive decline(subjective memory complain ≥3);~4. with literacy;~5. without regular exercise habits (\<150 minutes/weekly);~6. without receiving cognitive training~Exclusion Criteria:~1. incapable of walking independent;~2. with diagnosis of cancer, dementia,neurological diseases (e.g., stroke, head injury, and brain tumor), psychiatric disorders (e.g.,depression, bipolar, and schizophrenia), cardiac infraction,and hemodialysis.",,,t,f,t
6260142,NCT01512537,,ALL,15 Years,70 Years,t,,"Inclusion Criteria:~* Vitamin D deficiency (\< 25 nmol/l)~* Age 15 or above~Exclusion Criteria:~* Travel south of 45 degrees latitude during the trial.~* Ongoing treatment with vitamin D supplementation.~* Intake of light sensitive medicine, such as tetracyclins.~* Skin light eruptions",,,t,t,t
6159071,NCT05509218,,ALL,18 Years,29 Years,t,,Inclusion Criteria:~* Age 18-29 years~* Own a smartphone and use it daily~* Heavy episodic drinking (4+/5+ drinks for women/men) at least weekly in past month~* At least one of 10 negative consequences assessed~* at least somewhat willing to consider drinking even a little less than current~Exclusion Criteria:~* current participation in treatment for an alcohol or other substance use disorder~* participation in an earlier phase of the study~* enrollment in ongoing alcohol studies at the same university,,,t,f,f
6260143,NCT04078516,NON_PROBABILITY_SAMPLE,ALL,18 Years,70 Years,t,"The study population include four well-defined groups of subjects:~1. Patients with Type 1 diabetes and painful diabetic peripheral neuropathy (DPN).~2. Patients with Type 1 diabetes and non-painful diabetic peripheral neuropathy (DPN)~3. Patients with Type 1 diabetes and without diabetic peripheral neuropathy (VPT\<15) (DPN).~4. Healthy control subjects matched for age, BMI, and gender. Diabetes duration, HbA1c, insulin use, ethnicity, and co-morbidities will be matched between group 1, 2 and 3 to best ability.","Inclusion Criteria:~1. Men and women minimum 18 years of age and maximum 75 years of age~2. Signed informed consent form~3. Diagnosed with diabetes type I (for group 1-3)~4. Diagnosed with DPN defined as a threshold above 25-volt biothesiometry or absent feeling on the big toe using 10g-monofilament. (for group 1-2)~5. Answered questionnaire: PainDETECT~6. Nothing abnormal on initial tests (group 4)~7. Accepted initial screening blood samples~8. MRI-compatible participant~Exclusion Criteria:~* 1. Current or previous alcohol- or drug abuse 2. Abnormal screening blood samples 3. Not being able to understand Danish written and/or verbally 4. Not being able to corporate to examination (e.g. not being able to speak, suffering from senile dementia etc.) 5. Previous chemotherapy or intake of experimental medicine 6. Active HSV- or VZV-infection or known HIV 7. Known severe skin disease 8. Known neural damage or disease in the neural system (e.g. MS, Guillain-Barre etc.) 9. Critical limb ischemia defined as in current clinical consensus 10. Allergy or intolerance to histamine or inability to make do without for one day 11. Pregnancy 12. Active cancer-disease",,,t,f,t
6057067,NCT01567410,,ALL,18 Years,67 Years,t,,"Inclusion Criteria:~* registered nurse and postgraduate nurse working at somatic ward, emergency ward, surgical department, intensive care unit,recovery, nursinghome or homecare~Exclusion Criteria:~* working at maternity ward, pediatric ward, psychiatric ward",,,t,f,t
6058734,NCT00988390,,FEMALE,18 Years,,f,,"Inclusion Criteria for Intervention/Control, mother living with HIV:~* Mother or primary female caregiver~* Enrolled in HIV-related clinical cares~* At least one child between the age of 6 and 20 years~Inclusion Criteria for neighborhood control, non-HIV-affected mother:~* Mother or primary female caregiver~* not HIV-positive~* At least one child between the age of 6 and 20 years~Exclusion Criteria (Intervention/Control/Neighborhood):~* Mother less than 18 years old~* Unable or willing to give informed consent~* Psychosis or neurological damage as judged by the investigator in consultation with clinical supervisor",,,t,f,t
6159072,NCT01934218,,ALL,40 Years,80 Years,f,,Inclusion Criteria:~* Have a knee pain~* Grade 1 to 3 on the Kellgren-Lawrence grading scale~Exclusion Criteria:~* BMI greater than 35 kg/m2~* Received an intra-articular hyaluronic acid injection for the treatment of OA of the knee within 6 months prior to screening~* Had a joint replacement of the target knee,,,t,f,t
6159073,NCT06213818,,ALL,18 Years,55 Years,t,,"Inclusion Criteria:~* Ability to comprehend and willingness to sign a written ICF for the study.~* Age 18 to 55 years, inclusive, at the time of signing the ICF.~* Body mass index between 18.0 and 32.0 kg/m2 (inclusive).~* Willingness to adhere to study-related prohibitions, restrictions, and procedures.~* Ability to swallow and retain oral medication.~* Willingness to avoid pregnancy or fathering children based on the criteria below.~  * Male participants with reproductive potential must agree to use 1 of the highly effective methods of contraception to avoid fathering children from screening through the last follow-up visit and must refrain from donating sperm during this period. Permitted methods in preventing pregnancy should be communicated to the participants and their understanding confirmed.~ * Female participants who are WOCBP must have a negative pregnancy test at screening and check-in, must agree to use 1 of the highly effective methods of contraception to avoid pregnancy from screening through the last follow-up visit, and must refrain from donating oocytes during this period.~Permitted methods in preventing pregnancy should be communicated to the participants and their understanding confirmed. Positive pregnancy tests may be confirmed at the investigator's discretion.~• Female participants not considered to be of childbearing potential are eligible and must have a negative pregnancy test at screening and check-in.~Exclusion Criteria:~* History of uncontrolled or unstable cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening.~* History of rheumatologic/autoimmune disorders and immune deficiency/immunologic defects.~* Prior history of major bleeding or thrombosis, including myocardial infarction/stroke and pulmonary embolism/deep vein thrombosis.~* Known tuberculosis infection that is active or participant-reported history of tuberculosis or treatment thereof.~* Resting pulse \< 40 bpm or \> 100 bpm, confirmed by repeat testing at screening.~* History or presence of an abnormal ECG before initial dose administration that, in the investigator's opinion, is clinically significant (QTcF interval \> 450 milliseconds, QRS interval \> 120 milliseconds, and PR interval \> 220 milliseconds).~* Presence of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn disease or chronic pancreatitis).~* Hemoglobin level, WBC count, platelet count, or absolute neutrophil count below the laboratory lower limit of normal at screening or at check-in, confirmed by repeat testing and clinically significant in the opinion of the investigator.~* Hepatic transaminase (ALT and AST), ALP, or total bilirubin levels \> 1.25 × the laboratory-defined ULN at screening or at check-in, confirmed by repeat testing (except participants with Gilbert disease, for which total bilirubin must be ≤ 2.0 × ULN).~* History of malignancy within 5 years of screening, with the exception of cured basal cell or squamous cell carcinoma of the skin, ductal carcinoma in situ, or prostate cancer.~* Current or recent (within 3 months of screening) clinically significant gastrointestinal disease or surgery (including cholecystectomy) that could affect the absorption of study drug, with the exception of appendectomy.~* Any major surgery within 12 weeks of screening.~* Donation of blood to a blood bank within 4 weeks of screening (within 2 weeks for plasma only).~* Blood transfusion within 4 weeks of check-in.~* Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment.~* Positive test for hepatitis B virus, hepatitis C virus, or human immunodeficiency virus.~Note: Participants whose results are compatible with prior immunization or immunity due to infection for hepatitis B may be included at the discretion of the investigator.~* Regular alcohol consumption \> 21 units per week (1 unit = ½ pint beer or a 25-mL shot of 40% spirit, 1.5 to 2 units = 125-mL glass of wine, depending on type).~* Positive urine or breath test for ethanol or positive urine or serum screen for drugs of abuse that are not otherwise explained by permitted concomitant medications or diet.~* Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug with another investigational medication or current enrollment in another investigational drug protocol.~* Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug with an inducer or inhibitor of CYP3A4, P-gp, or BCRP (refer to the Drug Interaction Database for prohibited drugs).~* History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.~* Known hypersensitivity or severe reaction to INCB160058 or any excipients of INCB160058 (refer to the IB).~* Inability to undergo venipuncture or tolerate venous access.~* Inability or unlikeliness of the participant to comply with the dose schedule and study evaluations, in the opinion of the investigator.~* Use of tobacco- or nicotine-containing products within 1 month of screening.~* Use of prescription drugs (including oral, implantable, transdermal, injectable, intravaginal, or hormonal intrauterine contraceptives) or topical steroids within 14 days prior to study drug administration or nonprescription medications/products (including vitamins, minerals, and phytotherapeutic, herbal, or plant-derived preparations) within 7 days prior to study drug administration and during the study.~Note: Occasional use of acetaminophen (see Section 6.6.1) is permitted during the study.~* Women who are pregnant or breastfeeding.~* eGFR \< 90 mL/min/1.73 m2 based on the Chronic Kidney Disease Epidemiology Collaboration formula.~* Any history of hypersensitivity or intolerance to esomeprazole or any other PPI.~* Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.",,,t,f,f
6159074,NCT05354518,,ALL,,,t,,"Inclusion Criteria:~* Agreeing to participate in the research,~* Being a midwifery 3rd year student and taking the risky pregnancy course,~* Those who have no previous clinical experience in GDM (Health College, Health Vocational High School Graduate, etc.)~Exclusion Criteria:~* To fill in the data collection forms of the study incompletely,~* Not participating in all applications of simulation training with high proximity to reality,~* Desire to leave the research.",,,t,t,t
6159075,NCT03726918,NON_PROBABILITY_SAMPLE,ALL,40 Years,,,Male and female patients of age \>40 years undergoing surgery of endo or arthroplasty for osteoarthritis or ifor other causes requiring the implantation of a prosthesis,Inclusion Criteria:~1. Male and Female patients \> 40 years old hospitalized for surgery of endo- or arthroplasty for Osteoarthritis or for surgery for joint traumatic diseases (eg femoral neck fractures) requiring the implantation of a prosthesis~2. Interval of at least three months from any previous infiltrative treatment of any kind;~3. Patients able to provide written informed consent to the study.~Exclusion Criteria:~1. Severe cognitive defects or psychiatric disorders;~2. Tumor pathologies or concurrent antineoplastic therapies;~3. Autoimmune diseases (rheumatoid arthritis);~4. Surgery that involves the joint,,,t,f,t
6159076,NCT01799252,NON_PROBABILITY_SAMPLE,FEMALE,,,t,"This study will enroll 610 women. Women will be recruited from 5 clinics and will self-administer, or if necessary, a study coordinator will administer, a computer-based questionnaire 7-14 days following administration of mifepristone.","Inclusion Criteria:~* Women who are having MA at the study clinic and are willing to complete a self-administered, computer-based questionnaire 7-14 days after taking mifepristone~* Women who can read English or Spanish~* In the doxycycline arm: Women who have been prescribed doxycycline~Exclusion Criteria:~* Women who were treated with antibiotics for a medical condition unrelated to their medical abortion between the initial visit and follow-up appointment~* Women who have previously enrolled in this study",,,t,t,t
6159077,NCT05902052,,ALL,18 Years,95 Years,f,,"Inclusion Criteria:~* Patient with sternotomy who underwent Coronary Artery Bypass Graft surgery,~* Patient with sternotomy who underwent valve surgery,~* Being 18 years or older,~* Volunteering to participate in the research,~* Being at a level to adequately answer the questions asked cognitively,~* Experiencing pain at least once after the surgery,~* No complications (unable to wean from mechanical ventilator support, inability to discontinue inotropic support) until the period of transfer to the postoperative service.~Exclusion Criteria:~* Desiring to leave the study group during the conduct of the research,~* Delirium development in the patient during the conduct of the study,~* The patient for whom emergency surgery has been decided.",,,t,f,t
6159078,NCT01666418,,ALL,18 Years,,f,,"Inclusion criteria:~* Age ≥ 18 years~* Diagnosis of histologically or cytologically confirmed melanoma stage III or IV.~* Fresh tumor tissue must be provided for all subjects for biomarker analysis before (within 14 days prior to treatment start) and during (on day 10 of the pazopanib monotherapy and the last day of the treatment with pazopanib, day 70) treatment with investigational product (asservation in RNAlater, for kryo asservation, and for cell cultures)~* Assessable metastases (skin or superficial lymph nodes with a minimal diameter 1 cm)~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~* Adequate organ system function~Exclusion criteria:~* Prior malignancy.~* Central nervous system (CNS) metastases~* Corrected QT interval (QTc) \> 480 msecs using Bazett's formula.~* History of any one or more of the following cardiovascular conditions within the past 6 months:~  * Cardiac angioplasty or stenting;~ * Myocardial infarction;~ * Unstable angina;~ * Coronary artery bypass graft surgery;~ * Symptomatic peripheral vascular disease;~ * Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA).~* Poorly controlled hypertension~* History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.~* Presence of uncontrolled infection~* Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding~* Evidence of active bleeding or bleeding diathesis~* Any ongoing toxicity from prior anti-cancer therapy that is \>Grade 1 and/or that is progressing in severity, except alopecia.~* Prior exposure to the study drug pazopanib",,,t,f,t
6159079,NCT00974818,,ALL,18 Years,,f,,"Inclusion Criteria:~* Age 18 years or older~* Patients must have pathologically confirmed non-muscle invasive urothelial bladder carcinoma by the Department of Pathology New York Presbyterian Hospital, Weill Medical College of Cornell University or Memorial Sloan Kettering Cancer Center or a documented past history of Ta or T1 non-muscle invasive urothelial bladder tumors.~* Intermediate Risk UBC patients: Recurrence Total Score = 1 to 9~Exclusion Criteria:~* Any intravesical therapy within the past six months prior to current diagnosis~* Currently being treated or scheduled to have radiation treatment for bladder cancer during the study~* Scheduled to have surgery for bladder cancer during the study~* Currently being treated or scheduled to have treatment with any chemotherapeutic agent during the study",,,t,f,t
6159080,NCT02000518,NON_PROBABILITY_SAMPLE,ALL,18 Years,80 Years,f,histologically confirmed non-small cell lung cancer and bone metastases of the thoracic or lumbar segments of the vertebral column,"Inclusion Criteria:~* Inclusion criteria are an age of 18 to 80 years, acute neurological symptom caused by metastatic spinal cord compression, no RT in this spinal area before, and written consent to participate.~Exclusion Criteria:~* neurological symptom more than 12 hours before",,,t,f,t
6260144,NCT05344456,,ALL,18 Years,100 Years,f,,"Inclusion Criteria:~* ST Jude Medical or Abbott physiological ICD or CRT-D device~* PVC response setting ''Atrial Pace''~* Atrial tachycardia episode duration \> 30s preceded by ventricular extrasystole and atrial pace in year 2020 or 2021~Exclusion Criteria:~* Permanent atrial fibrillation, duration ≥ 6 months before the enrollment to the study~* PVC response has been switched off before enrollment",,,t,f,t
6260145,NCT02127437,,ALL,18 Years,,f,,"Inclusion Criteria:~* autosomal dominant polycystic kidney disease (clinical, familial, imaging grounds)~* measured GFR : 30 to 89 ml/mn/1.73m2~* age \> 18~* affiliated with health insurance~* written informed consent~Exclusion Criteria:~* iohexol /iodine allergy~* diabetes mellitus~* other associated nephropathy suspected~* evolutive or recent malignant disease ( in the previous 5 years)~* cholelithiasis~* uncontrolled hypertension (BP\>160/100 mmHg)~* cardiac failure of grade III or IV according to the NYHA (New York Heart Association) classification~* liver failure~* psychiatric illness~* pregnancy, lactation, lack of contraception~* use of somatostatin analogs during the last 6 months",,,t,f,t
6260146,NCT05044156,PROBABILITY_SAMPLE,FEMALE,18 Years,50 Years,t,"women with regularly menstrual cycle, diagnosed candidal vaginosis and not have any vaginal infection.","Inclusion Criteria: women with regularly menstrual cycle , diagnosed candidal vaginosis and not have any vaginal infection.~-~Exclusion Criteria: diabetes, immun deficiency, menopause, premature ovarian failure, pregnancy, virgin~-",Female,t,t,f,f
6159081,NCT02753452,,ALL,14 Years,21 Years,f,,"Inclusion Criteria:~* All youth must be between 14 and 21 years of age, have a child-onset disability, be able to set goals for themselves, and speak English.~* Parents who are enrolled must speak English.~Exclusion Criteria:~* Youth with severe behavioral issues will be excluded, since these would restrict the youth's ability to participate in a group learning experience.",,,t,t,f
6159082,NCT05522491,,FEMALE,18 Years,70 Years,f,,"Inclusion Criteria:~* 1. Age 18-70 years old, female; 2. Histologically confirmed recurrent and metastatic TNBC patients without BRCA1/2 mutation and BRCA1 promoter methylation.~Note: Triple-negative breast cancer is defined as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2) negative. ER and PR negative were defined as: ER\<1% positive, PR\<1% positive. HER2 negativity was defined as: HER2 (-) or (1+) or HER2 (2+) FISH negative by immunohistochemistry.~3. The number of treatment lines at the stage of recurrence and metastasis should not exceed 2 lines.~4. According to RECIST1.1 criteria, there is at least one evaluable lesion; 5. ECOG physical condition score ≤ 1 point; 6. Expected survival period ≥ 3 months;~Exclusion Criteria:~* 1. Pregnant, breastfeeding women, or those who are fertile and unwilling to take effective contraceptive measures; 2. Patients who have received chemotherapy, radiotherapy, targeted therapy and other anti-tumor treatments within 4 weeks before enrollment; 3. Previous use of PARP inhibitors, including olaparib and other PARP inhibitors; 4. Known serious cardiovascular disease, myocardial infarction, or arterial thrombosis, or unstable angina pectoris, or known heart failure in the past 6 months, QT interval\>450ms; 5. The toxicity of the previous treatment regimen has not recovered before enrollment, and there are still toxic reactions of grade 1 or above (except for alopecia); 6. Clinically obvious gastrointestinal abnormalities that may affect the intake, transport or absorption of drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.) or patients with total gastrectomy; 7. Patients with known or suspected brain metastases, including central nervous system and spinal cord compression or meningeal metastases; 8. History of severe central nervous system disease (including epilepsy patients); 9. In the past 5 years, suffering from a second primary malignant tumor other than breast cancer and receiving related treatment; 10. Known congenital or acquired immunodeficiency, active hepatitis, active tuberculosis and other active infections; 11. Patients who are allergic to this test drug or similar drugs; 12. Those who have participated in clinical trials of other drugs within 28 days before screening, or plan to participate in any other clinical trials during this study; 13. Any other disease or condition of clinical significance (such as active or uncontrolled infection, etc.) that the investigator believes may affect compliance with the protocol or affect the patient's signing of ICF",,,t,f,t
6159083,NCT03019991,,ALL,18 Years,45 Years,t,,"Inclusion Criteria:~* Willing and able to provide written informed consent~* Healthy men or women based on history, physical examination, laboratory examination and ECG.~* Negative serum or urine pregnancy test result (sensitivity of 25 mIU or better) for women with childbearing potential within the 24-hour period before the first dose of study drugs~* Female patients with childbearing potential (menopause within 1 year) must agree to use two reliable forms of effective non-hormonal contraception (i.e., condoms, cervical barriers, intrauterine device, spermicides, or sponge), at least 1 of which must be a physical barrier method, during treatment and for at least 6 months following the last dose of ribavirin~* All male patients with female partners of childbearing potential must use two reliable forms of effective contraception (combined) during treatment and for 6 months following the last dose of ribavirin~* Others as specified in the detailed protocol~Exclusion Criteria:~* Have medical history, or has disease, such as cardiovascular system, respiratory system, endocrine and metabolic system, urinary system, digestive system, blood system, nerve system disease or psychiatric disease and acute or chronic infectious diseases and malignant tumors.~* Has a history of drug or food allergy.~* Positive hepatitis A antibody，positive hepatitis B surface antigen， positive hepatitis C antibody，syphilis antibody or HIV antibody at screening.~* Had gastrointestinal surgery, vagotomy, intestinal resection or any possible interference with gastrointestinal peristalsis, pH or absorbed by surgery.~* Pregnant, lactating or menstrual period and unwilling to reliable contraception period women of childbearing age.~* Female partners have fertility and reliable contraceptive measures of men.",,,t,f,f
6159084,NCT01034891,NON_PROBABILITY_SAMPLE,FEMALE,18 Years,,f,patients of the breast center at New York Presbyterian Hosptial/ Columbia University Medical Center,"Inclusion Criteria:~* one or more first-degree relatives (mother, daughter, or sister) with pre-menopausal breast cancer~* two or more first-degree relatives with post-menopausal breast cancer~* tested positive for a BRCA1 or BRCA2 mutation~* a history of biopsy-proven atypical ductal hyperplasia or atypical lobular hyperplasia~* a history of biopsy-proven lobular neoplasia (lobular carcinoma in situ)~Exclusion Criteria:~* DCIS (ductal carcinoma in situ)~* previous diagnosis of breast cancer",,,t,f,t
6260147,NCT05520307,NON_PROBABILITY_SAMPLE,ALL,18 Years,,,Patients with heart failure: HFrEF (LVEF \< 40%) and NYHA I-III.~And~Patients with Ischemic heart disease,Inclusion Criteria:~* Fulfilling the guidelines for rehabilitation sat out by the Danish Society of Cardiology.~* Approved for exercise testing on a cycle ergometer by a specialized doctor in cardiology.~Exclusion Criteria:~* Absolute contraindications with training~* Conditions that prevent maximal exercise testing assess by a specialized doctor in cardiology.,,,t,f,t
6260148,NCT04469478,,ALL,18 Years,,t,,"Inclusion Criteria:~* Willingness to sign and date the consent form.~* Willingness to comply with all study procedures and be available for the duration of the study.~* Male or female patient 18 years or older.~* Available diagnostic imaging (MRI, CT and/or PET)~* Consultation in radiation oncology for consideration of radiation therapy.~* English speaking.~Exclusion Criteria:~* Inability to complete virtual reality, survey and interview.~* Non-English speaking~* Patients with visual defects that affect their ability to view content in VR",,,t,f,t
6260149,NCT00006511,,MALE,,100 Years,f,,No eligibility criteria,,,t,t,t
6260150,NCT03682978,,ALL,5 Years,17 Years,f,,"Inclusion Criteria:~1. Signed Written Informed Consent~   1. Participants or their legal representative must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal participant care. Participants who do not have the capacity to consent will give developmentally appropriate assent.~  2. Participants must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.~  3. The subject's parent/caregiver/LAR must be able to speak and understand the local language where the study is conducted sufficiently to understand the nature of the study and to allow for the completion of all study assessments. The same parent/caregiver/LAR must be capable of providing reliable information about the subject's condition, agree to oversee the administration of study drug, and accompany the subject to all clinic visits.~  4. Patient must be able to speak and understand the local language where the study is conducted sufficiently to understand the nature of the study and to allow for the completion of all study assessments.~2. Type of Participant and Target Disease Characteristics~   1. Diagnosis of an Autism Spectrum Disorder according to the DSM-5 criteria~  2. Complex language as defined in ADOS-2 to qualify for a Module 3 or 4.~  3. Current pharmacological treatment regimen affecting behaviour has been stable for at least 6 weeks prior to screening and is expected to be stable during the duration of the study~  4. Current psychotherapeutic/psychosocial interventions affecting behaviour stable for 3 months prior to screening and expected to be stable during the duration of the study (standard regular school breaks and/or annual teacher/classroom change do not qualify for intervention change).~  5. Subjects with a history of seizure disorder must currently be receiving stable treatment with anticonvulsant medication and must have been seizure free for 6 months prior to screening, or must be seizure free for 3 years prior to screening if not currently on a stable (\>3 months) dose of antiepileptics.~3. Age, Residential and Reproductive Status~   1. Male or female participants 5 to 17 years of age at the time of providing consent, inclusive.~  2. Reside with the parent/carer who is interviewed for the Vineland.~  3. Negative pregnancy test for females of childbearing potential (subject has experienced onset of menses) within 24h prior to study treatment starts.~  4. Females of childbearing potential who are sexually active must agree to use a highly effective form of contraception (i.e., existing surgical sterilization, complete abstinence, or a combination of two effective forms of contraception, such as, for example, condoms plus hormonal treatment).~  5. Male participants with female partners of childbearing potential are eligible to participate if they agree to the following conditions:~      * Inform any and all partner(s) of their participation in a clinical drug study and the need to comply with contraception instructions as directed by the investigator.~     * Male participants are required to use a condom for study duration and until end of relevant systemic exposure defined as 7 months after the end of study treatment.~     * Female partners of males participating in the study to consider use of effective methods of contraception until the end of relevant systemic exposure, defined as 7 months after the end of treatment in the male participant.~     * Male participants with a pregnant or breastfeeding partner must agree to remain abstinent from penile vaginal intercourse or use a male condom during each episode of penile penetration during the treatment and until 7 months after the end of study treatment.~     * Refrain from donating sperm for the duration of the study treatment and until 7 months after the end of study treatment.~Exclusion Criteria:~1. Medical Conditions~   a. Subjects with any condition that might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being. This includes, but is not limited to impairment of renal function, evidence or history of malignancy or any significant haematological, endocrine, respiratory, hepatic, cardiovascular or gastrointestinal disease, including any clinically significant abnormalities on ECG. In general, any co-morbid conditions that may interact with study procedures.~2. Prior/Concomitant Therapy~   1. Subjects who are currently receiving treatment with racemic baclofen, vigabatrin, tiagabine, or riluzole or other GABA-related medications (e.g. gabapentin or pregabalin). Only occasional benzodiazepine (or derivative drugs) use (PM, i.e. at night) will be allowed.~  2. Subjects who are currently receiving pharmacologic treatment affecting behaviour (see concomitant medication section) need to have a stable dose during the 6 weeks prior to the screening visit and for the duration of the study.~  3. Participating in programs including non-pharmacologic educational, behavioural, and/or dietary interventions affecting behaviour, participation in these programs must have been continuous during the 3 months prior to screening and participants or their parent/caregiver/LAR may not electively initiate new or modify ongoing interventions for the duration of the study. Typical school vacations are not considered modifications of stable programming.~  4. Subjects who have taken another investigational drug within the last 30 days.~3. Physical and Laboratory Test Findings~   a. Patients with evidence of any significant hematological, endocrine, cardiovascular (including uncorrected symptomatic congenital heart disease), respiratory, renal, hepatic, or gastrointestinal disease, not including mild common pediatric diseases in these areas that are stable (e.g. mild asthma, constipation, etc.), as judged by the investigator.~4. Study Medication Related~   1. Subjects who are not able to take oral medications.~  2. Subjects who have a history of hypersensitivity to racemic baclofen.~  3. Subjects with rare hereditary problems of galactose intolerance, the lactase deficiency or glucose-galactose malabsorption should not take this medicine.~  4. Active peptic ulceration as Baclofen stimulates gastric acid secretion.~  5. Porphyria.~5. Other Exclusion Criteria~   1. Subjects who are currently engaged in illicit drug use or alcohol abuse, according to DSM-5 criteria.~  2. Subjects who have previously participated in a clinical trial of Arbaclofen.~  3. Women who are breastfeeding.",,,f,t,f
6260151,NCT04629378,,ALL,18 Years,65 Years,f,,"Inclusion Criteria:~* Provide written, informed consent prior to all trial-related procedures including HIV testing.~* Male or female, aged between 18 and 65 years, inclusive.~* Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive.~* Newly diagnosed, previously untreated, rifampicin-susceptible pulmonary TB.~* A chest X-ray picture which in the opinion of the Investigator is consistent with TB.~* Sputum positive on microscopy for acid-fast bacilli on at least one sputum sample (at least 1+ on the IUATLD/WHO scale).~* Ability to produce an adequate volume of sputum as estimated from an overnight sputum collection sample (estimated 10 ml or more).~* Be of non-childbearing potential or using effective methods of birth control throughout participation in the study until Visit 19 (day 28).~Non-childbearing potential:~1. Female participant/sexual partner - bilateral oophorectomy, bilateral tubal ligation and/or hysterectomy or hasbeen postmenopausal with a history of no menses for at least 12 consecutive months; or~2. Male participant/sexual partner - vasectomised or has had a bilateral orchidectomy minimally three month prior to screening;~Effective birth control methods:~1. Participant - not heterosexually active or practicing sexual abstinence; or~2. Double barrier method which can include a male condom, diaphragm, cervical cap, or female condom (male and female condoms should not be used together); or~3. Barrier method combined with hormone-based contraceptives or an intra-uterine device for the female partner.~Exclusion Criteria:~* Evidence of clinically significant conditions or findings, other than the indication being studied, particularly epilepsy, that might compromise safety or the interpretation of trial endpoints, per discretion of the Investigator.~* Poor general condition where any delay in treatment cannot be tolerated per discretion of the Investigator.~* Clinically significant evidence of extrathoracic TB (miliary TB, abdominal TB, urogenital TB, osteoarthritic TB, TB meningitis), as judged by the Investigator.~* Significant history of cardiovascular disease such as heart failure, a personal or family history of congenital QT prolongation, Torsade de Pointes, or QTcF interval \> 500 ms (confirmed by repeat electrocardiogram).~* History of allergy to any of the trial IP/s or related substances i.e. β-lactams and penicillin, as confirmed by the clinical judgement of the Investigator.~* Alcohol or drug abuse, that in the opinion of the Investigator, is sufficient to compromise the safety or cooperation of the participant.~* HIV positive ONLY IF:~  * CD4 \< 350cells/mm3~ * On ART~* Having participated in other clinical studies with investigational agents within 8 weeks prior to trial start.~* Female participant who is pregnant, breast-feeding, or planning to conceive a child within the anticipated period of participating in the trial. Male participant planning to conceive a child within the anticipated period of participating in the trial.~* Subjects with diabetes (Type 1 or 2), or random glucose over 11.1 mmol/L.~* Hypersensitivity to local anaesthesia of amide type.~* Treatment received with any drug active against Mtb (including but not limited to isoniazid, ethambutol, amikacin, cycloserine, fluoroquinolones, rifabutin, rifampicin, streptomycin, kanamycin, para-aminosalicylic acid, rifapentine, pyrazinamide, thioacetazone, capreomycin, thioamides, metronidazole), or with immunosuppressive medications such as TNF-alpha inhibitors or systemic corticosteroids, within 2 weeks prior to screening.~* Participants with the following toxicities at screening as defined by the enhanced CTCEA toxicity table~  1. creatinine \>1.5 times upper limit of normal (ULN);~ 2. haemoglobin \<8.0 g/dL;~ 3. platelets equal to or \<50x10E9 cells/L);~ 4. serum potassium \<3.0 mEq/L;~ 5. aspartate aminotransferase (AST) ≥3.0 x ULN;~ 6. alanine aminotransferase (ALT) ≥3.0 x ULN;~ 7. APTT grade 3~ 8. INR grade 3~ 9. Total white cell count grade 3",,,t,f,t
6260152,NCT06270407,,ALL,18 Years,,f,,Inclusion Criteria:~* Patients are eligible to be included in the study only if all of the following criteria apply:~  1. They are to undergo a surgical procedure within the field of plastic surgery where the procedure involves use of topical TXA at the participating center.~ 2. They are over 18 years of age and capable of independently providing informed consent~ 3. They have received adequate oral and written information about the study and signed the informed-consent form~Exclusion Criteria:~* Patients with known allergy to tranexamic acid. Insufficient knowledge of national language or English.,,,t,f,t
6263718,NCT02474407,,ALL,12 Years,65 Years,f,,"Inclusion Criteria:~* Diagnosis of refractory epilepsy~* Body weight 26 to 111 kilogram (kg) inclusive~* Other inclusion criteria apply~Exclusion Criteria:~* Male or female subject who is not surgically sterile or female subject who is less than 2 years postmenopausal, and does not agree to use a highly effective birth control method during the study and up to 3 months after the last dose of investigational product~* Female subject who is pregnant, breastfeeding, or planning to become pregnant~* Presence or history of any abnormality or illness that may affect the absorption, distribution, metabolism or elimination of diazepam~* Other exclusion criteria apply",,,t,t,t
6159085,NCT05856591,,ALL,35 Years,75 Years,f,,"Inclusion Criteria:~1. Fluent in English~2. Marion County resident~3. 35-75 years~4. Systolic BP of ≥120 in prior 12 months~5. Ability to see and read street signs (self report)~6. Stable housing with independent access to kitchen, including functional stove or hotplate, oven, refrigerator, and freezer (self report)~7. Activity independence per functional activities questionnaire (FAQ; \<3 responses of Require Assistance and 0 responses of Dependent)~8. Food insecurity per first two items of USDA 18-item survey with ≥ 1 response of Often true or Sometimes true \[1) Within the past 12 months, you worried that your food would run out before you got the money to buy more; 2) Within the past 12 months, the food you bought just didn't last and you didn't have money to get more.\] OR currently listed as food insecure in Eskenazi EMR; OR currently receiving SNAP benefits.~9. normal cognition per six-item screener (SIS; score of ≥ 5)~10. At Eligibility Visit: Mean systolic BP of ≥120 from 24-hour ABPM (from a minimum of 6 daytime readings and 2 nighttime readings)~Exclusion Criteria:~1. lives in nursing home~2. diagnosis of dementia or Alzheimer disease or mild cognitive impairment; Parkinson disease; brain tumor/infection/surgery (within the last 10 years with residual symptoms and/or functional loss/deficit, such as impaired learning, memory, or communication); psychosis, schizophrenia, or bipolar disorder~3. ICD 10 code I11/hypertensive heart disease, ICD 10 code I12/hypertensive CKD, ICD 10 code I13/hypertensive heart disease and CKD, ICD 10 code I15, or ICD 10 code I16~4. alcohol consumption ≥ 8 drinks per week for women, or ≥15 drinks per week for men~5. drug use/abuse (excluding marijuana) per EMR~6. moving out of area during study timeline~7. scheduling conflicts with intervention schedule~8. unwilling to use a touchscreen~9. unwilling to be on video conferencing~10. low communicative ability, functional status, or other disorders (examiner rated) that would interfere with interventions and assessments~11. unable to provide informed consent",,,t,f,t
6159086,NCT01345591,,ALL,18 Years,,f,,"Inclusion Criteria:~1. Aged 18 years or older and able to provide informed consent~2. Have suffered injury resulting in craniofacial volume defects which could be treated with a graft volume of between 5 and 150 cc of lipoaspirate~3. Be at least 3 months post-injury or post-surgery (from trauma procedures) so that acute edema is resolved~4. Volume defects are covered by intact skin and do not communicate with oral cavity or sinuses~5. The three dimensional geometry of the volume defects would allow for treatment with lipoaspirate injection that in a manner that at least two distinct treated areas could be discerned on gross examination and radiographically (e.g. treated regions are on opposite sides of the face, on lower face versus upper face, or separated by a bony landmark such as zygoma. This would include the ability to treat an uninjured contralateral region with lipoaspirate in order to obtain symmetry.~6. Willing and able to comply with follow up examinations, including radiographic studies -~Exclusion Criteria:~1. Age less than 18 years~2. Inability to provide informed consent~3. Craniofacial defects intended for treatment have open wounds or communicate with oral cavity or sinus (note: presence of such a defect in the setting of another defect(s) that meets treatment criteria will not exclude the patient from participating).~4. Active infection anywhere in the body~5. Diagnosed with cancer within the last 12 months and /or presently receiving chemotherapy or radiation treatment~6. Known coagulopathy~7. Pregnancy -",,,t,f,t
6159087,NCT04048291,,ALL,30 Years,,f,,"Inclusion Criteria:~* Parkinson disease diagnosed by neurologist with Hoehn \& Yahr stage 2 or 3~* Having a 30-meter walking ability~Exclusion Criteria:~* Significant neurological condition (other than Parkinson's disease)~* Musculoskeletal conditions affecting gait, balance or upper limb functions~* Had received deep brain stimulation surgery~* Cognitive impairment with Montreal Cognitive Assessment score \<24~* Present with on-off motor fluctuations.",,,t,f,t
6159088,NCT04871191,,ALL,18 Years,,f,,"Inclusion Criteria:~* Newly diagnosed or relapsing granulomatosis with polyangiitis according to American College of Rheumatology criteria, EMA classification algorithm and/or the 2012 revised Chapel Hill Consensus Conference definition.~* Aged 18 years or older~* Active clinical manifestations attributable to GPA~* An inadequate response to previous standard of care therapy including~  1. Both a combination of glucocorticoids plus cyclophosphamide and a combination of glucocorticoids plus rituximab~ 2. Or an inadequate response to a combination of glucocorticoids plus rituximab and a contraindication to cyclophosphamide~* An inadequate response to treatment defined as follows:~  1. A progressive disease unresponsive to previous standard of care therapy after 12 weeks of treatment~ 2. Or a lack of response, defined as \< 50% reduction in the disease activity score, after 12 weeks of treatment~ 3. Or a persistent active disease attributable to either a vasculitic or a granulomatous manifestation of GPA that requires the maintenance of corticosteroids ≥ 7.5 mg/day of equivalent prednisone after ≥ 12 weeks of treatment.~* A stable dose of oral glucocorticoids of ≥ 7.5 mg/day of equivalent prednisone within the 4 weeks before enrollment. Pulses of methylprednisolone (1 to 3 pulses of 7.5 to 15 mg/kg each; ≤ 1000 mg) are allowed if necessary, according to severity before starting the experimental treatment.~* A stable dose of conventional disease-modifying anti-rheumatic drugs (cDMARD) within 4 weeks before enrollment if the patient is currently treated with a cDMARD~* Patients must have the ability to understand the requirements of the study, provide written informed consent prior to participation in the study (including consent for the use and disclosure of research-related health information) and comply with the study protocol procedures (including required study visits)~* Patients must have an affiliation with a mode of social security (profit or being entitled)~Exclusion Criteria:~* An allergy or hypersensitivity to monoclonal antibodies or either of the study drugs (rituximab, abatacept or tocilizumab) or to their excipients~* A previous treatment with a combination of rituximab plus a cDMARD, with abatacept, or with tocilizumab~* A contraindication to a combination of rituximab plus a cDMARD, to abatacept, or to tocilizumab (including an ongoing infection; history of recent cancer \<5 years before enrollment, except for cured non-melanoma skin cancer); pregnancy; and breastfeeding.~* Patients with severe vasculitis manifestations that requires plasma exchange therapy including severe renal failure with a creatinine level ≥350 µmol/L or severe alveolar haemorrhage~* Patients with vasculitis in remission~* Patients with symptoms attributable to chronic and non-active GPA~* Patients with severe cardiac failure defined as class IV in New York Heart Association~* Patients with acute infections or chronic active infections (including HIV, HBV or HCV)~* Patients with active cancer or recent cancer (\<5 years), except basocellular carcinoma and prostatic cancer of low activity controlled by hormonal treatment~* Pregnant women and lactation. All women with childbearing potential are required to have a negative serum pregnancy test before treatment and must agree to maintain highly effective contraception from the date of consent through the end of the study, and for women who are taking abatacept through 14 weeks after the last treatment administration, for women who are taking tocilizumab through 3 months after the last treatment administration, for women who are taking rituximab in combination with methotrexate through 6 months after the last treatment administration, for women who are taking rituximab in combination with mycofenolate mofetil or with azathioprine through 3 months after the last treatment administration~* Patients with other uncontrolled diseases, including drug or alcohol abuse, severe psychiatric diseases, that could interfere with participation in the trial according to the protocol~* Patients included in other investigational therapeutic study within the previous 3 months~* Patients suspected not to be observant to the proposed treatments~* Laboratory parameter exclusions~  1. aspartate or alanine aminotransferase (AST/SGOT or ALT/SGPT) \> 5 times upper limit of normal~ 2. Platelet count \<100.000/mm3~ 3. White blood cell count \<2000/mm3",,,t,f,t
6159089,NCT02953691,,ALL,21 Years,70 Years,t,,Inclusion Criteria:~* Patients undergoing anterior cervical discectomy and fusion~Exclusion Criteria:~* Pregnancy~* Breast Feeding Women~* Diagnosis of Depression~* Diagnosis of mental or behavioral disorder~* Recent anxiolytic use (within 1 week of enrollment)~* Long-term opiate use (greater than 1 week prior to enrollment)~* Recent systemic steroid use (within 1 week of enrollment)~* Diagnosis of cancer~* Oral or intravenous antibiotic use within 1 month of enrollment,,,t,f,t
6159090,NCT01853618,,ALL,18 Years,99 Years,f,,"-INCLUSION CRITERIA:~1. Patients must have histopathological confirmation of hepatocellular carcinoma (HCC) or (Cohort E only) biliary tract carcinoma (BTC) by the Laboratory of Pathology of the National Cancer Institute (NCI) prior to entering this study OR histopathological confirmation of carcinoma in the setting of clinical and radiological characteristics which, together with the pathology, are highly suggestive of a diagnosis of HCC (or biliary tract carcinoma in Cohort E). Fibrolammelar variant is also allowed. For cohort E, the term BTC includes intraor extrahepatic cholangiocarcinoma, gallbladder cancer or ampullary cancer, as long as there is an intrahepatic component amenable to radiofrequency ablation (RFA).~2. Patients must have disease that is not amenable to potentially curative resection, transplantation or ablation. For Cohorts A, C and D patients must have progressed on, been intolerant to, or refused prior sorafenib therapy. Cohort E patients must have received at least one line of chemotherapy for BTC.~3. Disease must be technically amenable to transhepatic arterial chemoembolization (TACE), radiofrequency ablation (RFA) or cryoablation. Each case will be discussed at gastrointestinal (GI) tumor board with interventional radiology. Patients must have evaluable disease.~4. If liver cirrhosis is present, patient must have a Child-Pugh A/B7 classification.~5. Age greater than or equal to 18 years~6. Life expectancy of greater than 3 months.~7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.~8. Patients must have normal organ and marrow function as defined below:~   * leukocytes greater than or equal to 3,000/mcL~  * absolute neutrophil count greater than or equal to 1,000/mcL~  * platelets greater than or equal to 60,000/mcL~  * total bilirubin, If cirrhosis present: Part of Child Pugh requirement. If no cirrhosis: Bili should be less than or equal to 2 times upper limit of normal (ULN)~  * Serum albumin, If cirrhosis present: Part of Child Pugh requirement. If no cirrhosis: albumin should be greater than or equal to 2.5g/dl~  * Patients are eligible with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 5 times ULN.~  * creatinine, less than 1.5 times institution upper limit of normal OR~  * creatinine clearance greater than or equal to 45 mL/min/1.73 m(2), as calculated below, for patients with creatinine levels above institutional normal~9. Patients must have recovered from any acute toxicity related to prior therapy, including surgery. Toxicity should be less than or equal to grade 1 or returned to baseline.~10. Patients must not have other invasive malignancies within the past 5 years (with the exception of non-melanoma skin cancers, non-invasive bladder cancer or localized prostate cancer for whom systemic therapy is not required).~11. Patient must be able to understand and willing to sign a written informed consent document.~EXCLUSION CRITERIA:~1. Patients who have had standard of care chemotherapy, large field radiotherapy, or major surgery must wait 2 weeks prior to entering the study. For recent experimental therapies a 28 day period of time must elapse before treatment.~2. Patients who have undergone prior liver transplantation are ineligible.~3. Patients with known brain metastases will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.~4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active systemic infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (excluding insignificant sinus bradycardia and sinus tachycardia) or psychiatric illness/social situations that would limit compliance with study requirements.~5. History of chronic autoimmune disease (e.g., Addison's disease, multiple sclerosis, Graves disease, Hashimoto's thyroiditis, rheumatoid arthritis, hypophysitis, etc.) with symptomatic disease within the 3 years before randomization. Note: Active vitiligo or a history of vitiligo will not be a basis for exclusion.~6. Dementia or significantly altered mental status that would prohibit the understanding or rendering of Information and Consent and compliance with the requirements of the protocol.~7. Diverticulitis (either active or history of) within the past 2 years. Note that diverticulosis is permitted.~8. Active or history of inflammatory bowel disease (colitis, Crohn's), irritable bowel disease, celiac disease, or other serious, chronic, gastrointestinal conditions associated with diarrhea. Active or history of systemic lupus erythematosus or Wegener's granulomatosis.~9. Currently receiving immunosuppressive doses of steroids or other immunosuppressive medications (inhaled and topical steroids are permitted)~10. History of sarcoidosis syndrome~11. Patients should not be vaccinated with live attenuated vaccines within 1 month of starting Tremelimumab treatment.~12 Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)~13. HIV-positive patients receiving anti-retroviral therapy are excluded from this study due to the possibility of pharmacokinetic interactions between antiretroviral medications and Tremelimumab. HIV positive patients not receiving antiretroviral therapy are excluded due to the possibility that Tremelimumab may worsen their condition and the likelihood that the underlying condition may obscure the attribution of adverse events.~14. History of hypersensitivity reaction to human or mouse antibody products.~15. Pregnancy and breast feeding are exclusion factors. The effects of Tremelimumab on the developing human fetus are unknown. Enrolled patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, the duration of study participation and 3 months after the end of the treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.~16. Patients with unhealed surgical wounds for more than 30 days.",,,t,f,t
6260153,NCT00002278,,ALL,12 Years,65 Years,f,,"Inclusion Criteria~Concurrent Medication:~Allowed:~* Zidovudine (AZT).~* Didanosine (ddI) allowed but discouraged, must have been stabilized on a constant dose for 3 weeks or more.~* Aerosolized pentamidine.~* Nystatin for control of oropharyngeal infections. Nystatin must not be taken within two hours of diclazuril.~* Ganciclovir therapy only for CMV retinitis is permitted if the patient has been treated for at least 4 weeks prior to study entry and is stable on the drug.~* Loperamide may be taken if patient has been on long term loperamide prior to study entry but should not be started during the course of this protocol.~Patients must have the following:~Written informed consent given after the purpose and nature of the study, as well as the possible adverse effects related to the study drug, have been explained.~* Be willing and able to return for all subsequent weekly visits and the two week visit post completion of therapy (follow-up).~Prior Medication:~Allowed:~* Diclazuril.~Exclusion Criteria~Co-existing Condition:~Patients with the following conditions or symptoms are excluded:~* Uncontrolled vomiting.~* Estimated survival less than 28 days.~* Other treatable enteric pathogens must be treated and eradicated prior to study entry.~Concurrent Medication:~Excluded:~* Amphotericin B.~* Other antibiotics or antiprotozoal drugs.~* Other investigational agents.~* Trimethoprim/sulfamethoxazole.~* Antifungal medications except nystatin.~* Ganciclovir for other than Cytomegalovirus (CMV) retinitis.~* Antidiarrheal agents other than patients on long term loperamide prior to study entry.~Patients with the following are excluded:~* Undependable in following the instructions of the investigator.~* Not able to swallow capsules.~* Uncontrolled vomiting.~* Estimated survival less than 28 days.~Prior Medication:~Excluded:~* Diclazuril within 2 weeks of study entry.",,,t,t,t
6159091,NCT05556018,,ALL,18 Years,,f,,Inclusion Criteria:~* Adult (aged 18 or above) of both sexes~* Candidate for CRT therapy according to international guidelines.7~* Informed consent by the patient~* Already received stable dose of guideline directed medical therapy for at least 3 months~Exclusion Criteria:~* Pregnant~* Participating in another study,,,t,f,t
6159092,NCT05611918,PROBABILITY_SAMPLE,ALL,,,f,"The study populations includes all surviving cases identified and recruited through the 5-year durations of the MISTIE III and ENRICH trials and with follow-up periods extending from 2013-2017 and 2016-2022, respectively.",Inclusion Criteria:~* Participants in the study must be survivors enrolled in MISTIE III and ENRICH trials at end of each trial's final follow-up (day 365 in MISTIE III and day 180 in ENRICH). Relatives of known survivors that are found to be deceased since the end of each trial will be interviewed to capture relevant data.~Exclusion Criteria:~* None,,,t,t,t
6260154,NCT02956993,,ALL,18 Years,100 Years,f,,"Screening: Initial study inclusion criteria~1. Age of at least 18 years.~2. Clinical diagnosis of PAD secondary to atherosclerosis affecting a lower limb.~3. Rutherford category 3-5.~4. De novo lesion, not previously treated by angioplasty, atherectomy or stenting.~5. Scheduled to undergo angioplasty of the distal popliteal, tibial or peroneal arteries.~6. If female and of childbearing potential (premenopausal and not surgically sterile) must have a negative pregnancy test at the screening visit and be willing to use contraception from the time of the screening visit to 1 week following study drug administration. Acceptable methods of birth control include abstinence, barrier methods with spermicide, implants, injectables, oral contraceptives, intra-uterine device, or a vasectomized partner.~7. Ability to understand and comply with the requirements of the entire study and communicate with the study team.~8. Ability to provide written informed consent using a document that has been approved by the required institutional review board.~   Procedure: Study inclusion criteria to be determined at the time of the angioplasty procedure~9. Atherosclerotic lesion with \>50% stenosis in the popliteal (distal to the center of the knee joint space, the P3 segment), tibial or peroneal artery prior to angioplasty.~10. Successful revascularization without the use of stenting of the target lesion; no flow limiting dissection and \<30% residual lumen stenosis as compared with an adjacent non-diseased lumen diameter.~Exclusion Criteria Screening: Initial study exclusion criteria~1. Patients in whom arterial insufficiency in the lower extremity is the result of an immunologic or inflammatory non-atherosclerotic disorder (e.g., Buerger's disease, vasculitis).~2. Planned above ankle amputation on ipsilateral limb within 4 weeks of study drug administration.~3. Prior or planned stenting of the target lesion.~4. Deep vein thrombosis within the past 3 months.~5. Known bleeding disorder.~6. Known hypercoagulable state (e.g., protein C deficiency, factor V Leiden, prothrombin G20210A mutation).~7. Platelet count \<130K, hematocrit \<30%, bilirubin or ALT \>3.0 times the upper limit of normal.~8. Renal failure with existing dependence on dialysis or an eGFR by MDRD calculation of \< 20 mL/min/1.73 m2.~9. Pregnancy, lactation or plans to become pregnant during the course of the study.~10. Presence of any significant medical condition that might significantly confound the collection of safety and efficacy data in this study.~11. Malignancy or treatment for malignancy within the previous 12 months with the exception of localized basal cell or squamous cell skin cancer, or any cancer in situ.~12. Treatment with any investigational drug within the previous 30 days or investigational antibody therapy within 90 days prior to signing informed consent.~13. Known allergy to radiocontrast agents.~    Procedure:~    Exclusion criteria to be determined at the time of the angioplasty procedure~14. Reference vessel diameter \< 2 mm and \> 8 mm.~15. Severe concentric medial calcification of the target lesion thought to interfere with study drug delivery to the adventitia based on fluoroscopic appearance.~16. Aneurysm in the target vessel.~17. Failure to cross the target lesion with a guide wire; however subintimal wire crossing is allowed.~18. Stenting of the target lesion.",,,t,f,t
6260155,NCT02900911,,ALL,18 Years,,f,,Inclusion Criteria:~* Patients with advanced head and neck cancer receiving radiotherapy~Exclusion Criteria:~* Candidates to surgical treatment~* Previous head and neck cancer~* Dysphagia due to causes other than cancer~* Previous head or neck radiation therapy.,,,t,f,t
6260156,NCT01706107,PROBABILITY_SAMPLE,ALL,18 Years,65 Years,f,Patients who choose to participate in the study will receive a thorough description of the study protocol and an informed consent document describing the study and the risks and benefits of participating. Recruitment will continue until approximately 150 patients have been enrolled in the study at approximately 15 sites across Canada.,"Key Inclusion Criteria:~* Ability to understand the purpose and risks of the study and provide signed and dated informed consent.~* Documented diagnosis of Relapsing Multiple Sclerosis (McDonald 2010 Criteria).~* Must have an Expanded Disability Status Scale (EDSS) score from 0 to 4.0, inclusive.~* Must satisfy the approved therapeutic indications for Tysabri as per Product Monograph.~* Must either be treatment naïve or have been treated with disease modifying therapy DMT(s) (such as, but not limited to, Avonex, Betaseron, Rebif, Copaxone, Extavia, Tecfidera and/or Gilenya) for ≤5 years total prior to date of informed consent.~* Decision to treat with Tysabri must precede enrollment.~Key Exclusion Criteria:~* Any prior treatment with Tysabri.~* Contraindications to treatment with Tysabri as described in the Product Monograph.~* History of progressive multifocal leukoencephalopathy (PML) or other opportunistic infections, or an increased risk for such infections.~* History of diagnosis of Primary Progressive Multiple Sclerosis \[PPMS\] and/or Secondary Progressive Multiple Sclerosis \[SPMS\].~* Receiving immunomodulatory or immunosuppressive therapy.~* Prior history of immunosuppressive use (mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate, cladribine, rituximab).~* Immunocompromised at the time of enrollment.~* Known active malignancies (subjects with cutaneous basal cell carcinoma that has been completely excised prior to study entry remain eligible).~* Women breastfeeding, pregnant, or planning to become pregnant; women who are not post-menopausal or surgically sterile who are unwilling to practice contraception.~* Inability to comply with study requirements.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",,,t,f,t
6159093,NCT02432352,,ALL,,,t,,"Inclusion Criteria:~PARENTS/GUARDIANS/CAREGIVERS~1. 18+ years~2. primary caregiver or the person responsible for childcare in the household on a day to day basis (as identified by the household);~3. when more than one primary caregiver exists in the household, one will be chosen at random;~4. lives in the household at least 4 days a week~5. sub clinical thresholds of depressive symptoms~Adolescent inclusion criteria are:~1. 13-15 years;~2. concurs that the adult identified is their primary caregiver;~3. when more than one child in the family falls within the eligible age range, one child will be chosen at random;~4. lives in the household at least 4 days a week;~5. sub clinical thresholds of depressive symptoms~Exclusion Criteria:~PARENTS/GUARDIANS/CAREGIVERS \& Adolescents~1. cognitive impairments that would not allow them to provide informed consent or assent;~2. if they participated in qualitative phases of the study~3. report no or low symptoms or clinically significant thresholds of depression -",,,t,t,t
6260157,NCT00337688,NON_PROBABILITY_SAMPLE,ALL,12 Years,80 Years,t,subjects with CP and controls,"Inclusion criteria:~1. subjects must be between the ages of 12-80~2. subjects must be able to give written informed consent or consent by proxy to participate~3. subjects with the diagnosis of CP must have a score of 2 or 3 on the Modified Ashworth Scale in at least one of the following in the operating limb: wrist flexors, wrist extensors, elbow flexors, or elbow extensors~4. control subjects must have a Modified Ashworth score of 0 for all of the above muscle groups in both upper limbs~5. subjects must have the minimal motor ability necessary to participate in the trial. This will be measured as follows: after 3 trials, subjects must be able to complete a basic virtual driving with an average minimum speed of no less than 1.2 m/s, an average trial time of no more than 18 seconds, and an average deviation of the center of the virtual wheelchair of no more than 1.5 m from the path center, for each of the two joysticks used. These values are derived from Americans with Disabilities Act (ADA) standard dimensions and human walking speed.~Exclusion Criteria:~1. subjects who are not able to tolerate sitting for 2 hours (the estimated length of the experiment)~2. subjects who have active pelvic or thigh wounds (they may be worsened by prolonged sitting)~3. subjects with a history of seizures in the last 90 days (uncontrolled seizures may be induced by a computer screen task)",,,t,t,t
6260158,NCT05030688,,ALL,50 Years,80 Years,f,,"Inclusion Criteria:~* Patients with ASA classification I-III, aged 50-80 years, who were scheduled for hip arthroplasty under general anesthesia, will be included in the study.~Exclusion Criteria:~* history of bleeding diathesis,~* receiving anticoagulant treatment,~* known local anesthetics and opioid allergy,~* infection of the skin at the site of the needle puncture,~* patients who do not accept the procedure",,,t,f,t
6159094,NCT00933218,,MALE,20 Years,60 Years,t,,Inclusion Criteria:~* men aged 20-60 years~Exclusion Criteria:~* manifested heart disease~* insulin dependent diabetes mellitus~* multi drug therapy~* GFR \< 60 ml/min~* smokers~* neoplasia~* (former) alcoholism~* known malabsorption~* known chronic inflammatory disease,,,t,f,f
6260159,NCT06272058,,ALL,18 Years,80 Years,t,,"Inclusion Criteria:~* Male or female subjects aged ≥18 and ≤80 years at screening~* Body mass index (BMI) of 18.5 to 42 kg/m2 (inclusive)~* Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial~* Either male subject, or female subject who meet any of the following criteria for a highly effective contraception from at least 30 days before the first administration of trial medication until 30 days after trial completion:~  * Use of combined (estrogen and progestogen containing) hormonal contraception that prevents ovulation (oral, intravaginal or transdermal), plus condom~ * Use of progestogen-only hormonal contraception that inhibits ovulation (only injectables or implants), plus condom~ * Use of intrauterine device (IUD) or intrauterine hormone-releasing system (IUS)~ * Sexually abstinent~ * A vasectomised sexual partner who received medical assessment of the surgical success (documented absence of sperm) and provided that partner is the sole sexual partner of the trial participant~ * Surgically sterilised (including hysterectomy)~ * Postmenopausal, defined as no menses for 1 year without an alternative medical cause (in questionable cases a blood sample with levels of Follicle stimulating hormone (FSH) above 40 U/L and estradiol below 30 ng/L is confirmatory)~Applying only to participants with impaired hepatic function:~* Stable hepatic impairment (Child-Pugh score 10 - 15 point consistent with severe hepatic impairment) due to parenchymal liver disease, which is confirmed and documented by at least one of the following: medical history, physical examination, hepatic ultrasound, computed tomography (CT) scan, magnetic resonance imaging (MRI), and/or liver biopsy and defined as no clinically significant change in disease status within 4 weeks, as judged by the Investigator~* Absence of significant abnormalities, as based on a complete medical history including a full physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests at both screening and admission to trial site, with the exception of findings that in the opinion of the investigator are consistent with the participant's hepatic impairment.~* Medication and/or treatment regimens must have been stable (i.e., no dose adjustments) for at least 7 days or 5 half-lives whichever longer prior to the planned randomisation, and should be kept stable until study completion. Fluctuating treatment regimens may be considered for inclusion on a case-by-case basis if the underlying disease is under control in the opinion of the investigator and must be agreed to by both the investigator and the sponsor's medical monitor.~Applying only to healthy participants with normal hepatic function:~- Healthy subjects according to the assessment of the investigator (as based on a complete medical history including a physical examination, vital signs (BP, PR), 12- lead ECG, and clinical laboratory tests), and individually matched to participants with hepatic impairment according to sex, age and weight.~Exclusion Criteria:~* Any medical condition or finding in the medical examination that in the investigator's opinion assessed as clinically relevant, poses a safety risk for the subject or may interfere with the study objectives (except for conditions associated with hepatic impairment in subjects with compromised hepatic function)~* Repeated measurement of systolic blood pressure outside the range of 100 to 150 millimetre(s) of mercury (mmHg), diastolic blood pressure outside the range of 70 to 100 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (bpm)~* Any surgical or medical condition that may significantly interfere with the pharmacokinetics of the trial medication (eg, prior bariatric surgery, gastrectomy, ileal resection)~* History of relevant orthostatic hypotension, fainting spells, or blackouts~* History of relevant allergy or hypersensitivity (including allergy to the trial medication or its excipients)~* Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin~* Intake of restricted concomitant therapy or any concomitant therapy considered likely (based on Investigator judgement) to interfere with the safe conduct or may influence the primary and/or secondary endpoints of the trial within 30 days or 5 half-lives whichever longer prior to planned administration of the trial medication.~* Ongoing chronic alcohol or drug use, that in the investigator's opinion, makes the patient an unreliable trial participant or unlikely to complete the trial.~Further exclusion criteria apply.",,,t,f,t
6260160,NCT01360996,,FEMALE,16 Years,35 Years,f,,"Inclusion Criteria:~* •Adult female-16 years to 35 years of age who have been diagnosed with PCOS desiring contraception~  * Actual BMI \>18 to \<35kg/ m2~ * Written consent for participation in the study~ * Patient completed lactation~Exclusion Criteria:~* Metabolic abnormalities requiring pharmacological intervention (except controlled thyroid disease)~  * Uncontrolled hypertension~ * Cancer or history of hormone-dependent cancer~ * History of cholestasis~ * Presence of contradictions for OC administration~ * Personal history of cardiovascular events.~ * Use of drugs known to exacerbate glucose tolerance.~ * No prescription or over-the-counter weight-loss drugs~ * Diabetes~ * Use of medications that affect blood pressure or lipid profile~ * Smoking in past 6 months~ * Known thrombogenic mutations (e.g. Factor V Leiden)~ * Current or history of deep venous thrombosis/pulmonary embolism~ * Major surgery with prolonged immobilization~ * Injectable hormonal contraceptive use within 6 months~ * Use of hormonal (e.g., oral contraceptive \[OC\] pill) or insulin-sensitizing medication unless willing to cease medications for 3 months before study measurements",,,t,t,f
6263719,NCT00373256,,ALL,18 Years,,f,,Inclusion Criteria:~* Diagnosis of advanced breast cancer.~* Measurable disease as per RECIST (Response Evaluation Criterion) in Solid Tumors or bone-only disease.~* ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1.~Exclusion Criteria:~* No prior treatment with cytotoxics in the advanced disease setting.~* HER2/neu positive disease unless trastuzumab was previously received or is contraindicated.~* Treatment with a taxane in the adjuvant setting unless disease free interval \>12 months after end of treatment.,,,t,f,t
6159095,NCT01180218,,ALL,18 Years,,t,,"Inclusion Criteria:~* Subject must be at least 18 years of age.~* Subject is able to verbally confirm understandings of risks, benefits and treatment of culprit or complete revascularization using everolimus eluting coronary stent (Promus™ Element™ Stent) and he or she or his or her legally authorized representative provides written informed consent prior to any study related procedure.~* Subject must have significant more than two target lesions and requiring primary PCI for acute ST elevation myocardial infarction (STEMI) within 48hrs~* Target lesion(s) must be located in a native coronary artery with visually estimated diameter of less than 2.5 mm and more than 4.0 mm.~* Target lesion(s) must be amenable for percutaneous coronary intervention~Exclusion Criteria:~* The patient has a known hypersensitivity or contraindication to any of the following medications:~Heparin Aspirin Both Clopidogrel and Ticlopidine Everolimus Platinum chromium Contrast media~* Patients with documented sensitivity to contrast media which can be effectively pre medicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled.~* Systemic (intravenous) everolimus use within 12 months. Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study.~* History of bleeding diathesis or known coagulopathy (including heparin- Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months,induced thrombocytopenia), or will refuse blood transfusions.~* An elective surgical procedure is planned that would necessitate interruption of thienopyridines during the first 6 months post enrollment.~* Non-cardiac comorbid conditions are present with life expectancy over 1 year or that may result in protocol non-compliance (per site investigator's medical judgment).~* Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.~* Patients with more than 25 percentage of LVEF or those with cardiogenic shock~* Creatinine level more than 3mg per dL or dependence on dialysis.",,,t,f,t
6260161,NCT02580058,,FEMALE,18 Years,,f,,"Inclusion Criteria:~* Histologically confirmed epithelial ovarian, fallopian tube, or peritoneal cancer, including malignant mixed Müllerian tumors with high grade serous component.~* Platinum resistant/refractory disease, defined as disease progression within 180 days following the last administered dose of platinum therapy (resistant), or lack of response or disease progression while receiving the most recent platinum based therapy (refractory), respectively.~* Received up to 3 lines of systemic anticancer therapy for platinum sensitive disease, most recently platinum containing, and no prior systemic therapy for platinum resistant disease~* Measurable disease by investigator assessment with at least 1 unidimensional measurable lesion by RECIST v.1.1 that has not previously been irradiated~* Active autoimmune disease that might deteriorate when receiving an immunostimulatory agents. Patients with diabetes type I, vitiligo, psoriasis, hypo or hyperthyroid disease not requiring immunosuppressive treatment are eligible.~Mandatory tumor biopsy must be performed prior to enrollment for all patients (unless there is a documented clinical contraindication). In addition, availability of archived FFPE tumor tissue should be confirmed. If a patient underwent tumor tissue collection within 3 months prior to enrollment with no intervening treatment, and the sample is provided, then a new de novo tumor biopsy is not required.~Exclusion Criteria:~* Non epithelial tumor or ovarian tumors with low malignant potential (ie, borderline tumors).~* Prior therapy with an anti PD 1, anti PD L1, anti PD L2, anti CD137, or anti cytotoxic T lymphocyte associated antigen 4 (CTLA 4) antibody (including ipilimumab, tremelimumab or any other antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways).~* Known symptomatic brain metastases requiring steroids. Patients with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study entry, have discontinued corticosteroid treatment for these metastases for at least 4 weeks prior to study entry and are neurologically stable.~* Diagnosis of any other malignancy within 5 years prior to registration, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix.~* Severe gastrointestinal conditions such as clinical or radiological evidence of bowel obstruction within 4 weeks prior to study entry, uncontrolled diarrhea in the last 4 weeks prior to enrollment, or history of inflammatory bowel disease.",,t,t,f,t
6159096,NCT03838718,PROBABILITY_SAMPLE,ALL,18 Years,,f,Patients diagnosed with a primary RPS amenable to surgical resection.,Inclusion Criteria:~* primary RPS operated on in the participating center;~* age\>18 years at the time of the first treatment (pediatric patients can not be included)~* histological confirmed diagnosis according to the WHO criteria done on biopsy or surgical specimen by dedicated sarcoma pathologist;~* radiological examinations performed (contrast enhanced abdominal CT scan and/or MRI) prior to surgical resection;~* signed informed consent form;~* adequate compliance of the patients to the plan of follow-up~Exclusion Criteria:~* age\<18 years;~* recurrent tumor;~* benign retroperitoneal tumors;~* serious psychiatric disease that precludes informed consent or limits compliance;~* impossibility to ensure adequate follow-up,,,t,f,t
6159097,NCT06113718,,FEMALE,18 Years,,t,,"Inclusion Criteria:~* Patients who underwent surgery for endometrium, cervical and ovarian cancer indications,~* Patients with American Society of Anesthesiologists (ASA) score 1 or 2~Exclusion Criteria:~* Patients with American Society of Anesthesiologists (ASA) score 3 or 4~* Those with inflammatory bowel disease,~* Those who have abdominal fluid severe enough to prevent exercise,~* Patients with liver, kidney and thyroid function disorders,~* Patients with orthopedic problems affecting mobility,~* Patients with a history of abdominal bowel surgery,~* Those who received abdominal radiotherapy, hyperthermic intraperitoneal chemotherapy or neoadjuvant chemotherapy,~* Patients who had bowel injuries during surgery, bowel resection, anastomosis or colostomy,~* Patients who underwent Hipec,~* Patients who underwent relaparotomy before discharge due to reasons such as bleeding or evisceration",The study was conducted in patients undergoing gynecologic oncology surgery.,t,t,f,t
6159098,NCT05676918,,FEMALE,18 Years,,f,,"Inclusion Criteria:~* Women who have been mothers in the last year~Exclusion Criteria:~* Women who have been mothers in the last month,~* Women who meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for substance abuse and/or dependence within 30 days prior to study participation,~* Women who have a serious mental disorder that makes it difficult to follow the protocol (e.g. serious neurocognitive problems or brain damage; schizophrenia and other psychotic disorders).",,,t,f,t
6159099,NCT02770118,,ALL,20 Years,49 Years,t,,"Inclusion Criteria:~* Normal scores on:~  * Pittsburgh Quality of Sleep Questionnaire~ * Epworth Sleepiness Scale~ * Berlin Questionnaire~ * Sleep Disorders Inventory Questionnaire~ * Beck Depression Inventory~ * Composite Scale of Morningness/Eveningness~ * Three Factor Eating Questionnaire~* Sleep 7-9 hours in bed/night with no daytime nap~* Age 20-49 years, premenopausal women~* All racial/ethnic groups~* Body mass index 25-29.9 kg/m2~Exclusion Criteria:~* Smokers (any cigarettes or ex-smoker \<3 years)~* Neurological, medical or psychiatric disorder, diabetics~* Eating and/or sleep disorders~* Contraindications for MRI scanning~* Travel across time zones within 4 weeks~* History of drug and alcohol abuse~* Shift worker (or rotating shift worker)~* Caffeine intake \>300 mg/d~* Pregnancy or within 1 y post-partum~* Heavy equipment operators Commercial long-distance drivers",,,t,f,f
6159100,NCT01392118,NON_PROBABILITY_SAMPLE,ALL,18 Years,,f,"In a tertiary care hospital, every adult patient with at least one episode of ESBL-EK bloodstream infection from August 2004 to July 2010 will be recruited into this study. Patients who died within 48h after first episode of ESBL-EK bloodstream infection will be excluded.",Inclusion Criteria:~* Adult patients (age\>=18 years) with at least one episode of ESBL-EK bloodstream infection from August 2004 to July 2010~Exclusion Criteria:~* Patients who died within 48h after first episode of ESBL-EK bloodstream infection,,,t,f,t
6159101,NCT01073618,NON_PROBABILITY_SAMPLE,ALL,,,f,Patients who are indicated for VFEND according to drug package insert.,Inclusion Criteria:~* Invasive aspergillosis and other serious fungal infections.~Exclusion Criteria:~* N/A,,,t,t,t
6260162,NCT03165396,,ALL,50 Years,75 Years,t,,"Inclusion Criteria:~* Elective orthopaedic surgery~* American Society of Anesthesiologists physical status: II~Exclusion Criteria:~* Neurological diseases that may affect cognitive function (e.g., subdural hematoma)~* Hypothyroidism~* Alcoholic dementia",,,t,f,t
6260163,NCT01902407,NON_PROBABILITY_SAMPLE,ALL,1 Year,90 Years,f,All patients seen at CCHMC (up to 90 years of age) who are scheduled to have a clinical sleep MRI or CT scan for their OSA airway or lung disease.~Scheduled for both Sleep diagnostic tests (Sleep MRI and CT scans),Inclusion Criteria:~1. All patients seen at CCHMC (up to 90 years of age) who are scheduled to have a clinical sleep MRI or CT scan for their OSA airway or lung disease.~2. Both Sleep diagnostic tests (Sleep MRI and CT scans).~Exclusion Criteria:~* Those patients whose body weight (\>350 pounds) or circumference is greater than what can be safely accommodated by the MRI scanner~* Patients with pacemakers or other non-MRI compatible devices~* Patients with extensive dental hardware that causes MR artifact obscuring visualization of the area of interest.~* Body Mass Index (BMI) \> 40,,,t,t,t
6260164,NCT02276456,,ALL,18 Years,,t,,"Inclusion Criteria:~* Patients with acute MI (STEMI or NSTEMI) will be recruited from the PAC-CCU service and may have been admitted through the Duke Emergency Department or transferred from a referring hospital. - Clinical events and treatment during the hospitalization (e.g., medical management versus cardiac catheterization, ICU vs. non-ICU care, choice of medications, etc.) will not influence inclusion in the trial and inclusion in the trial will not influence treatment during hospitalization or during follow up, except for the timing of the follow-up appointment.~Exclusion Criteria:~* Patients treated with coronary artery bypass grafting will be excluded for the purposes of this trial to avoid conflicts with usual post-operative management.~* Additionally, patients with features or clinical courses that would preclude the possibility of readmission will be excluded.~* Examples include transition of care goals to comfort care, transition of care to inpatient or outpatient hospice, or the development of complications during the hospitalization that require early follow up appointments (e.g., diagnosis of malignancy).~* Patients discharged to skilled nursing facilities will be eligible for this study.",,,t,f,t
6260165,NCT04375358,NON_PROBABILITY_SAMPLE,ALL,18 Years,,,Inpatients in intensive care,Inclusion Criteria:~* Dialysis for AKI with minimum 12 hours of continuous renal replacement therapy (CVVH-CVVHD)~* Patient in whom dialysis withdrawal is being considered~* Patients over 18 years of age~Exclusion Criteria:~* Pre-existing chronic end-stage renal failure on chronic dialysis~* Extrarenal purification during hospitalization prior to admission to intensive care unit~* Inability to assess the primary outcome~* Kidney Transplantation~* Pregnant Women~* Person not affiliated to a national health insurance~* Decision to limit or stop therapy~* Isolated hyperkalemia~* Refusal of patient participation,,,t,f,t
6361038,NCT04889573,,ALL,18 Years,70 Years,t,,"Inclusion Criteria:~* healthy volunteers aged between 18 and 70~* volunteers free from lymphoid hemopathy, immune deficiency and autoimmune disease.~  3 categories : volunteers between 18 and 34 years of age, volunteers between 35 and 50 years of age, volunteers between 51 and 69 years of age.~Exclusion Criteria:~* any recent vaccination (\< 4 weeks)~* tumoral pathology~* lymphoïd hemopathy~* immune deficiency~* autoimmune disease~* transplanted patients~* inflammatory / systemic diseases~* hypersensitivity or allergies~* treatments likely to modify the immune response :~  * calcineurin inhibitors: ciclosporin, tacrolimus -antimetabolite: azathioprine, mycophenolate mofetil / mycophenolic acid, 6-mercaptopurine, methotrexate~ * cyclophosphamide~ * antilymphocyte serum (rabbit, horse)~ * mTOR inhibitors: everolimus, sirolimus~ * anti-CD25 (anti IL2-R): basiliximab, dacliximab -belatacept (anti CD80-86)~ * abatacept (CTLA4-Ig)~ * OKT3 (Muronomab-CD3, anti-CD23)~ * glucocorticoids: methylprednisolone, prednisone, prednisolone.~ * entuzumab (anti-CD52)~ * rituximab, ocrelizumab (anti-CD20)~ * eculizumab (anti-C5)~ * anakinra (analogue IL1-RA)~ * leflunomide (dihydroorotate dehydrogenase inhibition)~ * bortezomib (proteasome inhibitor)~ * fingolimod (S1P receptor antagonist)~ * alentuzumab (anti CD52)~ * Ig G -antiTNF (etanercept, infliximab, adalimumab, certolizumab)~ * vedolizumab (Anti-integrin α4β7 Ab)~ * ustekinumab (anti-IL12)~ * natalizumab (anti-integrin a4)~ * mitoxantrone (topoisomerase type II inhibitor)~ * tocilizumab (anti-IL6)",,,t,f,t
6159102,NCT03706118,,ALL,18 Years,60 Years,t,,"Inclusion Criteria:~1. Each participant must provide informed consent in accordance with local regulations~2. Age 18-60 years.~Exclusion Criteria:~1. Not able to undergo MRI examination~2. Not able to be examined 4 times, i.e. M 0, 12, 24, 36 during the next 3 years~3. Pregnancy at the time of enrollment into the study~4. Other disease or medical condition that can influence the volume of brain or spinal cord",,,t,f,f
6159103,NCT05076591,,ALL,18 Years,,f,,"Inclusion Criteria:~* Age ≥ 18 years~* Weigh greater than 30 kg~* life expectancy of at least 3 months~* Phase 1a Histologically or cytologically confirmed HER2-expressing advanced solid malignancy, who have been treated with at least one regimen of prior systemic therapy, or who refuse systemic therapy, and for which there is no curative therapy available.~* Phase 1b Histological Diagnsis There will be 5 cohorts:~Cohort 1: Histologically confirmed HER2 overexpression (HER2 IHC 3+ or HER2 IHC 2+/ISH-positive) locally advanced (unresectable) and/or metastatic breast cancer who have progression on or after at least 2 prior lines of anti-HER2 directed therapy with trastuzumab, pertuzumab, tucatinib, Fam-trastuzumab deruxtecan-nxki and T-DM1 or other anti-HER2 therapy.~Cohort 2: Histologically confirmed HER2-low (HER2 IHC 1+ or HER2 IHC 2+/ISH-negative and/or HER2 gene amplification in tumor specimen or in circulating tumor cells by ISH, NGS, or ctDNA-NGS) locally advanced (unresectable) and/or metastatic breast cancer who have progression after 2 or more lines of systemic therapy.~Cohort 3: Histologically confirmed HER2 overexpression (HER2 IHC 3+ or HER2 IHC 2+/ISH-positive) locally advanced (unresectable) and/or metastatic gastric/esophageal/gastroesophageal junction (GEJ) cancer who have progression on or after at least one prior therapy, including prior fluoropyrimidine + platinum and prior trastuzumab, and/or fam-trastuzumab deruxtecan-nxki or other prior anti-HER2 (including investigational) therapy.~Cohort 4: Histologically confirmed HER2-low (HER2 IHC 1+ or HER2 IHC 2+/ISH-negative and/or HER2 gene amplification in tumor specimen or in circulating tumor cells by ISH, NGS, or ctDNA-NGS) locally advanced (unresectable) and/or metastatic gastric/esophageal/gastroesophageal junction (GEJ) cancer who have progression after 2 or more lines of systemic therapy.~Cohort 5: Histologically confirmed HER2 overexpression (HER2 IHC 3+ or HER2 IHC 2+/ISH-positive) any other solid tumor types, including but not limited to colorectal cancer, non-small cell lung (NSCLC), ovarian cancers, that are not breast~* Has at least non-irradiated evaluable disease (target or non-target lesions) per RECIST version 1.1.~* Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.~* Completion of prior chemotherapy systemic anticancer therapy at least 2 weeks prior to study entry.~* Radiation therapy must be completed at least 2 weeks prior to study entry. Radiated lesions may not serve as measurable disease unless they have been radiated ≥12 months prior to enrollment.~* Patients may have parenchymal brain metastases if stable (no evidence of progression) for at least 1 month after local therapy (radiation or surgery). Leptomeningeal disease is excluded.~* Patients must have adequate organ and bone marrow function within 14 days of first dose of study drug administration~* Female subject must either be of non-reproductive potential or must have a negative urine or serum prenancy test within 7 days prior to the first dose of IMM2902.~Exclusion Criteria:~* Prior anti-cancer therapy including chemotherapy, hormonal therapy, or investigational agents within 2 weeks or within at least 4 half-lives prior to IMM2902 dosing (up to a maximum of 4 weeks).~* Prior treatment with neoadjuvant or adjuvant anthracyclines within cumulative dose of doxorubicin of \>400 mg/m2 or epirubicin of \>800 mg/m².~* Prior treatment with CD47 or SIRPα-targeting agents.~* Trastuzumab, pertuzumab, lapatinib, tucatinib, fam-trastuzumab deruxtecan-nxki or T-DM1 within 3 weeks before first IMM2902 dosing.~* Any unresolved toxicity NCI CTCAE v5.0 Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.~* Mean QT interval corrected for heart rate (QTc) ≥ 450 ms for males or QTc ≥ 470 ms for females calculated from 2 electrocardiograms (ECGs) using Fridericia's formula. Two EKGs 5 minutes (+/-2 min) apart are mandatory.~* Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \[eg, colitis or Crohn's disease\], diverticulitis \[with the exception of diverticulosis\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\]).~* Symptomatic congestive heart failure New York Heart Association (NYHA) Function Classification II-IV, uncontrolled hypertension, acute myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia.~* Uncontrolled diabetes mellitus, Interstitial lung disease, serious gastrointestinal conditions associated with diarrhea.~* Pulmonary embolism or deep vein thrombosis within 3 months prior to the first dose of study drug.~* Uncontrolled pulmonary, renal, or hepatic dysfunction.~* Ongoing or active infection requiring systemic treatment.~* Psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.~* Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints.~* Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancy for which treatment was completed at least 3 years ago and for which there is no evidence of recurrence.~* Known allergic reactions to any component or excipient of IMM2902 or known allergic reactions to trastuzumab or other prior anti-HER2 (including investigational) or other monoclonal antibody ≥ Grade 3.~* Patients requiring concomitant therapeutic anticoagulation, excluding those taking low dose of anticoagulation agents for diseases such as pulmonary embolism, deep venous thrombosis.~* Known active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus.~* Known inherited or acquired bleeding disorders.~* History of hemolytic anemia or Evans syndrome, sickle cell disease, thalassemia, G6PD deficiency, hereditary spherocytosis, or hypersplenism in the last 3 months.~* Current or prior use of immunosuppressive therapy within 14 days before the first dose of IMM2902.~* Receipt of live attenuated vaccination within 30 days prior to registration.",,,t,f,t
6159104,NCT04243291,NON_PROBABILITY_SAMPLE,ALL,18 Years,65 Years,t,"Malaysian Medical Association (MMA) members who are fully or partially registered with the Malaysian Medical Council (MMC) and their contacts. MMA is the main representative body for all registered medical practitioners in Malaysia. MMA members include senior and junior doctors, private and public, specialists and general practioners, medical officer and house officer.","Inclusion Criteria:~* Malaysian citizen~* Full or partial registration with MMC~* Work a minimum of six (6) months in public healthcare sector in Malaysia. Doctors who have just been working for less than six months are still adapting to the duties and atmosphere of the hospital, and the responsibilities they hold are also different from those of a senior doctor making them not suitable to include in this study.~Exclusion Criteria:~* Medical doctors currently on a long leave. As we only have a short period of data collection, so we will exclude this group of subject.~* Does not self-commute to work",,,t,f,t
6361039,NCT06029218,,ALL,18 Years,,f,,"Inclusion Criteria:~* Chordoma, chondrosarcoma of the skull base and spine, Ewing's sarcoma, and osteosarcoma meeting the criteria for treatment by proton therapy~* Tumour requiring 2 beams~* MRI less than one month old~* PS 0-2.~* Patient who has read the patient information note and signed the consent form.~* Patient with healthcare insurance cover.~* Age over 18 years.~* For women of childbearing age, negative urine pregnancy test and effective contraception in place for the duration of treatment and for six months following the end of treatment.~Exclusion Criteria:~* Persons deprived of their liberty or under guardianship.~* Unable to undergo the medical follow-up of the clinical investigation for geographical, social or psychological reasons.~* Patient eligible for symptom reduction surgery Vulnerable populations and participants defined in Articles 64 to 68 of Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017.",,,t,f,t
6159105,NCT00134550,,ALL,30 Years,,f,,"Inclusion Criteria:~* Provision of a written informed consent at the enrolment visit~* Men or women above 30 years of age~* Fertile women need to take contraceptives or have to be sterilised~* Diagnosed with any diabetes mellitus type 1 or type 2~* Present foot ulcer with an ulcer duration \<= 12 months~Exclusion Criteria:~* Intolerance to statins at any time in the past.~* Unwillingness to participate~* A history of alcohol or drug abuse within the last 2 years~* Foot ulcer with the etiology from vasculitis, pyoderma gangrenosum, angiodermatitis necroticans (hypertensive ulcer), necrobiosis lipoidica, hydrostatic pressure/venous insufficiency or any neoplasms (basalioma, kaposis sarcoma, squamous cell carcinoma etc).~* History of drug-induced hepatitis or previous liver enzyme elevations (\> 3 times the upper limit of normal) while taking statins.~* History of drug-induced creatine phosphokinase (CPK) \> 3 times the upper limit of normal.~* Critical limb ischemia that requires re-vascularisation procedures within 2 months~* Brachial-ankle index \< 0.5~* Other serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the patient's safety or successful participation in the trial.~* Any clinically significant abnormality identified in the enrolment medical history, physical examination, laboratory test which, in the judgement of the investigator, would preclude safe completion of the study.~* Active liver disease or hepatic dysfunction defined as ALAT or ASAT elevations \> 2 times the upper limit of normal or total bilirubin \> 1.5 times the upper limit of normal.~* Pregnancy",,,t,f,t
6159106,NCT03742700,,ALL,18 Years,30 Years,t,,"Inclusion Criteria:~- smoking status (cigarette or e-cigarette smoking)~Exclusion Criteria:~* occurrence of any chronic diseases,~* history of lung conditions (eg.: asthma or bronchial hyperactivity in childhood),~* presence of any allergic diseases,~* medication intake within the last 2 weeks,~* acute illnesses or infections in the last 2 weeks,~* influenza vaccination in the last 2 weeks,~* or current pregnancy or lactation.",,,t,f,f
6159107,NCT03629691,NON_PROBABILITY_SAMPLE,ALL,18 Years,90 Years,f,"1. Between February 1, 2015 and May 19, 2018, 433 adult patients with gastric adenocarcinoma, lung adenocarcinoma and lung squamous cell carcinoma~2. Multiline chemotherapy failure and lack of standard treatment, received oral apatinib 250 mg daily at the Affiliated Hospital of Qingdao University.~3. Histologically proven were identified retrospectively using the Clinical Research Information Systems (CRIS) database.~4. All patients were with Karnofsky performance status over 70% or an Eastern Cooperative Oncology Group performance status of 0 to 1, with stable hepatic, hematologic, and renal functions.","Inclusion Criteria:~1. Between February 1, 2015 and May 19, 2018, 433 adult patients with gastric adenocarcinoma, lung adenocarcinoma and lung squamous cell carcinoma~2. Multiline chemotherapy failure and lack of standard treatment, received oral apatinib 250 mg daily at the Affiliated Hospital of Qingdao University.~3. Histologically proven were identified retrospectively using the Clinical Research Information Systems (CRIS) database.~4. All patients were with Karnofsky performance status over 70% or an Eastern Cooperative Oncology Group performance status of 0 to 1, with stable hepatic, hematologic, and renal functions.~Exclusion Criteria:~1. Cardiac disease and hemorrhagic disease were excluded.~2. Patients with lung cavitation before apatinib treated.",,,t,f,t
6260166,NCT03810807,,ALL,19 Years,,f,,"Inclusion Criteria:~* Written informed consent~* Advanced biopsy-proven metastatic non-small cell lung cancer~* Somatic activating mutation in EGFR in a tumor biopsy~* No prior EGFR inhibitor treatment (gefitinib, afatinib, erlotinib, dacomitinib, osimertinib) however, prior treatment with other chemotherapies are allowed~* Archival tissue available from a pre-treatment tumor biopsy or willing to undergo a tumor biopsy prior to study initiation.~* Measurable (RECIST 1.1) indicator lesion not previously irradiated~* Karnofsky performance status (KPS) ≥ 70%~* Age \>18 years old~* Ability to swallow oral medication~* Agree to use effective methods of contraception from the time of screening until 3 months after treatment discontinuation (for males and females of child-bearing potential)~* Adequate organ function~  * AST, ALT ≤ 3 x ULN~ * Total bilirubin ≤1.5x ULN~ * Creatinine ≤ 1.5x ULN OR calculated creatinine clearance ≥ 60ml/min~ * Absolute neutrophil count (ANC) ≥ 1000 cells/mm\^3~ * Hemoglobin≥9.0 g/dL~ * Platelets ≥100,000/mm\^3~Exclusion Criteria:~* Pregnant or lactating women~* Any radiotherapy within 1 week of starting treatment on protocol.~* Any major surgery within 1 weeks of starting treatment on protocol.~* Any evidence of active clinically significant interstitial lung disease~* A mean QTc \>470ms (Fridericias correction), clinically important arrhythmia, conduction or morphology of resting ECG (eg complete LBBB, 1st -3rd degree heart block, any factors that increase the risk of QTc prolongation or risk of arrhythmia)~* Cardiovascular disease or cerebrovascular disease, CVA or MI \< 6 months prior to study enrollment, unstable angina, NYHA \>Grade II CHF, or serious cardiac arrhythmia uncontrolled by medication or with the potential to interfere with protocol treatment~* History of pneumonitis or interstitial lung disease (ILD), drug induced ILD, radiation pneumonitits that required steroid treatment, and any evidence of clinically active ILD~* Serious chronic GI conditions associated with diarrhea~* Symptomatic, unstable brain metastases requiring escalating doses of steroids~* Continue to have unresolved \> CTCAE grade 1 toxicity from any previous treatment",,,t,f,t
6260167,NCT00630032,,FEMALE,18 Years,,f,,"DISEASE CHARACTERISTICS:~Inclusion criteria:~* Histologically proven invasive unilateral breast cancer (regardless of the type)~  * Initial clinical condition compatible with complete initial resection~ * No residual macro or microscopic tumor after surgical excision~* Node-positive disease (i.e., positive sentinel node or positive axillary clearance) (N+) or node-negative disease (-) meeting the following criteria :~  * Stage II or III disease~ * pT \>20 mm (T1-4)~* Patients must meet 1 of the following hormone-receptor criteria:~  * Node-positive patients: triple-negative\* tumor (HER2 negative, estrogen-receptor \[ER\] negative, and progesterone receptor \[PR\] negative) OR double-negative (HER2 negative, PR negative, and ER+)~ * Node-negative patients: triple-negative\* tumor only~* NOTE: \*Hormone-receptor negativity is defined as ER \<10% and PR \<10% by IHC and HER2 negativity is defined as IHC 0-1+ OR IHC 2+ and FISH or CISH negative~* Must be able to begin chemotherapy no later than day 49 after the initial surgery~Exclusion criteria:~* Clinically or radiologically detectable metastases (M0)~* Bilateral breast cancer or contralateral ductal carcinoma in situ~* Any metastatic impairment, including homolateral subclavicular node involvement, regardless of its type~* Any tumor ≥T4a (cutaneous invasion, deep adherence, inflammatory breast cancer)~* HER 2 overexpression defined as IHC 3+ OR IHC 2+ and FISH or CISH positive~* Any clinically or radiologically suspect and non-explored damage to the contralateral breast~PATIENT CHARACTERISTICS:~Inclusion criteria:~* Female~* Pre- or postmenopausal~* ECOG performance status 0-1~* Peripheral neuropathy ≤grade 1~* Neutrophil count ≥2,000/mm³~* Platelet count ≥100,000/mm³~* Hemoglobin \>9 g/dL~* AST and ALT ≤1.5 times upper limit of normal (ULN)~* Alkaline phosphatase ≤2.5 times ULN~* Total bilirubin ≤1.0 times ULN~* Serum creatinine ≤1.5 times ULN~* LVEF ≥50% by MUGA scan or echocardiography~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for up to 8 weeks after completion of study treatment~Exclusion criteria:~* Previous cancer (except cutaneous baso-cellular epithelioma or uterine peripheral epithelioma) in the preceding 5 years, including invasive contralateral breast cancer~* Patients with any other concurrent severe and/or uncontrolled medical disease or infection that could compromise participation in the study~* Clinically significant cardiovascular disease within the past 6 months including any of the following:~  * Unstable angina~ * Congestive heart failure~ * Uncontrolled hypertension (i.e., blood pressure \>150/90 mm Hg)~ * Myocardial infarction~ * Cerebral vascular accidents~* Known prior severe hypersensitivity reactions to agents containing Cremophor EL~* Patients with any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule~* Patients deprived of liberty or placed under the authority of a tutor~PRIOR CONCURRENT THERAPY:~* At least 2 weeks since prior minor surgery (excluding breast biopsy) and adequately recovered~* At least 3 weeks since prior major surgery and adequately recovered~* No prior chemotherapy, hormonal therapy, or radiotherapy~* More than 72 hours since prior and no concurrent treatment with any of the following strong inhibitors of CYP3A4:~  * Amiodarone~ * Clarithromycin~ * Amprenavir~ * Delavirdine~ * Voriconazole~ * Erythromycin~ * Fluconazole~ * Itraconazole~ * Ketoconazole~ * Indinavir~ * Nelfinavir~ * Ritonavir~ * Saquinavir~* No concurrent participation in another therapeutic trial involving an experimental drug",,,t,f,t
6260168,NCT01896232,,ALL,18 Years,85 Years,f,,"Inclusion Criteria:~* Eligible subjects must be receiving adequate thrice weekly maintenance hemodialysis with a dialysate calcium concentration ≥ 2.5 mEq/L for at least 3 months prior to screening laboratory assessments~* Subjects must have SHPT as defined by one central laboratory screening predialysis serum PTH value \> 500 pg/mL, measured on separate days within 2 weeks prior to randomization~* Subjects must have one serum cCa value ≥ 8.3 mg/dL obtained before dialysis within 2 weeks of the date of randomization~* Subjects receiving calcium supplements must have no more than a maximum dose change of 50% within 2 weeks before screening laboratory assessments are obtained, and the dose must remain unchanged through randomization~Exclusion Criteria:~* Eligible subjects cannot have received cinacalcet during the 3 months preceding the first screening laboratory assessment~* Other criteria may apply",,,t,f,t
6260169,NCT04207658,,FEMALE,18 Years,,t,,"Inclusion Criteria:~* Women are accepted in the study on condition that they are aged 18 and more~* Primigravida~* bearing single foetus between 2500 and 3999gr of birth weight in vertex position~* in 38-42 gestation weeks~* they must also accept to participate in the study~* with a cervical dilatation of 6cm~Exclusion Criteria:~* obstetrical or medical complications during labour,~* expected to have spontaneous vaginal labour with risk factors",,,t,f,t
6260170,NCT03770858,NON_PROBABILITY_SAMPLE,ALL,2 Years,,t,Participants with mild to moderate atopic dermatitis,"Inclusion Criteria:~* Participants with mild to moderate atopic dermatitis ages 2 years or older. This will be determined by clinical diagnosis of AD according to the Hanifin and Rajka criteria with a baseline Investigators Global Assessment score of mild (2) or moderate (3)~* Systemic therapy use (e.g. oral corticosteroid, cyclosporine, methotrexate, phototherapy) within 28 days of subject enrollment~* Topical corticosteroid use or topical calcineurin inhibitor use within 14 days of subject enrollment~* Willingness and ability to set up an infrared video camera nightly~* Willing to apply topical crisaborole twice daily to affected atopic dermatitis areas of the body~Exclusion Criteria:~* Active skin or systemic infection~* Inability to operate a smartphone or video camera~* Active atopic dermatitis on he dorsum of the hand or suprasternal notch",,,t,t,t
6260171,NCT01367132,NON_PROBABILITY_SAMPLE,FEMALE,18 Years,,t,"Patients undergoing nuchal transluscency screening during 11-13+6 weeks gestation, followed by anatomy scan at 18-24 weeks gestation.",Inclusion Criteria:~* Singleton or multiple-gestation pregnancies in patients presenting for NT screening between 11 and 13 6/7 weeks gestation and CRL between 45-84mm as determined at the time of the ultrasound~* Age 18 and older~Exclusion Criteria:~* Patients who are incapable of informed consent or minors,,,t,f,t
6159108,NCT02551991,,ALL,18 Years,,f,,"Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the pancreas that has not been previously treated in the metastatic setting~* Unresectable, locally advanced or metastatic disease; diagnosed within 6 weeks prior to screening~* At least one tumor lesion measurable by CT or MRI scan (according to RECIST v1.1)~* ECOG performance status of 0 or 1 at screening and within 72 hours prior to first dose if first dose occurs more than 72 hours post-screening~* Adequate hematological, hepatic, renal and cardiac function~* Recovered from the effects of any prior surgery or radiotherapy~* Patient has a Karnofsky performance status (KPS) ≥ 70 at Screening, and within 72 hours prior to date of first dose if first dose occurs more than 72 hours after screening (Part 1B only)~Exclusion Criteria:~* Prior treatment of pancreatic cancer in the metastatic setting (or locally advanced setting) with surgery (placement of stent is allowed), radiotherapy, chemotherapy or investigational therapy~* Prior treatment of pancreatic cancer with chemotherapy in adjuvant setting, except those where at least 12 months have elapsed since completion of the last dose and no persistent treatment-related toxicities present~* Uncontrolled Central Nervous System (CNS) metastases~* Clinically significant gastrointestinal disorder~* History of any second malignancy in the last 3 years. Patients with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible~* Presence of any contraindications for nal-IRI, irinotecan, 5-FU, leucovorin, oxaliplatin~* Use of strong CYP3A4 or inducers or presence of any other contra indications for irinotecan~* Pregnant or breast feeding~* Neuroendocrine or acinar pancreatic carcinoma~* Serum albumin \< 3 g/dL at screening visit and within 72 hours prior to first dose if first dose occurs more than 72 hours post screening~* Patients with symptoms and signs of clinically unacceptable deterioration of primary disease at time of screening~* Previous treatment with irinotecan-based, nab-paclitaxel-based or gemcitabine-based resulting in disease progression",,,t,f,t
6260172,NCT01108783,,ALL,12 Years,70 Years,f,,"Inclusion Criteria:~* The study disease was diagnosed on the basis of clinical criteria: Nasal symptoms (presence of nasal blockage, sneezing, nasal itching and rhinorrhea) and non-nasal symptoms (ocular itching, lacrimation, itching of ears and/or palate and ocular redness), as well as the skin prick test performed at the time of selection or within the year prior to entering.~* Patients with history of Seasonal Allergic Rhinitis, positive skin prick test and symptoms were included if they were between 12 and 70 years old, gave their informed consent, attended the required visits scheduled and also underwent a complete medical examination..~Exclusion Criteria:~* Patients were excluded if they had a significant nasal abnormality which could interfere with the aim of the study, acute or chronic sinusitis, asthma or any condition, disease or hypersensitivity that could be harmed.~* Patients were not allowed to take forbidden medications or not comply the study requirements.~* Patients who were currently participating in or had participated in another clinical trial within the previous three months or were planning to travel outside of the study area during the course of the study were excluded.~* Pregnant or breast-feeding women were also excluded.~* Women of childbearing potential had a pregnancy test done",,,t,t,t
6159109,NCT02234518,,ALL,18 Years,75 Years,f,,"Inclusion Criteria:~* Men or women aged 18-75; female subjects of child-bearing potential must be willing to use a reliable method of contraception throughout the study period~* BMI: 18.5 - 29.9 kg/m2~* Recruitment based on simplified core ROME III diagnostic criteria for functional constipation (based on specific screening questions):a). average Bristol stool type of 1 - 4 AND frequency of 1 - 3 spontaneous bowel movements (SBMs) per week b). plus at least ONE of: straining on at least 25% of defaecations; sensation of incomplete evacuation on at least 25% of defaecations; sensation of anorectal obstruction / blockage on at least 25% of defaecations; use of manual manoeuvres on at least 25% of defaecations~* Cleveland Clinic constipation score (CCCS) of 8-20~* Low-moderate fiber intake (≤18g) determined by the semi-quantitative food intake screener known as the Block Fiber Screener~* Ability to understand the patient information sheet and instructions in Dutch, and able to provide informed consent~Exclusion Criteria:~* Subjects who report lactose intolerance and/or are allergic to soy or cow milk protein~* Pregnant or breast-feeding women~* Ongoing other diagnosed gastrointestinal disease or complication (Crohn's disease, Coeliac disease, chronic diarrhoea)~* Any clinical relevant abnormalities in the screening visit medical examination or alarm features such as sudden unintentional weight loss, rectal bleeding, recent change in bowel habit (\<3 months), abdominal pain and stool positive for occult blood~* Prior abdominal surgery (including gastric bypass or laparoscopic banding), except cholecystectomy and appendicectomy~* Neurologic diseases such as multiple sclerosis, stroke, spinal cord injury, Hirschsprung disease~* Chronic medication that in opinion of the investigator would impact gut motility~* Illness that may preclude the subject's ability to complete the study or that may confound the study outcomes (e.g. bowel cancer, prostate cancer, terminal illness, severe cardiovascular disease, chronic renal failure or eating disorders) or any other serious illness resulting in \>2 weeks inability to work in the 3 months before the study start~* Subjects with co-morbid illnesses such as cardiovascular, endocrine, renal or other chronic disease likely to affect gut motility or limit normal functions (e.g. reduced mobility or increased fragility)~* Ongoing alcohol, drug, or medication abuse (anamnesis only)~* Self-reported symptoms of pelvic organ prolapse~* Moderate or severe active local anorectal problems such as recurrent anal fissures, bleeding, large prolapsing haemorrhoids~* Regular use of fiber supplementation (e.g. Fybogel, Lactulose) (i.e. no more than 1 standard dose) over the week prior to the screening visit and no more than 6 standard doses in the past 1 month prior to the screening visit~* Participation in another study with any investigational product within 3 months of screening~* Investigator believes that the participant is physically or mentally unfit to participate in the trial",,,t,f,t
6057068,NCT00778050,,ALL,18 Years,,t,,"Inclusion Criteria:~1. All volunteers selected for this study will be healthy men or women 18 years of age or older at the time of dosing~2. The weight range will not exceed ± 20% for height and body frame as per Desirable Weights for Adults - 1983 Metropolitan Height and Weight Table~3. Each volunteer will complete a screening process within 28 days prior to Period I dosing. Consent documents for both the screening evaluation and HIV antibody determination will be reviewed, discussed, and signed by each potential participant before full implementation of screening procedures~4. If female and:~   * of child bearing potential, is practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence; or~  * is postmenopausal for at least 1 year; or~  * is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy)~Exclusion Criteria:~1. Volunteers with a recent history of drug or alcohol addiction or abuse~2. Volunteers with the presence of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined by the clinical investigators)~3. Volunteers whose clinical laboratory test values are outside the accepted reference range and when confirmed on re-examination are deemed to be clinically significant~4. Volunteers demonstrating a positive hepatitis B surface antigen screen or a reactive HIV antibody screen~5. Volunteers demonstrating a positive drug abuse screen when screened for this study~6. Female volunteers demonstrating a positive pregnancy screen~7. Female volunteers who are currently breastfeeding~8. Volunteers with a history of allergic response(s) to amoxicillin or related drugs~9. Volunteers with a history of clinically significant allergies including drug allergies~10. Volunteers with a clinically significant illness during the 4 weeks prior to period I dosing (as determined by the clinical investigators)~11. Volunteers who currently use tobacco products~12. Volunteers who have taken any drug known o induce or inhibit hepatic drug metabolism in the 30 days prior to period I dosing~13. Volunteers who report donating greater than 150 mL of blood within 30 days prior to period I dosing. All subjects will be advised not to donate blood for four weeks after completing the study~14. Volunteers who have donated plasma (e.g. plasmapheresis) within 14 days prior to period I dosing. All subjects will be advised not to donate plasma for four weeks after completing the study~15. Volunteers who report receiving any investigational drug within 30 days prior to period I dosing~16. Volunteers who report taking any systemic prescription medication in the 14 days prior to period I dosing.",,,t,f,t
6057069,NCT02947581,,ALL,18 Years,65 Years,f,,"Inclusion Criteria:~* - Male or female adult individuals (18 to 65 y.o.) with a diagnosis of basal subarachnoid cysticercosis (including locations in the Sylvian fissure or lower interhemispheric spaces) by neuroimaging and confirmed by serology.~* Baseline laboratory results along acceptable ranges (specifically defined in the study protocol).~* Willingness to accomplish the two-week minimum hospitalization required.~Exclusion Criteria:~* Previous therapy with ABZ or PZQ in the preceding 3 years (except for patients who received single-dose ABZ for intestinal parasites, or patients who received antiparasitic treatment between one and three years before enrollment but demonstrated lesion persistence or progression during the past 12 months).~* A type of NCC which can expose the patient to increased risk during the study, specifically: a) intraventricular cysts; b) cysts in brainstem; c) concomitant intraparenchymal lesions greater than 3 cm of diameter in addition to their SANCC lesions; d) more than 20 intraparenchymal cysts in addition to their SANCC lesions; or d) untreated ocular cysticercosis. Patients with a lateral ventricle cyst, less than 2 cm in diameter, without hydrocephalus or intracranial hypertension, can be included. The presence of concomitant intraparenchymal cysts of less than 3 cm in diameter will not exclude the patient unless there are more than 20 of them.~* Active pulmonary tuberculosis evidenced by positive chest X-ray and positive sputum smears, or symptoms compatible with tuberculosis (fever+sweats or fever+cough) not otherwise explained.~* Individuals with positive markers for active hepatitis.~* Systemic disease that may affect therapy or short-term prognosis, including but not limited to chronic renal failure, hepatic insufficiency, cardiac failure, and steroid-dependent immune diseases.~* Patients in unstable condition or with symptomatic intracranial hypertension (ICH). Definition of symptomatic ICH for this study is the presence of headaches, nausea, and vomiting, with papilledema at fundoscopic examination. Patients in this category can be considered for entrance into the study only after resolution of ICH by ventricular-peritoneal shunting or neuroendoscopic procedures involving CSF flow derivation. These procedures would be done as part of their standard medical care and are not part of the trial intervention.~* Pregnancy during anti-parasitic treatment. If a patient becomes pregnant after treatment, she will continue in the study but will have radiological exams delayed until after delivery.~* History of hypersensitivity to ABZ or PZQ~* Chronic or drug abuse as defined in the study protocol.~* Unwilling or unable to undergo MRI exams (like patients with ferromagnetic implants)~* Inability or unwillingness of subject or legal representative to give written informed consent.",,,t,f,t
6159110,NCT02236000,,FEMALE,18 Years,,f,,"Inclusion Criteria:~* The ECOG performance status must be less than or equal to 2.~* Patients must have the ability to swallow oral medication.~* Patients must have histologic or cytologic confirmation of the diagnosis of invasive adenocarcinoma of the breast.~* Patients must have had anti-HER2 based therapy with pertuzumab and trastuzumab for neoadjuvant therapy, adjuvant therapy or with first line therapy for metastatic disease (which may include trastuzumab and pertuzumab either sequentially or in combination).~* There must be documentation that the patient has evidence of measurable metastatic breast cancer that is accessible to biopsy at study entry.~* Patients must have estrogen receptor (ER) analysis performed prior to study entry. If ER analysis is negative, then progesterone receptor (PgR) analysis must also be performed. (Patients are eligible with either hormone receptor-positive or hormone receptor-negative tumors.)~* Breast cancer must be determined by local testing to be human epidermal growth factor receptor 2 (HER2)-positive prior to study entry using American Society of Clinical Oncology (ASCO) - College of American Pathologists (CAP) HER2 test guidelines.~* At the time of study entry, blood counts performed within 4 weeks prior to study entry must meet the following criteria:~  * absolute neutrophil count (ANC) must be greater than or equal to 1000/mm3;~ * platelet count must be greater than or equal to 100,000/mm3; and~ * hemoglobin must be greater than or equal to 9 g/dL. (Note: Patient must have discontinued growth factors greater than or equal to two weeks prior to entry labs.)~* The following criteria for evidence of adequate hepatic function performed within 4 weeks prior to study entry must be met:~  * Total bilirubin must be less than or equal to 1.5 x upper limit of normal (ULN), and~ * aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be less than or equal to 1.5 x ULN for the lab or less than or equal to 5 x ULN if liver metastasis.~* Serum creatinine performed within 4 weeks prior to study entry must be less than or equal to 1.5 x ULN for the lab.~* The left ventricular ejection fraction (LVEF) assessment by 2-D echocardiogram or multi-gated acquisition (MUGA) scan performed within 90 days prior to study entry must be greater than or equal to 50% regardless of the facility's lower limit of normal (LLN).~* Patients with reproductive potential must agree to use an effective non-hormonal method of contraception during therapy, and for at least 7 months after the last dose of study therapy.~Exclusion Criteria~* Previous therapy with T-DM1 or any HER2 tyrosine kinase inhibitor (TKI) including neratinib for any malignancy.~* Symptomatic brain metastases or brain metastases requiring chronic steroids to control symptoms.~* Active hepatitis B or hepatitis C with abnormal liver function tests; HIV positive patients receiving antivirals.~* Lung disease resulting in dyspnea at rest.~* Active infection or chronic infection requiring chronic suppressive antibiotics.~* Malabsorption syndrome, ulcerative colitis, inflammatory bowel disease, resection of the stomach or small bowel, or other disease or condition significantly affecting gastrointestinal function.~* Persistent greater than or equal to grade 2 diarrhea regardless of etiology.~* Conditions that would prohibit intermittent administration of corticosteroids for T-DM1 premedication.~* Chronic daily treatment with corticosteroids with a dose of greater than or equal to 10 mg/day methylprednisolone equivalent (excluding inhaled steroids).~* Uncontrolled hypertension defined as a systolic BP greater than 150 mmHg or diastolic BP greater than 90 mmHg, with or without anti-hypertensive medications. (Patients with hypertension that is well controlled on medication are eligible.)~* Cardiac disease (history of and/or active disease) that would preclude the use of any of the drugs included in the treatment regimen. This includes but is not confined to:~  * Active cardiac disease: symptomatic angina pectoris within the past 90 days that required the initiation of or increase in anti-anginal medication or other intervention; ventricular arrhythmias except for benign premature ventricular contractions; supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication; conduction abnormality requiring a pacemaker; valvular disease with documented compromise in cardiac function; and symptomatic pericarditis~ * History of cardiac disease: myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricular (LV) function; history of documented congestive heart failure (CHF); and documented cardiomyopathy~* Other nonmalignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow up.~* Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing should be performed within 14 days prior to study entry according to institutional standards for women of childbearing potential.)~* The investigator should assess the patient to determine if she has any psychiatric or addictive disorder or other condition that, in the opinion of the investigator, would preclude her from meeting the study requirements.~* Use of any investigational agent within 4 weeks prior to study entry.",,,t,f,t
6159111,NCT05014191,NON_PROBABILITY_SAMPLE,FEMALE,18 Years,80 Years,,"Women who were diagnosed with vulvar carcinoma, receiving adjuvant or definitive chemoradiation to primary disease and inguinal lymph nodes",Inclusion Criteria:~* Age \>= 18 years~* ECOG PS = 0-1~* Women with Bx confirmed vulvar cancer FIGO stage I-IVA (treated with curative intent)~Exclusion Criteria:~* Patients whom radiotherapy plans do not cover inguinal lymph nodes will be excluded.~Vulnerable patients will be excluded (pregnant),Females only,t,t,f,t
6260173,NCT02124096,,ALL,8 Years,,t,,* INCLUSION CRITERIA:~* Volunteers greater than or equal to 8 years of age~* Parental consent if a participant is less than 18 years of age~* Willing to have samples stored for future research~* Willingness to complete all study procedures~* Daily or nearly daily contact with swine during selected agricultural fairs~EXCLUSION CRITERIA:~Any medical condition or circumstance that may make it unsafe for the participant to have nasal swab performed.,,,t,t,t
6260174,NCT03153358,,ALL,18 Years,70 Years,f,,"Inclusion Criteria:~* Histologic documentation of primary lung carcinoma, non-squamous histology with EGFR mutation.~* Stage disease according to the 7th Edition of the American Joint Committee on Cancer staging system~* Not received radiotherapy, chemotherapy or other biological treatment~* Measureable disease~* Life expectancy of\>=12 months~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1~* Absolute neutrophil count (ANC)\>=2,500/mm\^3~* Hemoglobin\>=9.0 g/dL~* Total bilirubin\<=1.5 x upper limit of normal(ULN)~* Serum glutamic oxaloacetic transaminase (SGOT) (aspartate transaminase \[AST\]) and serum glutamic pyruvic transaminase (SGPT) (alanine transferase \[ALT\])\<=2.5 x ULN in patients without liver or bone metastases; \<5 x ULN in patients with liver or bone metastases~* Cockcroft-Gault calculated creatinine clearance of\>=45 ml/min or creatinine\<=1.5 x ULN~* Prothrombin time (PT)\<=1.5 x ULN~* Partial thromboplastin time (PTT)\<=ULN~* Negative pregnancy test done\<=7 days prior to randomization, for women of childbearing potential only~* Provide informed written consent~* Willing to return to Sichuan cancer hospital for follow-up~* Willing to provide tissue and blood samples for correlative research purposes~Exclusion Criteria:~* Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component~* Known allergic to EGFR TKI any ingredients~* Prior chemotherapy or treatment for metastatic non-small cell lung cancer~* Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive, per MD discretion~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm~* Other active malignancy\<=3 years prior to randomization;~* Ongoing or active infection, symptomatic congestive heart failure , cardiac arrhythmia, psychiatric illness/social situations, or any other medical condition that would limit compliance with study requirements~* History of bleeding diathesis or coagulopathy~* Inadequately controlled hypertension (systolic blood pressure of\>150 mmHg or diastolic pressure\>100 mmHg on anti-hypertensive medications)~* Serious non-healing wound, ulcer, bone fracture, or have undergone a major surgical procedure, open biopsy, or significant traumatic injury \<=28 days or core biopsy \<=7 days prior to randomization~* Pregnancy or breast-feeding women~* Other situation which researchers think that doesn't fit into the group",,,t,f,t
6260175,NCT03641807,,MALE,18 Years,50 Years,f,,"Inclusion Criteria:~* meet the diagnostic criteria according to the NIH CP/CPPS consensus: discomfort or pain in the pelvic region for at least 3 months in the previous 6 months~* 18-50 years~* NIH-CPSI total score ≥15~Exclusion Criteria:~* Urologic disease~* Residual urine volume ≥100 milliliter (mL)~* Qmax ≤15mL/s~* Use 5-alpha reductase inhibitor, alpha-blockers, antibiotics or any other prostatitis-specific medication during previous 1 month~* Diseases that influence urologic symptoms are multiple sclerosis, multiple system atrophy, stroke, Alzheimer disease, Parkinson's disease, spinal cord injury, cauda equina injury, and sexually transmitted disease~* Any acute disease or severe disease requiring treatment",,,t,f,f
6260176,NCT04358978,,FEMALE,,75 Years,f,,Inclusion Criteria:~-patients who required surgical treatment for symptomatic pelvic organ prolapse stage ≥ 2 with or without stress urinary incontinence~Exclusion Criteria:~* Age \> 75 years~* Severe cardiovascular or respiratory disease~* Pregnancy,,,t,t,t
6260177,NCT03901378,,ALL,18 Years,,f,,"Inclusion Criteria:~1. Be willing and able to provide written informed consent/assent for the trial.~2. Be 18 years of age on day of signing informed consent.~3. Must have cytologically or histologically proven high grade neuroendocrine carcinoma of the gastroenteropancreatic system or large cell neuroendocrine carcinoma as defined by the 2010 WHO classification.~   a. GEPNETs need to have Ki-67 greater than 55%.~4. Have metastatic or unresectable disease.~5. No prior systemic chemotherapy or immunotherapy for metastatic disease allowed.~6. Concurrent use of somatostatin analogs is allowed for symptom control.~7. Life expectancy greater than 12 weeks.~8. Have measurable disease based on RECIST 1.1.~9. Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the Sponsor/PI.~10. Have a performance status of 0 - 1 on the ECOG Performance Scale.~11. Demonstrate adequate organ function. All screening labs should be performed within 10 days of treatment initiation.~12. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.~13. Female subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication.~    Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.~14. Male subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.~    Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.~15. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.~Exclusion Criteria:~1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.~2. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.~3. Has a known history of active TB (Bacillus Tuberculosis)~4. Hypersensitivity to pembrolizumab or any of its excipients.~5. Has had prior systemic anti-cancer therapy for metastatic or unresectable neuroendocrine tumors other than somatostatin analogs.~6. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.~7. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.~   * Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study.~  * Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.~8. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.~9. Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.~10. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.~11. Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.~12. Has an active infection requiring systemic therapy.~13. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.~14. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.~15. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.~16. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).~17. Has a known history of Human Immunodeficiency Virus (HIV).~18. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.~19. Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist) are live attenuated vaccines and are not allowed.~    -",,,t,f,t
6260178,NCT02048878,NON_PROBABILITY_SAMPLE,ALL,21 Years,65 Years,t,Insomniacs and good sleepers,"Inclusion Criteria for Insomniacs:~* Men and women with primary insomnia of at least 3 months in duration~* ages 21-65 years old~* BMI \<35 kg/m2 to enable microneurography~* Moderate to severe insomnia based on the Insomnia Severity Index (ISI) questionnaire~* Pittsburgh Sleep Quality Index (PSQI) \> 5~* Self-reported habitual sleep duration \< 6.5 hours~Inclusion criteria for good sleepers:~* 21-65 years old men and women with BMI \<35 kg/m2~* No insomnia based on ISI questionnaire~* Self-reported habitual sleep duration ≥ 6.5 hours but \< 9 hours~* PSQI\<5~* Sleep efficiency on PSG with TRT of 8 hours \> 85%~* No history of mental illness, shift work, circadian rhythm disorders~Exclusion criteria for both insomniacs and good sleepers:~* Sleep disorders other than insomnia as assessed by screening PSG (apnea-hypopnea index or AHI ≥ 10, PLM arousal index ≥ 5)~* Circadian rhythm sleep disorders~* Diabetic based on HbA1c ≥ 6.5 %. For those with HbA1c ≥ 6.0 but \<6.5%, the non-diabetic condition will be confirmed by 2-h oral glucose tolerance test~* History of meeting DSM-IVR criteria based on the Mini International Neuropsychiatric Interview version 6.0 for any major psychiatric disorder~* Unstable or serious medical conditions~* Current, or use within the past month, of psychoactive (other than stable treatment with antidepressants), hypnotic, stimulant or analgesic medications (except occasional non-narcotic analgesics), beta blockers or alpha blockers~* Shift work or other types of self imposed irregular sleep schedules~* Habitual smoking~* Habitual alcohol consumption~* Pregnancy",,,t,f,t
6260179,NCT04531956,,ALL,60 Years,,f,,"Inclusion Criteria:~* Person has visited the general practitioner because of memory complaints no longer than 3 months ago (noticed by the person, a significant other and/or the general practitioner)~* Person is above the age of 60~* Person is able to complete baseline assessments~* Person must be mentally competent~* Person must give written informed consent prior to participation~Exclusion Criteria:~* Person has communication/language/comprehension/literacy or (severe) hearing problems~* Person has had a severe mental illness in the last 12 months, such as schizophrenia, depression or a bipolar disorder not otherwise specified~* Person has a life-threatening comorbid illness",,,t,f,t
6260180,NCT04795037,,ALL,19 Years,55 Years,t,,"Inclusion Criteria:~1. Healthy, adult, male or female (of non-childbearing potential only), 19-55 years of age, inclusive, at screening.~2. Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at screening.~3. Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dosing and throughout the study, based on subject self-reporting.~4. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee.~5. Female must be of non-childbearing potential and must have undergone one of the following sterilization procedures at least 6 months prior to the first dosing:~   * hysteroscopic sterilization;~  * bilateral tubal ligation or bilateral salpingectomy;~  * hysterectomy;~  * bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year prior to the first dosing and follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status.~6. A non-vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days after the last dosing.~   (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to the first dosing. A male who has been vasectomized less than 4 months prior to the first dosing must follow the same restrictions as a non-vasectomized male).~7. If male, must agree not to donate sperm from the first dosing until 90 days after the last dosing.~8. Able to swallow multiple capsules.~9. Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.~Exclusion Criteria:~1. Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.~2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.~3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.~4. History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing.~5. History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds.~6. Female subjects of childbearing potential.~7. Female subjects with a positive pregnancy test at screening or first check-in or who are lactating.~8. Positive urine drug or alcohol results at screening or first check-in.~9. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).~10. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg, at screening.~11. Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.~12. QTcF interval is \>460 msec (males) or \>470 msec (females) or has ECG findings deemed abnormal with clinical significance by the PI or designee at screening.~13. Unable to refrain from or anticipates the use of:~    * Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements (especially sulforaphane-containing supplement) beginning 14 days prior to the first dosing and throughout the study. After randomization, acetaminophen (up to 2 g per 24 hours) may be administered at the discretion of the PI or designee.~   * Food and beverages containing xanthines/caffeine for 24 hours prior to the first dosing (small amounts of caffeine derived from normal foodstuffs e.g.,250 mL/8 oz./1 cup decaffeinated coffee or other decaffeinated beverage, per day, with the exception of espresso; 45 g/1.5 oz. chocolate bar, per day, would not be considered a deviation to this restriction).~   * Food and beverages containing alcohol for 48 hours prior to the first dosing.~   * Food and beverages containing grapefruit/Seville orange for 14 days prior to the first dosing.~   * Food and beverages containing vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard) and charbroiled meats for 14 days prior to the first dosing.~14. Has received COVID-19 vaccine within 30 days of first dosing and until the end of the study.~15. Has been on a diet incompatible with the on-study diet, in the opinion of the PI or designee, within the 30 days prior to the first dosing and throughout the study.~16. Is lactose intolerant (FE cohort only).~17. Donation of blood or significant blood loss within 56 days prior to the first dosing.~18. Plasma donation within 7 days prior to the first dosing.~19. Participation in another clinical study within 30 days prior to the first dosing. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to the first dose of study drug in the current study.",,,t,f,f
6260181,NCT01764178,,MALE,20 Years,55 Years,t,,Inclusion Criteria:~* Healthy male volunteers~* Age 20-55 years at the time of Screening~* BMI 19-26 kg/m2 at the time of Screening~Exclusion Criteria:~* Received other investigational drug within 90 days prior to the first dose of study drug,,,t,f,f
6260182,NCT01413178,,ALL,18 Years,70 Years,f,,"Inclusion Criteria:~1. Patients with multiple myeloma in complete remission (CR), partial remission (PR), or very good partial remission (VGPR), or symptomatic stable disease (no evidence of progression) including patients with light chain MM detected in the serum by free light chain assay.~2. Patients with non-secretory multiple myeloma \[absence of a monoclonal protein (M protein) in serum as measured by electrophoresis (SPEP) and immunofixation (SIFE) and the absence of Bence Jones protein in the urine (UPEP) defined by use of conventional electrophoresis and immunofixation (UIFE) techniques\] but with measurable disease on imaging studies like MRI, CT scan or PET scan.~3. Who have received at least two cycles of initial systemic therapy and are within 2 to 12 months of the first dose. Mobilization therapy is not considered initial therapy.~4. 70 years of age or younger.~5. Karnofsky performance score 70% or higher.~6. Cardiac function: left ventricular ejection fraction at rest \> 40% within 3 months of registration.~7. Hepatic function: bilirubin \< 2x the upper limit of normal and ALT and AST \< 2.5x the upper limit of normal.~8. Renal function: creatinine clearance of \>/= 40 mL/min, estimated or calculated.~9. Pulmonary function: DLCO, FEV1, FVC \>/= 50% of predicted value (corrected for hemoglobin) within 3 months of registration~10. Signed informed consent form.~Exclusion Criteria:~1. Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and progression of clinical symptoms).~2. Patients seropositive for the human immunodeficiency virus (HIV).~3. Patients with history of myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.~4. Patients participating in an investigational new drug protocol within 14 days before enrollment.~5. Female patients who are pregnant (positive b-HCG) or breastfeeding.~6. Prior stem cell transplantation allogeneic or autologous.~7. Prior organ transplant requiring immunosuppressive therapy.",,,t,f,t
6159112,NCT01454791,,ALL,18 Years,,f,,"Inclusion Criteria:~* Diagnosis of Multiple Sclerosis (MS) made at least 3 months prior based on McDonald or Poser criteria.~* Age 18 or more~* Ongoing treatment with glatiramer acetate (Copaxone) for three months or more.~* No MS exacerbation for 60 days prior to screening.~* Mean score of greater than or equal to 1.0 on screening Local Injection Site Reaction scale of last 3 days.~* Written informed consent.~Exclusion Criteria:~* Regular use of any non-steroidal anti-inflammatory drug (NDAID), except Asprin (\<325 mg daily), between screening and end of study.~* Any contraindication to Diclofenac Sodium Topical Gel (DSTG)~  * allergy to DSTG or any NSAID.~ * history of asthma, urticaria, or other allergic reaction after taking any NSAID.~* Females who are breast feeding, pregnant or have potential to become pregnant during the course of the study(fertile and unwilling/unable to use effective contraceptive measures).~* Cognitive deficits that would interfere with the subject's ability to give informed consent or preform study testing.~* Any other serious and/or unstable medical condition.",,,t,f,t
6159113,NCT04808791,,ALL,18 Years,,f,,"Inclusion Criteria:~1. Patients must be 18 years of age or older.~2. Histologically documented locally advanced or metastatic gastric or GEJ adenocarcinoma not previously treated with palliative systemic therapy.~3. Patients must be capable of providing consent to enrolment and treatment.~4. Patients with a performance status of ECOG 0-1 will be eligible for enrolment (see appendix 1).~5. Measurable disease must be present according to RECIST criteria V1.1 (see appendix ).~6. Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test at the time of screening. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes.~7. Patients (men and women) of childbearing / reproductive potential should use highly effective birth control methods, as defined by the investigator, during the study treatment period and for a period of 6 months after the last dose of study drug. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly. Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard.~8. Female patients who are breast-feeding should discontinue nursing prior to the first dose of study treatment and until 30 days after the last dose of study drug.~9. Male patients should agree to not donate sperm during the study and for a period of at least 6 months after last dose of study drug.~10. Absence of any condition hampering compliance with the study protocol and follow- up schedule; those conditions should be discussed with the patient before registration in the trial.~11. Patients may have received prior surgery if this surgery was ≥ 4 weeks before study entry and patients must have recovered from the toxic effects of this treatment.~12. Patients who have treated brain metastasis (via local radiation standards or surgical resection or local ablative techniques) and who are either off steroids or on a stable dose of steroids for at least one month (30 days), AND who are off anticonvulsants, AND have radiological documented stability of lesions for at least 3 months may be eligible. Each case should be discussed with the study Chair.~13. Patients who have received prior chemotherapy or radiation delivered as part of initial curative therapy (i.e. neoadjuvant or adjuvant chemotherapy administered alone and/or concurrently delivered with radiation and/or surgery) are permitted as long as that treatment was completed at least 6 months prior to study start date.~14. Patients may have received prior palliative radiotherapy (unless radiation was curative therapy to pelvis or to ≥ 25% of bone marrow stores) if this radiation was ≥ 4 weeks before study entry and patients must have recovered from the toxic effects of this treatment.~15. Patients with unknown Her2/neu status, or negative Her2/neu status based on IHC and/or FISH/CISH (Testing does not need to be done unless it is standard of care at participating centres).~16. The following adequate organ function laboratory values must be met:~Hematological:~Absolute neutrophil count (ANC) \>1.5 x10\^9/L Platelet count \>100 x10\^9/L Hemoglobin \>8 g/dL (may have been transfused)~Renal:~serum creatinine ≤ upper limit of institutional normal OR calculated creatinine clearance of ≥ 50 mL/min using the Cockcroft-Gault formula (or local institutional standard method)~Hepatic:~Total serum bilirubin \<1.5x ULN AST and ALT \<2.5x ULN (or ≤ 5 x ULN for patients with documented metastatic disease to the liver)~Exclusion Criteria:~1. Patients who have received prior palliative chemotherapy for their advanced gastric or GEJ tumor.~2. Prior curative or palliative radiation treatment to the pelvis or radiation therapy to ≥ 25% of bone marrow stores.~3. History of bowel obstruction due to peritoneal metastases or clinically documented ascites requiring paracenteses.~4. Previous or concurrent malignancies, excluding curatively treated in situ carcinoma of the cervix or uterus or non-melanoma skin cancer or in-situ carcinoma of the prostate (Gleason score ≤ 7, with all treatment being completed 6 months prior to enrollment, unless at least 5 years have elapsed since last treatment and the patient is considered cured).~5. Active bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.~6. Known infection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection, or subject receiving immunosuppressive or myelosuppressive medications that would, in the opinion of the investigator, increase the risk of serious neutropenic complications.~7. Any serious medical condition within 6 months prior to study entry such as myocardial infarction, uncontrolled congestive heart failure, unstable angina, active cardiomyopathy, unstable ventricular arrhythmia, cerebrovascular diseases, uncontrolled hypertension, uncontrolled diabetes, uncontrolled psychiatric disorder, serious infection, active peptic ulcer disease, or other medical condition that may be aggravated by treatment.~8. Pre-existing neuropathy ≥ grade 2 from any cause.~9. Patients with unstable metastasis to the central nervous system (CNS). A CT scan or MRI is NOT required to rule out brain metastases unless there is clinical suspicion of CNS involvement.~10. Pregnant or lactating women; women of child bearing potential must have a negative serum pregnancy test within 7 days of trial registration. Women or men of child bearing potential must use effective contraception (defined by the treating physician) which must be documented in study CRFs.~11. History of allergic reaction to planned study medications.~12. Patient has a ≥ 20% decrease in serum albumin level between baseline visit, if available, and within 72 hours prior to first study treatment dose.~13. Patient is on coumadin.~14. History of interstitial lung disease.~15. History of connective tissue disorders (e.g. lupus, scleroderma, polyarteritis nodosa).~16. Enrollment in any other clinical protocol or investigational study with an interventional agent or assessments that may interfere with study procedures.~17. Any significant medical condition, laboratory abnormality, or psychiatric illness, that would prevent the subject from participating in the study, places the subject at unacceptable risk if he/she were to participate in the study, or any condition that confounds the ability to interpret data from the study.~18. Positive Her2/neu status (NOTE: if this is discovered after patient has already been enrolled on study, patient may continue on study per the discretion of the treating physician.)",,,t,f,t
6159114,NCT01040091,,ALL,18 Years,55 Years,t,,"Inclusion Criteria for HIV-Uninfected Participants:~* Ability to provide informed consent~* Ability to comply with the study procedures~Exclusion Criteria for HIV-Uninfected Participants:~* Positive screening test for HIV infection~* Positive screening test for hepatitis B (HBV) infection~* Pregnant or planning to become pregnant in the 3 months after study entry~* Breastfeeding~* If sexually active and fertile (no tubal ligation or hysterectomy), refusal to use two forms of birth control (e.g., condom and hormonal birth control) during the 60-day study~* Estimated glomerular filtration rate (GFR) less than 60 mL/min/1.73 m\^2 by the Modification of Diet in Renal Disease (MDRD) method~* Albuminuria (greater than 30 mg urine albumin per g of urine creatinine)~* Blood donation within 56 days of the screening visit~* Any grade I or higher abnormality in hemoglobin, platelets, serum phosphorous, and lipase on the screening visit; grade I abnormalities in other labs will be evaluated on a case by case basis (using DAIDS criteria)~* Any greater than grade I abnormality in screening laboratory tests (using DAIDS grading criteria)~* Medical history of chronic uncontrolled high blood pressure equal to or above 140/90 mm Hg~* Use of any investigational medication in the 30 days before study entry~* Daily anticoagulant therapy (daily aspirin or non-steroidal anti-inflammatory drugs \[NSAIDs\] will be allowed if discontinued for 1 week prior to the rectal biopsy)~* Any nephrotoxic concomitant medication (e.g., aminoglycosides, cyclosporine, cidofovir, foscarnet, amphotericin B)~* Active recreational drug or alcohol abuse~* Any concomitant medication (or herbal product) that, in the opinion of the investigators, would interfere with the study outcomes (acceptable medications include acetaminophen, occasional ibuprofen/NSAID, vitamins, and birth control pills)~* History of pathologic bone fractures~* Any chronic or acute medical condition that, in the opinion of the investigator, would interfere with study conditions, such as cancer, heart disease, or diabetes~* Body weight under 110 pounds~Inclusion Criteria for HIV-Infected Participants:~* HIV-infected adults (HIV documented in medical record or by the primary clinician)~* Clinician/participant plan to initiate TDF/FTC/EFV therapy and agree to separate TDF/FTC and EFV prescriptions for the initial 30 days of the study~* Ability to provide informed consent~* Ability to comply with the study procedures~Exclusion Criteria for HIV-Infected Participants:~* Antiretroviral therapy in the preceding 6 months~* Pregnant or planning to become pregnant in the 3 months after study entry~* Breastfeeding~* If sexually active and fertile (no tubal ligation or hysterectomy), refusal to use two forms of birth control (e.g., condom and hormonal birth control) during the 60-day study~* Estimated GFR less than 60 mL/min/1.73 m\^2 by the MDRD method~* Albuminuria (greater than 30 mg urine albumin per g of urine creatinine)~* Greater than a grade II abnormality in hemoglobin or platelets. Greater than a grade II abnormality in other clinical chemistry or hematology tests that, in the opinion of the investigators (principal investigator, study coordinator, and study physician) and primary clinician, would preclude participation in the study. DAIDS grading criteria will be used.~* Use of any investigational medication in the 30 days before study entry~* Daily anticoagulant therapy (daily aspirin or NSAIDs will be allowed if discontinued for 1 week prior to the rectal biopsy)~* Any nephrotoxic concomitant medication (e.g., aminoglycosides, cyclosporine, cidofovir, foscarnet, amphotericin B)~* Any concomitant medication (or herbal product) that, in the opinion of the investigators, would interfere with the study outcomes (acceptable medications include acetaminophen, occasional ibuprofen/NSAID, vitamins, and birth control pills)~* Any chronic or acute medical condition that, in the opinion of the investigator, could lead to emergent health complications, or could interfere with the participant's ability to follow study procedures~* Body weight under 110 pounds",,,t,f,f
6260183,NCT04513808,,ALL,18 Years,90 Years,f,,"Inclusion Criteria:~* Primary esophageal cancer without known extension beyond the esophagus. (i.e. believed to be Tumor Stage 1-3).~* Scheduled for potentially curative esophageal cancer surgery.~* Written informed consent, including willingness to be randomized to intravenous versus volatile anesthesia.~Exclusion Criteria:~* Previous surgery for esophageal cancer (except diagnostic biopsies) Age \<18 or \>85 years old.~* ASA Physical Status ≥4.~* Any contraindication to propofol or sevoflurane.~* Other cancer not believed by the attending surgeon to be in long-term remission.~* Systemic disease believed by the attending surgeon to present ≥25% two- year mortality.",,,t,f,t
6260184,NCT00000807,,ALL,12 Years,,f,,"Inclusion Criteria~Concurrent Medication:~Allowed:~* Maintenance therapy for opportunistic infections.~Patients must have:~* HIV infection.~* Kaposi's sarcoma that has relapsed or progressed.~* Mucocutaneous lesions (15 or more) and/or symptomatic mucosal lesions and/or visceral Kaposi's sarcoma (symptomatic lymphedema qualifies patients in the absence of these three conditions).~* NO active acute opportunistic infections requiring treatment with myelosuppressive antibiotics (maintenance for OIs is permitted).~* Consent of parent or guardian if less than 18 years of age.~NOTE:~* This study is approved for prisoner participation.~Exclusion Criteria~Co-existing Condition:~Patients with the following symptoms or conditions are excluded:~* Other active malignancies except basal cell carcinoma of the skin, or carcinoma in situ of the cervix.~* Grade 3 or worse peripheral neuropathy.~* Altered mental status that would prevent informed consent or prevent study compliance.~Patients with the following prior condition are excluded:~Neuropsychiatric history.~Prior Medication:~Excluded:~* Prior etoposide.~* Any other anti-KS drugs within 14 days prior to study entry.~* Any investigational drug other than antiretrovirals within 14 days prior to study entry.~* Any prior investigational agent, if given as the ONLY prior treatment for KS.~Prior Treatment:~Excluded:~* Radiation therapy within 7 days prior to study entry.~Continued alcohol consumption or continued intravenous drug use that would impair ability to comply with study requirements.",,,t,t,t
6260185,NCT05460208,,ALL,6 Years,18 Years,f,,"Inclusion Criteria:~* Age between 6 and 18 years~* Familial hypercholesterolemia~* Acceptance to participate by signing the informed consent~Exclusion Criteria:~* Children under 6 years of age~* Absence of hypercholesterolemia~* Children who receive some type of medication to control hypercholesterolemia, blood pressure, levels of glucose or dyslipidemia or any probiotic, which have invalid data for the variables of the present study~* Not to sign the informed consent.",,,t,t,f
6260186,NCT00739778,,ALL,18 Years,75 Years,t,,"Inclusion Criteria:~* Good general health as evidenced by the medical history.~* Male or non-pregnant, non-lactating females ages 18 to 75 inclusive.~* Caries experience in the past year.~* More than 5 decayed, missing, or filled teeth demonstrating a high caries experience.~* Acidogenic plaque as demonstrated by a drop in pH to 5.7 or lower when challenged with sucrose rinse at the screening visit.~* Willing to abstain from all oral hygiene procedures, brushing and flossing, for 48 hours prior to each test day and drink only water for the four (4) hours prior to each test.~* Willing to abstain from the use of mouthwashes during the study.~Exclusion Criteria:~* Presence of orthodontic appliances.~* Systemic conditions which could influence the pH of the oral cavity (i.e., diabetes, salivary gland disorders etc.).~* Use of medications that would influence the pH of the oral cavity. Specifically, concomitant use of neuroleptics, atropine, chemotherapeutic agents, diuretics, antibiotics, antihistamines, decongestants, and muscle relaxants. Also, anticipated need for intermittent use of any medications in these classes or history of use during the 72 hours immediately prior to the screening visit.~* Patients with aggressive periodontitis, acute necrotizing ulcerative gingivitis, or gross decay at discretion of Investigator.~* Females who by self report are pregnant, lactating, planning to be pregnant during the study period, or women of childbearing potential who are unwilling to commit to the use of a medically approved form of contraception during the study period.~* Exposure to any investigational agent within the 30 days prior to study visit 1~* Individuals requiring prophylactic antibiotics~* Allergy or intolerance to food ingredients and products including artificial sweeteners.",,,t,f,t
6361040,NCT04958018,,ALL,30 Years,65 Years,t,,"Inclusion Criteria:~* Male or female, ages 30-65 years.~* Non-smoker.~* Body mass index of 23 to 30 kg/m2.~* Not engaged in regular weight lifting (less than 3 sessions per week).~* Agree to train normally, maintain weight, and avoid the regular use of protein supplements, large-dose vitamin and mineral supplements, herbs, and medications that influence inflammation (especially Advil, Motrin, aspirin, and similar drugs) during the study.~* Categorized as low risk using a screening questionnaire.~* Generally healthy and without disease including heart disease, stroke, cancer, diabetes, arthritis.~* Willing to collect two 24-hour urine samples.~Exclusion Criteria:~* Inability to comply with study requirements.~* Engaged in regular weight training (3 or more times a week).~* Pregnant or breastfeeding.~* Any other condition that would interfere with successful completion of the study.~* Current diagnosis of heart disease, diabetes, or cancer (except for skin cancer).~* History of allergic reactions to almonds or cereal bars.",,,t,f,t
6057070,NCT04911374,,FEMALE,35 Years,65 Years,t,,"Inclusion Criteria:~* Women between the ages of 35 and 65 years~* Women with Fitzpatrick skin type I-VI~* Subjects must have mild to droopy eyelids, moderate crow's feet wrinkles, and moderate photodamage~* Subjects must have no known medical conditions that, in the investigator's opinion, may interfere with study participation.~* Subjects must be willing to provide verbal understanding and written informed consent.~Exclusion Criteria:~* Subjects which had a health condition and/or pre-existent dormant dermatological disease on the face~* Subjects that had any invasive or non-invasive skin treatments, or invasive medical procedures three months prior to the study~* Subjects that are unwilling to comply with the protocol~* Female subjects who are pregnant, breast feeding, or planning a pregnancy.~* Subjects who have any dermatological disorder, which in the investigator's opinion, may interfere with the accurate evaluation of the subject's skin, including rosacea, acne, and excessively oily or dry skin.~* Subjects who have demonstrated a previous hypersensitivity reaction to any of the ingredients of the study products.~* Subjects use of any medications that are known to potentially cause changes in the facial skin as determined by the Investigator.~* Subjects who spend excessive time out in the sun.",,,t,f,t
6260187,NCT05717907,,ALL,18 Years,65 Years,f,,"Inclusion Criteria:~* Patient undergoing elective oral and maxillofacial surgery in which nasotracheal intubation is preferred over orotracheal intubation to optimize surgical access.~* ASA physical status I-II~* Thai adult, aged 18-65 years old~* Normal Body Mass Index (BMI = 18.5-24.9)~Exclusion Criteria:~* Anticipated difficult airway (e.g., Mallampati classification 3-4, interincisal distance \< 35 mm., thyromental length \< 60 mm., limited neck mobility)~* Nasal infection or systemic infection~* Abnormal coagulation status or having bleeding disorder or taking anticoagulation/antiplatelet medication~* History of recurrent epistaxis since adulthood~* Allergic rhinitis that necessitates the use of glucocorticoids, antihistamine, antileukotriene or decongestant in the past 4 weeks~* History of nasal trauma or abnormality (e.g., trauma in mid-face region, nasal surgery, nasal polyps, chronic sinusitis, abnormal nasal vasculature, tumor in nasal region, radiotherapy in nasal region)~* Craniofacial deformity syndrome~* Using nasal oxygen or Continuous Positive Airway Pressure (CPAP)~* Previous nasotracheal intubation or nasogastric tube placement within 3 months~* Diagnosed as having a mental disorder~Drop-out criteria:~* Unable to complete intubation procedure~* Intubation failed on both nostrils~* When intubation was only possible with a tube smaller than 6.5 internal diameter (ID) in male and 6.0 ID in female~* Inadequate data collection",,,t,f,t
6260188,NCT04118556,,ALL,18 Years,,f,,"Inclusion Criteria:~1. Adult patients (age ≥ 18 years) with steroid refractory acute GvHD grades II-IV after allo-HSCT.~2. Signed written study informed consent once SR-aGvHD is confirmed.~Exclusion Criteria:~1. Presence of an active uncontrolled infection including significant bacterial, fungal, viral or parasitic infection requiring treatment.~2. Has received systemic treatment for aGvHD apart from steroids.~3. Clinical presentation resembling de novo chronic GvHD or GvHD overlap syndrome.~4. Pregnant or lactating women.~5. Significant respiratory disease.~6. Presence of severely impaired renal function~7. Any corticosteroid therapy for indications other than aGvHD~8. Previous participation in a study of any investigational treatment agent within 30 days~9. Known human immunodeficiency virus infection (HIV).~10. Patients suffering on active tuberculosis or viral hepatitis~11. Significant respiratory disease~12. Presence of severely impaired renal or liver function~13. History of progressive multifocal leuko-encephalopathy~14. Patients with coagulopathy~15. History of severe chronic history of heart disease~16. Any condition that would, in the Investigator's judgment, interfere with full participation in the study.",,,t,f,t
6260189,NCT02660658,,ALL,18 Years,65 Years,f,,Inclusion Criteria:~* American Society of Anesthesiologists physical class I to II.~* Patients scheduled for elective lower limb surgeries.~Exclusion Criteria:~* Morbid obese patients.~* Severe or uncompensated cardiovascular disease.~* Significant renal disease.~* Significant hepatic disease.~* Pregnancy.~* Lactating .~* Heart block.~* Bradyarrhythmias.~* Receiving adrenergic receptor antagonist medications.~* Receiving calcium channel blockers.~* Patients with pacemakers.~* Patients with implanted cardioverter defibrillator.~* Allergy to the study medications.~* Psychological disease.~* Neurological disorders.~* Communication barrier.~* Mental disorders.~* Epilepsy.~* Drug or alcohol abuse.~* Contraindications to spinal anaesthesia.~* Receiving opioid analgesic medications within 24 h before the operation.,,,t,f,t
6057071,NCT05354674,NON_PROBABILITY_SAMPLE,ALL,18 Years,79 Years,f,Initially unresectable CRLM patients with PET/CT images and colonoscopy biopsy specimens before treatment.,"Inclusion Criteria:~Age 18-75 years; Histologically proven colorectal adenocarcinoma; Simultaneous liver-limited metastases; Initially unresectable liver metastases determined by a local MDT; Life expectancy of \> 3 months; RAS mutation and BRAF V600E wild-type; ECOG 0-1; Available PET/CT imaging before treatment; Available colonoscopy biopsy specimens before treatment~Exclusion Criteria:~Previous systemic treatment for metastatic disease; Previous surgery for metastatic disease; Extrahepatic metastases; Unresectable primary tumor; Major cardiovascular events (myocardial infarction, severe/unstable angina, congestive heart failure, CVA) within 12 months before randomisation; Acute or subacute intestinal obstruction; Second primary malignancy within the past 5 years; Drug or alcohol abuse; No legal capacity or limited legal capacity; Pregnant or lactating women; Uncontrolled hypertension, or unsatisfactory blood pressure control with ≥3 antihypertensive drugs; Peripheral neuropathy;",,,t,f,t
6057072,NCT04938674,PROBABILITY_SAMPLE,ALL,,,f,All patients with severe trauma received in the emergency room of the Second Affiliated Hospital of Zhejiang University Medical College from April 2020 to March 2021,"Inclusion Criteria:~* ① airway obstruction, need tracheal intubation or intubation;② breathing stop, respiratory distress or significant slowing down;③ circulatory system shows various shock signs④GCS≤8;⑤ body table visible head, torso, chest open injury or yoke chest~Exclusion Criteria:~* All patients who stop the rescue room trauma evaluation and treatment midway through hospital transfer and automatic discharge",,,t,t,t
6057073,NCT06233110,,ALL,18 Years,80 Years,f,,"Inclusion Criteria~1. Patient is able and willing to provide written informed consent prior to any study related screening procedures are performed.~2. Age ≥ 18 years old at the time of informed consent~3. Have undergone allogeneic HCT from any donor source (matched unrelated donor, sibling, haploidentical) using bone marrow, peripheral blood, or cord blood stem cells.~4. Adequate bone marrow function defined as:~   1. Absolute neutrophil count (ANC) ≥ 750 /mm3~  2. Platelet count ≥ 40,000 /mm3~  3. Hemoglobin ≥ 8.0 g/dL without transfusion support Note: Use of growth factor supplementation (myeloid, erythroid or megakaryocytic) is permitted to meet eligibility criteria.~5. Patients with clinically diagnosed cGvHD staging of mild to severe according to NIH Consensus Criteria prior to Cycle 1 Day 1, and who have confirmed corticosteroid dependence or refractoriness irrespective of the concomitant use of a calcineurin inhibitor, as follows:~   1. Disease progression after administration of a minimum dose of 1.0mg/kg/day or equivalent for at least 1 week at any time following diagnosis of cGvHD OR~  2. Disease persistence despite continued treatment with prednisone ≥ 0.5mg/kg/d or equivalent for 4 weeks OR~  3. Increase to prednisone ≥ 0.25 mg/kg/d after 1 unsuccessful attempt to taper the dose OR~  4. Recurrence of chronic GVHD after attaining a complete response OR~  5. Progression of chronic GVHD after attaining a partial response~6. Patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0-2~Exclusion Criteria~1. Prior or ongoing treatment with ruxolitinib for treatment of cGvHD, unless initiation of ruxolitinib was within 3 weeks of Cycle 1 Day 1.~2. Ongoing second-line systemic therapy for cGvHD other than corticosteroids, calcineurin inhibitor, or mycophenolate mofetil, aside from fewer than 3 weeks of ruxolitinib. Ruxolitinib for the indication of acute GVHD is permitted.~3. Prior treatment with fostamatinib or another SYK inhibitor for the treatment of acute or chronic GVHD. Prior use of fostamatinib for immune thrombocytopenic purpura is permitted.~4. Patients with relapsed primary malignancy, or who have been treated for relapse after the allogeneic HCT was performed~5. Steroid refractory cGvHD occurring after a non-scheduled donor lymphocyte infusion (DLI) administered for pre-emptive treatment of malignancy recurrence. Patients who have received a scheduled DLI as part of their transplant procedure and not for management of malignancy relapse are eligible~6. History of progressive multifocal leuko-encephalopathy (PML)~7. Active uncontrolled bacterial, fungal, parasitic, or viral infection. Infections are considered controlled if appropriate therapy has been instituted and, at the time of screening, no signs of infection progression are present.~8. Evidence of active and uncontrolled viral disease including HIV, CMV, HHV-6, HBV, HCV, or BK virus.~9. Clinically significant and uncontrolled cardiovascular disease, including unstable angina, acute myocardial infarction, or stroke within 3 months, or NYHA Class III or IV congestive heart failure.~10. Patients on mechanical ventilation or have a resting O2 saturation \< 90% by pulse oximetry~11. Uncontrolled hypertension with systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg.~12. Creatinine clearance by Cockroft-Gault of \< 15 mL/min and not on dialysis~13. Total bilirubin \> 3 times upper limit of normal (ULN), Alanine Aminotransferase (ALT) \> 5 times upper limit of normal, or Aspartate Aminotransferase (AST) \> 5 times upper limit of normal per institutional laboratory standards~14. QTc ≥ 470 ms as calculated by the Fridericia Formula51~15. Active pregnancy or breast feeding, or currently seeking active pregnancy~16. Any patient who, in the opinion of the investigator, may not be able to comply with study procedures",,,t,f,t
6057074,NCT00002874,,MALE,,,f,,"Conditions for Patient Eligibility:~* The patient on entry will have no clinical evidence of disease by physical exam or by imaging studies. A positive ProstaScint scan alone without a confirmatory biopsy must not be used to exclude a patient. Eligible patients will be those who have undergone a radical prostatectomy (either retropubic or perineal) and pelvic lymphadenectomy (either open or laparoscopic) for carcinoma of the prostate, pathologic stage T3N0, or pT2 pN0 with positive inked resection margin, at least 12 weeks prior to study entry.~* Pathological T2 patients without positive margins, who are also pathologic N0 with prostatic fossa/anastamosis biopsy at the time of rising PSA documenting recurrent cancer, are eligible.~* At entry, the PSA must be between 0.2 and 4.0ng/ml, inclusive.~* A post-prostatectomy radioisotopic bone scan which was done within 16 weeks prior to entry must reveal no evidence of metastatic disease.~* Patient must be evaluated by both the radiation oncologist and the urologist prior to entry and judged to be a suitable candidate for radiation and hormonal therapy.~* Patient must have Karnofsky performance status \>= 80.~* Patients must have a life expectancy in excess of 10 years.~* Patients must have, within 6 weeks prior to entry, a hemoglobin (Hgb) of \>=10 gm, a white blood cell (WBC) count of \>= 4000 cells/ml3, a platelet count of \>= 100,000 cells/ml3, a serum bilirubin \<= the institutional upper limit of normal, a serum serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamic-pyruvic transaminase (SGPT) of \<= 2.5 times the institutional upper limit of normal, and a serum creatinine of \<= 2.0 times the institutional upper limit of normal.~* A post-prostatectomy pelvic computerized tomography (CT) scan, within 16 weeks prior to randomization, must reveal no evidence of metastatic disease.~* Patients must sign a study-specific informed consent form.~* Patients with prior invasive cancers are eligible if disease free for at least 5 years; prior or concurrent basal or squamous cell skin cancer is eligible.~Conditions for Patient Ineligibility:~* Pathologic stage T2 (without positive inked resection margin) or less except as stated in Section 3.1.1.1.~* Pathologic lymph node stage of pN1 or greater.~* An entry serum PSA of \> 4.0ng/ml.~* Patients with persistant urinary extravasation after prostatectomy.~* Patients who have been previously treated with any hormonal therapy after prostatectomy.~* Patients who have previously been treated with radiation therapy or biologic therapy for prostate cancer.~* Karnofsky performance status \< 80.~* Treatment start \> 4 weeks after randomization.~* Prior chemotherapy for any reason.",,,t,t,t
6260190,NCT00028158,,ALL,19 Years,,f,,"Main Inclusion Criteria:~* Age 19 years and older~* Phase Ib: Histologically confirmed recurrent glioblastoma multiforme or gliosarcoma (recurrent anaplastic astrocytoma also included in phase Ib) that is progressive despite previous radio- or chemotherapy~* Phase II: Histologically confirmed recurrent glioblastoma multiforme or gliosarcoma that is progressive despite previous radio- or chemotherapy~* Enhancing brain tumor measures at least 1.0 cm in diameter and evaluable by MRI within 14 days of G207 administration (and proposed area of study drug inoculation appears to be resectable en bloc--for phase Ib only)~* Steroid regimen stable for at least 1 week prior to G207 inoculation~* Karnofsky Performance Status 70% or greater~* Failed external beam radiotherapy of at least 5000 cGy 4 weeks or longer prior to G207 administration~* Candidate for brain tumor resection~* Females: negative urine pregnancy test within 24 hours prior to G207 administration~* Willing to use effective barrier birth control~* Able to give informed consent~Main Exclusion Criteria:~* Multiple (more than one) intracranial malignant glioma lesions~* Documented extracranial metastases~* Laboratory test values (CBC, platelets, clinical chemistry, liver and renal function tests) outside protocol specified limits~* Chemotherapy, cytotoxic or immunotherapy within 6 weeks of G207 administration~* Any contraindication for undergoing MRI such as pacemakers, infusion pumps, aneurysm clips, metal prosthesis, former welders etc.~* Surgical resection within 4 weeks of G207 administration~* Pregnant or nursing females~* History of any of the following: HIV seropositive (historical or known); other investigational agents or vaccinations within 30 days; encephalitis, multiple sclerosis or other CNS infection; prior gene transfer therapy or prior therapy with a cytolytic virus of any type~* Any of the following concurrent conditions: evidence of active herpes infection; requires antiviral therapy for HSV at baseline; previous history or current diagnosis of other cancer except curative cervical cancer in situ or basal or squamous cell carcinoma of the skin; active uncontrolled infection, granulocytopenia, any unstable or severe medical condition that precludes surgery; alcohol or other substance abuse",,,t,f,t
6260191,NCT04453956,,ALL,18 Years,,t,,"Inclusion Criteria:~1. Male or female aged 18 years or above;~2. Colonoscopy is needed to further characterize gastrointestinal diseases;~3. Ability to read, understand and sign informed consent forms;~4. The researchers believe that the subjects can understand the process of the clinical study and are willing and able to complete all the study procedures and follow-up visits to cooperate with the study procedures.~Exclusion Criteria:~1. Participated in other clinical trials, signed informed consent forms and followed up in other clinical trials；~2. Participate in a drug clinical trial and during the elution period of the trial or control drug；~3. Drug or alcohol abuse or mental disorder in the last 5 years;~4. Pregnant or lactating women;~5. Patients with multiple polyp syndrome;~6. Patients with a history of inflammatory bowel disease, colorectal cancer, or colorectal surgery;~7. Patients with known perforation or colonic obstruction;~8. Patients with a contraindication for biopsy;~9. The researchers did not consider the subjects suitable for colonoscopy;~10. The researchers determined that the subjects had high-risk diseases or other special conditions that were not appropriate for clinical trials.",,,t,f,t
6159115,NCT03494491,,ALL,18 Years,40 Years,t,,"Inclusion Criteria:~* Woman or man, aged of 18 to 40 years~* Body mass index (BMI) between 18 and 25 kg/m2~* In good general health as evidenced by medical history and physical examination~* Non-smoker~* Caucasian~* For women: use of highly effective contraception~* H2 - producer as evidenced by the screening test (described in latter section)~* Provision of signed and dated informed consent form~* Stated willingness to comply with all study procedures and availability for the duration of the study~Exclusion Criteria:~* Subjects presenting gastro-intestinal disorders such as ulcers, diverticulitis and inflammatory bowel diseases~* Subject presenting allergy or food intolerance (lactose, gluten,...)~* Subjects with psychiatric problems and/or using antipsychotics~* Current or recent (\< 4 weeks) intake of antibiotics, probiotics, prebiotics, fiber supplement, and/or any products modulating gut transit~* Feeding particular diet such as vegetarian diet or hyper protein diet~* Chronic intake of drug, excepted contraceptive drug~* Pregnant or lactating woman or woman who did not use highly effective contraception~* Subjects who drink more than 3 glasses of alcohol per day (\> 30 g of alcohol per day)~* Subjects having participated to another clinical trial 1 month before the screening test visit~* Subjects presenting an allergy or intolerance to one component of the product tested",,,t,f,f
6260192,NCT05445258,,ALL,18 Years,,f,,Inclusion Criteria:~* 18 years of age~* Patients with peripheral arterial occlusive disease and intended for endovascular therapy in the SFA and/or popliteal artery pars I/II~* Patients suitable for endovascular therapy in the SFA and/or popliteal artery pars I/II with a hyper-compliant balloon without further luminal widening~* Target vessels with a sufficient runoff to the foot with at least one vessel~* Rutherford classification 1-4 if physical and medicinal therapies have not been successful~Exclusion Criteria:~* Aneurysms at the site of inflation~* Application directly in the area of large vessel wall injuries with heavy bleeding~* Rutherford classification 5 and 6,,,t,f,t
6057075,NCT04764474,,ALL,18 Years,,f,,"Key Inclusion Criteria:~Subjects may be enrolled in this study only if they satisfy all the following criteria (NOTE: This is not an exhaustive list):~* Subjects aged ≥18 years.~* ECOG performance status ≤ 2~* Subjects with advanced relapsed, refractory, or resistant hematological malignancies, as defined below:~Part 1:~* Subjects with documented IDH mutation per local or institutional next generation sequence (NGS).~* Subjects must be refractory to or intolerant of established therapies.~* Subjects who have received prior IDH inhibitor treatment may be enrolled in the escalation phase.~Part 2:~* Subjects with documented IDH mutation of any of these subsets: IDH1 (R132C), IDH1 (R132H), IDH (R140Q), and IDH2 (R172K), including co-mutations and any combination thereof per local and institutional NGS.~* Patients must have received at least 1 prior line of therapy with an IDH inhibitor. An established standard of care with proven benefit for which the patient is eligible, must not be available at the time of enrollment.~* Patients with AML must not have standard therapeutic options available (including IDH inhibitors where approved) and have the following:~  * i. Relapsed AML unsuitable for intensive chemotherapy or venetoclax-based regimen or target agents;~ * ii. Primary refractory AML unsuitable for intensive chemotherapy or venetoclax-based regimen or target agents.~ * iii. Relapsed/refractory AML that has progressed on prior IDH treatment~Key Exclusion Criteria:~Subjects are not eligible for enrollment into this study if they meet any of the following criteria (NOTE: This is not an exhaustive list):~* Subjects who received an investigational agent \<14 days prior to their first day of study drug administration.~* Subjects who are pregnant or breastfeeding.~* Subjects with an active severe infection, some treated infections and with an expected or with an unexplained fever \>38.3°C during screening visits or on their first day of study drug administration.~* Subjects with some current or prior heart conditions.~* Subjects taking medications that are known to prolong the QT interval may not be eligible.~* Subjects with immediately life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation.~* Some subjects with some current or prior gastrointestinal or liver diseases.~* Subjects with inadequate organ function as defined by the protocol.~* Subjects with a medical condition, physical examination finding, or clinical laboratory finding that, in the Investigators opinion, contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the subject at high risk from treatment complications.~* Subjects with a known hypersensitivity to HMPL-306 or to any of its excipients.~* Subjects with presence of second primary malignant tumors within the last 2 years, with the exception of the following, if medically controlled: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and carcinoma in situ of the breast.~* Part 2 Only: The time since the last dose of prior IDH inhibitor treatment is within 30 days prior to the first day of study drug administration",,,t,f,t
6260193,NCT00848237,,ALL,,,f,,Inclusion Criteria:~* Must be a candidate for ablation of Barrett's esophagus with the HALO Ablation System.~* Must agree to the proposed follow-up schedule and provide informed consent for participation.~Exclusion Criteria:~* Pregnancy~* Prior radiation therapy to the esophagus~* Esophageal varices at risk for bleeding~* Prior Heller Myotomy,,,t,t,t
6260194,NCT04475107,,ALL,19 Years,,f,,"Inclusion Criteria:~1. Age ≥19 years at the time of signing Informed Consent Form~2. Body weight ≥45 kg at screening~3. Laboratory (rRT-PCR) confirmed infection with SARS-CoV-2 by testing specimens from upper airway (i.e. nasopharyngeal and oropharyngeal swab) or lower airway (i.e. sputum) within 96 hours of randomization~4. Oxygen saturation(SpO2) \> 94% at randomization, in room air condition~5. Willing and able to provide informed consent~Exclusion Criteria:~1. Diagnosed with severe pneumonia~2. Patients with clinically significant cardiovascular disease (including arrhythmia, QTc interval prolongation)~3. Patients with clinically significant anemia (Hemoglobin \<8.0 g/dL)~4. Patient with known allergic reaction or contraindication to any of the investigational medicinal product (pyronaridine tetraphosphate, artesunate)~5. Patients with known history of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, etc.~6. Patients with the gastrointestinal disease and surgery to affect the absorption, distribution, metabolism and excretion of the drug, active gastritis, gastrointestinal tract / rectal bleeding, gastric ulcer, pancreatitis abnormalities (except simple appendectomy or hernia surgery)~7. Patients who received antiviral drugs that is intended to treat COVID-19, within 28 days prior to screening evaluation (can be enrolled into the study, if the patient has gone through a sufficient wash-out period)~8. Patients with known severe renal impairment (estimated glomerular filtration rate ≤30 mL/min/1.73 m2)~9. Patients with known severe liver disease (i.e. ALT or AST\>5 times upper limit, nausea, abdominal pain associated with jaundice or Child-Pugh stage B or C)~10. Viral disease (HIV, HBV, HCV, etc.) other than COVID-19 that require administration of other antiviral agents~11. Patients that require ventilation therapy (e.g. non-invasive ventilation, invasive mechanical ventilation, extracorporeal membrane oxygenation, etc.)~12. Patients with chronic underlying disease (e.g. uncontrolled diabetes mellitus, chronic kidney disease, chronic liver disease, chronic pulmonary disease, chronic cardiovascular disease, blood cancer, cancer patients with cancer treatment, patients taking immunosuppressants), highly obese patients, dialysis patients, and transplant patients that are determined by the Physician, to be not suitable for trial involvement.~13. Pregnant or lactating women~14. Male or female of childbearing potential who has plans to become pregnant during the study period and for three months after the clinical study or who is not willing to take appropriate contraceptive measures~    \*Hormonal contraception (contraceptive implant, injections, pills, etc.), IUDs, condoms (male) and contraceptive diaphragm or cap (female), sterilization (vasectomy, tubal ligation, etc.)~15. Participating in another clinical trial currently or within 28 days from signing the informed consent~16. Patients that are deemed ineligible to participate in the clinical trial by the Investigator",,,t,f,t
6057076,NCT02442401,,FEMALE,20 Years,60 Years,f,,Inclusion Criteria:~* Age between 20-60 years Underwent breast reconstruction with LD Flap~Exclusion Criteria:~* Locally advanced cancer,,,t,f,f
6260195,NCT03974932,,ALL,18 Years,,f,,"Inclusion Criteria:~* Is scheduled to undergo primary unilateral TKA under spinal anesthesia.~* Has not previously undergone TKA in either knee.~* Has an American Society of Anesthesiologists (ASA) Physical Status of I, II, or III.~* Is able to walk at least 20 feet with optional use of a 4-legged walker for balance.~* Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or is at least 2 years post-menopausal; or is in a monogamous relationship with a partner who is surgically sterile; or using acceptable contraceptives.~Exclusion Criteria:~* Has a planned concurrent surgical procedure.~* Has other pre-existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain.~* Has a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.~* Using or expected to use Factor IX Complex or anti-inhibitor coagulant concentrates during the study.~* Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.~* Has taken NSAIDs within 10 days prior to the scheduled surgery with the exception of subjects on low-dose (≤100 mg) daily acetylsalicylic acid for cardioprotection.~* Has taken opioids within 24 hours prior to the scheduled surgery (3 days for long-acting).~* Has been administered bupivacaine within 5 days prior to the scheduled surgery.~* Has been administered any local anesthetic within 72 hours prior to the scheduled surgery.~* Has initiated treatment with medications within 1 month prior to study drug administration that can impact pain control.~* Has been administered systemic steroids within 5 half-lives or 10 days prior to administration of study drug.~* Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half lives.~* Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse.~* Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.~* Is currently undergoing treatment for hepatitis B, hepatitis C, or HIV.~* Has uncontrolled anxiety, psychiatric, or neurological disorder that, in the opinion of the Investigator, might interfere with study assessments.~* Has acquired defective color vision or acute gastrointestinal ulcers, either of which could interfere with scheduled study medications.~* Has any chronic neuromuscular deficit of either femoral nerve function or thigh musculature.~* Has any chronic condition or disease that would compromise neurological or vascular assessments.~* Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.~* Has undergone 3 or more surgeries within 12 months.~* Has a body mass index (BMI) \>39 kg/m2.",,,t,f,t
6159116,NCT04880291,,ALL,18 Years,75 Years,t,,"Inclusion Criteria:~* 18 to 75 years of age at the time of signing informed consent.~* Body mass index (BMI) between 25.0 and 40.0 kg/m2, inclusive, at Screening.~* Female participants will be of non-childbearing potential.~* Male participants will agree to use contraception while on study intervention and for at least 6 months after the last dose of study intervention.~* SAD cohorts only: Participants must be in good health.~* Repeat-dose cohort only: Type 2 diabetes mellitus (T2DM) treated with lifestyle modification or metformin, and in otherwise good health except for well-controlled common conditions associated with T2DM, such as hypertension and dyslipidemia.~Exclusion Criteria:~* History of, or treatment for, psychiatric illness, including anxiety or depression within 5 years of the Screening visit.~* Participants with a history of attempted suicide or clinically significant suicidal ideation.~* History of cardiovascular disease.~* Blood pressure \>155 mmHg systolic or \>95 mmHg diastolic.~* History of alcoholism or drug/chemical abuse within 2 years prior to Screening.~* Alcohol consumption of \>21 units per week for males and \>14 units for females. One unit of alcohol equals 12 oz (360 mL) beer, 1.5 oz (45 mL) liquor, or 5 oz (150 mL) wine.~* History of significant hypersensitivity, intolerance, or allergy to more than one class of drugs.~* Positive hepatitis panel and/or positive human immunodeficiency virus test. Participants whose results are compatible with prior immunization may be included.~* SAD cohorts only: Fasting glucose \>126 mg/dL.",,,t,f,t
6057077,NCT02801110,PROBABILITY_SAMPLE,ALL,30 Years,80 Years,f,Patients diagnosed with IPD suffering from asymmetrical motor signs.,"Inclusion Criteria:~1. Age above 30 below 80 years of age.~2. A clinical diagnosis of idiopathic PD.~3. Patients with asymmetric presentation of PD (by history/medical documentation).~4. Patients with persistent motor asymmetry (with side predominance respecting the side of symptom onset).~Exclusion Criteria:~1. Patients with history of other brain disorder/pathology.~2. Patients with atypical signs suggesting another neurodegenerative disorder, psychiatric disorders, signs of severe cognitive deterioration, severe cardiovascular comorbidity~3. Patients treated with levodopa.~4. Patients on medication known to interfere with the DAT or catechol O-methyltransferase inhibitors, or with dopamine receptor blocking / or catecholamine re-uptake blocking properties.~5. Patients suffering from dystonia.~6. Pregnancy/ Breastfeeding.~7. Contraindication to MR imaging.~8. Uncontrolled head/body movements.",,,t,f,t
6159117,NCT06097754,,ALL,18 Years,35 Years,t,,"Inclusion Criteria:~* Males or females between 18 and 35 years old~* Body Mass Index (BMI) between 18 and 25~* Physically fit and regularly involved in physical activity (2-5 exercise sessions of \> 30min per week)~* Good health status confirmed by a medical screening~* Non smoking~Exclusion Criteria:~* Any kind of injury/pathology that is a contra-indication for hypoxic exposure and/or to perform high-intensity exercise~* Intake of any medication or nutritional supplement that is known to affect exercise, performance or sleep~* Intake of analgesics, anti-inflammatory agents, or supplementary antioxidants, from 2 weeks prior to the start of the study.~* Recent residence or training under hypoxia; more than 7 days exposure to altitude \> 2000m during a period of 3 months preceding the study.~* Night-shifts or travel across time zones in the month preceding the study~* Blood donation within 3 months prior to the start of the study~* Smoking~* More than 3 alcoholic beverages per day~* Involvement in elite athletic training at a semi-professional or professional level~* Any other argument to believe that the subject is unlikely to successfully complete the full study protocol",,,t,f,f
6057078,NCT01530074,,ALL,18 Years,70 Years,t,,"Inclusion Criteria:~* Healthy subjects with no systemic diseases, chronic medication, past nerve injury, or sensory complaint.~Exclusion Criteria:~* Hypersensitivity/allergy to local anesthetic materials~* Systemic diseases, Chronic medication~* Past nerve injury~* Congenital or acquired deformity in the lower jaw~* Past fractures/neoplasm of the lower jaw~* Past surgery to the lower lip",,,t,f,t
6057079,NCT04002128,,ALL,18 Years,90 Years,f,,"Inclusion Criteria:~* Adult patients diagnosis of gastric cancer, or colorectal cancer or pancreatic cancer~* Scheduled for major abdominal surgery with organ resections~* Written informed consent~* Nasopharyngeal smears taken in the preoperative area~* Tracheal aspirates taken at the end of the surgical procedure~Exclusion Criteria:~* Patients unable to understand study protocol and patients who refused study participation at any time~* patients with clinically or radiologically confirmed acute respiratory infections at admission~* antibiotic therapy due to the respiratory infections a week prior to the surgery",,,t,f,t
6057080,NCT01819038,,ALL,18 Years,,f,,"Inclusion Criteria:~* The patient must have given his/her informed and signed consent~* patients with acute kidney injury in the intensive care ward.~Exclusion Criteria:~* The patient refuses to sign the consent~* The patient is pregnant, parturient, or breastfeeding~* End stage renal disease~* Chronic renal failure~* previous kidney transplant",,,t,f,t
6057081,NCT02003274,,ALL,18 Years,65 Years,t,,"Inclusion Criteria:~* patient must be aged between 18 (inclusive) and 65 years old;~* patient must have been diagnosed with type 1 diabetes(positive islet cell antibodies;~* use of an insulin pump to treat his/her diabetes for at least 1 year;~* actively using a carbohydrate/insulin ratio for insulin bolus adjustments in order to keep blood glucose in a predefined range;~* patient HbA1c is between 6,0% and 9,0% (standardized with DCCT);~* patient must be willing to avoid consumption of acetaminophen containing products during the study involving DexCom (one CGM system which will be employed in this study) use;~* patient must demonstrate proper mental status and cognition for the study;~* patient has signed informed consent from prior to study entry.~Exclusion Criteria:~* diabetic ketoacidosis within the 6 months prior to enrollment;~* severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment;~* pregnancy and breast feeding;~* uncontrolled microvascular (diabetic)complications (other than diabetic non-proliferative retinopathy)such as history of laser coagulation, proliferative diabetic retinopathy, known diabetic nephropathy (other than microalbuminuria with normal creatinine) or neuropathy requiring treatment;~* uncontrolled arterial hypertension (diastolic blood pressure \>90 mmHg and/or systolic blood pressure \>160 mmHg);~* conditions which may increase the risk of hypoglycemia such as uncontrolled coronary artery disease during the previous year (e.g. history of myocardial infarction, acute coronary syndrome, therapeutic coronary intervention, coronary bypass or stenting procedure, stable or unstable angina, episode of chest pain of cardiac etiology with documented EKG changes, or positive stress test or catheterization with coronary blockages \>50%), congestive heart failure, history of cerebrovascular event, seizure disorder, syncope, adrenal insufficiency, neurologic disease or atrial fibrillation;~* drugs affecting glucose metabolism (oral steroids, thiazide diuretic, beta-blockers,beta-agonist, nicotinic acid, immunosuppressant agents, antiretroviral drugs and antipsychotics);~* impaired hepatic function measured as alanine aminotransferase or aspartate aminotransferase \> three times the upper reference limit;~* impaired renal function measured as creatinine \>1.2 times above the upper limit of normal; anticoagulant therapy other than aspirin;~* known current or recent alcohol or drug abuse;~* psychiatric disorders that would interfere with study tasks (e.g. inpatient psychiatric treatment within 6 months prior to enrollment);~* mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.",,,t,f,t
6057082,NCT05673174,NON_PROBABILITY_SAMPLE,ALL,18 Years,,t,"Healthy Volunteers, no history of Heart Disease.",Inclusion Criteria:~1. Adult subjects \>21 years of age.~2. No known significant health problems.~3. Willing and able to participate in all study evaluations.~4. Ability to understand and sign informed consent.~Exclusion Criteria:~1. Open skin lesions at the site of Vivio application / examination.~2. Inability to obtain brachial artery blood pressure.,,,t,f,t
6057083,NCT00259220,,ALL,18 Years,,f,,Inclusion Criteria:~* Hematemesis or melaena~* No QT enlargement~Exclusion Criteria:~* Refusing endoscopy~* Glasgow \< 15,,,t,f,t
6057084,NCT04213820,,FEMALE,18 Years,35 Years,t,,"Inclusion Criteria:~* Being enrolled as a patient at the eating disorder unit of the Child and adolescent psychiatric clinic and Psychiatric clinic in Linköping~* Having a DSM-5 diagnosis of anorexia nervosa, atypical anorexia (restrictive type)~* Being at least 18 years of age~* Having a BMI of 20 or under.~* Being free of psychotropic medications or on stable (at least three months on the same dose) medication.~Exclusion Criteria:~* Clinical diagnosis of schizophrenia or psychotic disorder~* Clinical diagnosis of bipolar disorder~* Alcohol/drug dependence~* Ongoing treatment with antipsychotics or tricyclic antidepressants~* Previous severe head injury~* Birth before 33 weeks of gestation~* Hearing impairment~* Earlier epilepsy or seizures of other causes~* Having severe claustrophobia~* Being pregnant~* Having a cognitive disability",,,t,f,f
6057085,NCT02488174,,ALL,18 Years,,f,,Inclusion Criteria:~* Adult patients aged \> 18 in the hospital~* Identified as being at high risk for developing severe ARF requiring prolonged MV~Exclusion Criteria:~* Patients who are chronically ventilated~* Patients who have DNI orders on hospital admission~* Patients in areas of the hospital that are unable or unwilling to participate,,,t,f,t
6057086,NCT00634920,,ALL,18 Years,,f,,"Inclusion Criteria:~* First or second single renal transplant from deceased or living donor~Exclusion criteria~* Recipient of organs other than a renal transplant~* Present malignancy (within the last 2 years) other than excised basal cell or squamous cell carcinoma of the skin~* Severe liver disease~* At the time of randomization 7 weeks after transplantation~In addition to the above criteria the following must be met at time of randomization:~Inclusion Criteria:~* Patients maintained on a triple immunosuppressive regime consisting of cyclosporine, Enteric coated mycophenolate, and corticosteroids~* Patients completed the first 7 weeks without experiencing any rejection~Exclusion Criteria:~* Graft loss~* Low hemoglobin value, low number of white blood cells or platelets~* High cholesterol values~* Proteinuria~* Wound healing problems~* Current severe major local or systemic infection~* Renal insufficiency~Other protocol-defined inclusion/exclusion criteria may apply.",,,t,f,t
6057087,NCT04409808,,ALL,18 Years,,f,,"Inclusion Criteria:~* Patients that are scheduled for vitrectomy surgery, regardless of the indication~* Both vitrectomy-only and combined phaco-vitrectomy surgeries~* Primary or repeat vitrectomy~* General or local anesthesia, or combination~* All ages~* Informed consent (from parents in patients \<18 years old)~Exclusion Criteria:~* Unable to obtain informed consent from patient (or from parents in children)~* No post-operative 8 week visit is anticipated",,,t,f,t
6057088,NCT03947112,PROBABILITY_SAMPLE,MALE,6 Years,18 Years,f,Study population will be requited from all the Norwegian regional pediatric rehabilitation centre's out patient clinics. Verbal and written information about the study will be provided if inclution criteria to be met.,"Inclusion Criteria:~* Boys with conclusive diagnosis of Duchenne Muscular disease, attending Norwegian pediatric rehabilitation clinics.~* Signed written consent~* Able to answer questionnaires with help from parents, care giver(s) or health care professional with regular follow up of the participants.~Exclusion Criteria:~* Lack of consent.~* Language difficulties~* Cognitive dysfunction or mental retardation leading to difficulties in answering the questionnaires adequately",DMD is X-linked disease,t,t,t,f
6057089,NCT05750511,PROBABILITY_SAMPLE,ALL,18 Years,,f,Subjects with metastatic melanoma stage III or IV suitable for systemic treatment,"Inclusion Criteria:~1. Patients with histologically confirmed melanoma stage III or IV.~2. Clinically eligible for systemic cancer therapy (immune checkpoint inhibitors, targeted agents).~3. Tumor tissue biopsy already existing (metastasis tissue as recent as possible, but older tissue material or primary tumor tissue also possible).~4. Patient has given written informed consent for the current study as well as for his data to be entered into the ADOREG online database system.~5. Patient is ≥18 years old.~Exclusion Criteria:~-",,,t,f,t
6260196,NCT00451178,,ALL,18 Years,,f,,"Inclusion Criteria:~Participants must:~1. Have a histologically confirmed diagnosis of DLBCL based on the World Health Organization classification (Harris et al. 1999) at the time of original diagnosis. Pathology must be reviewed and confirmed prior to enrollment at the investigational site where the participant is entered. Participants with a prior history of an indolent lymphoma or a histological diagnosis of follicular Grade 3 lymphoma will not be eligible for enrollment.~2. Have received no prior chemotherapy.~3. Have an International Prognostic Index (IPI) score ≥2 at time of original diagnosis.~4. Have a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology group (ECOG) scale.~5. Have adequate organ function as follows:~   * Hepatic: total bilirubin ≤1.5 times the upper limit of normal (x ULN); alanine transaminase (ALT) and aspartate transaminase (AST) ≤1.5 x ULN, (≤5 x ULN, if liver involvement).~  * Renal: serum creatinine ≤1.5 x ULN.~  * Adequate bone marrow reserve: platelets ≥75 x 10\^9 per Liter (L), absolute neutrophil count (ANC) ≥1.0 x 10\^9 per L, unless there is bone marrow involvement.~   Exclusion Criteria:~   Participants must not:~6. Have received treatment within the last 30 days with a drug (not including enzastaurin) that has not received regulatory approval for any indication at the time of study entry.~7. Are receiving concurrent administration of any other systemic anticancer therapy.~8. Are pregnant or breastfeeding.~9. Are unable to swallow tablets.~10. Are unable to discontinue use of carbamazepine, phenobarbital, and phenytoin at least 14 days prior to study enrollment.",,,t,f,t
6260197,NCT05547607,NON_PROBABILITY_SAMPLE,ALL,18 Years,,,"All consecutive patients referred for a echocardiography with a suspicion of bacterial endocarditis and those with a confirmed diagnosis of endocarditis independently by the request will potentially be eligible for the study. Only the patients with a positive findings of endocarditis will be prospectively followed for one year. For patients with no evidence of endocarditis on their echocardiogram, data on the following will be collected: i) size, type and position of valve prosthesis; ii) Duke criteria verification.",Inclusion Criteria:~* Patients above the age of 18 years.~* all consecutive patients referred for echocardiography (transthoracic or transesophageal approach) to exclude endocarditis.~* patients with a diagnosis of endocarditis on echocardiography independently by the request for the exam.~Exclusion Criteria:~* patient's refusal.,,,t,f,t
6260198,NCT05508178,,ALL,18 Years,40 Years,t,,"Inclusion Criteria:~1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.~2. Male or female aged 18 to 40 years (inclusive) at Screening.~3. Good general health as determined by a Screening evaluation that includes vital signs, medical history, physical examinations, and laboratory assessments within 28 days before administration of the study vaccine.~4. Expressed interest, availability and understanding to fulfil the study requirements, and in the opinion of the Investigator, can and will comply with the protocol requirements.~5. Female subjects of childbearing potential must be using a highly-effective licensed method of birth control for 30 days prior to the first vaccination and must agree to continue such precautions during the study until 60 days after the second vaccination. Male subjects must agree to employ barrier contraception from the day of first vaccination until 60 days after the second vaccination, if their female partner of childbearing potential doesn't use a highly effective method of birth control.~6. Agrees not to participate in another clinical study with an investigational product or to use any nonregistered product (drug, vaccine, or medical device) for the duration of the study.~Exclusion Criteria:~Any condition that may interfere with study participation or place the participant at increased risk of AEs would be excluded from the study. Additionally, subjects are excluded from the study if any of the following criteria apply:~1. Positive serology test results for hepatitis C virus, human immunodeficiency virus antibody, and/or hepatitis B surface antigen at Screening.~2. Pregnant or lactating women.~3. History of any of the following medical illnesses, which, in the opinion of the Investigator, may interfere with study participation or place the participant at increased risk of AEs, including but not limited to: immunosuppression (disease or treatments that may affect immune system function), diabetes, cancer (malignancy other than a resolved or excised skin lesion), heart disease (hospitalisation for a heart attack, arrhythmia, or syncope), unconsciousness (excluding single and brief concussion), seizures, asthma requiring treatment with inhaler or medication in the past 2 years, neuroinflammatory disease, autoimmune disease, recurrent infections (more than 3 hospitalisations for invasive bacterial infections such as pneumonia or meningitis).~4. Any current or chronic conditions requiring daily medication other than vitamins, minerals, or antihypertensives, as per the Investigator's discretion. Rescreening for acute illness that is expected to resolve quickly is allowed, as per the Investigator's discretion.~5. Known or suspected allergies or hypersensitivity to any component of the study vaccine.~6. Any clinically significant abnormality detected during physical examinations or vital sign evaluations, as per the Investigator's discretion.~7. Hypertension defined as a mean of triplicate sitting blood pressure measurements \>150/90 mmHg.~8. Any Screening hematology or biochemistry abnormalities considered clinically significant by the Investigator.~9. For women of child bearing potential, positive urine/serum pregnancy test at Screening or within 24 hours of the first dose of the study vaccine.~10. Body (oral) temperature \>38°C or symptoms of an acute self-limited illness such as an upper respiratory infection or gastroenteritis within 3 days of administration of the first dose of the study vaccine.~11. Administration of rNV-2v or any other experimental norovirus vaccine in the past.~12. Planned administration of other vaccines from 14 days before the first administration of the study vaccine and 60 days after the last study administration of the study vaccine, with the exception of inactivated influenza vaccine, which can be administered up to 14 days before or from 30 days after the last administration of the study vaccine.~13. Administration of immunoglobins or any blood products within 180 days prior to the first administration of the study vaccine and throughout the study duration, as per the Investigator's discretion.~14. Relatives of the Sponsor, clinical research organisation, or the study centre personnel are excluded from participating in the study.~15. History of psychiatric hospitalisation, alcohol abuse, or illicit drug use, which in the opinion of the Investigator, may affect the subject's participation in the study.~16. Other condition that in the clinical judgement of the Investigator would jeopardise the safety or rights of a subject participating in the study, would render the subject unable to comply with the protocol, or would interfere with the evaluation of the study vaccine.",,,t,f,f
6260199,NCT00005178,,MALE,,100 Years,f,,No eligibility criteria,,,t,t,t
6260200,NCT03725488,NON_PROBABILITY_SAMPLE,ALL,18 Years,23 Years,t,"The study population were both male and female students aged between 18-23 yrs who were students of Ajman University dental campus,they are attending preclinical dental labs and belong to the 2nd and third year of the dentistry program",Inclusion Criteria:~* Students were not taking any~* medication for anxiety~* did not suffer from depression~* did not have any systemic illness;~* and they had no aversion towards music.~Exclusion Criteria:~* Students who were taking~* medication for anxiety~* had depression~* had systemic illness~* they had aversion towards music,,,t,f,f
6260201,NCT05207111,,ALL,18 Years,55 Years,t,,"Inclusion Criteria:~* Provision of written informed consent~* Healthy male and female volunteers aged 18 to 55~* Males and/or non-pregnant, non-lactating females.~  1. Women will not be considered of childbearing potential if one of the following is reported and documented on the medical history:~     1. Postmenopausal with spontaneous amenorrhea for at least one (1) year, or spontaneous amenorrhea for less than one (1) year with serum FSH levels \>40mIU/ml as confirmed by lab test at screening, or~    2. Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or~    3. Total hysterectomy and an absence of bleeding for at least 3 months.~ 2. Women of childbearing potential will need to have a negative serum β-HCG pregnancy test performed within 14 days prior to the start of the study.~* Weight at least 50 kg (110 lbs) for men and 45 kg (99 lbs) for women and have a Body Mass Index (BMI) value less than or equal to 26.0 kg/m2 but greater than or equal to 19.0 kg/m2.~* Smoking Status: Non-nicotine users only.~* Adequate venous access in both arms for the collection of a number of blood samples during the study.~* Utilization of illiterate subjects is permitted when performed according to GCP, as well as regulations/guidance for the region of submission and country of conductance.~* Willing to follow the protocol requirements and comply with protocol restrictions.~* Negative chest X-ray for tuberculosis may be performed (within 6 months of study and documentation available) at the discretion of the Principal Investigator or Medical Sub Investigator.~* Normal spirometry assessment (FEV1 ≥ 80% predicted and FEV1/FVC ≥ 0.7).~* Negative urine drug screen including at a minimum amphetamines, benzodiazepines, cannabinoid, cocaine, and opiates.~* Negative Rapid Plasma Reagin (RPR, syphilis test) or Venereal Disease Research laboratory (VDRL) test. Tests for other sexually transmitted diseases (STD).~* Subjects should be judged by the Principal Investigator or Medical Sub- Investigator as normal and healthy during a pre-study medical evaluation performed within 14 days of the initial dose of study medication~Exclusion Criteria:~1. Institutionalized subjects.~2. Social Habits~   1. Ingestion of any alcoholic beverage within the 48 hours prior to the initial administration of study medication.~  2. Ingestion of any caffeine- or xanthine-containing food or beverage within the 24 hours prior to the initial administration of study medication.~  3. Ingestion of any vitamins or herbal products within 7 days prior to the initial administration of the study medication.~  4. Any recent, significant change in dietary or exercise habits.~  5. History of drug and/or alcohol abuse within one year of start of study.~  6. Use of any nicotine containing product(s) within 1 year of the initial dose of study medication.~3. Medications~   1. Use of any prescription or over-the-counter (OTC) medications within the 14 days prior to the initial administration of study medication.~  2. Use of any hormone replacement therapy within 3 months prior to initial administration of study medication.~  3. A depot injection or implant of any drug within 3 months prior to initial administration of study medication.~  4. Use of any medication, herbal supplement, or vitamin known to induce or inhibit hepatic enzyme activity or transporters within 28 days prior to the initial administration of study medication. (see https://go.usa.gov/xXY9C).~4. Use of any food (e.g. broccoli, Brussels sprouts, char-grilled meat, star fruit, pomegranate, seville oranges grapefruit, grapefruit-like, or grapefruit containing products) known to induce or inhibit hepatic enzyme activity must be limited to no more than 2 standard servings (e.g. one standard serving of char-grilled meat is approximately 12 ounces; one standard serving of vegetables/fruits is approximately 1 cup) per week within 4 weeks prior to the initial dose of study medication. These foods must be discontinued at least 7 days prior to the initial dose of study medication, during the study and until the end of the study.~5. Diseases~   1. History of any significant cardiovascular, hepatic, renal, pulmonary, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychological, genitourinary, musculoskeletal disease or malignancies unless deemed not clinically significant by the Principal Investigator or Medical Sub-Investigator~  2. History of tuberculosis.~  3. History of pulmonary problems, such as but not limited to asthma, bronchospasms, and COPD.~  4. Acute illness at the time of either the pre-study medical evaluation or dosing.~  5. History of glaucoma.~  6. History of urinary retention.~  7. History of bladder neck obstruction~  8. History of symptomatic benign prostatic hyperplasia~  9. History of chronic constipation~  10. History of long QT syndrome or Subject has an abnormal ECG at Screening or Day -1, including QT interval corrected for heart rate (HR) using Fridericia's formula (QTcF) \>470 milliseconds (msec) (applicable for any screening or baseline ECG), or subject has any cardiac rhythm other than sinus rhythm that is interpreted by the investigator to be clinically significant. All ECGs must be not clinically significant to qualify for enrollment into the study.~6. Any reason which, in the opinion of the Principal Investigator or Medical Sub- Investigator would prevent the subject from safely participating in the study.~7. Intolerance to venipuncture.~8. Donation or loss of blood or plasma: 50 mL to 499 mL within 30 days prior to the initial dose of the study medication; or more than 499 mL within 56 days prior to the initial dose of study medication.~9. Subjects who have received an investigational drug within 90 days prior to the initial dose of study medication.~10. Any food allergy, intolerance, restriction or special diet that, in the opinion of the Principal Investigator or Medical Sub-Investigator, could contraindicate the subject's participation in this study.~11. Allergy or hypersensitivity to Revefenacin, other related products, or any inactive ingredients",,,t,f,f
6260202,NCT04294407,NON_PROBABILITY_SAMPLE,ALL,20 Years,65 Years,t,Participants with stroke will be recruited from the Department of Rehabilitation in National Cheng Kung University Hospital.,"Inclusion Criteria:~* 20 to 65 years old~* with the clinical diagnosis of stroke~* Mini-mental state examination (MMSE) score ≥ 25 points~Exclusion Criteria:~* pain, subluxation or related medical history of shoulder, elbow, and wrist joints within six months~* surgery on shoulder, elbow or wrist~* with muscle or nerve disorders or diseases that significantly affect the performance of the upper extremities",,,t,f,t
6057090,NCT05153174,,ALL,18 Years,80 Years,f,,"Inclusion Criteria:~* eGFR ≥ 20 and \<60 ml/min/m2/year, and a decline in eGFR of ≥ 3 ml/min/m2/year in the previous 12 months~* Blood pressure \<140/90 mm Hg prior to initiation of sulphoraphane~* stable anti-hypertensive regimen for at least one month prior to initiation of sulphoraphane or successful run-in period~* able to provide consent~* able to swallow capsules~Exclusion Criteria:~* significant co-morbid conditions with life expectancy of \<1 year~* uncontrolled hypertension~* serum potassium of \>5.5 mEq/L at screening~* New York Heart Association Class 3 or 4 heart failure symptoms, known EF ≤30% or hospital admission for heart failure within the past 3 months~* factors judged to limit adherence to interventions~* current participation in another study~* pregnancy or planning to become pregnant or currently breastfeeding~* history of dementia~* on anticoagulants or immunosuppression~* under treatment for cancer",,,t,f,t
6260203,NCT04036058,,ALL,18 Years,,t,,"Inclusion Criteria:~VA inpatient units meeting the following criteria are eligible to participate in the study:~* Ability to identify one of the following inpatient units as defined by CDC National Healthcare Safety Network30 by reviewing prior 12-month patient mix data (at least 80% of patients meet patient type):~  * Adult Acute Medical Ward: Hospital area for the evaluation and treatment of patients with medical conditions or disorders.~ * Adult Acute Medical/Surgical Ward: Hospital area for the evaluation of patients with medical and/or surgical conditions.~ * Adult Acute Surgical Ward: Hospital area for evaluation and treatment of patients who have undergone a surgical procedure.~* Ability to collect and upload data (HAIs, mortality, length of stay, hand hygiene and barrier precaution compliance; glove use and glove plus gown use for contact precautions) required for analysis.~* Local R\&D Committee approval.~* Letter of support from the Hospital Director or Chief of Staff.~* Ability to enroll one unit to intervention and one unit to control.~To participate in interviews or focus groups, the individual must be:~* 18 years of age or older~* A patient admitted to the participating unit OR a healthcare worker who has regular work duties on the participating unit.~Exclusion Criteria:~* Intensive care units~* Long term care units",,,t,f,t
6260204,NCT03935178,NON_PROBABILITY_SAMPLE,ALL,18 Years,,f,"This study is for people who are18-years or older that are undergoing cardiac magnetic resonance imaging (CMR) as a standard of care at Dartmouth-Hitchcock Medical Center in Lebanon, NH.",Inclusion Criteria:~* Patient age is over 18 years~* Patient is undergoing Cardiac MRI with sequences that permit biventricular volumetric analysis~* Patient is capable of giving informed consent~* The cardiac MRI images are of diagnostic quality to provide accurate RV and LV volumes~Exclusion Criteria:~- Patient unable to under echocardiogram,,,t,f,t
6260205,NCT01281397,NON_PROBABILITY_SAMPLE,ALL,18 Years,,f,All patients undergoing elective cardiac surgery with cardiopulmonary bypass are enrolled in study.,Inclusion Criteria:~1. \> 18 years old~2. Elective cardiac surgery patients~3. Coronary artery disease~4. Aortic valve disease~5. Mitral valve disease~6. Ascendent aorta aneurysm~7. Combine coronary and valve disease~8. Cardiac surgery procedures using cardiopulmonary bypass~Exclusion Criteria:~1. Missing consent~2. Patients with emergent cardiac surgical procedures~3. Patients on antiplatelet therapy other than aspirin or clopidogrel~4. Patients with inaccurate antiplatelet therapy administration documentation~5. Missing data~6. Off-pump procedures~7. Patients younger than 18 years old~8. Patients with severe mental disorders~9. Intrinsic coagulopathy,,,t,f,t
6260206,NCT03081832,,ALL,3 Years,4 Years,f,,"Inclusion Criteria:~* Infants with Prader Willi Syndrome (genetic diagnosis confirmed)~* For treated group : infant included in the ancient study~* For not treated group: infant never treated with oxytocin~Exclusion Criteria:~* Subject involved in another search including an exclusion period still in progress at the time of inclusion.~* Impossibility to give parents or legal guardian informed information~* No coverage by a Social Security scheme~* Refusal of parents or legal representative to sign consent.~If a patient has a contraindication to Magnetic resonance imaging, it may be included in the study but Magnetic resonance imaging will not be performed.",,,f,t,f
6159118,NCT05239000,,ALL,65 Years,,f,,"Inclusion Criteria:~* Age ≥ 65~* Pathologically (histologically or cytologically) diagnosis of head and neck cancer of oral cavity, oropharynx, larynx, or hypopharynx~* Patient will receive a 6 to 7 week course of intensity modulated radiation therapy and concurrent chemotherapy either in definitive or post-operative setting~* Able to read and understand English~* Able to provide informed consent~Exclusion Criteria:~* Patients who have previously consulted with or are followed by a geriatrician~* Inability to use telemedicine if unable to present to clinic visits in person~* Inability to complete the eRFA (patient is unable to comprehend or answer questions included on the eRFA)~* Treatment with proton therapy~* Patients on therapeutic clinical trials of experimental therapies or those not receiving standard of care",,,f,f,t
6159119,NCT01920100,NON_PROBABILITY_SAMPLE,ALL,,,t,Nursing home Memory clinics In-home care Persons without dementia (Control),"Memory clinic sample~Inclusion Criteria:~* All patients examined at a memory clinic with mild cognitive impairment or mild dementia~Exclusion Criteria:~* None~In-home care sample~Inclusion Criteria:~* Persons 70 years of age or older receiving in-home care from the municipality~Exclusion Criteria:~* None~Nursing-home sample~Inclusion Criteria:~* All persons admitted to the nursing home with an expected stay of more than four weeks.~* Participants should be 65 years or older, unless established dementia disease, in which case younger persons also will be included~Exclusion Criteria:~* Life expectancy of less than six weeks~Control sample~Inclusion Criteria:~* Persons 65 years or older without any sign of dementia~Exclusion Criteria:~* None",,,t,t,t
6159120,NCT03641300,,ALL,18 Years,,f,,"Inclusion Criteria:~Patients will be included if they:~1. are inpatients or outpatients;~2. are voluntary and competent to consent to treatment and research procedures according to ECT/MST attending psychiatrist;~3. have a MINI International Neuropsychiatric Interview diagnosis, Version 6 (MINI-6.0) diagnosis of non-psychotic Bipolar Disorder (Type I or II)~4. are 18 years of age or older~5. have a baseline HRSD-24 score \> 21;~6. are considered to be appropriate to receive convulsive therapy as assessed by an ECT attending psychiatrist and a consultant anaesthesiologist~7. are agreeable to keeping their current antidepressant treatment constant during the intervention;~8. are likely able to adhere to the intervention schedule;~9. meet the MST safety criteria;~10. If a woman of child-bearing potential: is willing to provide a negative pregnancy test and agrees not to become pregnant during trial participation.~Exclusion Criteria:~Patients will be excluded if they:~1. have a history of MINI diagnosis of substance dependence or abuse within the past three months;~2. have a concomitant major unstable medical illness;~3. are pregnant or intend to get pregnant during the study;~4. have a MINI diagnosis of any primary psychotic disorder~5. have a MINI diagnosis of obsessive compulsive disorder, or post-traumatic stress disorder deemed to be primary and causing more functional impairment than the depressive disorder~6. have probable dementia based on study investigator assessment;~7. have any significant neurological disorder or condition likely to be associated with increased intracranial pressure or a space occupying brain lesion, e.g., cerebral aneurysm;~8. present with a medical condition, a medication, or a laboratory abnormality that could cause a major depressive episode or significant cognitive impairment in the opinion of the investigator (e.g., hypothyroidism with low TSH, rheumatoid arthritis requiring high dose prednisone, or Cushing's disease);~9. have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed;~10. require a benzodiazepine with a dose greater than lorazepam 2 mg/day (or equivalent benzodiazepine) or any anticonvulsant due to the potential of these medications to limit the efficacy of both MST and ECT;~11. are unable to communicate in English fluently enough to complete the neuropsychological tests;~12. have a non-correctable clinically significant sensory impairment (i.e., cannot hear or see well enough to complete the neuropsychological tests).~    These eligibility criteria are congruent with the criteria that have been used in the major ECT trials conducted during the past decade;~13. elevated mood, defined as a score of 20 or higher on the Young Mania Rating Scale (YMRS).",,,t,f,t
6260207,NCT03110237,,ALL,16 Years,69 Years,f,,Inclusion Criteria:~1. inpatients admitted to GFS with a diagnosis of ABI;~2. medical stability~3. has the cognitive ability to understand and follow instructions and participate in a class setting~4. a Berg Balance Score of ≥52;~5. able to walk independently with or without a mobility aid.~Exclusion Criteria:~1) unable to attend class in a group setting and/or unable to follow instructions.,,,t,t,t
6260208,NCT01129297,NON_PROBABILITY_SAMPLE,ALL,18 Years,65 Years,t,Recruiting: Clinical Medical Center from the north of France,"Inclusion Criteria:~* Age between 18 and 65 years~* Indication of abdominal surgery requiring a laparotomy or laparoscopy for bariatric surgery, cholecystectomy, or parietal surgical~* Phenotype corresponding to one of the following four cases :~  1. Body Mass Index ≥ 35 kg/m2 and diabetes defined by a fasting blood glucose ≥ 7 mmol/l and/or ≥ to 11.1 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)~ 2. Body Mass Index ≥ 35 kg/m2 with intolerance glucose defined by a fasting blood glucose\> 6 mmol/L and \<7 mmol/l and/or\> 7.8 mmol/l and \<11.1 mmol/l , 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)~ 3. Body Mass Index ≥ 35 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)~ 4. Body Mass Index \<27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)~5)27 \<Body Mass Index \<35 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)~Exclusion Criteria:~* unable to receive clear information~* refusal to sign the consent form~* pathology associated judged by the surgeon, may increase the risk of adverse events related to sampling tissue",,,t,f,t
6159121,NCT04742413,PROBABILITY_SAMPLE,ALL,18 Years,,f,"Patients ≥ 18 years old, with schizophrenia based on the DSM-5, treated with oral SGA monotherapy for a minimum of 3 months before switching to lurasidone or another SGA, will be included.","Inclusion Criteria:~1. Female and male patients ≥ 18 years of age.~2. Patients with schizophrenia based on the Diagnostic of Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).~3. Patients currently treated with oral SGA monotherapy for a minimum of 3 months that are prescribed\* to switch to another oral SGA medication. Patients will be included in a cohort depending on the switching treatment prescribed:~   * Cohort A: patients who are prescribed to switch to lurasidone (lurasidone cohort)~  * Cohort B: patients who are prescribed to switch to any other monotherapy SGA (other SGA cohort) \*Treatment switch and overlap period will be performed according to clinical practice and medical criteria.~4. Written informed consent prior to participation.~Exclusion Criteria:~1. Patients with a known cardiovascular disease or suspected of having a heart disease.~2. Pregnant or breastfeeding women.~3. Patients diagnosed with at least one of the following: depression with psychotic symptoms, schizoaffective disorder, bipolar disorder or organic brain syndromes; Patients with active suicidal ideation or patients who have habitual and sustained consumption of alcohol and / or other toxic substances are also excluded.~4. Patients who had been treated with a long-acting within the last 6 months, or within last year in case of Trevicta®.~5. Concomitant treatments with antipsychotics for insomnia or anxiety (i.e., low doses of quetiapine, etumine, levomepromazine or similar). Concomitant treatment with sedative substances not considered antipsychotics (i.e., benzodiazepines or similar) when they are being taking regularly and at unchanged low doses are allowed.~6. Patients with history of seizures, stroke, neuroleptic malignant syndrome or epilepsy are excluded.~7. Current participation in any clinical trial.~8. Patients for whom further follow-up is not possible at the enrolling site.",,,t,f,t
6159122,NCT01265654,PROBABILITY_SAMPLE,FEMALE,,,f,Postmenopausal women with hormone sensitive advanced breast cancer that have been treated with minimum two hormonal agents according to approved SmPC.,Inclusion Criteria:~* Women with at least two finished lines of hormonal treatment for advanced breast cancer Tumor markers (CEA. CA15-3) values available at the time of onset and discontinuation of therapy Imaging methods results available at the time of onset and discontinuation of therapy~Exclusion Criteria:~* None,,,t,t,t
6159123,NCT05693350,NON_PROBABILITY_SAMPLE,ALL,18 Years,60 Years,f,Patients with previous history of intervention for varicose veins,Inclusion Criteria:~* 1) Ages eligible for the study: 18-60. 2) Sexes eligible for the study: All. 3) Patients with previous intervention for varicose veins. 4) Patients with primary or secondary varicosities. 5) Patient's compliance to follow-up.~Exclusion Criteria:~1) Patients with no history of interventions for varicose veins. 2) Patients treated with injection sclerotherapy alone. 3) Pregnant women. 4) Patients with arterial disease in the same limb (ABI \<0.8). 5) Patients with post-thrombotic syndrome~-,,t,t,f,f
6159124,NCT04772833,NON_PROBABILITY_SAMPLE,ALL,,,f,"Patients with COVID-19 infection confirmed by PCR, whose death is related to active COVID-19 infection or its complications.",Inclusion Criteria:~* Patients with COVID-19 infection confirmed by PCR.~* Death related to active infection by COVID-19 or its complications.~* Informed consent given by the subject's relatives to perform an autopsy according to the autonomous community requirements.~* Informed consent given by the subject's relatives for the inclusion of samples in the Biobank.~Exclusion Criteria:~* COVID-19 infection diagnosed exclusively by serological methods.~* Advanced or terminal chronic disease.~* Inadequate security level of the autopsy room.,,,t,t,t
6159125,NCT02691650,NON_PROBABILITY_SAMPLE,ALL,18 Years,,f,Patients admitted to the emergency unit of the trauma and burns center,Inclusion Criteria:~* signed written consent~* 18 years and older~* severe trauma (ISS \> 15)~* burns injury (2. degree more than 15% body surface or 3 degree more than 10% body surface)~* SIRS~Exclusion Criteria:~* not fulfilling the inclusion criteria~* failure to adhere,,,t,f,t
6159126,NCT06319950,,ALL,18 Years,80 Years,f,,"Inclusion Criteria:~* Male or female subjects aged \>=18 and \<=80 years old.~* Patients with histologically or cytologically confirmed NSCLC with adenocarcinoma or adenocarcinoma components predominant, and with central nervous system metastases (with measurable lesions).~* The tissue or blood sample is determined to be EGFR positive (including rare EGFR mutations) by testing by a tertiary Class A hospital or a qualified testing institution, and the tissue submitted for testing cannot be from a tumor lesion that has been treated with radiation, but can be used for a new lesion after local treatment.~* Patients who had not previously received systemic anti-tumor therapy for locally advanced or metastatic non-small cell lung cancer (patients who had received first-line chemotherapy but had not received TKIs could be enrolled). Patients who have undergone radical surgery, radical chemo-radiotherapy, or adjuvant therapy (chemotherapy, radiation) for early NSCLC may be enrolled if they later develop disease recurrence or metastasis.~* Stable brain metastases that do not require local treatment of brain metastases either immediately or planned during the study period.~* According to RECIST v1.1, enrolled patients should have at least one tumor lesion in all tumors that can meet the following requirements: they have not been treated with local therapy such as radiotherapy in the past, and can be accurately measured at baseline, and the longest diameter at baseline is ≥10mm (in the case of lymph nodes, the short diameter is ≥15mm). Lesions that have previously received local treatment (radiotherapy or other treatment) can only be measured if disease progression occurs more than 6 months after the end of treatment.~* ECOG PS 0-1, and with no deterioration during the first 2 weeks of the study and expected survival time of no less than 3 months.~* Patients should have sufficient bone marrow reserve function, and no liver, kidney, coagulation dysfunction, laboratory test values must meet the following conditions:~  1. Absolute neutrophil count ≥ 1.5×109/L, and white blood cell count ≥3×109/L;~ 2. PLT ≥100×109/L;~ 3. Hb ≥90g/L;~ 4. Serum Cr ≤1.5×ULN and eGFR ≥50 mL/min;~ 5. AST and ALT≤2.5×ULN (or AST and ALT≤5×ULN for patients with liver metastasis)~ 6. In the absence of proven liver metastasis, TB ≤1.5×ULN (or TB ≤3×ULN for patients with liver metastasis or Gilbert syndrome;~ 7. INR ≤1.5, and APTT ≤1.5×ULN.~* Male patients and female patients of reproductive age should take adequate contraceptive measures within 3 months after signing the study informed consent to the last study drug treatment; In women of childbearing age, pregnancy test results are negative within 7 days before the first dose.~* All previous treatment-related toxicities (except alopecia and grade 2 neurotoxicity associated with previous platinum chemotherapy) had been recovered (to ≤ grade 1) before first administration of the investigational drug.~* The subject is able to understand and voluntarily sign a written informed consent (which must be signed prior to performing any procedure specified in the study protocol).~* Be able to voluntarily complete the study procedures and follow-up examinations as required by the study protocol.~Exclusion Criteria:~* Patients with the following treatments:~  1. Previous use of any EGFR TKIs therapy;~ 2. Previously received systemic antitumor therapy (such as targeted therapy, biotherapy, immunotherapy, etc.) for advanced/metastatic non-small cell lung cancer;~ 3. Standard chemotherapy within 28 days before the first administration of the study drug; The study received anti-tumor therapy with traditional Chinese medicine within 7 days before the first administration of the drug;~ 4. Previous WBRT; Had received \>30% of bone marrow radiotherapy or extensive radiotherapy within 28 days prior to the first dose of the study drug; Local radiotherapy (e.g., thoracic and rib radiotherapy) or palliative radiotherapy for bone metastases within 7 days prior to initial administration of the study drug;~ 5. Uncontrolled pleuroperitoneal effusion and pericardial effusion;~ 6. Uncontrollable cancerous pain; Anesthetic painkillers did not reach a stable dose at the time of enrollment;~ 7. Study major surgery within 28 days before the first administration of the drug ( major surgery refers to grade 3 and grade 4 surgery in Measures for the Clinical Application of Medical Technology in China, on May 1, 2009 );~ 8. Has received a strong inducer or suppressor of CYP3A4 within 14 days prior to initial administration of the investigatory drug or requires continued treatment during the study period (including Chinese herbal medicine, see Appendix for a list of drugs);~ 9. Patients who are receiving and require continued treatment during the study with drugs known to prolong the QTc interval or that may cause tip torsion ventricular tachycardia (see Appendix for a list of drugs);~ 10. Participants who have participated in other clinical trials within 28 days prior to the first administration of the investigational drug (except non-interventional drug trials);~* Patients with primary malignant brain tumors and unstable brain metastases. Definition of unstable brain metastases: Patients with CNS complications who require emergency neurosurgical treatment (such as surgery); Patients with an equivalent dose of dexamethasone or more than 5mg of glucocorticoids, mannitol or diuretics to control symptoms of brain metastases should be administered within 14 days prior to the first dose; The first study looked at patients who had received local radiotherapy or gamma knife treatment within 14 days prior to administration. Patients with meningeal metastasis were excluded.~* Patients who have had or have a history of other malignancies within the past 5 years (except cured basal cell or squamous cell carcinoma of the skin, papillary carcinoma of the thyroid gland, carcinoma in situ of the cervix, and ductal carcinoma in situ of the breast).~* The patient had symptoms of spinal cord compression caused by the tumor.~* Clinically significant gastrointestinal dysfunction that may affect the intake, transport, or absorption of investigational drugs, such as inability to take oral drugs, difficult to control nausea or vomiting, a history of extensive gastrointestinal resection, Untreated recurrent diarrhea, atrophic gastritis (onset age less than 60 years), untreated stomach disease requiring long-term use of PPI acid suppressants, Crohn's disease, ulcerative colitis.~* Cardiovascular and cerebrovascular diseases/symptoms/indications that meet any of the following conditions:~  1. Average resting QTc≥470ms (corrected QT interval, calculated according to Fridericia's formula, see Appendix 18-9), the average QTc of 3 ECG intervals of more than 5 minutes, and the QT interval should be measured from the beginning of the QRS complex wave to the end of the T wave;~ 2. Any abnormalities in rhythm, conduction, or morphology of the clinically significant resting ECG, such as complete left bundle branch block, 2nd and 3rd degree heart block, PR interval \> 250ms;~ 3. Any factors that increase the risk of prolonged QTc or arrhythmia, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or sudden unexplained death in a first-degree relative under the age of 40-year-old, or any combination of medications known to prolong the QT interval;~ 4. LVEF \<50%;~ 5. Patients with a history of decreased myocardial contractility and related symptoms in the 6 months prior to study administration, such as chronic congestive heart failure, pulmonary edema, or decreased ejection fraction;~ 6. Patients with a history of acute and chronic cardiovascular and cerebrovascular disease and related symptoms within 6 months prior to study administration, such as myocardial infarction, severe or unstable angina pectoris, cerebral infarction, cerebral hemorrhage, or transient ischemic attack.~* Persons infected with HIV, syphilis, HCV or HBV, meeting the following conditions:~  1. HBs Ag positive and HBV DNA ≥2000cps/ mL (or 500IU/ mL);~ 2. Anti-HCV antibody and HCV RNA positive;~ 3. HIV antibody positive.~* Prior or screening history of interstitial lung disease or ILD, or drug-induced ILD, or radiation pneumonia requiring hormone therapy, or any evidence of active ILD (such as acute onset or progressive pneumonia/pulmonary fibrosis at baseline), or pulmonary symptoms deemed unsuitable for inclusion by the investigator or risk factors deemed unsuitable for interstitial lung disease.~* Had previously received allogeneic bone marrow transplantation.~* Pregnant and lactating women.~* The patient has any other disease or medical condition that is unstable or may affect their safety or study compliance, any serious or uncontrolled systemic disease, including autoimmune disease requiring corticosteroid therapy, uncontrolled hypertension (SBP ≥150 mmHg or DBP ≥95 mmHg), Uncontrolled diabetes, active bleeding, eye lesions, and other serious mental, neurological, cardiovascular, or respiratory diseases.~* Known or suspected allergy to the investigational drug ingredient or its analogues.~* The subjects were judged by the investigator to be unfit for this study.",,,t,f,t
6159127,NCT03608150,,ALL,4 Years,7 Years,f,,"Inclusion Criteria:~* Age 4 to 7 years at the time of consent.~* Amblyopia associated with anisometropia and/or mild strabismus.~* Current refractive correction worn for at least 16 weeks or until 2 consecutive visual acuity measurements at least 8 weeks apart do not change by more than 1 logMAR lines.~* Amblyopic eye best-corrected visual acuity (BCVA) 20/40 to 20/200 inclusive.~* Fellow eye BCVA 20/32 or better.~* Interocular difference ≥ 3 logMAR lines.~* Heterotropia ≤ 5 prism diopters in current refractive correction at distance measured by SPCT.~Exclusion Criteria:~* Atropine treatment in the past 2 weeks.~* Prior amblyopia treatment (other than refractive correction) for \> 12 months in total.~* High myopia, previous intraocular / refractive surgery, severe ocular co-morbidities or development / cognitive delay.~* History of low adherence with amblyopia treatment or light-induced seizures.",,,f,t,f
6159128,NCT04628533,,FEMALE,18 Years,,t,,"Inclusion Criteria:~* female~* BMI between 25-55~* free of medical problems that might contraindicate participation in a behavioral weight reduction program containing an exercise component~* not currently on medication that might affect weight loss~* not currently pregnant or pregnant in the previous 6 months or currently breastfeeding~* not enrolled in another weight reduction program~* must have a computer (at home or work) with access to the Internet and a video camera~* must have a smart phone (to allow use of step counting and dietary intake self-monitoring apps)~* Only one member of a household will be eligible to participate~* must successfully complete a self-monitoring diary of foods consumed for a week during screening for study eligibility~* demonstrate the ability to access the website successfully (practice chat)~* agree to be randomized to either group~* must be willing to share access to self-monitoring information collected via the app MyFitnessPal, and Fitbit.com weight data collected via the digital smart scale (scale will be provided)~Exclusion Criteria:~* have had a heart attack or a stroke in the past 6 months,~* have ever had weight loss surgery,~* have lost more than 10 pounds in the previous 6 months,~* are currently taking medications for weight loss,~* are required by their doctor to follow a special diet (other than a low fat diet)~* have plans to move from the area in the upcoming 12 months~* who have schedules that will make it likely that they will have difficulty attending the scheduled chat groups",,t,t,f,t
6159129,NCT05048550,,ALL,,8 Weeks,f,,"Inclusion criteria:~1. All term infants undergoing therapeutic hypothermia for hypoxic ischaemic encephalopathy (HIE).~2. All preterm infants born at \<29 weeks gestational age.~Specifically, all children fulfilling these criteria will be eligible. Evidence of hypo-accommodation is not required.~Exclusion criteria:~1. Infants that are still an inpatient at 8 weeks corrected gestational age.~2. Ocular exclusion criteria: children with unrelated congenital or developmental ocular abnormality such as cataract requiring surgery, genetic retinal disease, coloboma. Retinopathy of prematurity will not be an exclusion criterion.~3. Infants with high refractive error (more than -6.00D spherical equivalent or +8.00D spherical equivalent).",,,f,t,f
6159130,NCT01707433,NON_PROBABILITY_SAMPLE,ALL,,21 Years,f,Males/females less than or equal to 21 years of age who have been seen at Gillette Children's Specialty Healthcare or Children's Hospitals and Clinics of Minnesota and carry a diagnosis of spondyloepiphyseal dysplasia or multiple epiphyseal dysplasia or bilateral Legg-Calve-Perthes disease or bilateral proximal femoral epiphyseal dysplasia.,"Inclusion Criteria:~* Less than or equal to 21 years of age~* Diagnosis of spondyloepiphyseal dysplasia or multiple epiphyseal dysplasia or bilateral Legg-Calve-Perthes disease or bilateral proximal femoral epiphyseal dysplasia.~Exclusion Criteria:~* Definitive etiology for above-mentioned diagnosis (i.e. other MPS disease, known chondrodysplasia, Meyer's dysplasia)",,,t,t,f
6159131,NCT03193333,,ALL,18 Years,,f,,"Inclusion Criteria:~* Signed informed consent~* Age greater or equal to 18 years~* Both sexes~* Women of childbearing age with birth control method~* Diagnosis of Primary open-angle glaucoma (according to the Guidelines of the Preferred Practice Pattern of the American Academy of Ophthalmology) or ocular hypertension (OHT)~* Intraocular pressure (IOP) not controlled with dual therapy according to the principal investigator (PI) judgment.~* IOP on the selection visit at 9 am, after the washing period, from 21 - 36 mmHg in at least one eye.~Exclusion Criteria:~General criteria~* Pregnant, breastfeeding or planning to get pregnant women.~* Women of childbearing age and who do not intake a hormonal contraceptive method, intrauterine device or bilateral tubal obstruction.~* Participation in another clinical research study greater or equal 30 days before the screening visit.~* People who cannot comply with their attendance at appointments or with all the - Protocol requirements~Medical and therapeutic criteria:~* Anterior chamber angle grade less than 2 of Shaffer rating.~* Excavation of optic nerve greater than 0.80 horizontal or vertical (ratio cup-disc)~* Serious loss of central visual field in any eye (sensitivity less or equal to 10 decibels in greater or equal to 2 of 4 points of the visual field test close to the fixation point)~* People not able to safely suspend ocular hypotensives drug products for the washout period according to the PI judgement.~* Chronic, recurrent, or active ocular inflammatory diseases (e.g. uveitis, scleritis, keratitis, herpetic) in any eye.~* Eye trauma less or equal to 6 months prior to the study~* Eye infection / inflammation less or equal to 3 months prior to the study~* Clinically significant or progressive retinal disease (e.g. degenerations, diabetic retinopathy, retinal detachment)~* Ability Visual 20/200 or worse in any of the eyes.~* Subject with only one eye~* Eye diseases that contraindicate the use of Beta-blocker (BB) Alpha-adrenergic agonist (AA) or Carbonic anhydrase inhibitors (CAIs)~* Intraocular surgery less or equal to 6 months prior to the study~* Laser intraocular surgery less or equal to 3 months prior to the study~* Any abnormality preventing reliable applanation tonometry~* Unstable or uncontrolled cardiovascular disease~* Chronic pulmonary disease (e.g. bronchial asthma)~* Any condition or illness that do not fit the subject for the study according to the PI judgment.~* Use of high doses of salicylate (1 g daily) less or equal to4 weeks before the eligibility visit~* In treatment with psychotropic medications that increase the adrenergic response~* Known hypersensitivity to BB medications (e.g. timolol), AA (e.g. brimonidine) and CAI (e.g. dorzolamide), sulfonamide derivatives, or any of the components of the study drugs~* Concomitant use of monoamine oxidase inhibitors~* Systemic or topical use of corticosteroids",,,t,f,t
6159132,NCT04040933,,ALL,25 Years,55 Years,t,,"Inclusion Criteria:~* Fitzpatrick Skin Type II or III~* Uniform skin color on both volar forearms~* Generally in good health based on medical history reported by the participant~* -Individual has signed the Photographic Release and Informed Consent Documents along with (HIPAA) disclosure~* Willing to have temporary (semi-permanent) dot-tattoos applied to the volar forearms~Exclusion Criteria:~* Has known allergies, hypersensitivity, or adverse reactions to anesthetics, adhesive bandages, latex, wound treatment products, or any component/ingredient present in the Investigational Products (IPs)/auxiliary/ancillary products~* Has a known history of a blood-clotting disorder, keloid formation, or a cardiovascular, hepatic, or renal disease~* Presents with a skin condition that would, in the opinion of the PI or Study Physician, confound study results, increase risk to participant, or interfere with study evaluations~* Has excessive hair or tattoos on either volar forearm~* Has a known history of severe systemic immune system disorders~* Has self-reported Type 1 or Type 2 diabetes~* Has self-reported uncontrolled chronic diseases~* Is taking medication that would mask an adverse event, confound study results or alter/compromise the bleeding/healing process~* Is self-reported to be pregnant or planning to become pregnant~* Has a body mass index (BMI) above 35~* Is self-reported to be an alcohol or drug abuser~* Has participated in another clinical trial within 10 days~* Either is or lives with someone who is a current employee of any company that makes/markets adhesive bandages or first-aid products",,,t,f,f
6159133,NCT01517191,PROBABILITY_SAMPLE,ALL,16 Years,,f,This observational study is open to adults admitted to hospital with test postitive influenza or with an influenza like illness who test negative.,"Inclusion Criteria:~* Adult patients ≥ 16 years of age admitted to participating SOS Network hospitals with the following admitting diagnoses will be eligible for screening:~* pneumonia~* acute exacerbation of chronic obstructive pulmonary disease (AECOPD) or asthma~* unexplained sepsis~* Any other respiratory infection or diagnosis Or any respiratory or influenza-like symptom )(eg dyspnea, cough, sore throat, myalgia, arthralgia, fever, delirium/altered level of consciousness, CHF)~Exclusion Criteria:~* Patients whose reason for admission was clearly unrelated to the presence of influenza (for example, patients admitted due to trauma, elective surgery, or patients who have an alternative diagnosis that is clearly not respiratory,, e.g. cellulitis, intra-abdominal process, or gastrointestinal bleeding) Unless being enrolled as a nosocomial influenza case~* Patients whose onset of symptoms was prior to or within 72 hours of hospital admission but who were not tested for influenza within 7 days of hospital admission. These should be captured on the screening form as screen failures.~* No children in care will be enrolled in the study",,,t,t,t
6159134,NCT02498054,,ALL,16 Years,,f,,Inclusion Criteria:~* Diagnosed with Type 1 diabetes Mellitus (T1DM) or Type 2 diabetes Mellitus (T2DM) for ≥ 3 months~* Currently performing self monitoring of blood glucose (SMBG) at home~* Aged ≥16 years~Exclusion Criteria:~* Previous use of any blood glucose meter with the colour range indicator feature to be evaluated in this study.,,,t,t,t
6159135,NCT02373124,,ALL,21 Years,55 Years,f,,"Inclusion Criterion Method of Ascertainment~1. Active cocaine dependence with at least 8 days of use or at least 4 binges of large amounts (\>$200/occasion) over the past 30 days, and displaying at least one positive utox during screening SCID, Psychiatric Interview, self-report, utox~2. Physically healthy Laboratory tests (urinalysis, blood chemistry, 12-lead ECG in normal limits), physical examination, self-reported medical history~3. No adverse reactions to study medications Subjects will be asked about previous exposure to ketamine and midazolam~4. 21-55 years of age Self-reported age, verification with legal identification~5. Capacity to consent and comply with study procedures, including sufficient proficiency in English A short written test about study procedures, SCID, psychiatric interview~6. Seeking treatment Psychiatric Interview, self-report~Exclusion Criterion Method of Ascertainment~1. Meets DSM IV criteria for current major depression, bipolar disorder, schizophrenia, any psychotic illness, including substance induced psychosis, and current substance-induced mood disorder with HAMD score \> 12. Psychiatric Interview, SCID, HAMD~2. Physiological dependence on another substance, such as alcohol, opioids, or benzodiazepines, excluding caffeine, nicotine, and cannabis SCID, Psychiatric Interview~3. Delirium, Dementia, Amnesia, Cognitive Disorders, or Dissociative disorders SCID, Psychiatric Interview~4. Current suicide risk or a history of suicide attempt within the past year SCID, Psychiatric Interview~5. Pregnant or interested in becoming pregnant during the study period Blood and urine pregnancy testing, self-report~6. Any of the following cardiac conditions: clinically significant left ventricular hypertrophy, angina, clinically significant arrhythmia, or mitral valve prolapse Laboratory tests (12-lead ECG in normal limits), physical examination, self-reported medical history~7. Unstable physical disorders which might make participation hazardous such as end-stage AIDS, hypertension (\>140/90), WBC \< 3.5, active hepatitis or other liver disease with elevated transaminase levels (\< 2-3 X upper limit of normal will be considered acceptable if PT/PTT is normal), renal failure (creat \> 2, BUN \>40), or untreated diabetes Physiological tests (urinalysis, blood chemistry, 12-lead ECG), physical examination, self-reported medical history~8. Previous history of ketamine or midazolam misuse or abuse, and a history of an adverse reaction/experience with prior exposure to cocaine, ketamine or midazolam Physical examination, self-reported medical history~9. Recent history of significant violence (past 2 years) SCID, Psychiatric Interview~10. Abnormal pseudocholinesterase level Blood testing~11. First degree relative with a psychotic disorder (bipolar disorder, schizophrenia, schizoaffective disorder, or psychosis NOS) SCID, Psychiatric Interview~12. BMI \> 35, or a history of documented obstructive sleep apnea Physical examination, self-reported medical history~13. On psychotropic or other medications whose effect could be disrupted by participation in the study Psychiatric interview, self-reported medical history~14. Patients who cannot comply with study procedures during the initial hospitalization phase Study Performance",,,t,f,f
6057091,NCT01663610,,ALL,18 Years,,f,,"Inclusion Criteria:~* have problems organizing daily activity measured by more then 17 points on the ASRS questionaire item 1-4 and 7-11-~* has acces to a smartphone (android or iphone) with internet acces.~* at least 18 years~* speaks, writes and read Swedish~* can not foresee any practical barriers to participation.~Exclusion Criteria:~* has a high alcohol or drug use assessed by the AUDIT / DUDIT and assessment interview.~* somatic or psychiatric problems that are directly contraindicated or seriously hamper the implementation of the treatment (eg, psychotic disorders).~* have severe depression, defined as MADRS-S over 30 or suicidal risk judged by more than 4 points on the MADRS-S question 9 or according to the structured telephone assessment.~* currently undergoing some form of treatment that focuses on reducing symptoms of ADHD.",,,t,f,t
6260209,NCT00126178,,ALL,18 Years,,f,,"This does not represent the full set of inclusion/exclusion criteria~Inclusion Criteria:~* Patients must have primary-intact resectable renal cell cancer, without distant metastasis and be scheduled to have surgery with curative intent~* Tumor size \> 5 cm OR macroscopic nodes OR vena cava thrombus by radiologic evaluation~* At least 18 years old~* Signed informed consent~Exclusion Criteria:~* Prior surgery, chemo-, hormonal-, immuno-, or radiotherapy for kidney cancer~* History of other cancers within the last five years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma of the skin~* Current malignancies of any type in other sites~* No active uncontrolled infection, other serious medical illnesses, or splenectomy~* History of primary or secondary immunodeficiencies",,,t,f,t
6260210,NCT03583307,,ALL,0 Years,18 Years,f,,"Inclusion Criteria:~* All patients included in the present research must be diagnosed with one of the following vascular anomalies:~  1. Kaposiform Hemangioendotheliomas without Kasabach-Merritt Phenomenon~ 2. Tufted Angioma without Kasabach-Merritt Phenomenon~ 3. Capillary Malformations~ 4. Lymphatic Malformations~ 5. Venous Malformations~ 6. Capillary-Venous Malformation (CVM)~ 7. Capillary-Lymphatic Malformation (CLM)~ 8. Lymphatic-Venous Malformation (LVM)~ 9. Capillary-Lymphatic-Venous Malformation (CLVM)~ 10. Multifocal Lymphangiomatosis and Thrombocytopenia (MLT)~* Patients must be 0 - 18 years of age at the time of study entry.~* Without functional impairment requiring treatment of corticosteroid.~* Organ function requirements:~* Adequate liver function Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN)for age, and alanine transaminase (ALT) and aspartate aminotransferase (AST) less than or equal to 2.5 x upper limit normal (ULN) for age.~* Adequate renal function 0-5 years of age maximum serum creatinine (mg/dL) of 0.8 6-10 years of age maximum serum creatinine (mg/dL) of 1.0 11-15 years of age maximum serum creatinine (mg/dL) of 1.2 16-18 years of age maximum serum creatinine (mg/dL) of 1.5~* Adequate bone marrow function:~Absolute Neutrophil Count (ANC) greater than or equal to 1 x 10 to the ninth/Liter~* Consent of parents (or the person having parental authority in families): Signed and dated written informed consent.~Exclusion Criteria:~* Allergy to sirolimus or other rapamycin analogues.~* Allergy to sirolimus or other rapamycin analogues.~* Any known evidence of significant local or systemic uncontrolled infection, defined as receiving intravenous antibiotics at the time of randomization.~* Patients must not be known to be Human Immunodeficiency Virus positive or known immunodeficiency. Testing is not required unless a condition is suspected.~* Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (e.g. uncontrolled diabetes, uncontrolled hypertension, severe malnutrition, chronic liver or renal disease, active upper gastrointestinal tract ulceration).~* Impairment of gastrointestinal function or chronic gastrointestinal disease that may significantly alter the absorption of sirolimus.~* Patients who have a history of malignancy.~* Patients with an inability to participate or to follow the study treatment and assessment plan.~* Patients who have a history of treatment with sirolimus or other mTOR inhibitor.",,,t,t,f
6260211,NCT01288508,,ALL,18 Years,75 Years,f,,"Inclusion Criteria:~* Constipation as defined by Rome III criteria (3,4). Also, patients should have insufficient criteria for IBS, and only rarely experience loose stools without the use of laxatives.~* Adults between the ages of 18-75 years~Exclusion Criteria:~* Patients taking drugs that are known to be constipating will be excluded or asked to discontinue medications for at least 2 weeks and reassessed. Patients who remain constipated will be eligible for enrollment.~* Co-morbid illnesses such as severe cardiovascular disease, chronic renal failure~* Previous gastrointestinal surgery except cholecystectomy and appendectomy.~* Neurologic diseases such as multiple sclerosis, strokes, spinal cord injuries, and those who have problems with cognizance, i.e. a mini-mental score of \<15 and/or are legally blind~* Hirschsprung' s disease, or active local anorectal problems such as anal fissures, bleeding hemorrhoids,~* Alternating constipation and diarrhea and those who fulfill the Rome-III criteria for irritable bowel syndrome.~* Subjects with a known allergy to psyllium or plums.",,,t,f,t
6260212,NCT01875978,,ALL,25 Years,80 Years,f,,"Inclusion Criteria:~* (1)25-80 years~* (2)Fatty liver was diagnosed by abdominal echo by the same gastrologist, review by another gastrologist~Exclusion Criteria:~* (1)Serological markers of hepatitis B virus(hepatitis B surface antigen and anti-HBs antibody) and hepatitis C virus infection (anti-HCV antibody)~* (2)Autoimmune liver disease or alcoholic liver disease(alcohol intake more than 20g per day by using a questionnaire)~* (3)Malignant diseases~* (4)Pregnancy or breast feeding~* (5)Clinical evidence of angina, congestive heart failure, valvular heart disease, inflammatory disease or thyroid dysfunction",,,t,f,t
6260213,NCT05080296,PROBABILITY_SAMPLE,ALL,18 Years,85 Years,,All Patients who performed a DaTSCAN SPECT scan in the nuclear medicine department of the Nancy CHRU between 21/11/2011 and 01/09/2017.,Inclusion Criteria:~* Patients who performed a DaTSCAN SPECT scan in the nuclear medicine department of the Nancy CHRU between 21/11/2011 and 01/09/2017.~* Reviews that took place between 11/21/2011 and 9/1/2017 were repatriated from PACS to the processing consoles.,,,t,f,t
6057092,NCT02416674,,ALL,18 Years,60 Years,f,,Inclusion Criteria:~* Abdominal wall defects as described above~* Strong motivation to proceed with transplantation~* Accepts dedicating at least 2 years towards extensive post transplant rehabilitation~* Age between 18 and 60 years~* Elapsed injury-to-transplant time of more than 6 months and less than 15 years~* Reports sub-optimal outcome with conventional reconstructive procedures~* Normal liver and kidney function tests:~Exclusion Criteria:~* Record of poor compliance~* Unable to receive adequate follow-up care~* Unable to receive immune suppression either due to geographic or financial limitations~* Unable to follow strict rehabilitation schedule.~* Documented psychological disorder(s) or incomplete psychological clearance~* Impaired renal or hepatic function~* Active cancer with or without metastases~* Severe cardiac/pulmonary dysfunction or other severe irreversible/uncorrectable disease,,,t,f,f
6057093,NCT00908674,NON_PROBABILITY_SAMPLE,MALE,18 Years,,f,Patients with advanced prostate cancer,"Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the prostate~* Inoperable prostate tumor or progradiated after surgery/ irradiation therapy~* Locally advanced tumor or distant metastases is present~Exclusion Criteria:~* Patient not fulfil the recruitment criteria~* Liver disease; Dubin-Johnson syndrome; Rotor syndrome; previous or existing liver tumours (in carcinoma of the prostate only if these are not due to metastases); wasting diseases (with the exception of carcinoma of the prostate); depression; previous or existing thromboembolic processes; diabetes with vascular changes; sickle-cell anaemia.~* As regards patients with prostatic carcinoma who have a history of thromboembolic processes and/or an existing sickle-cell anaemia, or diabetes with vascular changes, the risk:benefit ratio must be considered carefully in each individual case before the use of Androcur",,,t,f,t
6260214,NCT05405816,,ALL,18 Years,65 Years,f,,"Inclusion Criteria:~* 18 years and older and younger than 65 years.~* At least 5 years of morbid obesity (BMI \>40 or \>35 and comorbidity)~* Patients with transient or inadequate response weight loss despite dieting under the guidance of a dietitian.~Exclusion Criteria:~* Past upper gastrointestinal surgery,~* Paraesophageal (type 2), mixed (type 3), or sliding hiatal hernias of 3 cm or more,~* Patients with esophagitis and/or Barrett's metaplasia on upper GI endoscopy~* Those with peripheral vascular disease Those with a history of cerebrovascular accident~* Patients with coagulopathy~* History of chronic analgesic use",,,t,f,t
6159136,NCT03292991,NON_PROBABILITY_SAMPLE,ALL,20 Years,,f,HCC patients or colorectal cancer patients with secondary metastases in the liver.,"Inclusion Criteria, Patients who meet all inclusion criteria will be included:~* Males or non-pregnant females, at least 18 years of age (inclusive).~* Patients with clinically confirmed hepatocellular carcinoma (HCC) OR adenocarcinoma of colon/rectum with liver metastasis.~* Patients with liver dominant disease.~* Tumor burden ≤ 70% of total liver volume.~* HCC patients with child-Pugh Score class A or B.~* HCC patients with Barcelona-Clinic Liver Cancer (BCLC) stage A-C.~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.~* Patients who are unsuitable for resection or immediate liver transplantation or who cannot be optimally treated with local ablation.~* Patients who have provided written informed consent.~Exclusion Criteria, Patients who meet any exclusion criteria will be excluded:~* Patients known to be hypersensitive to any component of study product.~* Female patients who are pregnant or lactating. Women of child bearing potential who disagree to practice medically recognized birth control methods throughout the study (from Screening to approximately 6 months post SIRT). Medically recognized birth control methods include hormonal contraceptives, intrauterine device/IUD, barrier device, or abstinence. With the exception of women who had been surgically sterilized (defined as having undergone hysterectomy or bilateral oophorectomy or bilateral salpingectomy; tubal ligation alone is not considered sufficient), or one year post-menopausal.~Withdrawal criteria:~* Patients consent withdrawal.~* Lost to follow-up for 2 consecutive visits.",,,t,f,t
6159137,NCT00371033,,MALE,18 Years,,f,,"Inclusion Criteria:~* Participant has signed and dated the appropriate Informed Consent document.~* Participant must have had symptoms of discomfort or pain in the pelvic region for at least a three (3) month period within the last six (6) months.~Exclusion Criteria:~* Participant has continued evidence of facultative Gram negative or enterococcus with a value of ≥ 1000 and ≤ 100,000 CFU/ml in mid-stream urine (VB2), as demonstrated by repeat culture obtained no less than seven (7) days post antibiotic treatment.~* Participant has a calculated creatinine clearance of \<60 mL/min.~* Participant has a platelet count \<100,000/mm3.~* Participant is allergic to antiepileptic/antiseizure medications.~* Participant has a known allergy or sensitivity to pregabalin (Lyrica®).~* Participant is taking thiazolidinedione antidiabetic agents (i.e. rosiglitazone and pioglitazone).~* Participant has New York Heart Association Class III or IV congestive heart failure.~* Participant has a history of thrombocytopenia, or a bleeding diathesis.~* Participant has a history of prostate, bladder or urethral cancer.~* Participant has a history of alcohol abuse.~* Participant has inflammatory bowel disease (such as Crohn's disease or ulcerative colitis, but not irritable bowel syndrome).~* Participant has undergone pelvic radiation or systemic chemotherapy.~* Participant has undergone intravesical chemotherapy.~* Participant has been treated with intravesical BCG.~* Participant has unilateral orchalgia without other pelvic symptoms.~* Participant has an active urethral stricture.~* Participant has a neurological disease or disorder affecting the bladder.~* Participant has a neurological impairment or psychiatric disorder preventing his understanding of consent and his ability to comply with the protocol.",,,t,f,t
6159138,NCT00764634,,ALL,18 Years,55 Years,t,,"Inclusion Criteria:~1. The volunteer has signed the informed consent form.~2. The volunteer is 18 to 55 years of age.~3. The volunteer agrees not to donate blood or blood product for therapeutic or research purposes.~4. The volunteer is willing to comply with the requirements of the protocol.~5. The volunteer has no clinically significant abnormalities on electrocardiogram.~6. Female volunteers of childbearing potential must not be pregnant or lactating and agree to use two types of an acceptable form of FDA-approved contraception through Day 365 ± 7 days.~7. The volunteer is in good health.~8. The volunteer has clinical laboratory test results within the ranges listed in the protocol.~Exclusion Criteria:~1. The volunteer has a history of botulism or prior receipt of any botulinum vaccine, toxoid or antitoxin.~2. The volunteer has previously been treated or expects to be treated with any therapeutic products containing BoNTs such as Botox®, Myobloc®/Neurobloc™ and Botox® Cosmetic.~3. The volunteer has a history of hypersensitivity or significant adverse reaction to other vaccines, aluminum compounds or yeast.~4. The volunteer has donated one or more units of blood or undergone plasmapheresis within the past 28 days.~5. The volunteer received any blood product or immunoglobulin in the previous 6 months.~6. The volunteer received any investigational vaccine in the previous 6 months.~7. The volunteer received any licensed nonliving vaccine within 14 days before or after a scheduled vaccination.~8. The volunteer received any licensed live vaccine within 60 days before or after a scheduled vaccination.~9. The volunteer received any investigational drug therapy within 30 days before the first vaccination or before the last scheduled visit.~10. The volunteer received therapy with immunosuppressive agents, including use of moderate to high-dose oral inhaled or systemic corticosteroids (prednisone-equivalent dose of ≥ 20 mg/day).~11. The volunteer had neurological conditions associated with spasticity or abnormal muscle contraction, demyelination, other abnormalities of smooth or skeletal muscle function, migraine headache, or hyperhidrosis.~12. The volunteer had systemic or recurrent disease or condition that would place the volunteer at an unacceptable risk of injury or requires frequent or continuous medical intervention for treatment, has required hospitalization, or is likely to require surgical intervention during the course of the study.~13. The volunteer has a history of immunodeficiency or autoimmune disease.~14. The volunteer has a systemic medical condition that is ongoing or has required hospitalization or administration of antimicrobial agents within 6 months before screening.~15. The volunteer has a history of arthritis on more than one occasion not related to trauma or any episode of non-trauma-related arthritis within the previous 6 months.~16. The volunteer has an acute self-limited illness that has not resolved by the time of first vaccination including oral temperature greater than 99.5 °F.~17. The volunteer has a history of abuse of alcohol or drugs within the 12 months before study screening.~18. The volunteer has occupational or other responsibilities that would prevent completion of participation in the study.~19. The volunteer has a body mass index ≥ 35 kg/m2.~20. The volunteer has a confirmed positive result on a urine drug screen that tests for common substances of abuse such as amphetamines, barbiturates, benzodiazepines, cocaine, opiates and cannabinoids.~21. The volunteer was seropositive on screening tests for human immunodeficiency virus, hepatitis C virus or hepatitis B surface antigen.~22. The volunteer is currently on active duty in the U.S. military.",,,t,f,f
6159139,NCT01196624,,ALL,18 Years,65 Years,f,,"Inclusion Criteria:~* Consecutive patients fulfilling the DSM-IV diagnostic criteria for PTSD (as assessed by the Structured Clinical Interview) will be recruited from the inpatient and outpatient treatment programs at the Beer Sheva Mental Health Center.~Exclusion Criteria:~Subjects~The exclusion criteria includ:~* substance use disorder, cardiac pacemaker implant, or a history of epilepsy, neurosurgery, or brain trauma.~* Patients suffering from chronic medical conditions of any sort will be excluded from the study.",,,t,f,t
6159140,NCT05123118,,FEMALE,18 Years,,t,,"Inclusion Criteria:~* Be 18 years or older~* At ≤28 weeks of pregnancy~* Daily smoking cigarettes and/or cigars in the past 7 days~* Be able to read, listen, and talk in English~Exclusion Criteria:~* Being diagnosed with cancer~* Current heavy drinking (more than 2 drinks a day)~* Current use of illicit substances~* Medical conditions contraindicating breastfeeding such as HIV infection, active tuberculosis, and breast removal",,,t,f,t
6361041,NCT04818073,,ALL,18 Years,85 Years,f,,"Inclusion Criteria:~* Age 18 to 85 years~* Suffered from a single ischemic stroke (radiologically confirmed) at least 6-months prior to enrollment~* An ability to score at least 3 blocks on the Box and Block Test~Exclusion Criteria:~* A substantial decrease in alertness, language reception or attention~* Pregnant or lactating~* Advanced liver, kidney, cardiac or pulmonary disease~* Plan to alter any current participation in other rehabilitation therapy in the time period of the study~* A terminal medical diagnosis consistent with survival \< 1 year~* Coexistent major neurological disease~* Coexistent major psychiatric disease~* A history of significant alcohol or drug abuse in the prior 3 years~* Current enrollment in another study related to stroke or stroke recovery~* Any other medical contraindication to participation in this study evaluated by our team physician.",,,t,f,t
6260215,NCT03971396,NON_PROBABILITY_SAMPLE,ALL,25 Years,65 Years,f,physiotherapists working in cardiovascular intensive care,Inclusion Criteria:~* To worked or still working in cardiovascular surgery intensive care units~* To answer the survey questions~Exclusion Criteria:~* To Working or worked in cardiovascular surgery intensive care unit and but not answering questionnaire questions,,,t,f,t
6260216,NCT00450437,,ALL,11 Years,55 Years,f,,"Inclusion Criteria:~* Healthy subjects who are 11-55 years of age inclusive and who have given appropriate written assent and/or consent~Exclusion Criteria:~* Subjects with a previous or suspected disease caused by N. meningitidis~* previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s)~* previous or suspected disease caused by N. meningitidis~* Any serious acute, chronic or progressive disease~* Pregnant or breastfeeding",,,t,t,f
6361042,NCT05230173,,ALL,18 Years,,f,,"INCLUSION CRITERIA:~1. Male or nonpregnant, nonlactating females, ≥ 18 years of age.~2. An established diagnosis of CD or UC for at least 6 months based on standard clinical criteria, confirmed by the treating provider.~3. Current treatment with an approved TIM for treatment of IBD, including biologic agents (e.g., TNFα antagonists, ustekinumab, vedolizumab) and small molecule inhibitors (e.g., Janus kinase inhibitors, ozanimod), including future TIMs that become commercially available during the conduct of the trial.~4. Dose of TIM should be stable for 3 or more months prior to qualifying endoscopy/radiology. No treatment escalation of TIM or addition of IMM, corticosteroid, or mesalamines after the qualifying endoscopy/radiology procedure up to randomization is permitted. Dose de-escalation after qualifying procedure is permissible at the discretion of the treating provider.~5. In corticosteroid-free symptomatic remission based on validated PROs (PRO2 score) and deemed to be experiencing no other IBD-related symptoms in the opinion of the treating provider. Includes patients who may be in medically induced remission (on index TIM); or surgically induced remission with post-op initiation of index TIM for prophylaxis and colonoscopy/imaging performed at least 3 months after initiation/optimization of TIM showing moderate-severe bowel inflammation. Validated PROs are defined as:~   1. CD: PRO2 (2-item patient reported outcome) mean daily score of abdominal pain score ≤1 and stool frequency score ≤ 3; or~  2. UC: PRO2, with absence of rectal bleeding (rectal bleeding score = 0) and with stool frequency score ≤1.~6. Evidence of moderate to severe bowel inflammation on local reading of colonoscopy, flexible sigmoidoscopy, balloon-assisted enteroscopy, capsule endoscopy or MR, CT enterography, or intestinal ultrasound, performed within 6 months prior to screening, defined at the investigator's discretion or as follows:~   1. CD: Colonoscopy showing moderately to severely active inflammation based on 1 of the following variables/scores:~      * Simple Endoscopic Score for Crohn's Disease (SES-CD) score ≥7 or score ≥4 for those with isolated ileal disease, or~     * Presence of mucosal ulcers \>5 mm in size if SES-CD has not been recorded, or~     * Simplified Endoscopic Mucosal Assessment for Crohn's Disease (SEMA-CD) score ≥2, or~     * Rutgeerts score i2b or higher for patients in surgically induced remission with post-operative endoscopic recurrence \[Note, either SES-CD or Rutgeerts score can be used for participants with post-operative recurrence\]; or~  2. CD: MRE or CTE showing moderately to severely active inflammation based on 1 of the following variables:~      * Increased bowel wall thickness, or~     * Mural hyperenhancement, or~     * Peri-enteric fat stranding, or~     * Radiographic features of ulceration, or~     * Intramural T2 signal on fat suppressed images; or~  3. CD: Capsule endoscopy showing moderately to severely active small bowel disease based on Lewis score \>790 (in case the disease is not accessible via endoscopy), or per local endoscopist if Lewis score is not reported; or~  4. CD: Gastrointestinal ultrasound showing at least 1 of the following variables:~      * Increased bowel wall thickness \>5 mm, or~     * Color doppler score \>5/cm2, or~     * Bowel stenosis, or~     * Bowel stratification, or~     * Fatty wrapping; or~  5. UC: modified MES score of 2 to 3, or documentation of any endoscopic feature that would define an MES of 2 to 3 (e.g., friability, ulceration, spontaneous bleeding, complete loss of vascular pattern), if an MES has not been recorded.~7. Eligible to receive at least 1 alternative TIM (excluding their index TIM) for the treatment of their disease per approved drug label, based on clinical and reimbursement guidelines.~8. Able to participate fully in all aspects of this clinical trial.~9. Informed consent must be obtained and documented.~EXCLUSION CRITERIA:~1. Presence of ostomy or ileoanal pouches.~2. Serious underlying disease other than UC or CD that in the opinion of the investigator may interfere with the participant's ability to participate fully in the study.~3. History of alcohol or drug abuse or any other medical or health condition that in the opinion of the investigator may interfere with the participant's ability to comply with the study procedures.~4. Prior enrolment in the current study.~5. Mild endoscopic disease activity, where treating providers would not consider switching TIM.",,,t,f,t
6361043,NCT04001673,,ALL,18 Years,,f,,Inclusion Criteria:~* Outpatients from Rheumatology Department at Cochin Hospital~* Diagnosis of Spondyloarthritis~* Under treatment with subcutaneous bDMARDs for at least 6 months~* Disease activity stable for at least 6 months~* No treatment modification 3 months before or after inclusion in the study~* Informed consent signed and dated~* Older than 18 years~* Patients who speak french~Exclusion Criteria:~* Patients who have had a change in the treatment of SpA during the 3 months prior or after the inclusion~* History of psychological problems~* Patients who need other persons to manage their treatment.,,,t,f,t
6260217,NCT00882037,NON_PROBABILITY_SAMPLE,ALL,18 Years,,t,"This is a study of 150 rural and urban persons in treatment for methamphetamine dependence. We propose to enroll 150 participants (75 rural and 75 urban) over a two year period. Of these 150 participants, 75 will be Latino and 75 non-Latino (approximately 37 rural and 37 urban for each group).",Inclusion Criteria:~* Adults in SUD treatment facilities meeting DSM-IV criteria for methamphetamine dependence and able to provide informed consent.~* We intend to oversample Latinos in order to achieve a group with sufficient power to compare to non-Latinos. Our goal is to recruit 75 Latinos and 75 non-Latinos.~Exclusion Criteria:~* Persons not meeting the DSM-IV criteria for methamphetamine dependence and persons unable to complete informed consent.,,,t,f,t
6260218,NCT01492816,,ALL,16 Years,,f,,Inclusion Criteria:~1. The intervention group = Community members who become engaged in the coalitions and in the broader mobilization effort; and~2. The evaluation group = Key Informants within each C2P community who either work or reside within the sectors or systems where structural changes have been accomplished and/or the coalition has focused their strategic planning efforts.,,,t,t,t
6260219,NCT00395096,NON_PROBABILITY_SAMPLE,ALL,6 Years,12 Years,f,Cincinnati area children with asthma,Inclusion Criteria:~* Participated in the Cincinnati Asthma Prevention Study~* Diagnosis of asthma~* Lives with someone that smokes at least 5 cigarettes a day~Exclusion Criteria:~* No additional neuromuscular or respiratory disorder that may interfere with safe participation in the parent study~* Does not have electricity~* Plans to move within 1 year of entry into the parent study,,,f,t,f
6260220,NCT04072237,,MALE,18 Years,,f,,"Inclusion Criteria:~* Moderate or severe congenital Hemophilia A or B, with or without an inhibitor~* Male, age 18 or older~* Affirmation of informed consent with signature confirmation before any trial related activities~Exclusion Criteria:~* Inability to discontinue and washout prophylaxis treatment 72 hours prior to dosing.~* Previous participation in a trial involving SC Administration of rFVIIa or any trial using a modified amino-acid sequence FVIIa~* Known positive antibody to FVII or FVIIa detected by central laboratory at screening~* Have a coagulation disorder other than hemophilia A or B, with or without an inhibitor~* Significant contraindication to participate",,,t,f,t
6260221,NCT01258556,,FEMALE,18 Years,80 Years,f,,Inclusion criteria:~* Confirmed HIV infection;~* Being treated with anti-retroviral medication for \> 6 months.~Exclusion criteria:~* Pregnancy;~* Hypersensitive to fermented milk;~* Intolerant for lactose;~* Complaints of bacterial vaginosis requiring treatment,,,t,f,t
6057094,NCT04636710,,FEMALE,18 Years,,f,,"Inclusion Criteria:~* Stage III IBC (cT4d cN0-2). Inflammatory breast cancer is defined as the following constellation of symptoms (all of the following must be met):~  * Rapid onset symptoms (6 months or less from time of diagnosis)~ * Breast erythema, edema and/or peau d'orange and/or warm breast with or without an underlying palpable mass~ * Erythema occupying at least one-third of the breast~ * Pathologic confirmation (biopsy-proven) invasive breast carcinoma~* Women age ≥18 years~* ECOG performance status ≤2~* Ability to understand and willingness to sign informed consent document and comply with study procedures, including baseline research biopsy. If the research biopsy is not felt to be reasonably safe or feasible, a waiver must be obtained from the Principal Investigator. A formal exception would not be required in this case.~Exclusion Criteria:~* Participants who initiated pre-operative/neoadjuvant therapy prior to registration are ineligible.~* Participants with Stage IV (metastatic) breast cancer are excluded. The absence of any evidence of distant disease on staging studies needs to be confirmed at the time of diagnosis (within 42 days from initial presentation) using the staging studies that are standard for the participating institution.~* Participants with positive contralateral axillary nodes identified on standard imaging studies (MMG, MRI, US) are excluded. In participants with clinically suspicious axillary nodes, US guided biopsy will be performed prior to registration. If the contralateral axillary biopsy is positive, patients will not be eligible. If standard imaging does not identify contralateral disease yet drainage to the contralateral axillary basin is identified on pre-NAC lymphoscintigraphy, contralateral axillary US (if not already performed) will be obtained and any suspicious contralateral axillary nodes will undergo US guided biopsy. If the contralateral axillary biopsy is positive, patients will not continue on study for the evaluation of the primary endpoint, but their data will be used for the descriptive analyses of lymphatic drainage patterns in IBC. Contralateral invasive breast cancer without axillary involvement or in-situ carcinoma in either breast is allowed.",,t,t,f,t
6260222,NCT01574937,,MALE,18 Years,,f,,"Inclusion Criteria:~* CRPC with up to 2 prior chemotherapy regimens~* Progressive disease on CT, MRI or bone scan per mRECIST~* Has recovered to baseline/CTCAE less than or equal to Grade 1 from toxicities related to prior treatment (except alopecia)~* Agree to use accepted barrier method of contraception~Exclusion Criteria:~* Cytotoxic chemotherapy within 3 weeks~* Prior treatment with cabozantinib or other c-MET inhibitor~* Prior therapy with a lyase inhibitor~* Concurrent use of hormonal therapies other than LHRH analogue or orchiectomy~* Received radiation therapy to thoracic cavity or GI tract within 3 months, to bone or brain metastasis within 2 weeks or to any other site within 4 weeks of first dose of study drug~* Prior treatment with a small molecular kinase inhibitor within 2 weeks of study entry~* Received another investigational product within 28 days prior to study entry~* Active brain metastases or epidural disease~* Requires concomitant treatment in therapeutic doses with warfarin or warfarin-related agents~* No uncontrolled significant intercurrent or recent illness",,,t,f,t
6057095,NCT03645174,,ALL,20 Years,40 Years,t,,Inclusion Criteria:~* Residents of Anesthesiology~* Who has less than 10 times of experience of fiberoptic intubation~Exclusion Criteria:~* Who has more than 10 times of experience of fiberoptic intubation~* Who deny participating in the study,,,t,f,f
6159141,NCT05038319,,ALL,18 Years,70 Years,t,,"Inclusion Criteria:~* Age ≥18 years old, patients diagnosed with~* gastric varices larger than 2.0 cm in total diameter of the vascular pseudotumor type GOV2 or IGV 1.~* Active bleeder~* Secondary prophylaxis - h/o previous bleed~* High risk GV (GOV 2/IGV 1) - Baveno VI-~* Primary prophylaxis~Excusion criteria:~* Previous HRS~* MOF~* Platelet \<50,000/cumm~* INR\>2~* Esophageal stricture~* Iodine allergy (for EV)",,,t,f,t
6260223,NCT01346137,,FEMALE,18 Years,40 Years,t,,"Inclusion Criteria:~* Healthy~* Proven fertility in the past~* 18- 40 years old~* Regular menstrual cycles in the past 3 months (24-35 days)~* Surgically sterilized~* Non-lactating~* Hemoglobin of at least 11 g/dl~* Willing to give informed consent in writing~Exclusion Criteria:~* Allergy to meloxicam, aspirin, or other NSAIDs~* Currently pregnant or breast feeding~* History of gastrointestinal problems like stomach ulcer, bleeding or bowel problems~* History of heart attack, stroke, or blood clot~* Hemorrhagic or coagulation disorders~* Known liver and renal disorder~* History of or signs and symptoms of cancer, hyperprolactinemia, bloody breast discharge, diabetes, or any endocrine disturbance~* History of asthma, skin or mucosal allergies~* Hypertension: systolic blood pressure \> 135 mm Hg or diastolic blood pressure \>85 mmHg~* History of mental illness including depression or epilepsy~* Cigarette smoker~* Habitual user of anti-inflammatory drugs~* Alcoholism or any drug abuse~* Use of anticoagulants or steroids",,,t,f,f
6260224,NCT05432037,NON_PROBABILITY_SAMPLE,ALL,18 Years,,f,Target population for this study will be reported cases of low back pain.,Inclusion Criteria:~* Patients or the ones next to them who gave informed consent~* Participants with complain of low back pain for more than 3 months.~* Age at least above 18 years.~Exclusion Criteria:~* Inability to understand or follow the instructions of the Fear Avoidance Belief Questionnaire.~* Any musculoskeletal pathologies~* Suffering from any cardiovascular pathologies~* Any history of tumor and cancer~* Any history of fracture~* Any histories of infections~* Any history of neurological disorders~* Having any spinal deformity,,,t,f,t
6260225,NCT01444183,,ALL,18 Years,,f,,"Inclusion Criteria:~* Age 18 years and above~* English speaking~* Partial epilepsy consistent with ILAE criteria supported by either EEG or MRI data~* Experiencing at least 2 seizures/month~* Reported awareness of all seizures, including seizures in a cluster~* One of the following:~  1. Patient-reported ability to self-predict seizures~ 2. Patient-reported awareness of trigger factors, including stress~ 3. Patient-reported awareness of premonitory features~* Able to maintain accurate e-diary independently~* Minimum 6th grade reading level as screened by WRAT administration~* Must be on a stable dose of anti-epileptic drugs for at least 30 days prior to study entry~* May be on stable dose of SSRI, SNRI, or atypical antipsychotic for at least 6 months~* May be on a stable dose of benzodiazepines (if so, dose stable for at least 30 days prior to study entry)~For inclusion in clinical trial phase, patient must be/have:~* A minimum of 4 seizures documented in the 8-week baseline phase (or 6 seizures in the 12-week extended baseline phase)~* At least 1 seizure per 4-week period in two of the three 4-week periods in the extended baseline phase~* Diaries satisfactorily completed during baseline phase~* Complied with study requirements during the baseline phase~Exclusion Criteria:~* Non-motor simple partial seizures only~* Concurrent VNS use~* History of suicide attempt within the past 2 years~* Current suicidality~* Not competent to sign consent~* Status epilepticus within the previous 6 months~* Began regularly using behavioral techniques for stress reduction within past 3 months~* Did not benefit from an adequate trial of a valid stress reduction technique~* Progressive neurologic condition that the investigator believes would affect seizure frequency~* Any history of substance abuse within the previous 2 years~* History of poor medication compliance as judged by the investigator~* Psychiatric illness that requires change in medication dose~* Any medical or psychiatric condition that would impair reliable participation in the trial~* Intermittent use of benzodiazepines (if used for sleep, will be determined case by case)",,,t,f,t
6260226,NCT06195137,,ALL,18 Years,75 Years,f,,"Inclusion Criteria:~* Adults over 18 years of age~* Diagnosis of BMS according to the 3rd edition of the International Classification of Headache Disorders (ICHD-3)~* Daily intraoral burning or dysaesthesia lasting for more than 2 hours for over 3 months~* Normal oral mucosa and sensory testing~* Condition not better accounted for by another ICHD-3 diagnosis~Exclusion Criteria:~1. Secondary BMS due to local or systemic disorders~2. Prior treatment for BMS~3. Psychiatric or progressive neurological disorders~4. Systemic disorders potentially associated with oral disease~5. Long-term history of smoking, drinking, or medication use~6. Consumption of caffeinated products~7. Poor oral hygiene~8. Abnormal blood test results (including blood count, glucose, serum iron, ferritin and transferrin, folic acid, or vitamin B12 levels)~9. Incomplete medical records~10. Unwillingness to participate",,,t,f,t
6260227,NCT02773758,,ALL,18 Years,65 Years,t,,"Inclusion Criteria:~* Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.~* Aged 18-65 years inclusive.~* Good general and mental health with:~No clinically significant and relevant abnormalities of medical history or oral examination.~Absence of any condition that would impact on the participant's safety or wellbeing or affect the individual's ability to understand and follow study procedures and requirements.~* Self-reported history of dentinal hypersensitivity (DH) lasting more than six months but not more than 10 years.~* Minimum of 20 natural teeth.~* Minimum of 2 accessible non-adjacent teeth (incisors, canines, pre-molars), preferably in different quadrants, that meet all of the following criteria at screening: Signs of facial/cervical gingival recession and/or signs of erosion or abrasion (EAR).~Tooth with MGI score =0 adjacent to the test area (exposed dentine) only and a clinical mobility of ≤1.~Tooth with signs of sensitivity measured by qualifying evaporative air assessment (yes\[Y\]/No\[N\] response).~* Minimum of two, non-adjacent accessible teeth (incisors, canines, pre-molars), that meet all of the following criteria at screening:~Tooth with signs of sensitivity, measured by response to a qualifying tactile stimulus (Yeaple ≤ 20g) and evaporative air assessment (Schiff sensitivity score ≥ 2).~Exclusion Criteria:~* Women who are breast-feeding, known to be pregnant or who are intending to become pregnant over the duration of the study.~* Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.~* Previous participation in this study or participation in another clinical study (including cosmetic studies) or receipt of an investigational drug within 30 days of the screening visit.~* Recent history (within the last year) of alcohol or other substance abuse.~* Presence of chronic debilitating disease which, in the opinion of the investigator, could affect study outcomes or causing xerostomia.~* Dental prophylaxis within 4 weeks of Screening.~* Tongue or lip piercing or presence of dental implants.~* Gross periodontal disease, treatment of periodontal disease (including surgery) within 12 months of Screening, scaling or root planning within 3 months of Screening.~* Teeth bleaching within 8 weeks of Screening.~* Tooth with evidence of current or recent caries, or reported treatment of decay within 12 months of Screening.~* Tooth with exposed dentine but with deep, defective or facial restorations, teeth used as abutments for fixed or removable partial dentures, teeth with full crowns or veneers, orthodontic bands or cracked enamel. Sensitive teeth with contributing aetiologies other than erosion, abrasion or recession of exposed dentine.~* Sensitive tooth not expected to respond to treatment with an over-the-counter dentifrice.~* Use of an oral care product indicated for the relief of dentine hypersensitivity within 8 weeks of screening.~* Daily doses of medication/treatments which, in the opinion of the investigator, could interfere with the perception of pain.~Examples of such medications include analgesics, anticonvulsants, antihistamines that cause marked or moderate sedation, sedatives, tranquilisers, anti-depressants, mood-altering and anti-inflammatory drugs.~* Currently taking antibiotics or has taken antibiotics within 2 weeks of Baseline.~* Daily dose of a medication which, in the opinion of the Investigator, is causing xerostomia.",,,t,f,t
6260228,NCT04567316,,MALE,18 Years,65 Years,t,,"Inclusion Criteria:~* Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests~* Age of 18 to 65 years (inclusive)~* BMI of 18.5 to 29.9 kg/m2 (inclusive)~* Signed and dated written informed consent prior to admission to the study, in accordance with GCP and local legislation~* Male subjects who meet any of the following criteria from screening until 90 days after trial completion:~  * Use of adequate contraception of the female partner, e.g. any of the following methods plus condom: implants, injectables, combined oral or vaginal contraceptives, intrauterine device that started at least two months prior to first study drug administration or barrier method (e.g. diaphragm with spermicide) or,~ * Sexually abstinent or,~ * A vasectomy performed at least 1 year prior to screening (with medical assessment of the surgical success) or,~ * Surgically sterilised female partner (including hysterectomy, bilateral tubal occlusion, or bilateral oophorectomy) or,~ * Postmenopausal female partner, defined as at least 1 year of spontaneous amenorrhea (in questionable cases a blood sample with levels of follicle-stimulating Hormone (FSH) above 40 U/L and estradiol below 30 ng/L is confirmatory)~Exclusion Criteria:~* Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator~* Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 40 to 100 bpm~* Any laboratory value outside the reference range that the investigator considers to be of clinical relevance~* C-reactive protein (CRP) \> upper limit of normal (ULN), liver or kidney parameter above ULN~* Any evidence of a concomitant disease assessed as clinically relevant by the investigator~* Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders~* Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)~* Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders~* For Part 1 only:~  * Participation in another absorption, distribution, metabolism, and excretion (ADME) pharmacokinetics study with a radiation burden of \>0.1 millisievert (mSv) in the period of 1 year prior to screening~ * Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays of thorax and bony skeleton (excluding spinal column)) in the period of 1 year prior to screening~ * Irregular defecation pattern (less than a mean of one bowel movement every 1 or 2 days)~In addition, the following Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) specific exclusion criterion apply:~* A positive test indicating an ongoing infection with SARS-CoV-2 and clinical symptoms suggestive of the disease~* Further exclusion criteria apply",,,t,f,t
6159142,NCT03117452,,ALL,18 Years,60 Years,f,,"Inclusion Criteria:~* Between the ages of 18-60.~* Meets DSM-5 criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder.~* Currently attends the Rutgers UBHC Partial Hospital Program and plans to continue attending for at least the next 16 weeks.~* If the participant is treated with antipsychotic medication, he/she is on stable treatment with this medication (i.e. no change in medication type, or substantial change in dose, for at least 4 weeks prior to participating in the study and no anticipated change for the next 16 weeks).~* Has capacity to provide informed consent.~* Is fluent in English.~* Has a minimum binocular visual acuity of 20/100, as assessed at baseline using a standard eye chart, with the participant's typical vision correction (e.g., with glasses if the participant typically wears glasses).~Exclusion Criteria:~* Has met DSM-5 criteria for a substance-use disorder within the last 12 months (with the exception of tobacco use disorder, which will be permitted).~* Has a verbal IQ score of \< 70 per the Wechsler Test of Adult Reading (WTAR).~* Current or recent history of a medical condition that significantly affects the structure or function of the brain or eye (e.g., ocular or retinal disease, thyroid disease, untreated hypertension, uncontrolled diabetes).~* Current or past neurological or neurodevelopmental disorder such as seizure disorder, cerebral palsy, intellectual disability, or pervasive developmental disorder.~* Has a lazy eye or history of severe eye injury.~* Has received electroconvulsive therapy within the last 8 weeks.~* Has a history of head injury with loss of consciousness lasting more than 10 minutes or with neurobehavioral consequences of the injury (e.g., need for follow-up treatment, cognitive or behavioral changes following the injury, etc.).~* Any current use (last month) of non-prescribed amphetamines, opiates, cocaine, sedative-hypnotics, and/or cannabis.",,,t,f,f
6260229,NCT03810716,,FEMALE,18 Years,49 Years,t,,Inclusion Criteria:~* Mothers of children who attend the service of growth and development who are of legal age~* Women who do not currently use some modern contraceptive method~* Women whose partners have not received voluntary surgical contraception~Exclusion Criteria:~* Teen mothers~* Illiterate women~* Women who currently do not have a partner~* Women who are currently gestating,,,t,f,f
6159143,NCT06319118,,ALL,18 Years,,f,,"Inclusion Criteria:~1. Patients with Parkinson\&#39;s disease diagnosed by the British Parkinson\&#39;s Disease Brain Bank Diagnostic Criteria can come to the hospital accompanied by family members~2. drooling score using the Parkinson\&#39;s Comprehensive Rating Scale (UPDRS) Part II (Item 6) ≥3;~3. MMSE ≥ 10 points (recording the patient\&#39;s education level)~4. Adults over the age of 18~5. The applicant or his/her caregiver must be able to complete the record of the salivation score~6. Patients or family members voluntarily participate and sign an informed consent form.~Exclusion Criteria:~1. Patients with non-primary Parkinson\&#39;s disease~2. Known allergy to dihydroergotamine mesylate~3. Drug-induced hypersalivation, such as olanzapine, antipsychotics, clonazepam and other antiepileptic drugs, as well as direct and indirect cholinergic agonists for the treatment of Alzheimer\&#39;s disease and myasthenia gravis~4. BoNT treatment for saliva within the previous 3 months~5. Patients with symptomatic bradycardia, severe orthostatic hypotension, symptomatic coronary insufficiency, severe organic cardiac damage, severe liver and kidney insufficiency: including ALT≥2.5ULN (upper limit of normal value of the executive laboratory); AST≥2.5ULN (upper limit of normal for the execution laboratory); Creatinine ≥ 1.5 ULN (upper limit of normal at the execution laboratory), active psychosis, pregnancy/pregnant woman",,,t,f,t
6159144,NCT01903252,,ALL,18 Years,,f,,"Induction phase - Main criteria for inclusion include:~1. Male or non-pregnant, non-lactating females, 18 years of age or older. Females of child bearing potential must have a negative serum pregnancy test prior to randomisation, and must use a hormonal (oral, implantable or injectable) or barrier method of birth control throughout the study. Females unable to bear children must have documentation of such in the source records (i.e., tubal ligation, hysterectomy, or post-menopausal \[defined as a minimum of one year since the last menstrual period\]).~2. Documented diagnosis of UC with disease extending at least 15 cm from the anal verge.~3. Active UC defined by:~   * a. Mayo score of ≥ 5~  * b. Sigmoidoscopy component score ≥ 2 confirmed by central review and~  * c. Rectal bleeding component score ≥ 1~4. Ability of the subject to participate fully in all aspects of this clinical trial.~5. Written informed consent must be obtained and documented.~Induction Phase - Main criteria for exclusion include:~Subjects who exhibit any of the following conditions are to be excluded from the study:~(1) Severe UC defined by the following criteria: 6 bloody stools daily with one or more of the following:~* a. oral temperature \> 37.8 degrees C or \> 100.0 degrees F~* b. pulse \> 90 beats/min~* c. haemoglobin \< 10 g/dL (2) Treatment with oral mesalamine at a dose of \> 2.4 g/day within 4 weeks prior to randomisation.~  (3) Treatment with topical therapy (mesalamine or corticosteroids) within 2 weeks prior to randomisation (4) Treatment with systemic or rectal steroids within 4 weeks prior to randomisation.~  (5) Treatment with immunosuppressants within 6 weeks prior to randomisation. (6) Treatment with infliximab or other biologics within 3 months prior to randomisation.~  (7) Treatment with antibiotics within 7 days prior to randomisation. (8) Treatment with probiotics within 7 days prior to randomisation. (9) Treatment with anti-diarrhoeal treatment within 7 days prior to randomisation.~  (10) Treatment with nicotine patch within 7 days prior to randomisation. (11) Received any investigational drug within 30 days prior to randomisation. (12) History of colectomy or partial colectomy. (13) History of definite dysplasia in colonic biopsies. (14) Crohn's disease. (15) Immediate or significant risk of toxic megacolon. (16) Known bleeding disorders. (17) Hypersensitivity to salicylates, aspirin, sulfasalazine or mesalazine. (18) Serum creatinine \> 1.5 times the upper limit of the normal range. (19) Aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin or alkaline phosphatase \> 2 times the upper limit of the normal range.~  (20) Serious underlying disease other than UC which in the opinion of the investigator may interfere with the subject's ability to fully participate in the study.~  (21) History of alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures.~  (22) Stools positive for Clostridium difficile toxin. (23) Pregnant or lactating women. (24) Prior enrolment in the study.~OLE - Main criteria for inclusion include:~1. Attendance at the Week 8 visit and completion of disease activity assessments prior to enrolment in OLE at Week 12 (responders or remitters) or Week 8 (non-responders).~2. At least 75% compliance with study medication in the induction phase.~OLE - Main criteria for exclusion include:~(1) Withdrawal from the induction phase prior to the Week 8 visit.",,,t,f,t
6159145,NCT01835418,,ALL,40 Years,75 Years,f,,Inclusion Criteria:~* Age 40 to 80~* Newly diagnosed hypertension based on 24 hour ambulatory blood pressure monitor criteria.~* Minimum Asleep SBP mean of ≥ 120mmHg for inclusion.~Exclusion Criteria:~* Current antihypertensive medication use~* Baseline GFR \< 45~* Preexisting macroproteinuria~* Chronic congestive heart failure~* History of CVA~* Diabetes Mellitus~* Pregnancy~* Night-shift work~* Other preexisting contraindication to amlodipine or lisinopril,,,t,f,t
6159146,NCT04258891,NON_PROBABILITY_SAMPLE,ALL,18 Years,,,"Kidney recipients aged over 18 and of all sexes recruited from 2004 in European and North American centers, who have estimated glomerular filtration rate and proteinuria repeated measurements, data from protocol and for cause biopsies, as well as immunological, clinical, functional parameters and survival data for allograft and patient survival assessment. Additional kidney recipients from RCTs with longitudinal data including baseline and follow-up clinical, functional, immunological and histological data.",Inclusion Criteria:~* Kidney recipients transplanted after 2004~* Kidney recipients over 18 years of age~* Kidney recipients with at least two estimated glomerular filtration rate and proteinuria measurements after transplantation~Exclusion Criteria:~* Combined transplantation,,,t,f,t
6159147,NCT04795518,PROBABILITY_SAMPLE,ALL,25 Years,45 Years,f,Group of pediatric dentists,Inclusion Criteria:~Dentists of pediatric dentistry working for children aged. Dentists who have BDS degree in the last 20 years.~Exclusion Criteria:~-,,,t,f,f
6159148,NCT00846118,,ALL,20 Years,80 Years,f,,Inclusion Criteria:~* patients under hemodialysis~* patients with hypercholesterolemia as defined by any of following parameters:~  * LDL-C ≧ 100 mg / dL~ * TC ≧ 180 mg / dL~ * patients required cholesterol-lowering treatment by investigators.~* patients aged 20-75 years~* patients with written consent by their own volition after being provided sufficient explanation for the participation into this clinical trial~Exclusion Criteria:~* patients taking statins or fibrates~* patients enrolled to the other trials using contraindication drugs of pitavastatin~* patients who had acute myocardial infarction within six months before the day of the agreement acquisition~* patients scheduled PCI and CABG within six months after the day of the agreement acquisition~* Patients who had diagnosis or doubt of malignant tumor~* patients corresponded to Contraindications of pitavastatin~* Familial hypercholesterolemia patients~* patients judged ineligible by investigators,,,t,f,t
6159149,NCT01769352,,ALL,18 Years,,f,,"Inclusion Criteria:~* Age more than or equal to 18 years~* Diagnosis of PSCME in study eye confirmed by FA showing leakage from retinal vessels resulting in pooling of dye in the fovea and Spectralis SD-OCT showing intraretinal fluid in or around the fovea.~* BCVA score in the study eye of 20/30 to 20/400 inclusive (Snellen equivalents using the ETDRS protocol at a distance of 4 meters).~* In the opinion of the investigator, decreased vision in the study eye is due to foveal thickening from PSCME and not to any other reason.~Exclusion Criteria:~* Any patient who has other retinal diseases known to cause macular edema (choroidal neovascularization, vein occlusion, diabetic macular edema in the study eye). Patients with nonexudative Age Related Macular Degeneration (ARMD) or non-proliferative diabetic retinopathy without macular edema can be included in the study.~* Other reason for decreased visual acuity (such as amblyopia, foveal atrophy, optic atrophy).~* Pre-existing diagnosis of glaucoma in the study eye~* Inability to comply with study or follow up procedures~* Pregnancy (Women of child bearing age will be asked to take a urine pregnancy test prior to enrolling in the study).",,,t,f,t
6159150,NCT00481052,,ALL,18 Years,,f,,"Inclusion Criteria:~* Patients with a cytologic and cytogenetic confirmed diagnosis of Ph+ CML.~* Age ≥ 18 years old~* Early CP (within 6 months from diagnosis)~* No prior treatment with any antileukemic drugs with the exception of Hydroxyurea (HU) and Anagrelide.~* WHO performance status of ≤ 2~* Normal serum level of potassium, total calcium corrected for serum albumin, magnesium and phosphorus, or correctable with supplements~* ALT and AST ≤ 2.5 x ULN or ≤ 5.0 x ULN if considered due to leukaemia.~* Alkaline phosphatase ≤ 2.5 x ULN unless considered due to leukemia.~* Serum bilirubin ≤ 1.5 x ULN~* Serum creatinine ≤ 1.5 x ULN~* Serum amylase ≤ 1.5 x ULN and serum lipase ≤ 1.5 x ULN.~* Written informed consent prior to any study procedures being performed.~Exclusion criteria:~* Impaired cardiac function, including LVEF \< 45% as determined by MUGA scan or echocardiogram, uncontrolled congestive heart failure, uncontrolled hypertension~* History of myocardial infarction within three months, or uncontrolled angina pectoris.~* Significant electric heart abnormalities, including history or presence of significant ventricular or atrial tachyarrhythmias, congenital long QT syndrome and/or QTc \> 450 msec on screening ECG (using the QTcF formula).~* Patients with ventricular pacemakers and clinically significant bradycardias.~* Patients with heart blocks.~* History of acute or chronic pancreatitis.~* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of nilotinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)~* Use of therapeutic coumarin derivates (i.e. warfarin, acenocoumarol, phenprocoumon).~* Acute or chronic liver or renal disease considered unrelated to leukaemia~* Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes, active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol~* Patients who are currently receiving treatment with any of the medications listed in Appendix E and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. The medications listed in Appendix E have the potential to prolong QT, with the exception of HU and Anagrelide.~* Patients who have received any antileukemic agents and treatments, including HSCT, with the exception of HU and Anagrelide.~* Patients who have received any investigational drug ≤ 4 weeks.~* Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.~* Patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control. (Women of childbearing potential must have a negative serum pregnancy test within 48 hrs prior to administration of nilotinib). Post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.~* Treatment with any hematopoietic colony-stimulating growth factors (e.g. G-CSF, GM-CSF) 1 week prior to starting study drug.~* Patients who have received immunotherapy 1 week prior to starting study drug or who have not recovered from side effects of such therapy.~* Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory).~* Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention.~* Patients unwilling or unable to comply with the protocol.",,,t,f,t
6159151,NCT01315418,,ALL,18 Years,29 Years,t,,"Inclusion Criteria:~* male and female aged 18-29 years~* attending 7 weeks of firemen training school~* a 19 to 29 kg/m2 body mass index~* found medically healthy (in particular, free of respiratory and GI tract symptoms)~* agreeing to a written informed consent, and who appreciates dairy products and multi-fruit flavour.~Exclusion Criteria:~* Subject who is not reading and writing French, or not understanding informed consent or study protocol~* subject with allergy or hypersensitivity to milk proteins or dairy foods components (ex: lactose), or with any known food or respiratory allergy;~* subject presenting a severe evolutive or chronic pathology (Ex: cancer, tuberculosis, Crohn disease, cirrhosis, multiple sclerosis, Type I diabetes...) or any past or actual health condition that may interfere with the outcome of the study (Ex: HIV, Chemotherapy, malabsorption, ulcer, celiac disease...)~* subject having experienced any infectious disease during the last 7 days~* subject with current diarrhoea or constipation~* subject who is frequently using laxatives or who has been using laxatives during the week prior his participation to the study~* subject who was under artificial nutrition, had gastro-intestinal surgery or any intervention requiring general anaesthesia the last 2 months prior to his participation to the study~* subject with special medicated diet (obesity, anorexia, metabolic pathology, nutritional complementation...) or with eating disorders (anorexia, bulimia, alcoholism...)~* subject currently receiving, or who has received during the last months, systemic treatment or topical treatment likely to interfere with evaluation of the study parameters: antibiotics, antiseptics,antifungal, corticoids, vaccines, anti-histaminic molecules, non-corticoid anti-inflammatory substances, immunosuppressant treatment...~* subject already enrolled in another clinical study, or currently under an exemption period from a previous study~* female subject who is currently pregnant or breast-feeding, or willing to become pregnant during the 2 coming months after enrolment in the study~* subject in a situation which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the subject",,,t,f,f
6159152,NCT06441500,,ALL,3 Years,5 Years,t,,Inclusion Criteria:~* children aged 3-5 years attending public nurseries in Romania~Exclusion Criteria:~* enamel fluorosis~* enamel developmental defects~* incapacity to perform tooth brushing by themselves,,,f,t,f
6159153,NCT00317291,,ALL,18 Years,70 Years,f,,"Inclusion Criteria:~* Men and women who are HIV positive or Centers for Disease Control (CDC)-defined AIDS diagnosed subjects who are 18 years of age or older, and have a history of distal symmetrical peripheral neuropathy of the lower extremities (legs and feet) for two months or greater.~* Patients experiencing moderate pain severity.~* Verification from primary provider of subject's: HIV status, diagnosis of DSP, and agreement that patient is clinically suitable for the study.~* Individuals able to successfully complete a mini-mental status exam.~* Individuals who understand and agree to complete daily symptom diaries for the duration of the study.~* Individuals taking antiretroviral combinations must have completed an initial 8 weeks of a stable regime (same drug\[s\], dose, and frequency) prior to entry into the study.~* Individuals taking chronic pain medications must be on a stable regime (same drug, dose, and frequency) for at least twenty-one (21) days prior to entry into the study.~* Individuals on all other medications which may have neuropathy listed as a side effect must be on a stable regime (same drug\[s\], dose, and frequency) for at least 21 days prior to entry in the study.~Exclusion Criteria:~* Individuals with an acute medical condition, i.e. pneumocystis carinii pneumonia, tuberculosis, and/or other opportunistic infections or conditions that would require medical attention.~* Individuals with diagnosis of diabetes mellitus, B-12 deficiency~* Topically applied medications to the lower extremities.~* Individuals with alcohol and/or substance dependence.~* Individuals with bleeding tendency~* Currently receiving treatment with corticosteroids~* Use of isoniazid (INH), dapsone, or metronidazole within 8 weeks prior to enrollment.~* Severe heart disease, uncontrolled high blood pressure, lung disease, or renal failure.~* Pregnant women~* Individuals receiving acupuncture currently and less than 6 months prior to enrollment.~* Individuals with a history of receiving moxibustion.~* Individuals currently receiving other types of complementary therapies such as herbs, massage, reiki, etc.~* Individuals with plans for travel, lifestyle change, or other activity that would preclude attending all of the planned study sessions and/or recording daily diary information.",,,t,f,t
6159154,NCT00456118,PROBABILITY_SAMPLE,FEMALE,18 Years,45 Years,f,"Neonatal pathologies can be caused by an alloimmunisation maternal fetal tissue, it's conceivable that certain pathologies. Obstetrics may be part of the same mechanism. Among these pathologies placentaires, for whom a maternal-fetal incompatibility is often mentioned, could be secondary to tissue alloimmunization against antigens independent of the immune system","Inclusion Criteria:~* Recurrent pregnancy losses : patient having or having suffered from at least 3 consecutive, unexplained recurrent pregnancy losses, during the first 3 months of pregnancy, with the same paerson/man.~* Preeclampsia : blood pressure \> 140/90 mm Hg ; proteinuria \> 0,3 g/ 24 h~* Intervillositis : patient suffering or having suffered from intervillositis~Exclusion Criteria:~* Recurrent pregnancy losses : uterine pathology, endocrine pathology, autoimmune pathology, coagulation and hemostasis pathology, karyotype anomaly.~* Preeclampsia : pre-existing high blood pressure, pre-existing diabetes, pre-existing renal disease, antiphospholipid antibodies syndrome~* Intervillositis : intervillositis with villositis",,,t,f,f
6260230,NCT04880083,,ALL,3 Days,28 Days,t,,"Inclusion Criteria:~1. Evidence of personally signed and dated informed consent document indicating that the infant's parent(s)/ legally accepted representatives LAR have been informed of all pertinent aspects of the study.~2. Infants whose parent(s)/LAR have reached the legal age of majority in the countries where the study is conducted.~3. Infants whose parent(s)/LAR are willing and able to comply with scheduled visits, and the requirements of the study protocol.~4. Infants whose parent(s)/LAR can be contacted directly by telephone throughout the study.~5. Infants whose parent(s)/LAR have a working freezer.~6. Infants must meet all the following inclusion criteria to be eligible for enrolment into the study:~   * Healthy term infant (37-42 weeks of gestation).~  * At enrolment visit, post-natal age 3-28 days (date of birth = day 0)~  * Birth weight ≥ 2500g and ≤ 4500g.~  * Formula-fed infants only: Infants must predominantly consume and tolerate a standard cow's milk infant formula prior to enrolment and their parent(s)/LAR must have independently elected, before enrolment, not to exclusively breastfeed. Predominantly formula feeding means that the infant's predominant source of nourishment has been formula. Specifically, infants are fed with formula for at least 75% of total milk feeds per day.~  * Breastfed infants only: Infants must have been predominantly breastfed since birth, and their parent(s)/LAR must have made the decision to continue predominant breastfeeding for the duration of the study. Predominant breastfeeding allows infants to be mix fed with breastmilk and other milks. It means that the infant's predominant source of nourishment has been breastmilk. Specifically, infants are fed with breast milk for at least 75% of total milk feeds per day.~Exclusion Criteria:~1. Infants with conditions requiring infant feedings other than those specified in the protocol.~2. Infants receiving complementary foods or liquids defined as 4 or more teaspoons per day or approximately 20 g per day of complementary foods or liquids at or prior to enrollment.~3. Infants who have a medical condition or history that could increase the risk associated with study participation or interfere with the interpretation of study results, including:~   * Evidence of major congenital malformations (e.g., cleft palate, extremity malformation).~  * Documented systemic or congenital infections (e.g., human immunodeficiency virus, cytomegalovirus, syphilis).~  * Previous or ongoing severe medical or laboratory abnormality (acute or chronic) which, in the judgment of the investigator, would make the infant inappropriate for entry into the study.~4. Infants who are presently receiving or have received prior to enrollment probiotic supplements or any of the following: medication(s) or supplement(s) which are known or suspected to affect the following: fat digestion, absorption, and/or metabolism (e.g., pancreatic enzymes); stool characteristics and microbiota (e.g., oral and systemic antibiotics, glycerin suppositories, bismuth-containing medications, docusate, Maltsupex, or lactulose); growth (e.g. insulin or growth hormone); gastric acid secretion.~5. Currently participating or having participated in another clinical trial since birth.~6. Subjects or subjects' parent(s) or legal representative who are not willing and not able to comply with scheduled visits and the requirements of the study protocol.",,,f,t,f
6260231,NCT01608607,PROBABILITY_SAMPLE,ALL,,,f,Varied,Inclusion Criteria:~* Trials in humans~* Oral fructose intervention~* Suitable control (i.e. another carbohydrate source in isocaloric exchange for fructose or a control diet which is compared with the same diet supplemented with excess energy from fructose)~* \>= 7-days diet duration~* Viable endpoint data~Exclusion Criteria:~* Non-human studies~* IV or parenteral fructose~* High fructose corn syrup or sucrose intervention (except where these are the comparators)~* Lack of a suitable control~* \< 7-days diet duration.~* No viable endpoint data,,,t,t,t
6260232,NCT05294497,,ALL,21 Years,60 Years,t,,"Inclusion Criteria:~1. Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.~2. Generally healthy males or females, 21 to 60 years of age, inclusive, at the time of consent.~3. Smokes combustible, filtered, non-menthol or menthol cigarettes, 83 mm to 100 mm in length as primary source of tobacco.~4. Smokes an average of at least 10 cigarettes per day (CPD) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of the PI.~5. Smokers who also use ST products (e.g., moist snuff, snus), and have used ST within 30 days prior to screening will be enrolled.~6. Agrees to smoke the same UB cigarette throughout the study period. The UB cigarette is defined as the reported cigarette brand style currently smoked most frequently by the subject.~7. Expired breath carbon monoxide (ECO) level is ≥ 10 ppm and ≤ 100 ppm at Screening and at check-in Day 1.~8. Positive urine cotinine test at Screening.~9. Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1 (How soon after you wake up do you smoke your first cigarette?) is either Within 5 minutes or 6-30 minutes (Heatherton et al., 1991).~10. Willing to use UB cigarette, nicotine pouch IPs, and Nicorette® gum during the study period.~11. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to the start of each of six Test Sessions.~12. Females must be willing to use a form of contraception acceptable to the PI from the time of signing the informed consent until End-of-Study.~    Examples of acceptable means of birth control are, but not limited to:~   1. Surgical sterilization (hysterectomy, bilateral tubal ligation/occlusion, bilateral oophorectomy, bilateral salpingectomy);~   2. physical barrier method (e.g., condom, diaphragm/sponge/cervical cap) with spermicide;~   3. non-hormone releasing intrauterine devices (IUD) or hormone-releasing IUDs (e.g., Mirena or Kyleena);~   4. vasectomized partner; and~   5. post-menopausal and not on hormone replacement therapy.~13. Agrees to an in-clinic confinement of 7 days (6 nights).~Exclusion Criteria:~1. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of the PI, makes the study subject unsuitable to participate in this clinical study.~2. History, presence of, or clinical laboratory test results indicating diabetes.~3. Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at the PI's discretion pending approval from the Medical Monitor.~4. History or presence of bleeding or clotting disorders.~5. Any history of cancer, except for primary cancers of skin such as localized basal cell/squamous cell carcinoma that has been surgically and/or cryogenically removed.~6. Systolic blood pressure of \> 160 mmHg or a diastolic blood pressure of \> 95 mmHg, measured after being seated for five minutes at Screening and at check-in Day 1.~7. Weight of ≤ 110 pounds.~8. Hemoglobin level is \< 12.5 g/dL for females or \< 13.0 for males g/dL at Screening.~9. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.~10. A positive urine drug screen without evidence of prescribed corresponding concomitant medication(s) at Screening or check-in Day 1.~11. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).~12. Use of any medication or substance that aids in smoking cessation, including but not limited to any nicotine replacement therapy (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract within (≤) 30 days prior to signing the informed consent.~13. Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or self-reports a previous quit attempt within (≤) 30 days prior to signing the informed consent.~14. Any use of daily aspirin (≥ 325 mg) or any use of other anticoagulants.~15. Individuals ≥ 35 years of age currently using systemic, estrogen-containing contraception or hormone replacement therapy.~16. Whole blood donation within 8 weeks (≤ 56 days) prior to signing the informed consent and between Screening and check-in Day 1.~17. Plasma donation within (≤) 7 days prior to signing the informed consent and between Screening and check-in Day 1.~18. Employed by a tobacco or nicotine company, the study site, or handles tobacco- or nicotine-containing products as part of their job.~19. Participation in another clinical trial within (≤) 30 days prior to signing the informed consent. The 30-day window for each subject will be derived from the date of the last study event in the previous study to the time of signing the informed consent in the current study.~20. Drinks more than 21 servings of alcoholic beverages per week.~21. Has a positive alcohol result at Screening or check-in Day 1.~22. Determined by the PI to be inappropriate for this study.",,,t,f,f
6260233,NCT01214616,,ALL,20 Years,74 Years,f,,"Inclusion criteria:~* Histologically confirmed diagnosis of malignancy that is advanced and for which standard therapies do not exist or are no longer effective.~* Life expectancy at least 12 weeks~* Eastern Cooperative Oncology Group Performance Status 0 or 1~* Adequate hepatic, renal, haematologic and other organ function~* Written informed consent~Exclusion criteria:~* Chemotherapy, immunotherapy, surgery and radiotherapy within the past 4 weeks~* Prior treatment with afatinib and or vinorelbine~* Clinically significant active infectious disease",,,t,f,t
6260234,NCT04066556,PROBABILITY_SAMPLE,ALL,20 Years,100 Years,f,Acute ischemic stroke patients who received intravenous (IV) thrombolysis and/or intra-arterial (IA) recanalization treatment,Inclusion Criteria:~1. Age ≥20 years old~2. Acute ischemic stroke patients who underwent CT angiographies before IV thrombolysis and/or IA recanalization treatment~3. Patients who give an informed consents for participation in the study or the legal representative or immediate family give informed consent on behalf of patients in case of difficulty to decide study enrollment.~Exclusion Criteria:~1. Age \<20 years old~2. Acute ischemic stroke patients who did not receive IV thrombolysis and/or IA recanalization treatment~3. No informed consents from patients,,,t,f,t
6159155,NCT03524352,,ALL,18 Years,,f,,"4.2. INCLUSION CRITERIA~Subjects must satisfy the following criteria to be enrolled in the study:~1. Male or female ≥ 18 years at the time of signing the informed consent form (ICF).~2. Subject must understand and voluntarily sign an ICF prior to conduct the study related assessments/procedure.~3. Willing and able to adhere to the study visit scheduled and other protocol requirements.~4. Subjects must have been operated with ileal pouch anal anastomosis (IPAA) with a duration of at least 6 month prior the screening visit.~5. Subject must have a diagnosis of recurrent pouchitis defined as at least 2 episodes in the last year or relapsing immediately after a reasonable response to antibiotherapy (the antifungal medication is allowed until the day before transplantation).~6. Subject must be in remission with a Pouchitis Disease Activity Index (PDAI) \< 7 at the screening~7. Subject must affiliation with social security system or beneficiary from such system~8. Female of childbearing potential must have a negative pregnancy test at screening and must agree to practice effective methods of contraception~4.3. NON-INCLUSION CRITERIA~Subjects who meet any of the following non inclusion criteria could not be enrolled in this study:~1. Crohn disease or indeterminate colitis~2. Anastomotic stenosis~3. Subject with prior treatment by probiotic within 3 month prior to the transplantation visit~4. Subject with prior treatment by corticosteroids within 6 weeks prior to the transplantation visit~5. Subject with prior treatment by immunosuppressors within 3 month prior to the transplantation visit~6. Prior treatment with a biologic within 3 month prior the transplantation visit~7. Documented active infection of any kind in the last 6 months likely to require anti-infective treatment during the next months~8. Absolute neutrophil count (ANC) \< 1.5 x 109 /L (1,500 mm3)~9. Infection with chronic HIV~10. Pregnant female or breastfeeding~11. Chronic medical or psychiatric disease that may interfere with subject's ability to comply with study procedures~12. Administration of investigational drug within 3 months prior to planned FMT~13. Adults under guardianship, Safeguard justice or trusteeship~14. Subject with difficulty in follow-up (vacation, job transfer, geographical distance, lack of motivation).~15. Patients with contraindication to colonoscopy or anesthesia (if necessary)",,,t,f,t
6159156,NCT01383252,,ALL,50 Years,75 Years,f,,"Inclusion Criteria:~* Adult (\>50 years old)~* Male and female patients~* Scheduled and consented for screening or surveillance colonoscopy without medications~* Accept randomization to the study or the conventional method~* Agree to complete study questionnaires~* The adults will be normal healthy patients or patients with mild systemic disease, ASA 1 or ASA 2.~Exclusion Criteria:~* Patients who decline to participate~* Unable to give informed consent or complete the questionnaires due to language or other difficulties",,,t,f,t
6159157,NCT04639791,NON_PROBABILITY_SAMPLE,ALL,18 Years,,f,Asthma patients who are on Steps 4 and 5 of GINA asthma therapy,"Inclusion Criteria:~* Asthma patients with age ≥18. Asthma is defined as those with a consistent history and prior documented evidence of variable airflow obstruction.~* Subjects on steps 4 and 5 of GINA asthma therapy~Exclusion Criteria:~* Patients with respiratory diseases with other known respiratory diseases including chronic obstructive pulmonary disease, bronchiectasis, tuberculosis (TB)-destroyed lung parenchyma, history of lung resection and lung cancer~* Individuals older than 40 years with a smoking history of more than 10 pack-years~* Pregnant women",,,t,f,t
6159158,NCT05264818,NON_PROBABILITY_SAMPLE,ALL,18 Years,,t,"Case group: patients with primary open angle glaucoma Control group : patient with no optic nerve pathology, matched with patients in case group on age (± 5 years), sex (male/female), and smoking status (active smoker/non-smoker or non-smoker or former smoker who had quit smoking for more than 6 months).",Inclusion Criteria:~* Express consent to participate in the study~* Only for case group: primary open angle glaucoma (defined as the presence of visual field damage attributed to glaucomatous optic neuropathy) in both eyes~* Only for control group: Absence optic nerve pathology (including primary open angle glaucoma)~Exclusion Criteria:~* Pregnant or breastfeeding woman~* Sleep apnea~* Renal insufficiency~* Parkinson's disease~* Alzheimer's disease~* Antiphospholipid syndrome~* Cancer for which treatment ended less than 2 years ago~* Stroke less than 1 year ago~* Myocardial infarction less than 1 year ago,,,t,f,t
6260235,NCT01756183,,ALL,18 Years,75 Years,f,,"Inclusion Criteria:~-Unresectable gastric cancer as proven histologically (AJCC, Version 7) under any following condition: Unable radical excision due to the local metastasis or invasion Metastasis to the lymph node beside the abdominal aorta Non-extensive metastasis to liver (not more than three metastatic foci of radical excision)~* Definitely diagnosed as above stage of stomach cancer before the operation via CT or MRI, ultrasonic endoscopy and blood tumor antigen test, or through the laparoscopy if necessary~* Untreated (e.g. radiotherapy, chemotherapy, target therapy and immunotherapy)~* ECOG (Eastern Cooperative Oncology Group) : 0\~2~* Age: 18\~75 years old~* Normal hemodynamic indices before the recruitment (including blood cell count and liver/kidney function). For example: WBC\>4.0×109/L, NEU \>1.5×109/L, PLT\>100×109/L, BIL\<1.5 times of upper limit of normal reference value, ALT and AST\<2.5 times of upper limit of normal reference value, and CRE\<1.2mg/dl~* Good cardiac function before the recruitment, no seizure of myocardial infarction in past half year, and controllable hypertension and other coronary heart diseases~* Not concomitant with other uncontrollable benign diseases before the recruitment (e.g. the infection in the lung, kidney and liver)~* Not participating in other study projects before and during the treatment~* Signed the Informed Consent Form~Exclusion Criteria:~* Not conforming to above inclusion criteria~* Distal metastasis to lung, brain and bone (except the liver)~* Ever operation on the stomach~* Operation intolerance due to other systemic basic diseases~* Ever administered other drugs (including TCM drugs) before the recruitment, or no guarantee of progress according to the study requirement after the recruitment~* Allergy to the drugs in this protocol~* Pregnant or lactating women~* Women at childbearing age and of pregnancy desire during the study",,,t,f,t
6159159,NCT00890318,,ALL,18 Years,55 Years,t,,"Inclusion Criteria:~* Main Selection Criteria for Healthy Volunteers:~  * Subject has provided written consent.~ * Subject is in general good health.~ * If female, subject is postmenopausal for at least 2 years or surgically sterile.~ * If female, subject is not pregnant and is not breast-feeding.~ * Male or female between 18 and 55 years old, inclusive.~ * If male, subject must be surgically sterile or practicing at least 1 method of birth control.~ * Body Mass Index (BMI) is 18 to 29, inclusive.~Exclusion Criteria:~* Use of medications including over the counter and vitamines.~* Abuse of alcohol, drugs, or nicotine.~* Current diseases or disorders.~* History of cardiac disease.~* If after consideration by the investigator, for any reason, that you are unsuitable to receive ABT-072.",,,t,f,f
6159160,NCT04473300,PROBABILITY_SAMPLE,ALL,18 Years,,f,Adult patients with ARDS due to SARS-CoV-2 pneumonia under mechanical ventilation in intensive care unit.,"Inclusion Criteria:~1. Patients with positive SARS-CoV-2 infection＊~2. Patients with ARDS under mechanical ventilation＊＊~3. Patients ≧ 18 years old~   * Definition of SARS-CoV-2 infection positive: SARS-CoV-2 infection is defined as being positive in RT-PCR (real time reverse transcriptase-polymerase chain reaction) assay using nasal or pharyngeal swab samples.~     * Definition of ARDS is as per the Berlin definition (PaO2/FiO2 ≦ 300 mmHg with PEEP ≧ 5 cmH2O)~Exclusion Criteria:~1. Contraindication for EIT monitoring~   1. Unstable spine or pelvic fractures~  2. Pacemaker, automatic implantable cardioverter defibrillator~  3. Skin lesions between the 4th and 5th ribs where the EIT belt is worn~2. Home mechanical ventilation before inclusion~3. Pregnancy~4. DNR (do-not-resuscitate)~5. Increased intracranial pressure (\> 18 mmHg)",,,t,f,t
6057096,NCT02978612,,ALL,75 Years,,f,,"Inclusion Criteria:~* Radical surgery (R0/R1) for colon cancer~* Histologically verified adenocarcinoma of the colon~* Histologically verified lymph node metastases (Stage III)~* Age ≥ 75 years~* Able to undergo ambulatory treatment (adequate physical and mental function)~* Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH GCP) and national regulations.~Exclusion Criteria:~* Distant metastases (stage IV)~* Frail according to geriatric assessment~* Significant cardiovascular disease (congestive heart failure, symptomatic coronary artery disease and cardiac dysrhythmia) or myocardial infarction within the past 12 months~* Previous treatment with chemotherapy for colorectal cancer~* Metastatic disease from other cancer~* Reduced cognitive function not enabling ability to give informed consent or compliance with the study~* History of prior or concurrent malignant neoplasm other than colorectal adenocarcinoma within the past five years, except curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix~* Adverse reactions or hypersensitivity to capecitabine or related drugs and/or its excipients. Need to use medications contraindicated according to SmPC of the IMP(s), such as sorivudine, brivudin or chemically related compounds. Any other contraindication listed on the summary of product characteristics (SmPC) of the investigational medicinal Product (IMP)~* Use of methotrexate or other cytotoxic drugs as treatment of rheumatoid arthritis or other inflammatory disease and where it is considered contraindicated to stop this medication~* Known dihydropyrimidine dehydrogenase (DPD) deficiency~* Any reason why, in the opinion of the investigator, the patient should not participate",,,f,f,t
6057097,NCT01110174,,FEMALE,18 Years,,f,,"Inclusion Criteria:~* Patient must sign informed consent to participate in the study.~* Patient must be ≥ 18 years of age.~* Histologic diagnosis of invasive breast cancer(ductal or lobular)~* Stage II or III breast cancer and considered a candidate for curative mastectomy.~* Selected mastectomy for surgical option of treatment.~* Patient must agree to receive standard or dose-dense adriamycin, cyclophosphamide, and taxane-based chemotherapy given preoperatively.~* Patient must have the following preoperative laboratory values confirmed within 28 days prior to registration: Creatinine ≤ 1.5 times ULN. Platelets ≥ 90,000/mm3. White blood count ≥ 1,500/mm3. PT/PTT ≤ the institution ULN. Patients of child-bearing potential must have a negative urine or serum pregnancy test.~* If a patient is a cancer survivor, the patient must have undergone potentially curative therapy for all prior malignancies, with no evidence of prior malignancy for at least 5 years (except for effectively treated basal cell or squamous cell carcinoma of the skin, or carcinoma-in-situ of the cervix treated by surgery alone).~* The primary breast tumor must be detectable by mammogram at the time of diagnosis~* Estimated cardiac ejection fraction ≥ 50% by echocardiogram or MUGA~* ECOG performance status 0-1.~Exclusion Criteria:~* Non-invasive breast cancer, benign breast disease, or tumor histology other than stage II or stage III invasive ductal carcinoma, invasive lobular carcinoma, or mixed ductal and lobular carcinoma.~* The patient has known distant metastatic disease.~* The patient wishes to pursue breast conservation.~* The patient is male.~* The patient is receiving preoperative chemotherapy other than adriamycin, cyclophosphamide, and a taxane (ACT) in standard or dose-dense fashion.~* The patient is pregnant or breast feeding.~* The primary tumor is not visualized by mammogram at the time of diagnosis.~* The patient's estimated cardiac ejection fraction is \<50% by echocardiogram or MUGA.~* The patient has a documented intravenous contrast allergy or iodine allergy.~* Her-2/neu positive patients by IHC or FISH who receive trastuzumab neoadjuvantly; patients who are Her-2/neu positive but elect not to receive trastuzumab neoadjuvantly are still eligible for participation.",,,t,f,t
6057098,NCT01735474,,ALL,18 Years,65 Years,t,,Inclusion Criteria:~* subjects with respiratory conditions~* Must be able to do spirometry~Exclusion Criteria:~* subjects with acute processes in their pathologies,,,t,f,t
6057099,NCT03724474,,ALL,50 Years,64 Years,t,,"Inclusion Criteria:~* 50-64 years of age~* Prehypertensive (120/80 mmHg - 139/89 mmHg) or stage 1 hypertensive (140/90 mmHg - 159/99 mmHg)~* Physically inactive (\<100 minutes of MVPA in the previous week)~* Report insufficient sleep duration (\<6 hours/night on \>7 nights in the past month)~* Own a smartphone~* Non-smoker~* No signs or symptoms of chronic disease~* Have no chronic pain~* Have no major depressive disorder, general anxiety disorder, or sleep disorder~* Do not work alternating day-night shifts~* Medical clearance obtained from individual's physician~Exclusion Criteria:~* Younger than 50 years; older than 64 years~* Not prehypertensive or blood pressure is \>159/99 mmHg~* Physically active (\>100 min of MVPA in the previous week)~* Report sufficient sleep duration (\>6 hours/night on 7 or more nights in the past month)~* Does not own a smartphone~* Current smoker~* Report signs/symptoms of chronic disease~* Experiences chronic pain~* Have major depressive disorder, general anxiety disorder, or sleep disorder~* Works alternating day and night shifts~* Medical clearance not obtained from individual's physician",,,t,f,f
6057100,NCT04408274,,ALL,18 Years,65 Years,f,,"Inclusion Criteria:~* diagnosis of Multiple Sclerosis or Traumatic Brain Injury~* Fluent in English~* processing speed impairment (based on evaluation)~Exclusion Criteria:~* currently taking steroids and/or benzodiazepines~* prior stroke or neurological diease~* history of significant pyschiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) or a current diagnosis of Major Depressive Disorder, Schizophrenia, Epilepsy, Bipolar Disorder~* significant alcohol or drug abuse history",,,t,f,t
6057101,NCT03209050,,ALL,18 Years,80 Years,f,,Inclusion Criteria:~* referred for placement of central venous access catheter~* have limited or diminishing upper body venous access~* have pathology impeding standard access methods~* willing to give written informed consent~Exclusion Criteria:~* occlusion of the right femoral vein~* occlusion of the iliac vein~* occlusion of the inferior vena cava~* contraindicated by physician~* acute thrombosis within any vessel planned to be crossed by the Surfacer \*tortuous anatomy which precludes a straight line from femoral vein to subclavian~* diagnosed with active pericarditis~* diagnosed with active endocarditis~* suspected pericardial effusion~* known or suspected aneurysm or ectasia of ascending aorta~* innominate artery or subclavian artery~* pregnant or of childbearing potential not taking adequate contraceptive measures or nursing during study,,,t,f,t
6057102,NCT06119750,,ALL,18 Years,75 Years,t,,"Inclusion Criteria:~* Individuals eligible for inclusion in the study were those who:~  1. Were male or female, 18 - 75 years of age, in general good health (confirmed by medical history);~ 2. If females of childbearing potential, were using an acceptable form of birth control (i.e., oral contraceptive, intra-uterine device \[IUD\], diaphragm, condom, abstinence, bilateral tubal ligation, or are in a monogamous relationship with a partner who had a vasectomy);~ 3. In the case of females of childbearing potential, had a negative urine pregnancy test (UPT) at Screening (a woman was considered to be of non-childbearing potential if she was postmenopausal for at least 12 months or was surgically sterile \[hysterectomy, bilateral oophorectomy\]);~ 4. Agreed not to use systemic/topical corticosteroids within 3 weeks prior to and/or during the study, or systemic/topical antihistamines 72 hours prior to and during the study;~ 5. Agreed not to use systemic/topical analgesics such as aspirin (81 mg daily aspirin were allowed at the discretion of the Investigator), Aleve, Motrin, Advil, or Nuprin for 72 hours prior to and during the study (occasional use of acetaminophen was permitted);~ 6. Were free of any systemic or dermatologic disorder which, in the opinion of the investigative personnel, interfered with the study results or increased the risk of adverse events (AEs);~ 7. Were of any skin type or race providing the skin pigmentation allowed for discernment of erythema;~ 8. Completed a medical screening procedure; and~ 9. Read, understood, and signed an informed consent agreement~Exclusion Criteria:~* Had any visible skin disease at the study site which, in the opinion of the investigative personnel, would have interfered with the evaluation; 2. Were receiving systematic or topical drugs or medication which, in the opinion of the investigative personnel, would have interfered with the study results; 3. Had psoriasis and/or active atopic dermatitis/eczema; and/or 4. Had a known sensitivity to cosmetics, skin care products, or topical drugs as related to the material being evaluated. 5. Had a history of allergies or sensitivity to study material being tested. 6. Were pregnant women. 7. Were women who were breast-feeding.",at least 1/3 males and 1/3 females,t,t,f,t
6260236,NCT04338607,NON_PROBABILITY_SAMPLE,ALL,18 Years,,f,"Patients will be identified in the clinic by an attending orthopaedic foot and ankle surgeon or his physician assistant based on clinical exam and radiographic findings. Patients will be screened for eligibility by the research coordinator/ key personnel in close coordination with the surgeon.~Patients at institute with end-stage talocalcaneal (subtalar) joint arthritis from any etiology will be eligible to enroll in the study. Frequently, subtalar arthritis is caused by trauma. Traumatic injuries have no predilection for race, religion, cultural background, etc. Therefore, all demographic groups will have access to this study and should be represented. Approximately 60 patients will be recruited for the study.","Inclusion Criteria:~* End-stage talocalcaneal (subtalar) joint arthritis from any etiology will be eligible to enroll in the study~* Meets indications for subtalar arthrodesis to receive the DynaNail Mini implant~* Able to understand the requirements of the study, provide a written consent, and willing to comply with the study protocol~* 18 years of age or older~Exclusion Criteria:~* Investigator determines that the subject is unlikely to comply with the requirements of the study~* Non-English speaker~* Blind~* Illiterate~* Prisoner~* Pregnant women",,,t,f,t
6260237,NCT06484257,,ALL,40 Years,55 Years,f,,"Inclusion Criteria:~* The age of Participant will be 40 to 55 years~* Participant diagnosed with myopia having -0.50 to -3.00DS and astigmatism up to -0.75DC~* Patient diagnosed with Hypermetropia having +050 to +3.00 DS and Astigmatism up to +0.75DC~* Presbyopia addition will range from +1.00 to +2.50 DS~* Participants who have worked more than 4 hours on the computer screen.~* Participants who will be already progressive users and first-time users.~* Patients with no Ocular disease.~Exclusion Criteria:~* Participants with Pre Presbyopia and above 55 years of age~* Participants with significant ocular disease.~* Participants with uncontrolled diabetes and hypertension~* Participants who will not be willing for PAL,s~* Participants with more than 0.75 astigmatism~* Participants with known allergies and sensitivity.",,,t,f,f
6159161,NCT01081418,,ALL,18 Years,65 Years,f,,"Inclusion Criteria:~* Age 18-65 years~* Met the diagnostic criteria of a first- or multiple episode of a schizophrenia spectrum disorders, i.e. schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, or psychotic disorder NOS~* New initiation or current treatment with quetiapine Immediate Release (IR)~Exclusion Criteria:~* Other psychotic disorders (e.g., due to medical condition)~* Mental retardation (IQ lower than 70 points)",,,t,f,t
6159162,NCT01004718,,ALL,18 Years,,f,,"Inclusion Criteria:~* Subjects with a pathologically-proven diagnosis of classic HL or DLBCL with measurable disease by any imaging technique or physical examination.~Exclusion Criteria:~* Pregnant or nursing,~* Uncontrolled diabetes mellitus,~* Active infection,~* Inability to give informed consent or to comply with all study procedures,~* Subjects may be excluded at the discretion of the principal investigator or study team members.",,,t,f,t
6260238,NCT03046732,,ALL,18 Years,80 Years,f,,"Inclusion Criteria:~* Age \>18 years, \< 80 years~* Patients undergoing maintenance hemodialysis for more than 3 months~* Able to understand English at a grade 5 level~* Those willing and able to provide informed consent~Exclusion Criteria:~* Patients with severe acute illness or condition that hampers questionnaire completion~* Dementia indicated in the medical record, indicated by the managing healthcare team~* Dialysis initiation between 0-90 days prior to enrollment~* Current, active malignancy or a history of malignancy within 2 years of successful treatment~* Current active chronic infection that is an absolute contraindication to kidney transplantation~* Unwilling or unable to provide informed consent",,,t,f,t
6159163,NCT02892318,,ALL,18 Years,,f,,"Inclusion Criteria:~* Life expectancy of at least 12 weeks~* Diagnosis of AML per World Health Organization criteria~* Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2~* Specifically, for participants in Cohorts A1 and A2: Age greater than or equal to (\>=) 18 years, disease progression or failure to achieve complete or partial response after intensive cytotoxic therapy, participants cannot have received more than two prior intensive regimens (e.g., induction + consolidation and one salvage therapy + consolidation)~* Specifically, for participants in Cohorts A3 and A4: Treatment naïve participants unfit for induction chemotherapy for AML as defined by the following: Age \>= 70 or age 65 to 69 years with at least one of the following: ECOG performance status of 2, Intermediate I/II or adverse risk cytogenetic and molecular alterations per ELN 2010 guidelines or secondary AML, or other comorbidity judged incompatible with intensive chemotherapy~* Adequate end-organ function~* Willing and able to undergo a pre-treatment bone marrow aspirate and biopsy and subsequent bone marrow aspirates and biopsies during treatment~* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than (\<) 1 percent (%) per year during the treatment period and for at least 30 days after the last dose of guadecitabine or 5 months after the last dose of atezolizumab, whichever is longer~* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm~Exclusion Criteria:~* In Cohorts A3 and A4 only, participants with AML eligible for standard intensive induction therapy with an anthracycline and cytarabine~* Prior allogeneic stem cell transplant or solid organ transplant~* Active central nervous system involvement by leukemia~* Pregnant or lactating, or intending to become pregnant during the study~* History of idiopathic pulmonary fibrosis, organizing pneumonitis, drug-induced pneumonitis, idiopathic pneumonitis, or autoimmune disease~* Treatment with investigational therapy within 14 days prior to initiation of study drug~* Any approved AML-related therapy within 14 days prior to enrollment~* Immunosuppressive therapy within 6 weeks of Cycle 1, Day 1~* Daily requirement for corticosteroids (\> 10 mg prednisone daily or equivalent) (except for inhalation corticosteroids) within 2 weeks prior to Cycle 1, Day 1~* Prior treatment with immune checkpoint blockade therapies (anti-cytotoxic T-lymphocyte-associated protein 4 \[anti-CTLA-4\], anti-programmed death-1 \[anti-PD-1\] or anti-PD-L1) or immune agonists (anti-cluster of differentiation \[CD\]137, anti-CD40, anti-OX40)~* Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to Cycle 1, Day 1~* Treatment with denosumab (or other receptor activator of nuclear factor kappa-B ligand \[RANKL\] inhibitor) 4 weeks before the first dose and for 10 weeks after the last dose of atezolizumab~* Administration of a live, attenuated vaccine within 4 weeks of Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study~* Planned major surgery during the study~* Positive for hepatitis C virus (HCV) antibody at screening~* Active hepatitis B virus (HBV) infection~* Positive for human immunodeficiency virus (HIV)~* Illicit drug or alcohol abuse within 12 months prior to screening~* Poor peripheral venous access~* Active infection~* Serious infection requiring hospitalization or intravenous (IV) antibiotics within 14 days prior to enrollment~* Any serious medical condition or abnormality in clinical laboratory tests~* History or presence of an abnormal electrocardiogram (ECG)~* History of other malignancy within 2 years prior to screening~* Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab or guadecitabine formulations~* History of severe allergic, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins",,,t,f,t
6159164,NCT05990218,,ALL,40 Years,80 Years,t,,"Inclusion Criteria:~* participants age 40-80 years~Exclusion Criteria:~* History of colonic surgery (except appendectomy)~* Lower gastrointestinal bleeding~* unstable vital sign during endoscopy of pregnancy~* history of inflammatory bowel disease, polyposis syndrome, colon cancer, colonic stricture, abnormal coaglulation, organ failure",,,t,f,t
6159165,NCT00977418,,ALL,60 Years,75 Years,t,,"Inclusion Criteria:~* The study will include 60 cognitively normal seniors between the ages of 60 and 75 years.~* Participants will have normal IQ, be native speakers of English and have a minimum of high school education.~Exclusion Criteria:~* Participants with a previous history of stroke, diabetes, untreated hypertension, major surgeries within the past 6 months, major psychiatric disorder, depression or cognitive impairment will be excluded.~* Additionally, anyone that has a condition that would exclude them from MRI will not be included.",,,t,f,t
6260239,NCT04808778,PROBABILITY_SAMPLE,ALL,16 Years,26 Years,f,A total of 250 participants with sickle cell anemia between 16 through 25 years of age living in northern Nigeria receiving care at the Aminu Kano Teaching Hospital in Kano Nigeria.,"Inclusion Criteria:~1. Patients with hemoglobin S-S or Sβ0 thalassemia confirmed by hemoglobin electrophoresis or High-Performance Liquid Chromatography (HPLC);~2. Participant is 16 through 25 years of age;~3. Informed consent from participants above 18 years, and informed consent from a parent or legal guardian and assent of participants aged \< 18 years (assessment can take place up until the 26th birthday);~4. Participant resides within an hour driving distance from the medical center to facilitate weekly phone calls between the scheduled monthly clinic visits;~5. Participant is willing to be enrolled and followed for the duration of the study.~Exclusion Criteria:~1. Young adults with co-morbidities that may have an impact on neurological status, such as epilepsy;~2. Young adults enrolled in clinical trials upon entry;~3. Participants with an implanted defibrillator or certain other implanted electronic or metallic devices contraindicated for MRI;~4. Young adults with known HIV diagnosis;~5. Any other condition or chronic illness, which in the opinion of the site's Principal Investigator (PI) makes participation ill-advised or unsafe.",,,t,t,f
6057103,NCT04670250,PROBABILITY_SAMPLE,ALL,18 Years,80 Years,,All newly diagnosed patients with ulcerative colitis will be included in the study,Inclusion Criteria:~- Patients who are newly diagnosed to be ulcerative colitis. Patients \>18 years old.~Exclusion Criteria:~* Patients who are \>18 years old. Pregnant patients . Patients with colonic malignancies.,,,t,f,t
6057104,NCT05470374,,ALL,18 Years,79 Years,f,,"Inclusion Criteria:~* single supratentorial gliomas without contrast enhancement in preoperative magnetic resonance imaging (presumed low-grade gliomas)~* newly diagnosed~* previously untreated~* Karnofsky Performance Status 60-100%~* age 18-79 years~* performed magnetic resonance imaging with contrast enhancement~Exclusion Criteria:~* glioma spreading to brainstem~* previously performed radiotherapy, chemotherapy or immunotherapy~* planned supratotal tumor resection until neurophysiologically revealed eloquent areas",,,t,f,t
6159166,NCT02221518,,ALL,18 Years,55 Years,t,,"Inclusion Criteria for Patients:~* Male and females with OCD aged 18-55~* Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Diagnosis of OCD~* Not on psychotropic medication~Exclusion Criteria for Patients:~* Presence of metallic devices or dental braces in the body that are contraindicators for MR imaging~* Comorbid psychiatric conditions that significantly elevate the risk of study participation (e.g. psychotic disorders, bipolar disorder, evidence of dementia or other cognitive disorder, suicidality)~* Unstable medical conditions that need attention and would make participation in the study unsafe (e.g. very high blood pressure)~* Use of psychotropic medication~* Females who are pregnant or post-menopausal~Inclusion Criteria for Healthy Volunteers~- Male and females aged 18-55~Exclusion Criteria for Healthy Volunteers~* Presence of metallic devices or dental braces in the body that are contraindicators for MR imaging~* Any psychiatric diagnosis~* Use of psychotropic medication~* Diagnosis of OCD in a first degree relative~* Females who are pregnant or post-menopausal~* Unstable medical conditions that need attention and would make participation in the study unsafe (e.g. very high blood pressure)",,,t,f,f
6159167,NCT05861518,,FEMALE,35 Years,65 Years,t,,Inclusion Criteria:~* Female~* FMS patients~* 35 to 65 years~* receiving treatment for FMS for at least six months~Exclusion Criteria:~* Patients with communication problems~* other rheumatological diseases~* major another medical diseases~* neurological and/or central nervous system diseases~* severe mental illnesses~* antipsychotic medication use,35-65,t,t,f,t
6260240,NCT03156556,,ALL,18 Years,25 Years,f,,"Inclusion Criteria:~* Resident of New Brunswick;~* 18 to 25 years of age;~* French as their native language;~* Good comprehension of written French;~* Reliable access to the Internet;~* Clinical levels of depression, generalized anxiety disorder, panic disorder or social anxiety disorder, as indicated by the total score of at least one of the following measures: QSP-9 ≥ 5; GAD-7 ≥ 5, PAS ≥ 19, SPIN ≥ 19;~* Not currently following another cognitive-behavioral therapy (CBT);~* No change of medication at least one month prior to the study and no change expected over the next two months;~* In agreement to share relevant personal information.~Exclusion Criteria:~* Severe depression or suicide intent or plan (score ≥ 23 or a score \> 2 on item 9 (suicidal ideation) of PHQ-9;~* Currently experiencing psychotic symptoms.",,,t,f,f
6159168,NCT05019118,,FEMALE,40 Years,65 Years,f,,"Inclusion Criteria:~* Diagnosis of subclinical hypothyroidism~* TSH levels between 3 and 10 mIU / L~* Normal levels of free triiodothyronine ( T3) and free thyroxine (T4)~* Without previous or current treatment with levothyroxine~Exclusion Criteria:~* Thyroid surgery or reception of radioactive iodine in a previous period of 12 months~* History of cardiovascular disease and / or thrombosis~* Established diagnosis or clinical suspicion of kidney or liver failure, chronic infections, blood diseases, type I diabetes and type II diabetes~* Drug treatments that affect thyroid function (corticosteroids, amiodarone, propranolol, lithium)~* Statin treatment and / or hormone replacement therapy~* Adjuvant treatment with trace elements, vitamins or antidepressant and antipsychotic drugs~* Hospitalization for serious illness or elective surgery in the past 4 weeks~* Diseases and / or treatments that affect intestinal absorption (proton pump inhibitors)~* Pregnant, planning to become pregnant or breastfeeding women~* Consumption of ω-3 PUFA type food supplements~* Intolerance and / or allergy to lactose and / or cow's milk proteins~* Any pathology that requires close control, advises against their participation or there is an inability to move independently~* Habitual residence outside the study's influence area~* Participation in another clinical trial with drugs, or in other experimental studies~* Refuse to sign the informed consent",,,t,f,t
6159169,NCT05629091,,ALL,1 Year,,f,,"Inclusion Criteria:~1. Signed written informed consent (by the patient and/or the patient's parent\[s\]/legal guardian\[s\] as applicable).~2. Patient with superficial dermal burn wound(s) (class II/A) ≤36h as assessed by the Investigator.~3. Patient at least 1 year old.~4. Patient who has at least 3 superficial dermal burn wounds on anatomically equivalent areas or a superficial dermal burn large enough to allow a lateral comparison.~5. Wound area at least 50 cm2 (per wound, if 3 separate wounds) or at least 150 cm2 (if single wound) as judged by the Investigator.~Exclusion Criteria:~1. Patient hyper-sensitive or allergic to, or have had a hypersensitivity/allergic reaction to, any of the dressing components.~2. Pregnant or breast-feeding female.~3. Patient with chemically or electrically induced burns.~4. Other non-burn wound in target wound area.~5. Not suitable for inclusion according to the Investigator.~6. Cognitive dysfunction or psychiatric history (Investigator's discretion).~7. Chronic or presently active skin condition that is judged as interfering with normal wound healing process (Investigator's discretion)~8. Target burns on sensitive skin areas, such as the facial or genital area.~9. Inability or unwillingness of participant or parent(s)/legal guardian(s) to give written informed consent.",,,t,t,t
6159170,NCT00260728,,ALL,18 Years,,f,,"Inclusion Criteria:~1. Need for early dialysis access (≤72 hours after implantation):~   * Initiation of maintenance dialysis is recommended per K/DOQI or institutional guidelines; or~  * Patient is currently receiving dialysis via catheter~2. No prior implantation of synthetic graft in the arm to be treated~3. Life expectancy of at least 2 years, based on physician's assessment of medical condition~Exclusion Criteria:~1. Patient younger than 18 years of age~2. Any stenosis in the veins proximal to (downstream of) implant site, as determined previously or by current ultrasound~3. Pregnancy~4. Bleeding disorder, e.g., low platelet count (\<50,000), hypercoagulable state, e.g., antithrombin III deficiency; antiphospholipid or anticardiolipin antibodies; Factor V Leiden; circulating Lupus anticoagulant; current, active heparin-induced thrombocytopenia; Protein C or S deficiency; or history of recurrent deep vein thrombosis not related to AV access.~5. Active malignancy, e.g., condition either being treated or considered untreatable~6. Active systemic infection, e.g., condition either being treated or considered untreatable~7. Uncontrolled major symptomatic medical problem, e.g., undiagnosed severe pain, metabolic disturbance, fever, etc.~8. Likelihood of poor compliance to required dialysis protocol, e.g., history of poor attendance to required clinic sessions or non-compliance to medication~9. Mental incapacity; inability to understand treatment instructions~10. Currently participating in another investigational drug or device study that clinically interferes with the endpoints of this study",,,t,f,t
6057105,NCT06256211,,ALL,1 Day,28 Days,t,,"Inclusion Criteria:~* All the neonates with hemodynamic significance PDA10,13 that is indicated for closure.~Exclusion Criteria:~* Neonates with the following criteria are excluded.~  * Without PDA.~ * With insignificant PDA.~ * Rectosigmoid abnormalities.~ * Neutropenia less than 1500 cells/ml.~ * Platelets less than 30000 cells/ml.~ * Liver failure or elevated liver enzymes.~ * Hypovolemic or septic shock.~ * Renal failure.",,,f,t,f
6159171,NCT02919891,NON_PROBABILITY_SAMPLE,FEMALE,18 Years,,t,Patients that have undergone mastectomy surgery with a Tissue Bank sample stored in the Edinburgh Experimental Cancer Medicine Centre (ECMC) / SAHSC BioResource.,"Inclusion Criteria:~* Patient has Tissue Bank sample stored in the Edinburgh Experimental Cancer Medicine Centre (ECMC) / SAHSC BioResource.~* At the time of their surgery, the patient provided written consent for the sample to be used by future researchers and to be contacted by those researchers.~* Patient has undergone surgery for breast cancer.~* Contact details for the patient are available.~* Patient is able to provide informed consent for the questionnaire component of the study.~* Patient is able to complete and return study questionnaires. Telephone support to help complete the study documentation will be provided if requested.~Exclusion Criteria:~* Patient who had their surgery outwith the timeframe of the original study consent (2006-2012)~* Patients receiving active oncological treatment.~* Patients who have died.~* Patients with cognitive impairment or significant mental health disorder.~* Patients with active complications of their surgical wound site.",,,t,f,t
6159172,NCT00565318,,ALL,40 Years,75 Years,f,,"Inclusion Criteria:~* Type 2 diabetes mellitus~* Patients are on treatment with angiotensin converting enzyme inhibitors (ACEi) and/or angiotensin II antagonists (AIIA) in an unchanged dose for at least 3 months~* Active diabetic nephropathy as indicated by presence of microalbuminuria (15-300 mg/24 h urine) in at least two samples within 2-6 weeks in advance of inclusion in the trial~* HbA1c \< 8.5%, a higher HbA1c \< 9.5% is acceptable if the treating physician and the patient have accepted that striving for lower values is an unreachable goal (patients with high HbA1c values are the ones that one would expect to be benefit most from treatment with benfotiamine)~* eGFR (estimated by MDRD formula) \> 30 ml/min~* Males and postmenopausal females~* Written informed consent~Exclusion Criteria:~* Renal impairment by other causes than diabetes~* Stage of the disease more severe than indicated in Inclusion criteria (macroalbuminuria or renal insufficiency)~* Severe hypoglycemia during the last 3 months, needing help from another person~* Severe hepatopathy (laboratory values about three times higher than normal~* Endocrine disorders, e.g. hyper/hypothyroidism~* Blood pressure \> 160/90 mmHg~* Severe cardiac function disturbances and severe heart rhythm disturbances~* Neoplasm's (excluding history of treated skin cancer of the type basal cell carcinoma BCC or squamous cell carcinoma SCC)~* Severe general diseases or mental disorders making the participation in the study impossible~* Drug abuse~* Female patients during pregnancy and lactation period and female patients with active menses during the past year~* Hypersensitivity to benfotiamine~* HbA1c \> 9.5%~* Use of thiamine containing supplements during the last 3 months~* Participation in another study within one month before joining the benfotiamine study",,,t,f,t
6159173,NCT01468324,,ALL,18 Years,100 Years,f,,"* INCLUSION CRITERIA:~* Patients with histologically proven malignant primary gliomas who have progressive disease after radiotherapy will be eligible for this protocol.~* Patients must have an MRI scan performed within 14 days prior to registration and on a fixed dose of steroids for at least 5 days. If the steroid dose is increased between the date of imaging and registration a new baseline MRI is required.~* Patients having undergone recent resection of recurrent or progressive tumor will be eligible as long as all of the following conditions apply:~  1. Patients will be eligible four weeks after surgery if they have recovered from the effects of surgery.~ 2. Residual disease following resection of recurrent tumor is not mandated for eligibility into the study. To best assess the extent of residual disease postoperatively, an MRI should be done:~* no later than 96 hours in the immediate post-operative period or~* at least 4 weeks post-operatively, and~* within 14 days of registration, and~* on a stable steroid dosage for at least 5 days.~If the 96 hour scan is more than 14 days before registration, the scan needs to be repeated. If the steroid dose is increased between the date of imaging and registration, a new baseline MRI is required on a stable steroid dosage for at least 5 days.~* Patients must have failed prior radiation therapy.~* Ability of subject or Legally Authorized Representative (LAR) (if the patient is deemed by the treating physician to be cognitively impaired or questionably impaired in such a way that the ability of the patient to give informed consent is questionable) to understand and the willingness to sign a written informed consent document indicating that they are aware of the investigational nature of this study.~* Patients must be greater than or equal to18 years old, and must have a life expectancy \> 8 weeks. Because no dosing or adverse event data are currently available on the use of AZD7451 in patients \<18 years of age, children are excluded from this study, but may be eligible for future pediatric trials.~* Patients must have a Karnofsky performance status of greater than or equal to 60~* Patients must be at least 4 weeks from radiation therapy. Additionally, patients must be at least 6 weeks from nitrosoureas, 4 weeks from temozolomide, 3 weeks from procarbazine, 2 weeks from vincristine and 2 weeks from last bevacizumab administration. Patients must be at least 4 weeks from other cytotoxic therapies not listed above and 2 weeks for non-cytotoxic agents (e.g., interferon, tamoxifen) including investigative agents. With the exception of alopecia, all toxicities from prior therapies should be resolved to CTCAE less than or equal to grade 1.~* Patients must have adequate bone marrow function (WBC greater than or equal to 3,000/microl, ANC greater than or equal to 1,500/mm(3), platelet count of greater than or equal to 100,000/mm(3), and hemoglobin greater than or equal to 9 gm/dl), adequate liver function (AST, ALT and alkaline phosphatase less than or equal to 2.5 times ULN and bilirubin less than or equal to 1.5 times ULN), and adequate renal function (creatinine less than or equal to 1.5 times ULN and/or creatinine clearance greater than or equal to 50 cc/min calculated by Cockcroft-Gault) before starting therapy. Patients must also have serum potassium greater than or equal to 3.5 mmol/L, magnesium, phosphate and calcium levels within normal levels; supplementation is allowed. In cases where the serum calcium is below the normal range, 2 options would be available: 1) the calcium adjusted for albumin is to be obtained and substituted for the measured serum value. Exclusion is to then be based on the adjusted for albumin values falling below the normal limit. 2) Determine the ionized calcium levels. Exclusion is then to be based on whether these ionized calcium levels are out of normal range despite supplementation. These tests must be performed within 14 days prior to registration. Eligibility level for hemoglobin may be reached by transfusion.~* Patients must either not be receiving steroids, or be on a stable dose of steroids for at least five days prior to registration.~* The effects of AZD7451 on the developing human fetus are unknown. For this reason and because AZD7451 is known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or herpartner is participating in this study, the treating physician should be informed immediately.~* A 12 lead electrocardiogram (ECG) to be performed within 2 weeks of trial entry with QTc less than or equal to 470 msec.~* Patients must have normal left ventricular ejection fraction (LVEF greater than or equal to 55% or normal by NIH Clinical Center criteria).~EXCLUSION CRITERIA:~* Patients who, in the view of the treating physician, have significant active hepatic, renal, pulmonary or psychiatric diseases are ineligible.~* 2 Prior treatment with AZD7451.~* History of hypersensitivity to active metabolites or excipients of AZD7451.~* Clinically significant cardiovascular event (e.g. myocardial infarction, angina pectoris, coronary artery bypass graft, angioplasty, vascular stent, superior vena cava syndrome (SVC), New York Heart Association (NYHA, Appendix I) classification of heart disease \>2 within 6 months before entry; or presence of cardiac disease that, in the opinion of the investigator, increases the risk of ventricular arrhythmia.~* Hemorrhagic or ischemic stroke, including transient ischemic attacks and other central nervous system bleeding in the preceding 6 months that were not related to glioma surgery. History of prior intratumoral bleeding is not an exclusion criterion; patients with history of prior intratumoral bleeding, however, need to undergo a non-contrast head CT to exclude acute blood.~* Ventricular arrhythmias requiring continuous therapy or asymptomatic sustained ventricular tachycardia within 12 months before study entry. Continuous or intermittent atrial fibrillation requiring treatment. Patients with significant ECG abnormalities such as complete left bundle block and third degree heart block are not eligible.~* QTc prolongation with other medications that required discontinuation of that medication.~* Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age.~* QTc with Bazett s correction that is unmeasurable, or \>470 msec on screening ECG. (Note: If a subject has a QTc interval \>470 msec on screening ECG, the screen ECG may be repeated twice (at least 24 hours apart). The average QTc from the three screening ECGs must be less than or equal to 470 msec in order for the subject to be eligible for the study. Patients who are receiving a drug that has a risk of QTc prolongation excluded if QTc is greater than or equal to 460 msec.~* Any concurrent medication that may cause QTc prolongation or induce~Torsades de Pointes 1) Drugs listed in Appendix H, Table 2, that in the investigator s opinion cannot be discontinued are allowed; however, must be monitored closely.~* Concomitant medications that are moderate or potent inducers or inhibitors of CYP3A4 are not permitted within the specified wash-out periods prior to or during treatment with AZD7451~* Patients with a history of corneal disease such as corneal ulcers, corneal dystrophies, keratoconus.~* Refractory nausea and vomiting or significant gastrointestinal impairment, as judged by the investigator, that would significantly affect the absorption of AZD7451, including the ability to swallow the oral solution.~* Patients known to have active hepatitis B or C (testing not required for entry on study).~* Other concomitant anti-cancer therapy except corticosteroids.~* Patients with a peripheral neuropathy CTCAE \> 1 in the prior 4 weeks or active muscle diseases (including dermatomyositis, polymyositis, inclusion body myositis, muscular dystrophy and metabolic myopathy) or family history of myopathy. Patients with pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi syndrome or renal tubular acidosis.~* Evidence of active infection or active bleeding diatheses.~* Pregnant women are excluded from this study because AZD7451 is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with AZD7451, breastfeeding should be discontinued if the mother is treated with AZD7451. Female patients must have a negative pregnancy test prior to start of dosing if of child-bearing potential or must have evidence of non-childbearing potential by fulfilling one of the following criteria at screening:~* Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.~* Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.~* Patients known to have a malignancy (other than their malignant glioblastoma) that has required treatment in the last 12 months and/or is expected to require treatment in the next 12 months (except for non-melanoma skin cancer, carcinoma in situ in the cervix or ductal carcinoma in situ).~* Major surgery within 4 weeks or incompletely healed surgical incision before starting therapy.~* Patients known to be HIV-positive (testing is not required for entry on study) and on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with AZD7451. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.",,,t,f,t
6159174,NCT02878252,PROBABILITY_SAMPLE,ALL,,,f,Patients diagnosed with COPD who are seen at the outpatient clinics of Pulmonary Specialists,"Inclusion Criteria:~* All patients with confirmed diagnosis of COPD {post-bronchodilator FEV1/FVC\<0.7 (FEV1 - forced expiratory volume at one second, FVC - forced vital capacity) based on the medical records}~* Aged \>40 years old at time of diagnosis~* Seen at out-patient clinic~Exclusion Criteria:~* Patients currently with acute exacerbation of COPD by GOLD definition (any worsening of a patient's respiratory symptoms that is beyond normal day-to-day variations and requires a change in medication)~* Patients with respiratory diseases that can show similar symptoms to chronic airway diseases such as bronchiectasis, tuberculosis (TB)-destroyed lung parenchyma, endobronchial TB, and lung cancer, or those who have history of these diseases based on physician's judgment~* Patients currently diagnosed with pneumonia and acute bronchitis~* Patients currently randomized in other clinical studies",,,t,t,t
6159175,NCT03186352,,ALL,45 Years,,t,,Inclusion Criteria:~* more than 10 teeth~* at least one tooth with primary caries lesion with contraindicated non-invasive treatment (lesion which needs to be prepared and filled with material for permanent fillings); tooth with no clinical and/or radiological symptoms of pulp involvement.~* no systemic disease~Exclusion Criteria:~* systemic diseases (may affect saliva flow and properties)~* antibiotic therapy in previous 3 months before the appointment,,,t,f,t
6159176,NCT00006318,,ALL,,,t,,"INCLUSION CRITERIA:~Any healthy normal volunteer above the age of 18 who is capable of giving informed consent.~EXCLUSION CRITERIA:~Subjects will be excluded for the following reasons.~They have contraindications to MR scanning, such as the following: aneurysm clip, implanted neural stimulator, implanted cardiac pacemaker or autodefibrillator, cochlear implant, ocular foreign body (e.g., metal shavings), or insulin pump.~They have panic disorder or migraine (because of possible complications with CO2 inhalation).~They have cirrhosis, any renal dysfunction, or a chronic respiratory illness (such as asthma).~They have allergies to sulfonamide drugs or cyclo-oxygenase inhibitors (NSAIDS).",,,t,t,t
6159177,NCT03528954,,ALL,1 Year,5 Years,f,,Inclusion Criteria:~* Patient undergoing non-emergency surgery with general anesthesia~* Patient using sevoflurane as anesthetic agent~* Patient aged 1 - 5 years old~* American Society of Anesthesiologists (ASA) physical status 1 - 2~* Patient family signed the informed consent to be included in the study~Exclusion Criteria:~* Patient that will undergo ophthalmologic and otorhinolaryngologic surgery~* Patient that will require post operation stay in Intensive Care Unit~* Patient with psychological and neurological problem~* Patient with developmental delay~* Patient using sedative drugs~* Patient with allergy to propofol~* Patient or patient family with history of malignant hyperthermia~* Patient with difficulty on intubation and ventilation~* Patient with cardiovascular disease~* Patient with hemodynamic instability,,,f,t,f
6159178,NCT01020552,NON_PROBABILITY_SAMPLE,FEMALE,15 Years,,f,non healthy participants,"Inclusion Criteria:~* For Facilities: APHIA II facilities supported by the ESD project in Central Province and Nairobi, Kenya where: (1) PAC services are provided, (2) at least one provider has received PAC and Youth-friendly PAC training, (3) Community mobilization has been initiated, (4) PAC equipment and supplies have been procured, (5) PAC job aids have been distributed.~* For Clients: Women aged 15 years or older who have received PAC services at a study facility and who have a telephone on which they can be contacted~* For Providers: Any person who offers PAC services at a study facility",,,t,t,t
6159179,NCT03074695,,FEMALE,18 Years,42 Years,t,,"Inclusion Criteria:~* Women admitted to the Duke Birthing Center for spontaneous or induced vaginal delivery will be screened. After usual consultation with the anesthesia team is completed and consent for anesthesia services are obtained, eligible patients will be approached to by a member of the study team.~* ages 18-45~* singleton~* vertex fetuses at 37-41 weeks' gestation~* nulliparous and multiparous women~* cervical dilation of 2-7cm~* BMI ≥ 35 kg/m2,~* pain score \> 4~* English-speaking ability.~Exclusion Criteria:~* chronic opioid use~* Major cardiac disease~* contraindications to regional anesthesia",,,t,f,f
6159180,NCT03058354,NON_PROBABILITY_SAMPLE,ALL,,,f,"Patients undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016.",Inclusion Criteria:~* Anaesthetic records and acute pain service records of patient undergone surgery between 2014 to 2016 in Queen Mary Hospital would be retrieved from the computer.~Exclusion Criteria:~* Essential data were missing.~* Patient participating in other research projects.~* Changes in postoperative pain management technique.~* Patients could not be assessed post-operatively for pain (i.e. post-operative IPPV),,,t,t,t
6260241,NCT04781556,NON_PROBABILITY_SAMPLE,ALL,18 Years,65 Years,f,All patients treated between 01/01/2017 and 31/12/2018 in the Fracture sector will be screened through the computerized medical file,"Inclusion Criteria:~* Patients aged 18 to 65 at the time of the fracture~* French-speaking patient~* Patients treated in the Fracture Line between January 1, 2017 and December 31, 2018 for osteoporotic fracture~* Professionally active patients at the time of the fracture~Exclusion Criteria:~* Refusal to participate in the study~* Patient under guardianship or curatorship~* Patient deprived of liberty~* Patient under legal protection",,,t,f,t
6159181,NCT00370591,,ALL,18 Years,65 Years,f,,Inclusion:~* Physician documented diagnosis of asthma which has been present for at least 6 months.~* Receiving a total daily dose of 200-500mcg/day beclomethasone dipropionate or equivalent for at least 4 weeks prior to the start of the run-in period.~Exclusion:~* Has had 3 or more courses of oral corticosteroids in the 12 months previous to visit 1,,,t,f,t
6159182,NCT00958854,,ALL,18 Years,,f,,"DISEASE CHARACTERISTICS:~* Newly diagnosed angioimmunoblastic T-cell lymphoma~* Measurable disease (i.e., anatomically assessable)~PATIENT CHARACTERISTICS:~* WHO/ECOG performance status 0-2~* Serum creatinine ≤ 2.5 times upper limit of normal (ULN)~* Bilirubin ≤ 2.5 times ULN~* Alkaline phosphatase ≤ 2.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception before, during, and after study treatment~* No known seropositivity for hepatitis B virus, hepatitis C virus, or HIV~* No active second malignancy or other concomitant serious medical condition, in particular peripheral neuropathy~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy for angioimmunoblastic T-cell lymphoma",,,t,f,t
6159183,NCT02108691,,ALL,19 Years,65 Years,t,,"Inclusion Criteria:~* Males and females 19-65 years old~* BMI(body mass index) ≥ 25 kg/m\^2 or WC(Waist Circumference) ≥ 90(men), WC ≥ 85(women)~* Able to give informed consent~Exclusion Criteria:~* Significant variation in weight(more 10%) in the past 3 months~* Allergic or hypersensitive to any of the ingredients in the test products~* History of reaction to any of the test products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery~* History of alcohol or substance abuse~* Participation in any other clinical trials within past 2 months~* Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study~* Pregnant or lactating women etc.",,,t,f,t
6260242,NCT05713578,,ALL,18 Years,90 Years,f,,"Inclusion Criteria:~1. Age ≥ 18 years, male;~2. It was diagnosed as prostate adenocarcinoma by histological or cytological examination, and its pathological type was adenocarcinoma;~3. Bone imaging, CT or MRI showed ≥ 4 bone metastases (≥ 1 bone metastasis located outside the pelvis or spine) or visceral metastasis;~4. .Patients with recurrence after new or local treatment are sensitive to endocrine therapy;~5. Patients receiving ADT treatment (drug or surgical castration), with or without the first generation of antiandrogen drugs, for no more than 3 months, and without evidence of soft tissue imaging disease progression (according to RECIST 1.1 standard) or clinically significant PSA increase (after serum testosterone reaches the castration level, PSA increases by 50% from the lowest level), are allowed to be included in the group;~6. Plan to receive docetaxel combined with apantamide and ADT or apantamide combined with ADT;~7. ECOG PS score 0-1;~8. Adequate hematology and organ function:~   Adequate bone marrow function (no blood transfusion, no use of granulocyte colony stimulating factor): absolute neutrophil count (ANC) ≥ 1.5 × 109/L（1500/ μ L）； Hemoglobin ≥ 90 g/L (9.0 g/dL); Platelet count ≥ 100 × 109/L（100, 000/ μ L）；~   Adequate liver function: total bilirubin (TBIL) ≤ 1.5 × ULN； AST, ALT and alkaline phosphatase (ALP) ≤ 2.5 times the upper limit of normal value (ULN);~   Adequate renal function: serum creatinine ≤ 1.5 times the upper limit of normal (ULN) or calculated creatinine clearance ≥ 30 mL/min (calculated using Cockcroft Gault formula);~9. Sufficient coagulation function (without anticoagulation treatment): International normalized ratio (INR) ≤ 1.5;~Exclusion Criteria:~1. Have a history of hypersensitivity or intolerance to any drug used in the study;~2. Plan to receive any other anti-tumor treatment during the study period;~3. Patients who have received the second generation of androgen receptor (AR) inhibitors in the past, such as apantamide, enzalutamide, darotamide (ODM-201) or other AR inhibitors, CYP17 enzyme inhibitors, such as abietron acetate or oral ketoconazole, chemotherapy or immunotherapy, as well as adjuvant or new adjuvant therapy, should also be excluded;~4. Four weeks before the start of the study, he received plant drugs (such as saw palmetto) that have the effect of anti prostate cancer or reducing PSA level;~5. Have a history of epileptic seizures, a history of medication that can reduce the threshold of epileptic seizures, or a disease that can induce epileptic seizures within 12 months before the start of the study and treatment (including a history of transient ischemic attacks, cerebral apoplexy, brain trauma and disturbance of consciousness requiring hospitalization);~6. There were active heart diseases within 6 months before the start of study treatment, including severe/unstable angina, myocardial infarction, congestive heart failure \[NYHA III or IV\], or arrhythmias requiring drug treatment;~7. There is inability to swallow, chronic diarrhea, intestinal obstruction or other factors affecting drug administration and absorption;~8. Have a history of immunodeficiency (including HIV test positive, other acquired and congenital immunodeficiency diseases) or organ transplantation;~9. Known brain metastasis;~10. Malignant tumors other than prostate cancer in the past 5 years or at the same time, except for cured skin basal cell carcinoma and cervical carcinoma in situ;~11. Those who are receiving any other experimental drugs or experimental medical devices;~12. Poor compliance, difficult to cooperate with treatment and follow-up;~13. The investigator believes that the patient has concomitant diseases (such as poorly controlled hypertension, serious diabetes, neurological or mental diseases, etc.) that seriously endanger the patient's safety, may confuse the research results, or affect the patient to complete the study, or any other situation.",,,t,f,t
6260243,NCT00581178,NON_PROBABILITY_SAMPLE,ALL,18 Years,,f,All patients who will undergo surgery where a ureteral stent will likely be placed will be offered enrollment into this study.,Inclusion Criteria:~* Patient at UCI~* Scheduled to undergo surgery (standard of care) where ureteral stent will be placed~Exclusion Criteria:~* minors,,,t,f,t
6159184,NCT00057291,,ALL,,85 Years,f,,"Inclusion Criteria~* All caregivers and children in three Baby Homes in St. Petersburg, Russia, who remain in the Baby Homes for at least 4 months.",,,t,t,t
6159185,NCT04143191,,ALL,18 Years,75 Years,f,,"Inclusion Criteria:~1. Primary hepatocellular carcinoma without any treatments.~2. Received curative hepatic resection~3. ECOG score 0-1~4. Child-Pugh grade A~5. Sufficient liver and kidney function~Exclusion Criteria:~1. Diffused lesions; tumor thrombosis in SMV or IVC.~2. Extra-hepatic metastasis.~3. Contraindication of TACE, like portal-systemic shunt, obvious atherosclerosis, etc.~4. Allergic to the contrast agent of TACE~5. Dysfunction of liver, kidney or bone marrow.~6. Concomitant other malignant tumor or HIV infection",,,t,f,t
6260244,NCT02914496,,ALL,18 Years,70 Years,f,,Inclusion Criteria:~* Type 1 diabetes~* Duration of disease \>2 years -~* Hb1c\>60 mmol/mol~Exclusion Criteria:~* Insufficient knowledge to understand and express themselves in Swedish~* Untreated or severe ongoing psychiatric disease~* Cortisone treatment~* Untreated thyroid disease~* Insulin pump therapy started since \<3 months,,,t,f,t
6260245,NCT06113783,,ALL,18 Years,70 Years,f,,"Inclusion Criteria:~1. Voluntarily given informed consent to investigation participation in writing encompassing consent to data recording and verification procedures;~2. Male or female subjects aged ≥18 years and ≤70 years with active life-style;~3. BMI ≤40 kg/m2;~4. Patients affected by knee osteoarthritis, as defined by American College of Rheumatology (ACR) clinical and radiographic criteria for OA of the knee, and meeting the following conditions:~   * Kellgren-Lawrence Grade 2 to 3 severity OA of the target knee with presence of osteophytes determined from X-rays of the knee obtained within 6 months from the screening visit; i.e. in the tibio-femoral compartment of the target knee with at least 1 osteophyte and measurable joint space, as diagnosed by standard X-rays (anterior- posterior view \[weight bearing extension or semi-flexion\] and lateral). In the case that a patient has not a valid X-ray within 6 months prior to screening, the exam is to be performed during the screening period;~  * Patients suffering from OA symptoms of the target knee for at least 3 months prior to the screening visit; Note: patients with bilateral OA of the knee will be allowed as long as they can differentiate pain in the target knee, do not need to use analgesics for treatment of their contralateral knee, and do not expect to receive treatment of the contralateral knee during the investigation. In the case that both knees are eligible for the investigation based on pain intensity, the knee with the greater pain VAS score on the WOMAC pain VAS A1 subscale (walking on a flat surface) will be selected as the target knee;~5. Pain ≥50 mm on the WOMAC pain VAS A1 subscale (walking on a flat surface) in the target knee;~6. Patients having discontinued use of all systemic analgesic/non-steroidal anti-inflammatory drugs (NSAIDs) therapy for at least 7 days (24 hours for paracetamol) prior to the screening visit and agree not to resume them during the investigation. Note: paracetamol will be provided to patients as rescue medication.~7. If female of child-bearing potential, must have a negative urine pregnancy test at the screening visit and use a reliable form of contraception for more than 1 month prior to Screening and throughout the investigation. Note: to be considered females of non-child- bearing potential, females must be surgically sterile or postmenopausal as documented in medical history for at least 1 year. Highly effective birth control methods include: combined hormonal contraception (containing estrogens and progestogen) associated with inhibition of ovulation (oral, intravaginal, transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomised partner; sexual abstinence.\*~   * Note: According to 4.1 paragraph Birth control methods which may be considered as highly effective of the Clinical Trial Facilitation Group (CTFG)/Recommendations related to contraception and pregnancy testing in clinical trials.~Exclusion Criteria:~1. Radiographic assessment confirming abnormal patellofemoral tracking or articulation or abnormal/excessive patellar subluxation in lateral view;~2. Major injury to or disorder of the contralateral knee or other weight-bearing joint that would interfere with the study assessments;~3. Secondary OA due to a prior or concomitant condition (e.g., septic arthritis, inflammatory joint disease, gout, articular fracture, major dysplasia, or congenital abnormality, hemochromatosis, etc.);~4. Patients who have had arthroplasty at the target knee at any time;~5. Surgery in the target knee within the previous 12 months prior to Screening or any planned surgery throughout the duration of the investigation;~6. Surgery in the contralateral knee or other weight-bearing joint within the previous 12 months that would interfere with the study assessments;~7. Patients that are candidate for knee replacement within the next 12 months;~8. Patients having had diagnostic or surgical knee arthroscopy, or knee lavage in the target knee in the 6 months prior to the screening visit, or patients in which such procedures are planned during the study;~9. Patients with total joint replacement implants, unicondylar implants or patellofemoral replacement implants in the study joint;~10. Ligament reconstruction of the target knee in the previous 3 years;~11. Inflammatory arthropathies such as rheumatoid arthritis, lupus, or psoriatic arthritis;~12. Patients with clinically relevant intra-articular effusion of the target knee;~13. Episode of gout or calcium pyrophosphate (pseudogout) diseases within 6 months prior to Screening;~14. Patients having received:~    * Corticosteroids by systemic administration within 30 days prior to the screening visit.~    Inhaled corticosteroids are permitted if the Subject has been on a stable regimen for the past 1 month prior to Screening and remains on this regimen throughout the course of the investigation;~   * Analgesic/NSAIDs by systemic administration within 7 days prior to the screening visit;~   * Intra-articular drugs within 12 weeks prior to the screening visit;~   * Chondroitinsulphate, glucosamine, diacereine, bisphosphonates or matrix metalloproteinase (MMP) inhibitors within 30 days prior to the screening visit;~   * Viscosupplementation of the target knee within 6 months prior to the screening visit;~   * Paracetamol in the 24 hours prior to the screening visit;~   * Treatment with any other investigational product within 3 months prior to the screening visit.~15. History of allergic reaction to an intra-articular Hyaluronic acid injection;~16. Known hypersensitivity (allergy) to gram positive bacterial proteins;~17. Inability to perform the Timed Up and Go (TUG) test;~18. X-ray findings of acute fractures, severe loss of bone density, avascular necrosis and/or severe deformity;~19. Axial deviation of the lower limbs greater than 20 degrees in valgus or varus on standing X-ray, ligamentous laxity, or meniscal instability as per study investigator(s);~20. Significant surgery of lower limbs (hip, ankle, foot) that may interfere with knee assessments;~21. Patients with any musculoskeletal condition affecting the target knee that would impair assessment of the effectiveness in the target knee (e.g. Paget's disease of bone);~22. Patients with significant pain outside the target knee, including significant hip or back pain;~23. Chronic use of analgesia for pain (including pain in the other knee or any other joint) that may interfere with the evaluations of the test knee (such as possible use of rescue medication for these other conditions);~24. Known allergies to paracetamol and hyaluronan preparations;~25. Recurrent medical history of severe allergic or immune-mediated reactions;~26. Active infection or skin diseases in the area of the potential injection site or joint;~27. Any dermatological disease overlying the study joint that would contraindicate injections or aspirations;~28. Peripheral neuropathy that would be severe enough to interfere with the evaluation of the subject;~29. Psychological status (e.g., anxiety, depression, poor sleep quality, pain catastrophizing, etc.) that may interfere with functional assessment of the target knee;~30. Vascular insufficiency of lower limbs that is severe enough to interfere with the evaluation of the subject;~31. Any concomitant disease(s) or condition(s) that may interfere with the free use and evaluation of the affected knee for the 12 months course of the investigation (cancer, other rheumatic diseases, gout, severe congenital defects, etc.);~32. Continued participation in an experimental drug/device study or any clinical trial within the previous 8 weeks prior to Screening. Subjects must have fully completed participation in an experimental drug/device study of any clinical trial at least 8 weeks prior to screening;~33. Pregnancy, breastfeeding, planned conception, premenopausal women who have not had tubal ligation, hysterectomy, or are unwilling or unable to utilize contraceptive measures (or contraception);~34. Prior history of any malignancy with the exception of basal cell carcinoma of the skin treated more than 2 years prior to Screening;~35. Significant bleeding diathesis;~36. Patients who are not able to comply with study procedures or who are likely to be noncompliant or uncooperative during the study according to the investigator's opinion.",,,t,f,t
6260246,NCT01069458,,ALL,20 Years,65 Years,t,,"Inclusion Criteria:~* Smoking 10 cigarettes per day, BMI 25-40~Exclusion Criteria:~* Recent change in weight, contra-indications to use varenicline, a medication to assist smoking cessation",,,t,f,t
6260247,NCT00004883,,ALL,18 Years,,f,,"Inclusion Criteria:~* Histologically confirmed stage IIIB or IV non-small cell lung cancer~  * Supraclavicular node involvement allowed~ * Malignant pleural effusion allowed (cytological confirmation not required if pleural fluid bloody or exudative)~* No stage IIIB patients eligible for CLB protocols comprising combined chemotherapy and chest radiotherapy~* Recurrent disease allowed~* HER2 overexpression (2-3+)~* At least 1 unidimensionally measurable lesion~  * At least 20 mm by conventional techniques~ * At least 10 mm by spiral CT scan~ * The following are not considered measurable:~    * Bone lesions~   * Leptomeningeal disease~   * Ascites~   * Pleural/pericardial effusion~   * Abdominal masses not confirmed and followed by imaging~   * Cystic lesions~* No CNS metastases~* Performance status - ECOG 0-2~* Granulocyte count at least 1,500/mm3~* Platelet count at least 100,000/mm3~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* Creatinine no greater than 1.5 times ULN~* LVEF at least 45% (by echocardiogram or MUGA)~* Not pregnant or nursing~* Fertile patients must use effective contraception~* HIV negative~* No concurrent immunologic disease (e.g., autoimmune disease)~* No history of allergy to murine products~* No prior murine antibodies~* No prior anthracyclines~* No more than 1 prior chemotherapy regimen for lung cancer~* At least 4 weeks since prior chemotherapy~* No concurrent chemotherapy~* No concurrent steroids except for adrenal failure or dexamethasone as an antiemetic~* No concurrent hormonal therapy except for nondisease-related conditions (e.g., insulin for diabetes)~* At least 6 months since prior radiotherapy~* No concurrent palliative radiotherapy~* At least 4 weeks since prior major surgery",,,t,f,t
6159186,NCT03784391,PROBABILITY_SAMPLE,ALL,0 Years,,f,"The study population will comprise adult and pediatric patients diagnosed with Chagas' disease, respectively, who were treated with nifurtimox (nifurtimox groups). An untreated reference group comprising adult patients diagnosed with chronic Chagas' disease, who did not receive antitrypanosomal treatment will be considered.","Inclusion Criteria:~* Male and female patients aged ≥0 years at time of diagnosis with Chagas' disease~* Diagnosis of Chagas' disease confirmed by parasitological and/or serological method(s) before start of antitrypanosomal treatment or during the course of this antitrypanosomal treatment cycle for the first episode recorded.~Exclusion Criteria:~* Treatment with antitrypanosomal agent(s) other than nifurtimox, including experimental investigational products for Chagas' disease or antitrypanosomal combination treatment~* Patients with known evidence of organ manifestation of chronic Chagas' disease, e.g.Chagas' disease-related cardiomyopathy/heart disease, Chagas' disease-related digestive disease at time of primary diagnosis.",,,t,t,t
6159187,NCT02160652,NON_PROBABILITY_SAMPLE,ALL,18 Years,,f,"Patients with malignant ureteral obstruction, treated with laparoscopic ureteral re-implantation, who have a life expectancy of over 6 months and are willing and able to participate in the study.","Inclusion criteria:~1. Adult patient, older than 18 years of age.~2. Patient with malignant ureteral obstruction diagnosed by creatinine elevation with evidence of ureteral obstruction on imaging.~3. Patient is scheduled for ureteral reimplantation due to extrinsic malignant ureteral obstruction.~4. American Society of Anesthesiologist score ≤3, enabling the patient to undergo surgery.~5. Life expectancy of over 6 months ( see exclusion criteria for definition)~6. WHO performance status 0-2~7. The patient is willing and able to read, understand and sign the study specific informed consent form~Exclusion criteria:~1. Patients who underwent urinary diversion other than percutaneous nephrostomy or retrograde ureteral stenting prior to the planned treatment.~2. Patients unable to sign an informed consent for or unwilling to undergo so.~3. Life expectancy of less than 6 months, as defined according to the criteria by Ishioka et al. and predicted in the presence of:~   * Low serum albumin before percutaneous nephrostomy/ retrograde ureteral stenting (3 gm/dl or less).~  * Low grade hydronephrosis prior to percutaneous nephrostomy/ retrograde ureteral stenting placement (grade 1 or 2) as graded by the grading system of the Society for Fetal Urology~  * Malignant ascites or malignant pleural effusion.",,,t,f,t
6159188,NCT06111118,,ALL,18 Years,55 Years,t,,"Inclusion Criteria:~* Any gender and any ethnic origin, aged between 18 and 55 years (inclusive), in good general health and able to perform and complete the exercise regimen.~* No significant physical activity causing DOMS in the thighs/quads in the past 4 weeks.~Body mass index \<40 kg/m2.~* No clinically relevant cardiovascular disease, hepatic disease, diabetes, lower limb neuropathies or recent lower limb injuries.~* Normal blood pressure (systolic blood pressure 90 to 140 mmHg, diastolic blood pressure 60 to 90 mmHg, inclusive) at rest.~* Subject is either not of childbearing potential (defined as biological male sex or postmenopausal for at least 1 year or surgically sterile \[bilateral tubal ligation, bilateral oophorectomy, or hysterectomy\]) and must agree not to start a pregnancy from the signature of the informed consent up to the final visit or practicing one of the following medically acceptable methods of birth control:~  1. Hormonal methods such as oral, implantable, injectable, or transdermal contraceptives for a minimum of 1 full cycle (based on the subject's usual menstrual cycle period) up to the final visit~ 2. Total abstinence from sexual intercourse since the last menses before exposure to the device and up to the final visit~ 3. Intrauterine device~ 4. Double-barrier method (condoms, sponge, diaphragm, with spermicidal jellies or cream) up to the final visit -----Must have personal smartphone (i.e., iOS or Android).~* Capable of returning to the investigation center for all the visits according to requirement of CIP.~* Willing to comply with the policy, procedure, and restriction of the investigation.~* Capable of actively communicating with the investigator.~* Capable of completing the investigation-related documents.~* Capable of understanding the contents of the informed consent and personal data processing consent and legally ---capable of signing a written informed consent and a personal data processing consent prior to any investigation-related procedures.~Exclusion Criteria:~* Skin lesions (e.g., rash, bruising, laceration) in the thigh region, or spreading skin conditions (e.g., poison ivy, urticaria) in other regions, or any skin abnormality likely to be aggravated by the device such as dermatological disease or infection, rash, atrophic, fragile or abnormally dry skin, cuts or abrasions at the treatment site.~* Clinically significant abnormalities at medical history and/or physical examination at Visit 1, which in the opinion of the investigator could interfere with the investigation procedures or endpoint evaluations.~* Treatment with alpha or beta agonists/antagonists, any type of anti-inflammatory or analgesic medications, Cox-2 inhibitors, calcium channel blockers, pregabalin (Lyrica), other pain reducers, muscle relaxants, creatine, ephedrine or pseudoephedrine.~* Lactating or pregnant women.~* Suspected or confirmed coronavirus disease 2019 infection at Visit 1.~* History of (within the past 12 months) or current alcohol or substance abuse.~* Any history of radiculopathy and neurological deficits.~* Vulnerable subjects (i.e., individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response).~* Subjects who have participated in another interventional investigation within the past 30 days before enrollment or are currently participating in another non-interventional investigation which might impact the outcome of this investigation.~* Subjects who are involved in the conduct of the investigation (i.e., investigator or his/her deputy, first grade relatives, pharmacist, assistant or other personnel).~* Known skin hypersensitivity to adhesion products.~* Any other condition that, in the opinion of the investigator, interferes with the investigation endpoints/procedures and does not justify the inclusion of the subject in the investigation.",,,t,f,f
6159189,NCT03243500,,ALL,18 Years,75 Years,f,,"Inclusion Criteria:~* American Society of Anesthesiologists (ASA) physical status I-III~* high myopia (axial length 26mm or more)~Exclusion Criteria:~* Pregnant patients.~* ASA physical status \>III.~* Axial length less than 26 mm.~* Contraindication of regional anesthesia:~Absolute contraindications: Patient refusal to participate in the study, Local anesthetic allergy and Infection/marked orbital inflammation or, Relative contraindications: unable to lie flat for a sufficient length of time, Confusion or psychiatric illness, communication difficulties, bleeding diathesis or taking anticoagulants, Previous scleral buckling or space-occupying lesions within the orbit",,,t,f,t
6159190,NCT05834218,,MALE,20 Years,30 Years,f,,Inclusion Criteria:~* Only male cricketers will be recruited to the study.~* We have to select those individuals which are of ages 20 to 30 years.~* only those individuals will be recruited with no history of any systemic disease.~Exclusion Criteria:~* cricketers who have received surgery in the three years prior to the study or undergone rehabilitation within the past year.~* cricketers who would not commit to full participation in the study's training regimes.~* cricketers who will have any systemic disease which can hinder the training.~* Cricketers currently engaged in strength training as this may confound the study.,,,t,f,f
6159191,NCT03658018,,ALL,25 Years,70 Years,t,,"Inclusion Criteria:~* Skeletally mature subjects age 25-70 years, inclusive~* Chronic lower back pain for at least six months~* Failure to respond to at least six months of non-operative conservative management~* Oswestry Disability Index (ODI) at time of evaluation of at least 30 points~* Modic changes (Type 1 or 2) in at least one vertebral endplate, at one or more levels from L3 to S1~Exclusion Criteria:~* Radicular pain by history or evidence of pain neurological deficit within the past one year.~* Previous surgery performed on the lumbar spine~* Current or history of symptomatic spinal stenosis~* Current or history of osteoporotic or tumor-related vertebral body compression fracture~* Current or history of vertebral cancer or spinal metastasis~* Current or history of spinal infection~* Metabolic bone disease~* BMI greater or equal to 40~* Any radiographic evidence of other important back pathology~* MRI evidence of Modic changes, Type 1 or 2 at greater than 3 vertebral bodies or at non-consecutive levels, or at vertebral bodies other than L3 to S1~* Any back pathology related to trauma, evidence of vertebral compression fracture or other spinal pathology that could affect assessment of response to back pain~* Subjects who are bed bound~* Demonstrates 3 or more Waddell's signs of Inorganic Behavior~* Any evidence of current systemic infection",,,t,f,t
6159192,NCT01662791,,ALL,18 Years,,f,,"Inclusion criteria: Parkinson's Disease~Exclusion Criteria:~1. Wheelchair-bound, akinetic individuals~2. Tube-fed individuals~3. Presence of dementia~4. Unwilling or unable to complete the tests~5. Allergic or intolerant to rifaximin~6. Presence of chronic upper or lower gastrointestinal disorders that have symptoms that may be confused with SBBO (e.g., irritable bowel syndrome, inflammatory bowel disease, celiac disease, functional dyspepsia, gastroparesis, and chronic pancreatitis)~7. Presence of prior surgery on the gastrointestinal tract except cholecystectomy, appendectomy or herniorrhaphy~8. Presence of severe concomitant acute or chronic medical condition that may interfere with the completion or interpretation of the test results~9. Women of childbearing potential. Given the age of patients with Parkinson's disease, we do not anticipate this being a large population.~10. Use of antibiotics within 1 month of breath testing",,,t,f,t
6159193,NCT06298318,,MALE,18 Years,30 Years,t,,"Inclusion Criteria:~* Sign informed consent~Exclusion criteria~* a. Neurological disorders~* b. Alcohol allergy~* c. Alcohol addiction~* d. Gastrointestinal diseases~* e. Liver, kidney, cardiovascular or systemic diseases~* f. Antibiotics were administered within 2 weeks prior to the trial~* g. Participants who ate a vegetarian diet~* h. Unable to use a smartphone or computer with Internet access~* i. Participate in another intervention study",,t,t,f,f
6159194,NCT05554991,,ALL,2 Weeks,12 Weeks,f,,"Inclusion criteria:~1. Infants 2 weeks - 12 weeks of age at enrolment~2. Infants diagnosed with colic according to Rome IV criteria: Diagnostic criteria for research purposes (infant must meet all Rome IV criteria):~   1. An infant who is less than 5 months of age (in the current clinical trial, only infants 2 weeks to 8 weeks of age will be enrolled) when the symptoms start and stop~  2. Recurrent and prolonged periods of infant crying, fussing, or irritability reported by caregivers that occur without obvious cause and cannot be prevented or resolved by caregivers~  3. No evidence of infant failure to thrive, fever, or illness~  4. Excessive crying/fussiness for 3 or more hours per day during 3 or more days in the past 7 days as reported by parents to the clinician~  5. Total 24-hour crying plus fussing is 3 hours or more when measured by at least one prospectively kept 24-hour behavior diary. (The Structured Infant Crying and Fussing Diary will be dispensed at the screening visit (V0), completed for two 24-hour periods at H0 (days -3 to -1), and returned at V1 to be used as part of the diagnostic criteria for infantile colic.)~3. Term infants (≥ 37 weeks) generally healthy with normal birth weight (≥2.5kg) and singleton born~4. Predominantly formula fed\* (formula fed ≥ 80% of the time) for at least 7 days before randomization and the choice of formula feeding has been made by the parents before the beginning of the trial.~5. Infants who have been on the same formula for the past 5 days~6. Signed informed consent obtained for infant's and parents'/Legally Acceptable Representative (LAR) participation in the study~7. Parent/LAR of infant agrees not to enroll infant in another interventional clinical research study while participating in this study~8. Parent of the infant/LAR is willing and able to fulfill the requirements of the study protocol~9. Parent of infant can be contacted throughout the study~   * Predominantly formula feeding defined in the study means that the infant's predominant source of nourishment is formula. Specifically, infants are fed with formula for at least 80% of total milk feeds per day.~Exclusion criteria:~1. Presence of any congenital condition and/or previous or current illness/infection and (or) medication use that could interfere with the main study outcomes.~2. Clinical evidence of chronic illness or gastrointestinal disorders, major medical problems (e.g. ill, immunocompromised, major developmental or genetic abnormality).~3. Known cow's milk protein allergy, lactose intolerance, or galactosaemia; including presence of any allergic manifestations.~4. Received any special formula (e.g. lactose-free, hydrolyzed protein) within 5 days before randomization or switched formulas within 5 days before randomization.~5. Received any of the following products/medication within 5 days before randomization:~   * Antibiotics~  * Alginate~  * Prokinetics~  * Proton pump inhibitors~  * Simethicone~  * L. reuteri probiotic~  * Formula containing Human milk Oligosaccharides~6. Other infant(s) \<6months of age living in the same household.~7. Current participation in another interventional clinical trial.",,,f,t,f
6260248,NCT02811588,NON_PROBABILITY_SAMPLE,ALL,18 Years,,f,"Approximately 550 adult female and male patients with COPD eligible for NIV treatment will be enrolled, out of which 231 patients have been enrolled within the phase 1 of the study. If a patient is enrolled into the study but is never using the prescribed device (i.e. refusal of prescribed therapy) he/she will be replaced.~If a patient, who has already started NIV therapy, is enrolled, the start of therapy must not be longer than 7 days before enrolment.~Within this study population, data of a maximum of about 100 patients will be added by the French ANTADIR registry in line with in- and exclusion criteria of this observational study.","Phase1:Inclusion Criteria:~* Age ≥18 years~* GOLD stage 3 or 4 COPD~* pCO2 value available not older than one month~* Ability to fully understand the study information and willing to give informed consent~Phase2:~Age ≥18 years COPD eligible for NIV treatment (according to applicable medical guidelines and local policy in routine clinical care) Prescription of an adequate ResMed NIV device with tele-monitoring option (according to Annex 1, 3.) as part of routine clinical care Acceptance of tele-monitoring and corresponding data handling Naive to long-term NIV treatment with initiation of NIV either ≤7 days before or after enrolment into study Able to fully understand information on data protection and provide written informed consent for use of corresponding medical and telemetric data.~Phase1:Exclusion Criteria:Existing treatment with NIV Phase2:Exclusion Criteria Invasive ventilation therapy Another life-threatening disease with estimated survival \< 12 months (other than COPD, e.g. cancer) Further exclusion criteria according to IFU of the device intended and prescribed",,,t,f,t
6260249,NCT02440178,,ALL,18 Years,75 Years,f,,"Inclusion Criteria:~A. patients belong to either A-1 or A-2 A-1. patients with newly diagnosed acute myeloid leukemia who approve to get induction chemotherapy with (cytarabine plus idarubicin) or (modified Fludarabine + cytarabine + idarubicin ) A-2. patients with newly diagnosed acute lymphoid leukemia who approve to get induction chemotherapy with VPDL (vincristine + prednisolone + daunorubicin + L-asparaginase), C-VPDL (cyclophosphamide + vincristine + prednisolone + daunorubicin + L-asparaginase), or (R)-hyperCVAD ((Rituximab) + cyclophosphamide + vincristine + Adriamycin + dexamethasone) B. Eastern Cooperative Oncology Group performance status score is equal to or more than 2 C. patients who voluntarily sign the agreement~Exclusion Criteria:~A. evidence of proven/probable/possible fungal infection within 30 days before induction chemotherapy B. hypersensitivity to echinocandin C. patients had other malignancy within 5 years D. previous treatment history with chemotherapy, radiation therapy, or immunosuppressive therapy.~E. pregnant or breast-feeding women F. immunodeficient patients including AIDS G. patients with uncontrolled seizure or psychiatric disorder H. clinically significant heart disorder (myocardial infarction within 3 months or left ventricular ejection fraction \< 40%) I. interstitial lung disease J. previous organ transplantation history K. galactose intolerance L. patients who participated this study before.",,,t,f,t
6159195,NCT01485991,,ALL,18 Years,70 Years,f,,"Inclusion Criteria:~* Patient must have had a liver biopsy before screening (or between the screening and baseline visit), unless patient cannot undergo such a procedure or has evidence of portal hypertension not associated with cirrhosis. For patients who had a liver biopsy performed more than 2 years prior to screening or without a biopsy (because of a contraindication or portal hypertension), a non-invasive staging assessment needs to be available. Non-invasive staging assessments include FibroScan, MR-Elastography, or FibroTest/FibroSure and must not be older than 6 months prior to screening~* Chronicity of hepatitis C virus (HCV) infection, as confirmed by one or both of the following: presence of anti-HCV antibody and/or HCV ribonucleic acid (RNA) at least 6 months prior to the screening visit and/or presence of fibrosis on biopsy~* Genotype 1 HCV infection with plasma HCV RNA of \>10,000 IU/mL (both confirmed at screening)~* Patient must have had at least 1 documented previous course of treatment with PegINFα-2a or PegINFα-2b in combination with ribavirin (RBV) (at least 12 weeks for null responder and 20 weeks for partial responder)~Exclusion Criteria:~* Hepatic decompensation (impaired functioning of the liver), as indicated by significant laboratory abnormalities or other active diseases~* Infection with Human Immunodeficiency Virus (HIV) or non genotype 1 hepatitis C~* Liver disease not related to hepatitis C infection~* Previous chronic hepatitis C treatment, other than PegIFN and RBV",,,t,f,t
6159196,NCT04249518,,ALL,18 Years,99 Years,f,,Inclusion Criteria:~* candidate to CPAP~* over age of 18~Exclusion Criteria:~* Language issues~* sight or hearing handicap~* kognitive issues~* if drivers license is confiscated,,,t,f,t
6159197,NCT01237418,PROBABILITY_SAMPLE,ALL,18 Years,,f,"Patients will be recruited consecutively in the CIAU member during a period of 2 months, including sub-populations of specific interest (diabetes and / or elderly patients, for example). A list of eligible patients not included and must be completed by the participating centers during the same period, with reasons for non inclusion.~A questionnaire will be sent to each center prior to recruitment, including type of service and number of beds in the facility.~The study will be given to any medical facility, University Hospital, CHG, CHR, health facility of the Army, including a clinic or intensive care unit entitled to receive emergency ACS. In each center, a medical consultant will be appointed to collect phenotypic data for the study case report forms in electronic patient.","Inclusion Criteria :~* Patients over 18 years old~* Admitted patient for a myocardial infarction (MI) of less than 48 hours, characterized by the typical rise and fall of troponin or CPKMb associated with at least one of the following: symptoms of myocardial ischemia or appearance of pathological Q waves or repolarization disorders related to ischemia (in addition to or NSTEMI)~* Patient who consented to participate in the study~Exclusion Criteria:~* Refusal of consent~* MI occurring within 48 h after a therapeutic intervention (angioplasty or coronary bypass or other surgery)~* Diagnosis of SCA reversed in favor of an alternative diagnosis",,,t,f,t
6159198,NCT01909791,,ALL,18 Years,,f,,"Inclusion Criteria:~1. Age \>= 18 years~2. Diagnosis of diabetes mellitus (type 1 or type 2)~   Any one of the following will be considered to be sufficient evidence that diabetes is present:~  1. Current regular use of insulin for the treatment of diabetes~  2. Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes~  3. Documented diabetes by American Diabetes Association (ADA) and/or World Health Organization (WHO) criteria.~3. Able and willing to provide informed consent.~Meets all of the following ocular criteria in at least the one eye:~1. Best corrected E-ETDRS visual acuity letter score ≥ 79 (approximate Snellen equivalent 20/25 or better) at two consecutive visits within 1 to 28 days.~2. On clinical exam, definite retinal thickening due to DME involving the center of the macula.~3. Diabetic macular edema confirmed on OCT (equivalent to CSF thickness on OCT ≥250 microns on Zeiss Stratus or gender-specific spectral domain OCT equivalent) at two consecutive visits within 1 to 28 days.~   (a) Investigator must verify accuracy of OCT scan by ensuring it is centered and of adequate quality.~4. The investigator is comfortable with the eye being randomized to any of the three treatment groups (observation, laser, or anti-VEGF initially).~   (a) If focal/grid photocoagulation is contraindicated because all leaking microaneurysms are too close to the fovea or the investigator believes the DME that is present will not benefit from focal/grid photocoagulation, the eye should not be enrolled.~5. Media clarity, pupillary dilation, and individual cooperation sufficient for adequate OCT and fundus photographs.~Exclusion Criteria:~1. History of chronic renal failure requiring dialysis or kidney transplant.~2. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control).~3. Initiation of intensive insulin treatment (a pump or multiple daily injections) within 4 months prior to randomization or plans to do so in the next 4 months.~4. Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval for the indication being studied.~   (a) Note: study participants cannot receive another investigational drug while participating in the study.~5. Known allergy to any component of the study drug.~6. Blood pressure \>180/110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, individual can become eligible.~7. Systemic anti-VEGF or pro-VEGF treatment within 4 months prior to randomization.~   These drugs should not be used during the study.~8. For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 24 months.~   (a) Women who are potential study participants should be questioned about the potential for pregnancy. Investigator judgment is used to determine when a pregnancy test is needed.~9. Individual is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the 24 months of the study.~Individual has any of the following ocular characteristics:~1. Macular edema is considered to be due to a cause other than DME.~   a) An eye should not be considered eligible if: (1) the macular edema is considered to be related to ocular surgery such as cataract extraction or (2) clinical exam and/or OCT suggest that vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid or epiretinal membrane) are contributing to the macular edema.~2. An ocular condition is present such that, in the opinion of the investigator, any visual acuity loss would not improve from resolution of macular edema (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, nonretinal condition).~3. An ocular condition is present (other than DME) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.).~4. Cataract is present that, in the opinion of the investigator, may alter visual acuity during the course of the study.~5. Any history of prior laser or other surgical, intravitreal, or peribulbar treatment for DME (such as focal/grid macular photocoagulation, intravitreal or peribulbar corticosteroids, or anti-VEGF).~6. History of topical steroid or nonsteroidal anti-inflammatory drugs (NSAID) treatment within 30 days prior to randomization.~7. History of intravitreal or peribulbar corticosteroid within 4 months prior to randomization for an ocular condition other than DME.~8. Any history of or anticipated need for intravitreal anti-VEGF within the next 6 months for an ocular condition other than DME (e.g. choroidal neovascularization, central retinal vein occlusion, PDR).~9. History of PRP within 4 months prior to randomization or anticipated need for PRP in the 6 months following randomization.~10. Any history of vitrectomy.~11. History of major ocular surgery (cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior 4 months or anticipated within the next 6 months following randomization.~12. History of YAG capsulotomy performed within 2 months prior to randomization.~13. Aphakia.~14. Exam evidence of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis.",,,t,f,t
6159199,NCT03507218,NON_PROBABILITY_SAMPLE,ALL,3 Years,,t,"study population will include potential participants from primary care and specialty medical referrals, community samples, and self-referral from across the United States.","* INCLUSION CRITERIA:~Affected Probands (Children with PANS) will be eligible if they:~1. Are 3 to 14 years of age (initial enrollment must occur prior~2. Have a history of abrupt onset (less than 24-48 hours) of impairing OCD and/or eating restrictions.~3. Are able to travel safely to the regional medical center where the evaluations will be conducted and are able to be examined safely over a period of one or more days.~4. Assent to participate (if they are at least seven years old and have capacity to do so) and have legal guardians who consent to their minor child s participation.~5. Are under the care of a primary physician in their home community.~First-degree Relatives will be eligible if they:~1. Are a biologic parent or sibling of an affected proband.~2. Consent (or assent) to undergo study evaluations and to provide blood, microbial and genetic samples.~Children with Non-PANS Neuropsychiatric Symptoms may be enrolled if they:~1. Are 3 to 14 years of age (initial enrollment must occur prior to the participant s 15th birthday to permit prospective longitudinal evaluations)~2. Have OCD, tics, anxiety disorders, or other psychiatric symptoms, but do NOT have a history of acute symptom onset.~3. Are willing to participate in medical, psychiatric, and behavioral assessments and to provide bio-specimens including blood, urine, and microbial flora (mouth, oropharynx, and/or stool).~4. Assent to participate (if they are at least seven years old and have capacity to do so) and have legal guardians who consent to their minor child s participation.~5. Are under the care of a primary physician in their home community.~Healthy Pediatric Volunteers may be enrolled if they:~1. Are 3 to 14 years of age (initial enrollment must occur prior to the participant s 15th birthday to permit prospective longitudinal evaluations).~2. Are physically healthy and do not have psychiatric symptoms.~3. Are willing to participate in medical, psychiatric, and behavioral assessments and to provide bio-specimens including blood, urine, and microbial flora (mouth, oropharynx, and/or stool).~4. Assent to participate (if they are at least seven years old and have capacity to do so) and have legal guardians who consent to their minor child s participation.~EXCLUSION CRITERIA:~Participants will not be eligible if they:~1. Appear to the investigators to be too unstable psychiatrically or medically to participate safely in the protocol.~2. Are unwilling or unable to be evaluated and followed prospectively.~3. Have a parent/guardian who is not willing to participate at a distance through web-based or phone-based data collection.",,,t,t,t
6159200,NCT01264718,,ALL,,18 Years,t,,"Inclusion Criteria:~1. The parent/guardian is a primary caretaker of a least one child 0-18 years old who currently has no health insurance~2. The parent/guardian self-identifies the uninsured child as Hispanic/Latino, African-American/Black, or both~3. The uninsured child is eligible for either Medicaid or CHIP~4. The parent/guardian is willing to be contacted monthly by telephone, or in the form of a home visit (if no functioning telephone is present in the household).",,,t,t,f
6159201,NCT05538091,,FEMALE,18 Years,,f,,"Inclusion Criteria:~* Signed Informed Consent Form~* Age ≥ 18 years at time of signing Informed Consent Form~* Ability to comply with the study protocol, in the investigator's judgment~* Histologically or cytologically confirmed epithelial ovarian, fallopian tube or primary peritoneal cancer~* Platinum resistant disease, defined by disease progression during or following treatment with platinum-based chemotherapy within 6 months of completing therapy~* Measurable or non-measurable but evaluable disease per RECIST v1.1 {Previously irradiated lesions can be considered as measurable disease only if progressive disease has been unequivocally documented at that site since radiation.}~* Availability of a representative tumor specimen for exploratory biomarker research will be required for 12 patients (see Section 5.4.5 for information on tumor specimens)~* ECOG Performance Status of 0-1~* Life expectancy ≥ 3 months~* Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment: ANC ≥ 1.5 ⋅ 109/L (1500/μL) without granulocyte colony-stimulating factor support; Lymphocyte count ≥ 0.5 ⋅ 109/L (500/μL); Platelet count ≥ 100 ⋅ 109/L (100,000/μL) without transfusion; Hemoglobin ≥ 80 g/L (8 g/dL) (Patients may be transfused to meet this criterion.)~  * AST, ALT, and alkaline phosphatase (ALP) ≤ 2.5 ⋅ upper limit of normal (ULN), with the following exceptions:~    * Patients with documented liver metastases: AST and ALT ≤ 5 ⋅ ULN~   * Patients with documented liver or bone metastases: ALP ≤ 5 ⋅ ULN~ * Serum bilirubin ≤ 1.5 ⋅ ULN with the following exception:~    * Patients with known Gilbert disease: serum bilirubin ≤ 3 ⋅ ULN~ * Serum creatinine ≤ 1.5 ⋅ ULN~ * Serum albumin ≥ 25 g/L (2.5 g/dL)~ * For patients not receiving therapeutic anticoagulation: INR or aPTT ≤ 1.5 ⋅ ULN~ * For patients receiving therapeutic anticoagulation: stable anticoagulant regimen~* Negative HIV test at screening, with the following exception: patients with a positive HIV test at screening are eligible if they are stable on anti-retroviral therapy, have a CD4 count \> 200, and have an undetectable viral load.~* Negative hepatitis B surface antigen (HBsAg) test at screening~* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods as defined below:~  * Women must remain abstinent or use contraceptive methods with a failure rate of \< 1% per year during the treatment period and for 5 months after the final dose of atezolizumab and for 24 months after the final dose of vismodegib. Women must refrain from donating eggs during this same period.~ * A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements.~ * Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.~ * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.~Exclusion Criteria:~* Inability or unwillingness to swallow capsules~* Inability or unwillingness to comply with study procedures~* History of leptomeningeal disease~* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)~  o Patients with indwelling catheters (e.g., PleurX→) are allowed.~* Uncontrolled or symptomatic hypercalcemia (ionized calcium \> 1.5 mmol/L, calcium \> 12 mg/dL or corrected serum calcium \> ULN)~* Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis (see Appendix 9) for a more comprehensive list of autoimmune diseases and immune deficiencies), with the following exceptions:~  * Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.~ * Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.~ * Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:~* Rash must cover \< 10% of body surface area~* Disease is well controlled at baseline and requires only low-potency topical corticosteroids~* No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months~* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan (History of radiation pneumonitis in the radiation field (fibrosis) is permitted).~* Active tuberculosis~* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina~* Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study~* History of malignancy other than ovarian cancer within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \> 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer~* Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia~* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment~  * Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.~* Prior allogeneic stem cell or solid organ transplantation~* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications~* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab~* Current treatment with anti-viral therapy for HBV~* Treatment with investigational therapy within 28 days prior to initiation of study treatment~* Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 \[IL-2\]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment~* Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-α agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:~  * Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study after Principal Investigator confirmation has been obtained.~ * Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.~* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins~* Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab formulation~* Known allergy or hypersensitivity to any component of the vismodegib formulation~* Agreement not to donate blood or blood products during the study and for 24 months after discontinuation of vismodegib.~* Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of atezolizumab and for 24 months after the final dose of vismodegib.~  * Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment.",,t,t,f,t
6159202,NCT01614418,,ALL,18 Years,,f,,"Inclusion Criteria:~1. Histological confirmation of gastric IM or dysplasia.~2. The lesion is no larger than 5 cm in diameter.~3. Age ≥ 18 years.~4. No previous endoscopic mucosal resection or submucosal dissection.~5. No active H. pylori infection.~6. Subject is able to tolerate endoscopy and sedation.~7. Subject agrees to participate, fully understands content of the informed consent, and signs the informed consent form.~Exclusion Criteria:~1. Gastric cancer (intra-mucosal cancer or worse).~2. Prior gastric irradiation or surgery.~3. Anti-platelet or anti-thrombotic medication use that cannot be stopped for 7 days before and after RFA.~4. Gastric ulcers, fistulae and varices.~5. History of alcohol and/or controlled substance dependency.~6. Pregnancy.",,,t,f,t
6159203,NCT01779791,,ALL,18 Years,,f,,"Inclusion Criteria:~* Histologic proof of Grade 1, 2, or 3a follicular lymphoma (FL) without clinical or pathological evidence of transformation~* Previously treated with at least 2 prior lines of therapy, including at least 1 rituximab combination chemotherapy regimen; last prior line of therapy includes an anti CD20 monoclonal antibody-containing chemotherapy regimen (separate lines of therapy are defined as different regimens that are either separated by disease progression, refractory disease, or relapsed disease)~* Resistant disease to the last therapy, defined as progression of disease during or within 12 months of the last dose of chemotherapy in a CD20 antibody combination chemotherapy regimen~* At least 1 measurable site of disease according to International Working Group Revised Response Criteria for Malignant Lymphoma~* Eastern Cooperative Oncology Group performance status grade 0 or 1~* Hematology and biochemical laboratory values must be within protocol-defined parameters within 7 days prior to enrollment~* Agrees to protocol-defined use of effective contraception~* Women of childbearing potential must have a negative serum or urine pregnancy test at screening~Exclusion Criteria:~* Prior nitrosoureas within 6 weeks, chemotherapy within 3 weeks, therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy or other investigational agents within 3 weeks, or major surgery within 4 weeks of first dose of study drug~* Prior treatment with PCI-32765 or other Bruton's tyrosine kinase inhibitors (patients who progressed or became refractory while on treatment with PI3K inhibitors are excluded)~* Concurrent enrollment in another therapeutic investigational clinical treatment study~* Received a prior allogeneic hematopoietic stem cell transplant (prior autologous hematopoietic stem cell transplant is allowed)~* Known central nervous system lymphoma~* History of prior malignancy (except malignancy treated with curative intent and with no known active disease present for \>=3 years before enrollment, adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, or adequately treated cervical carcinoma in situ without evidence of disease)~* History of stroke or intracranial hemorrhage within 6 months prior to enrollment~* Requires anticoagulation with warfarin or equivalent vitamin K antagonists~* Requires treatment with strong cytochrome P450 (CYP)3A4/5 inhibitors~* Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification~* Known history of Human Immunodeficiency Virus (HIV) or active infection with Hepatitis C or active infection with Hepatitis B or any uncontrolled active systemic infection requiring intravenous antibiotics~* Women who are pregnant or breastfeeding~* Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of PCI-32765 capsules, or put the study outcomes at undue risk",,,t,f,t
6159204,NCT06156254,,ALL,18 Years,,f,,"Inclusion Criteria:18 years or older AND speak English or Spanish AND have no obvious physical or cognitive impairment that would make them unable to complete the assessment (as indicated by confusion or inability to understand the questions).~Exclusion Criteria: not willing to consent OR acutely sick OR have high suicide risk~Eligibility criteria: Have received a COVID-19 vaccine but not received an updated COVID-19 vaccine at the time of recruitment AND self-report being told by a physician they have one of the following health conditions; high blood pressure/hypertension OR diabetes OR asthma OR overweight/obese OR a one of the following mental health condition (probable depression, probable generalized anxiety, or probable PTSD)~-",,,t,f,t
6159205,NCT03907254,,ALL,18 Years,65 Years,f,,"Inclusion Criteria:~* Participant must be 18-65 years old at time of consent.~* Participants must be DEERS eligible men or women from active duty, reserve, National Guard components, retirees, dependents and other Secretarial Designees.~* Participants must have a diagnosis of one of the following:~* PTSD or PTS symptoms (participants must score greater than or equal to 30 on the PCL-5 at screening)~* Anxiety Disorder NOS, Unspecified Trauma Related Disorder, Unspecified Anxiety Disorder, or Adjustment Disorder with evidence of the Service Member experiencing one or more traumatic event (meeting Criterion A of PTSD in DSM 5), and evidence of intrusion symptoms, avoidance symptoms, negative changes in cognitions and mood, and alterations in arousal and reactivity related to the traumatic event or events (Criteria B, C, D, and E of PTSD in DSM 5) persisting beyond 30 days (Criterion F of PTSD in DSM 5)~* Participant may be of any race, ethnicity, or gender.~* Participants with a history of clinician diagnosed TBI are eligible to participate, given the considerable overlap between PTS symptomatology and post-concussive symptoms postacutely.~* Participant must be able to speak and read English, and be able to consent.~Exclusion Criteria:~* Participants must not be younger than 18 years old or other than 65 years old at the time of consent.~* Participant must not show current suicidal/homicidal plans (if the participant expresses current suicidal/homicidal plans, clearance from the participant's current behavioral health team can be provided).~* Participant must not exhibit violent or psychotic behavior.~* Participant must not currently or in the past month have been in an inpatient psychiatric health treatment program.~* Participant must not currently have an active substance abuse disorder or been in a substance abuse program in the past month.~* Participant must not have problems that limit cognitive competency to understand study procedures, including the ability to provide informed consent (e.g., severe TBI). Participant must not be unwilling to answer the study questionnaires.~* Participant must not be afraid of or allergic to dogs.~* Participant cannot be enrolled or participating in any other interventional study for PTS or PTSD treatment.~* Participants cannot currently or in the past six months have participated in clinical service dog training. Clinical service dog training is defined as a type of animal assisted therapy where patients train service dogs as part of a complementary treatment intervention aimed at reducing symptoms associated with physical and psychological injuries. Individuals who have completed a group or individual session in the past six months that only provided an informational overview of the service dog training program will be eligible for this study.",,,t,f,t
6159206,NCT00936754,,ALL,18 Years,60 Years,t,,Inclusion Criteria:~* Healthy volunteer~* BMI between 20 and 30~* Non-smoking~Exclusion Criteria:~* Iodine allergy~* Diabetes~* Use of dietary supplements for duration of study~* History of major surgeries or surgeries of the stomach or digestive tract,,,t,f,f
6159207,NCT01675050,,ALL,8 Years,18 Years,f,,"Inclusion Criteria:~* Age between 8 and 18 years-old~* Diagnosed with Functional Abdominal Pain using the Rome III Criteria must include all\* of the following:~  1. Episodic or continuous abdominal pain~ 2. Insufficient criteria for other FGIDs~ 3. No evidence of an inflammatory, anatomic, metabolic, or neoplastic process that explains the subject's symptoms~     * Criteria fulfilled at least once per week for at least 2 months prior to diagnosis~* Written informed consent obtained from the patient/guardian before the initiation of any study-specific procedures~Exclusion Criteria:~* Age \< 8 years-old or Age \>18 years-old~* Child or parent are non-English speakers~* Child is using other CNS depressants (cyproheptadine causes drowsiness, and may enhance the adverse/toxic effect of other CNS Depressants e.g. opioids, barbiturates, Droperidol, Hydroxyzine, Alcohol)(29)~* Child has a history of hypersensitivity to Cyproheptadine products~* Child is currently using monoamine oxidase inhibitor (MAOI e.g. Nardil, Marplan, Parnate) (can cause a prolonged or intensified anticholinergic effect)~* Child was treated with Cyproheptadine in the past 4 weeks~* Child is currently using anticholinergic (can cause an additive anticholinergic effect e.g. Pramlintide)~* Concomitant SSRI use ( being a serotonin antagonist, may oppose effects)~* Concomitant use of Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine~* Concomitant use of Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central) and vice versa.~* Child has a personal history of glaucoma~* Child has asthma (can cause thickening of bronchial secretions) (27,28)~* History of liver dysfunction/disease (can cause hepatitis)~* History of cardiac disease (not specific to Cyproheptadine, antihistamines have been associated with hypotension, palpitations, tachycardia and arrhythmias) (28,29).~* Females who are known to be pregnant will also be excluded. All females who are of child bearing age, or are already menstruating will perform a urine pregnancy test before enrolling.~* Any children who have difficulties swallowing tablets will receive teaching on how to swallow tablets. If they are still unable to do so, they will not participate in the study.",,,t,t,f
6159208,NCT02509650,NON_PROBABILITY_SAMPLE,ALL,2 Years,,t,Familial lipomatosis,Inclusion Criteria:~* patients affected by familial lipomatosis~* patients with rare dermatologic disease without molecular diagnosis~* written informed consent is obtained from the patient and his/her family~Exclusion Criteria:~* the patient does not want to participate to the protocol~* the patient is already included in another study using next generation sequencing technologies,,,t,t,t
6159209,NCT05260333,,FEMALE,18 Years,,t,,Inclusion Criteria:~* Pregnant women in the third trimester presenting for assessment of labor or admitted for labor and delivery.~Exclusion Criteria:~* Second trimester (less than 28 weeks)~* BMI\>50~* Does not wish to participate,,,t,f,t
6159210,NCT03075254,NON_PROBABILITY_SAMPLE,ALL,18 Years,70 Years,t,"Residents living within driving distance of Gainesville, FL.","Inclusion Criteria:~* diagnosis of FM will require a history of chronic widespread pain as well as the presence of at least eleven out of eighteen paired tender points.~* diagnosis of ME/CFS will require a history of chronic fatigue persisting or relapsing for more than 6 months as well as the presence of at least four out of eight designated symptoms.~* willing to reduce anti-depressants to low levels like amitriptyline 10 mg/day, trazodone 50 mg/day, citalopram 20 mg/day, for at least five half-lives of the medication.~Exclusion Criteria:~* Patients unwilling or unable to discontinue or modify analgesics, hypnotics, anxiolytics, or anti-depressants during the study period will be excluded from this trial.",,,t,f,t
6260250,NCT05912556,,ALL,25 Years,80 Years,t,,"Inclusion Criteria:~* Subjects 25-80 years of age.~* Ability to understand and speak English, follow written and verbal instructions (English), and give informed consent (English), as assessed by study staff.~* Ability to comply with all the testing and study requirements, including the ability to independently use a video conferencing tool and the ability to independently use a computer to access the web.~* Ability to independently complete a daily, online intervention and outcome assessments using a web browser compatible with the intervention and assessment software on a reliable, internet-connected laptop or desktop computer.~Exclusion Criteria:~* Current, controlled (requiring treatment) or uncontrolled psychiatric diagnosis, including but not limited to posttraumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder, conduct disorder, attention-deficit/hyperactivity disorder, or other symptomatic manifestations that in the opinion of the Investigator may confound study data/assessments.~* Current, controlled (requiring treatment) or uncontrolled neurological diagnosis, including but not limited to Alzheimer's Disease, other dementias, mild cognitive impairment, Huntington's Disease, Parkinson's Disease, multiple sclerosis, stroke, epilepsy, aphasia, or other condition that in the opinion of the Investigator may confound study data/assessments.~* Any other medical condition in the last 90 days that in the opinion of the Investigator may confound study data/assessments.~* Has been under the care of a caretaker or has not been living independently in the last 90 days.~* In the last three years has used any of the following for more than two weeks continuously: Online courses, Online brain training programs~* Known sensitivity (such as headaches, dizziness, nausea) to bright, stimulating video displays.~* History of seizures (excluding febrile seizures), or significant motor or vocal tics, including but not limited to Tourette's Disorder and photo-sensitive epilepsy.~* Visual acuity that cannot be corrected that prevents or negatively impacts computer activity.~* Has participated in a clinical trial within 90 days prior to screening.~* Pregnancy or planning to become pregnant.~Additional Exclusion Criteria for Cohort B only:~* Unwillingness or inability to comply with imaging safety protocols.~* Metal implants or exposure to shrapnel.~* Left-handed or ambidextrous.",,,t,f,t
6057106,NCT05753644,,ALL,18 Years,,f,,"Inclusion Criteria:~* 1.patients undergoing elective thoracoscopic lobectomy;~* 2.patients with one or more risk factors of POAF. According to literature, risks factors of POAF including male, aged over 65, obesity (BMI\>30kg/m2), cardiac co-morbidity ( hypertension, myocardial infarction, heart failure, arrhythmia, history of valve procedure), diabetes, chronic renal insufficiency (increased creatinine level), obstructive sleep apnea syndrome (diagnosed or STOP-BANG scores ≥3).~Exclusion Criteria:~* 1. patients with permanent atrial fibrillation, left ventricular or right ventricular pacemaker implantation or removal;~* 2. patients use antiarrhythmic drugs (except beta-blockers);~* 3.patients use immunosuppressive drugs preoperatively;~* 4.patients with active infection or sepsis;~* 5. patients with neurologic disorder;~* 6.patients with immune deficiency syndrome.",,,t,f,t
6159211,NCT04007354,,ALL,20 Years,75 Years,f,,"Inclusion Criteria:~* elective video-assisted thoracoscopic surgery (VATS) lobectomy~* 20 \< age \< 75~* American Society of Anesthesiologists (ASA) classification I\~II~Exclusion Criteria:~* preoperative inflammation (CRP\>10ng/㎖, WBC\>10,000/mm3, body temperature \>38℃)~* steroid administration within 1 month~* hematologic / autoimmune disease~* congestive heart failure (NYHA class III\~IV) or significant arrhythmia~* severe obstructive / restrictive pulmonary disease~* previous history of thoracic surgery~* BMI \>28kg/m2~* expected difficult airway",,,t,f,t
6260251,NCT04757337,,ALL,65 Years,,f,,"Inclusion criteria:~1. Patient must have signed a written informed consent form prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trust person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent~2. Age ≥65 years (inclusions will be managed to ensure that at least 50% of the randomized patients are ≥75 years old)~3. Diagnosis of soft-tissue sarcoma histologically confirmed by Réseau de Référence en Pathologie des Sarcomes et des Viscères (RRePS)~4. Metastatic or locally advanced disease not amenable to surgery, radiation, or combined modality treatment with curative intent. Palliative radiation therapy is permitted only if direct on nontarget lesion~5. Documentation of disease progression within the last 6 months before randomization~6. Measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT-scan as defined by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)~7. Life expectancy of at least 6 months~8. Eastern Cooperative Oncology Group (ECOG) performance status ≤2~9. G8 score \>14~10. Left ventricular ejection fraction (LVEF) value by echocardiogram or Multiple gated acquisition scanning (MUGA) ≥55%~11. Adequate bone marrow, renal, and hepatic function, as evidenced by the following within 7 days of study treatment initiation:~    1. Absolute neutrophil count (ANC) ≥1,500/mm³~   2. Platelets ≥100,000/mm³~   3. Hemoglobin ≥9.0 g/dL~   4. Serum creatinine ≤2 x upper limit of normal (ULN)~   5. Glomerular filtration rate (GFR) ≥50 ml/min/1.73m² (calculated with MDRD)~   6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN (≤5.0 × ULN for patients with liver involvement of their cancer )~   7. Total bilirubin ≤1.5 X ULN~   8. Alkaline phosphatase ≤2.5 x ULN (≤5 x ULN with liver involvement of their cancer)~   9. serum albumin \>25 g/L~   10. Prothrombin time (PT)/International normalized ratio (INR) ≤1.5 x ULN Patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until PT/INR is stable based on a measurement that is pre-dose as defined by the local standard of care~12. Male patients must agree to use adequate contraception for the duration of trial participation and up to 6 months after completing treatment/therapy. Adequate contraception is defined as any medically recommended method (or combination of methods) as per standard of care~13. Patients must be affiliated to a Social Security System (or equivalent)~14. Patient is willing and able to comply with the protocol for the duration of the study including scheduled visits, treatment plan, laboratory tests and other study procedures including follow-up~Exclusion Criteria:~1. Previous systemic treatment for advance or metastatic sarcoma~2. Previous neoadjuvant or adjuvant anthracycline treatment for localized sarcoma~3. Soft-tissue sarcoma with the following histological subtypes: dermatofibrosarcoma protuberans, desmoid tumor, alveolar or embryonal rhabdomyosarcoma, Desmoplastic small round cell tumor, Kaposi Sarcoma, Gastro-Intestinal stromal tumor, Peripheral neuroectodermal tumors~4. Primary bone sarcoma (including osteosarcoma, Ewing tumor, chondrosarcoma, and chordoma)~5. Symptomatic or known central nervous system (CNS) metastases~6. Known history of or concomitant malignancy likely to affect life expectancy in the judgment of the investigator and history of radiotherapy mediastinal in the last five years~7. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before Day 1 of treatment~8. Active cardio vascular disease including any of the following: Congestive heart failure (New York Heart Association (NYHA) ≥Class 2), unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months), acute inflammatory cardiopathy, severe arrythmia, high risk of bleeding, cerebrovascular accident within the last 6 months~9. Uncontrolled grade \>2 hypertension. (Systolic blood pressure ≥160 mmHg or diastolic pressure ≥100 mmHg despite optimal medical management)~10. Ongoing infection ≥Grade 2 according to NCI Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)~11. Known history of human immunodeficiency virus (HIV) infection~12. Known history of chronic hepatitis B or C~13. History of organ allograft~14. Pre-existing acute hemorrhagic cystitis, urinary tract obstruction, acute urinary tract infection~15. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study~16. Substance abuse, medical condition, that may interfere with the patient's participation in the study or evaluation of the study results~17. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation~18. Inability to swallow oral medications, any malabsorption condition.~19. Persons deprived of their liberty or under protective custody or guardianship~20. Participation in another therapeutic trial within the 30 days prior to randomization and during the study~21. Patients having received live attenuated vaccine therapy used for prevention of diseases as influenza, chickenpox, zoster, measles, mumps, rubella, tuberculosis, rotavirus or yellow fever within 4 weeks of the first dose of study drug. These vaccinations are not permitted during the study up to 6 months after the last treatment~22. Patients unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons",,,f,f,t
6159212,NCT03285633,,ALL,21 Years,,f,,"Inclusion Criteria:~* being at least 21 years of age~* a diagnosis of stage IV cancer in the past 3 years~* being able to speak/read English~Exclusion Criteria:~* visual or hearing impairment that would prevent ability to engage in the telephone session or study materials~* presence of a severe unmanaged psychiatric condition (i.e., psychotic disorder or episode) or a psychiatric condition (e.g., suicidal intent) that would contraindicate safe participation in the study as indicated by the medical chart, treating oncologist, or interactions with the medical/study staff.",,,t,f,t
6159213,NCT03639350,,ALL,35 Years,55 Years,t,,"Inclusion Criteria:~* BMI between 25-40~* No serious health issues~* Normal blood chemistry profile~* VAT ≥90cm2 for men and ≥80cm2 for women~* Japanese, Chinese, or Korean ancestry~* Resident of Hawaii.~Exclusion Criteria:~* Reported smoking tobacco products or marijuana in the past 2 years~* Taking medication for Type 1 or Type 2 diabetes~* Reported taking thyroid medication.",,,t,f,f
6159214,NCT02617433,,MALE,19 Years,64 Years,t,,"Inclusion Criteria:~* All patient who undergo general anesthesia.~* Male; weight 70-75kg , height 170-175cm~* Female; weight 53-58kg , height 158-163cm~Exclusion Criteria:~* Liver and kidney disease~* Any types of muscle disorder.~* Metal materials or pacemaker in body",,,t,f,f
6159215,NCT01809652,,ALL,18 Years,,f,,Inclusion Criteria:~* Planned IPG implant or planned ICD (without CRT) implant~* Signed informed consent~Exclusion Criteria:~* Pacing dependency~* Defibrillation threshold testing planned~* Basal ventricular rate \>110 beats per minute~* Younger than 18 years~* Pregnant~* Currently involved in another IPG or ICD related clinical trial,,,t,f,t
6159216,NCT04929054,PROBABILITY_SAMPLE,ALL,18 Years,,f,patients with nodules which were sonographically classified as BI-RADS 4 A breast lesion,Inclusion Criteria:~patients with BI-RADS 4A breast lesion~Exclusion Criteria:~(i) absence of a pathologic diagnosis; (ii) presence of breast nodules that were too large to compare with normal parenchyma; (iii) patients with radiotherapy and chemotherapy of breast cancer; and (iv) skin disorders.,,,t,f,t
6159217,NCT03844191,,ALL,18 Years,75 Years,t,,"Main Inclusion Criteria (all subjects)~* weight between 55-120 kg, inclusive, and BMI between 18-38 kg/m2~* females must be non-pregnant, non-lactating, and of non-childbearing potential.~* good general health as determined by no acute illness and no clinically significant abnormal findings on medical history, clinical laboratory test results, vital signs, or physical examination~* platelet count of 150,000/uL to 400,000/uL and mean platelet volume (MPV) within the normal range~Subjects with stable CAD, defined as history of documented myocardial infarction (MI) or angina, or evidence of CAD derived from cardiac stress test, or imaging (calcium score \[greater than 100 or abnormal for age\], angiography, computerized tomography, or magnetic resonance image); absence of angina, or presence of angina with no change in frequency, duration, precipitating causes or ease of relief for at least 60 days, and no ECG or biomarker evidence of myocardial damage in past 60 days~* blood pressure control achieved with 4 or fewer anti-hypertensive medications~* on a stable regimen of aspirin at a dose of 81 to 325 mg/day~Main exclusion criteria (all subjects):~* history of prior stroke or clinically significant cardiovascular (e.g., unstable angina, New York Heart Association \[NYHA\] class II, II or IV heart failure), dermatologic, endocrine, gastrointestinal (GI), hematologic, infectious, metabolic, neurologic, psychologic, or pulmonary disorder or any other condition, including active cancer that in the opinion of the PI would jeopardize the safety of the subject or impact the validity of the study results~* history of upper or lower GI bleeding requiring intervention or treatment within 12 months of Screening or endoscopic evidence of active peptic ulcer disease within 6 months of Screening~* bleeding score \> 3 on the International Society on Thrombosis and Haemostasis Bleeding Assessment Tool~* coagulation abnormality, bleeding disorder, or history of documented prior hemorrhagic or thrombotic stroke~* whole blood donation and/or diagnostic blood evaluation exceeding 500 mL within 8 weeks of Screening~* surgical procedure, major injury, or dental procedure with high risk of bleeding within 30 days of Screening~* alcohol consumption of \>210 mL of alcohol per week within 6 months of Screening, or alcohol detected in urine at Screening~* marijuana use within the past 3 months, or history/presence of substance abuse~* febrile illness within 14 days of Screening~* use of metformin within 7 days of Screening~* use of herbal or nutritional supplements/medicines within 7 days of Screening~* participation in another investigational product or device study within 30 days of Screening or during the study~* Presence of HIV antibody, HCV antibody, or HbsAg in serum at Screening~* employee of the Sponsor or The Lindner Center staff member directly affiliated with the study, or their immediate family member defined as spouse, parent, child, or sibling~* abnormal platelet aggregation or in vitro inhibition of platelet aggregation pattern by RUC-4~* receiving or have received in the past 30 days an anticoagulant or fibrinolytic agent~* a cardiac pacemaker~* history of allergy to any of the ingredients in the RUC-4 or placebo formulation~Healthy Subjects only:~* medication known to have an impact on platelet function within 30 days of Screening.~* abnormally low response to arachidonic acid-induced platelet aggregation~* screening ECG abnormality that is interpreted by the PI to be clinically significant~Stable CAD subjects only:~* medication known to have an impact on platelet function, with the exception of aspirin, within 30 days of Screening.~  -\>4 anti-hypertensive medications required to achieve blood pressure control~* incomplete inhibition of arachidonic acid-induced platelet aggregation~* acute changes on ECG",,t,t,f,t
6159218,NCT04501354,,ALL,40 Years,,f,,"Inclusion Criteria:~1. Male patients older than 50 yrs old.~2. Female patients older than 40 years old.~3. Patients enrolled in Cipto Mangunkusumo Hospital with osteoporosis confirmed by BMD test.~4. Patients with no history of autoimun disease (SLE, Addison's disease, Chron's disease) and other diseases related to osteoporosis.~5. Patients with no history of consuming drug related osteoporosis.~6. No active infection confirmed by HbsAg, HIV, CMV, Rubella and Toxoplasma examination.~7. Agree to participate the study by signing informed consent form.~Exclusion Criteria:~1. Patients with autoimun diesasde (SLE, Addison's diesase, Chron's disease and other osteoporosis related disease.~2. Patients under immunosuppressive, anticoagulant or corticosteroid treatment.~3. Paralysis patients after surgical treatment~4. Patients under 20 years old~5. Declined to participate in the study",,t,t,f,t
6159219,NCT05955391,,ALL,18 Years,,f,,"Inclusion Criteria:~1. Willing to follow the treatment protocol and visit schedule, and participate in the study with the ICF signed;~2. ≥ 18 years of age on the day of ICF signing, regardless of gender.~3. With ALK-positive advanced inoperable NSCLC and having disease progression or intolerance after continuous treatment with second-generation ALK inhibitors;~4. Providing prior ALK positive test results at screening;~5. Patients could have metastases to central nervous system at screening if the condition is asymptomatic, stable or completely recovered;~6. Drug discontinuation for ≥ 5 half-lives prior to the first dose for subjects previously treated with ALK inhibitors;~7. At least one measurable lesion;~8. An ECOG PS score within 0-2;~9. Adequate bone marrow, liver, kidney, coagulation and pancreatic functions;~10. Expected survival ≥ 3 months;~11. Willing to take effective contraceptive measures (for men of reproductive potential and women of reproductive age only) from ICF signing to 6 months after administration of the investigational drug. Women of reproductive age include women before menopause and within 2 years after menopause. Those women must have a negative pregnancy test ≤ 7 days prior to the first dose of the investigational drug.~Exclusion Criteria:~1. Previous use of any third-generation ALK inhibitors other than TGRX-326;~2. Known hypersensitivity to any of the active ingredients or excipients of TGRX-326 or a history of severe allergic reactions that makes himself/herself unsuitable for TGRX-326 treatment in the judgment of the investigator;~3. Having another type of cancer except for lung cancer;~4. Major surgery within 4 weeks prior to the first dose;~5. Spinal cord compression caused by tumor, unless the subject achieves significant pain control and full recovery of neurological function within 4 weeks prior to the first dose.~6. Abnormal gastrointestinal function that affect absorption within the past 6 months;~7. History of active pneumonia or clinically significant interstitial pneumonia, or radiation or drug-induced lung disorder with treatment needs;~8. Cardiac insufficiency;~9. Abnormal and clinically significant QTc on ECG or need of concomitant use of any drug known to prolong QT interval and cause torsades de pointes;~10. Uncontrolled hypertension after drug treatment;~11. Uncontrolled hyperglycaemia, acute attack of cholelithiasis, and susceptibility to acute pancreatitis;~12. Severe or uncontrolled systemic diseases causing expected intolerance to the investigational drug as judged by the investigator;~13. Use within 14 days before the first dose or expected concomitant use during the treatment period of drugs that pose risk of QTC interval prolongation and/or ventricular tachycardia;~14. Previous antineoplastic treatments within 28 days prior to the first dose of the investigational drug;~15. Toxic reactions associated with prior surgery and prior antineoplastic therapies that have not recovered and may affect the subject safety as assessed by the investigator.~16. Clinically significant active bacterial, fungal or viral infections, including a positive result for hepatitis B surface antigen and HBV DNA ≥ ULN, one or more positive results for hepatitis C antibody or HIV antibody, or the presence of any uncontrolled infection.~17. Use of strong CYP3A4 inducers or inhibitors or CYP3A4 substrates with a narrow therapeutic window within two weeks prior to the first dose of the investigational drug;~18. Pregnant and breastfeeding female;~19. Women of childbearing age who are unwilling or unable to use acceptable methods for contraception during the entire treatment period in the trial and within 6 months after the last dose of the investigational drug (women of childbearing age include: any one with menarche, and those who have not received successful artificial sterilization \[hysterectomy, bilateral fallopian tube ligation, or bilateral oophorectomy\] or premenopausal women); a fertile male patient who is unwilling or unable to take effective contraceptive measures, and whose partner is a woman of childbearing age;~20. Being involved in other clinical studies (except for the non-interventional phase of interventional clinical study, such as survival follow-up period); less than 4 weeks from the end of the dose of other investigational drug to the first dose of the investigational drug or 5 half-lives of the previous drug, whichever is shorter;~21. Any mental or cognitive disorders which may limit subjects' understanding and implementation of the informed consent form;~22. Other situations, such as poor compliance, which are considered by the investigator to be not suitable for participation in the study.",,,t,f,t
6159220,NCT03228654,,FEMALE,40 Years,70 Years,f,,"Inclusion Criteria:~* uterine size \<12 weeks.~* presence of benign cause for the hysterectomy e.g. fibroid uterus, perimenopausal beeding not responding to medical treatment or complex endometrial hyperplasia without atypia.~* Absence of significant scarring in the pelvis from previous surgeries.~Exclusion Criteria:~* Suspected or known gynecological malignancy.~* uterine size \>12 weeks.~* Endometriosis~* Presence of adnexal mass.~* cervix flushed with the vagina.~* presence of significant scarring in the pelvic area from previous surgery.",,t,t,f,t
6057107,NCT04445974,,ALL,18 Years,,f,,"Inclusion Criteria:~* Individuals with dermatological condition (including conditions that affect the skin, hair and/or nails). This includes, but is not limited to, acne, eczema, alopecia, psoriasis, vitiligo, rosacea, dermatitis, hyperpigmentation, hidradenitis suppurativa (HS), hyperhidrosis, hirsutism, neurofibromatosis, onychomycosis, melasma, cysts, herpes, ichthyosis, and lichen sclerosus.~* Individuals self-reporting that their body image is affected by their skin condition.~* Sufficient English to complete the measures and writing exercises~* Access to the internet.~Exclusion Criteria:~* As the focus of this research is on skin disease, individuals living with visible differences as a consequence of trauma (e.g. scarring from burns or scarring from traumatic injury) are not eligible to participate in this study.~* Individuals who do not feel their body image is affected by having a dermatological condition.",,,t,f,t
6057108,NCT02506881,,MALE,18 Years,45 Years,t,,"Inclusion Criteria:~* Signed written informed consent~* Male gender~* Age 18 - 45 years inclusively~* Body mass index (BMI) 19 - 29 kg/m2 inclusively~* Hemoglobin level 120-160 g/l (12 - 16 g/dL) inclusively during 14 days prior to first study drugs administration~* White blood cells count ≥3,0×109/L, Platelet count ≥140×109/L during 14 days prior to first study drugs administration~* Subjects must be in good health as determined by a medical history, medical examination, electrocardiogram, serum biochemistry, haematology, serology and urinalysis~* Absence of history of systematic alcohol and drug abuse~* Ability of the volunteer, in investigator's opinion, to follow the study protocol procedures and requirements~* Willingness of volunteers and their sexual partners of childbearing potential to use reliable contraception methods starting from 2 weeks before inclusion into the study and until 4 weeks after receiving the last dose of the investigational products. This criterion is not applicable to patients who underwent surgical sterilization. Reliable contraceptive measures include one barrier method in combination with one of the following methods: spermicides, intrauterine device or oral contraceptives used by participant's partner~* Consent to avoid alcohol intake within 24 hours before and 48 hours after each administration of the test or reference drugs~Exclusion Criteria:~* Clinically significant abnormalities on ECG or in laboratory tests, which could interfere with the objective of the study or the safety of the volunteer.~* Clinically significant illness within 4 weeks prior to the screening visit~* Subjects with past or present history of liver disease, angina, renal disease, hypertension, epilepsy, cardiovascular, cerebrovascular, peripheral vascular disease or thrombocytosis~* History of any oncological disease~* Prior exposure to any erythropoietins, darbepoetin~* Prior exposure to IV iron supplementation (within 2 years before randomisation)~* Subjects who have used any medication, including over-the-counter drugs, herbal medications, and nutritional supplements within 14 days prior to IDs administration with the exception of paracetamol (acetaminophen) up to 3g per day or ibuprofen up to 1g per day~* Subjects who smoke more than 10 cigarettes per day~* Subjects who have donated more than 450 ml of blood within the 1 month prior to ID injection~* Epileptic seizures within the 6 months prior to ID injection~* Major surgery within 1 month prior to the enrollment into the study~* Inability to install intravenous catheter (e.g., due to skin disease)~* Subjects who have received any experimental drug within 3 months preceding the 1st ID administration~* Subjects who have a clinically significant history of drug hypersensitivity or allergic disease~* Possibility that the subject will not cooperate with the requirements of the protocol as set out in the volunteer information~* Subjects who consume excessive amounts of caffeine (more than 5 cups of coffee per day)~* Participation in any other clinical study or any preceding participation in other studies within 3 months prior to the 1st ID administration",,,t,f,f
6159221,NCT06437054,,ALL,19 Years,,f,,"Inclusion Criteria:~* Patients with sudden hearing loss, Meniere's disease, ototoxic hearing loss, and noise-induced hearing loss of 25dB HL at the frequency at which hearing loss occurs as a result of pure tone hearing test~* Patients whose original hearing ability has not been restored with existing standard treatment (oral, intravenous steroids)~* Those who have not participated in clinical trials within 3 months are selected as subjects~Exclusion Criteria:~* Pregnant or lactating women~* When accompanied by lesion, infection, or anatomical deformity of the outer ear, middle ear, or inner ear~* Those with liver disease or metabolic disease or a history thereof~* History of hypersensitivity to indocyanine green or iodine hypersensitivity~* History of ear surgery~* Cases with posterior labyrinth lesions~* Patients with a history of hypersensitivity to the ingredients of this drug~* In addition, serious diseases such as end-stage renal disease, end-stage liver disease, cardiovascular surgery, progressive brain tumor, progressive hemorrhage, and progressive cerebral hemorrhage are included Cases with brain disease and cancer are excluded from the study",,,t,f,t
6159222,NCT03430050,,FEMALE,18 Years,45 Years,f,,"Inclusion Criteria:~1. Able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments and study procedures.~2. Age 18-45, with regular menses (every 25-35 days).~3. Report using cannabis at least 5 days per week, for at least the past year.~4. Consent to remain abstinent from alcohol for 12 hours prior to study visits, and all other drugs other than cannabis or nicotine for the duration of the study.~5. Consent to random assignment.~Exclusion Criteria:~1. Participants who are pregnant, nursing, amennorheic, or using oral contraceptives.~2. History of major medical illnesses; including liver diseases, abnormal vaginal bleeding, suspected or known malignancy, thrombophlebitis, deep vein thrombosis, pulmonary embolus, clotting or bleeding disorders, heart disease, diabetes, history of stroke or other medical conditions that the investigator deems as contraindicated for the patient to be in the study;~3. Regular use of psychotropic medication (antidepressants, antipsychotics, or anxiolytics) and recent/current psychiatric diagnosis and treatment for Axis I disorders including major depression, bipolar affective disorder, schizophrenia or panic disorder.~4. Current suicidal or homicidal risk. Any subject who endorses suicidal ideation will be seen by a licensed clinician in the Addiction Sciences Division who will determine the best course of action to ensure patient safety.~5. Known allergy to progesterone or peanuts (vehicle for micronized progesterone).~6. Unwilling or unable to maintain abstinence from alcohol 12 hours prior to study visits, and all other drugs other than cannabis or nicotine for the duration of the study.~7. Meet DSM-5 criteria for moderate to severe substance use disorder (other than nicotine, cannabis, or alcohol) within the past year.",Normally cycling menstruating females.,t,t,f,f
6057109,NCT01143740,,ALL,18 Years,,f,,"Inclusion Criteria:~* adult patients, \>/=18 years of age~* well differentiated and/or dedifferentiated liposarcoma eligible for tumor debulking surgery~* willing to undergo tumor biopsies before, during and after treatment~* ECOG performance status 0-1~Exclusion Criteria:~* previous chemotherapy and/or radiation for liposarcoma; previous debulking surgery is acceptable~* patients receiving any other agent or therapy to treat their malignancy~* patients requiring anticoagulant therapy and/or anti-platelet therapy~* pre-existing gastrointestinal disorders which may interfere with absorption of drugs~* history of seizure disorders or unstable CNS metastases~* clinically significant cardiovascular disease~* history of long QT syndrome",,,t,f,t
6159223,NCT06364891,,MALE,18 Years,,t,,Inclusion Criteria:~living in the catchment area 18 or older~Exclusion Criteria:~nil,,,t,f,t
6159224,NCT02238691,,ALL,18 Years,40 Years,t,,Inclusion Criteria:~* Male or female age 18-40 years~* Signed and informed consent~* Subject will and is assumed to be able to follow protocol~Exclusion Criteria:~* Known gastro intestinal/heart/lung/kidney or neurological disease~* Use of drugs that interfere with esophageal motility~* Diabetes~* Pregnancy or breastfeeding~* BMI \>30,,,t,f,f
6159225,NCT01716091,PROBABILITY_SAMPLE,FEMALE,18 Years,44 Years,t,all pregnant women between 18 years or older and who requıred cesarean delivery.,Inclusion Criteria:~1. Elective cesarean delivery~2. Gestational age greater 38 weeks~Exclusion Criteria:~1. chorioamnıonıtıs~2. type 1 diabetes mellitus~3. placenta previa and acreata~4. prior severe gastrointestional disease~5. emergency cesarean delivery,,,t,f,f
6159226,NCT00317902,,ALL,18 Years,75 Years,f,,"Inclusion Criteria:~* Understand and sign written informed consent~* HIV-infected patients (as documented by HIV-RNA values)~* HIV/HCV co-infected patients not receiving treatment~* Hemoglobin \< 12 g/dL unrelated to transfusion~* Estimated life expectancy of \> 9 months~* Has been maintained on a stable antiretroviral regimen for at least four weeks prior to enrollment into this study.~Exclusion Criteria:~* Acute, symptomatic opportunistic infection or other acute AIDS defining illness~* Anemia attributable to factors other than HIV infection (i.e., iron, B12 or folate deficiencies, hemolysis, gastrointestinal bleeding)~* HCV co-infected patients who are anticipated to receive treatment with ribavirin/interferon during the study period. Previous treatment with ribavirin/interferon must have been completed at least 12 weeks prior to study entry~* Ferritin level \< 40 ng/mL~* Uncontrolled or severe cardiovascular disease including recent (\< 6 months) myocardial infarction, uncontrolled hypertension or congestive heart failure",,,t,f,t
6159227,NCT05216952,,FEMALE,18 Years,,f,,"Inclusion Criteria:~* Female, age 18 years or older~* English- or Spanish-speaking~* Ultrasound examination showing a non-viable intrauterine pregnancy between 5- and 12-weeks' gestation or anembryonic gestation~* Stated willingness to comply with all study procedures and availability for the duration of the study~* Provision of signed and dated informed consent form~Exclusion Criteria:~* Desire for non-medical management of early pregnancy loss (either expectant management or surgical management)~* Hemodynamically unstable~* Evidence of incomplete or inevitable abortion (due to high efficacy of misoprostol alone)~* Contraindication or allergy to ulipristal acetate or misoprostol (glaucoma, mitral stenosis, sickle cell anemia, chronic glucocorticoid use)~* Evidence of a viable intrauterine pregnancy, ectopic pregnancy, or pregnancy with intrauterine device in place~* Evidence of pelvic infection~* Hemoglobin \<9.5g/dL~* Known cardiovascular disease (arrhythmia, cardiac failure, valvular disease, angina)~* Known clotting or bleeding disorder, or on anticoagulation therapy~* Use of the following medications that may influence metabolization of the study medications: barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's Wort, topiramate~* Use of CYP3A4 inhibitors within five elimination half-lives of ulipristal acetate or other strong CYP3A4 inhibitors~* Chronic adrenal failure (risk of acute renal insufficiency)~* Concurrent long-term corticosteroid therapy (risk of acute renal insufficiency)~* Any history of underlying liver disorder, including hepatitis~* Elevation of any or all liver enzymes (alanine aminotransferase, aspartate aminotransferase, total bilirubin) above the upper limit of normal (ULN) at baseline testing prior to enrollment~* A family history of hepatitis or currently living with a person who has been given a diagnosis of hepatitis~* A history of or currently working as a sex worker~* A history of or currently using intravenous (IV) drugs~* A self-reported history of alcohol dependency or abuse",,,t,f,t
6159228,NCT03751891,,ALL,18 Years,99 Years,f,,"Inclusion Criteria:~* Adult hearing impaired persons (minimum age: 18 years, mild to moderate Hearing loss) without hearing aid experience~* Good written and spoken (Swiss) German language skills~* Healthy outer ear~* Ability to fill in a questionnaire (p/eCRF) conscientiously~* willingness to wear Receiver in the canal hearing aids~* Informed Consent as documented by signature~* owning an iPhone 6 or higher~Exclusion Criteria:~* Contraindications to the MD in this study, e.g. known hypersensitivity or allergy to the investigational product~* Limited mobility and not in the position to attend weekly appointments in Stäfa (Switzerland)~* Limited ability to describe listening impressions/experiences and the use of the hearing aid~* Inability to produce a reliable hearing test result~* Known psychological problems~* Central hearing disorders",,,t,f,t
6057110,NCT04301310,,ALL,18 Years,55 Years,t,,"For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Healthy participants, as determined by no clinically significant deviation from normal in physical examination, ECGs, and clinical laboratory determinations; no significant findings in medical history.~* Body mass index of 18.0 kg/m2 to 30.0 kg/m2, inclusive, at screening~* Males must agree to follow specific methods of contraception, if applicable~Exclusion Criteria:~* Women of childbearing potential (WOCBP)~* Known previous exposure to BMS-986235~* History of any significant drug allergy~Other protocol-defined inclusion/exclusion criteria apply",,,t,f,f
6159229,NCT04912154,,ALL,18 Years,60 Years,f,,"Inclusion Criteria:~* acute closed single-legged complete Achilles tendon rupture .~* age of 18 to 60 years.~Exclusion Criteria:~* patients with prior Achilles tendon rupture or other situations that affected their lower limb functions or tendon healing (e.g., autoimmune disease, diabetes mellitus, systemic corticosteroid treatment).~* an inability to complete our suture technique (e.g., the distance from the rupture site to the Achilles tendon insertion was less than 3.5 cm) .~* those without rehabilitation or follow-up outcomes.",,,t,f,f
6057111,NCT00920010,NON_PROBABILITY_SAMPLE,ALL,,,f,Lung cancer patients registered to SWOG lung protocols.,"DISEASE CHARACTERISTICS:~* Enrolled on one of the following Southwest Oncology Group protocols:~  * SWOG-8805, SWOG-9019, SWOG-9416, SWOG-9509, SWOG-S9900, SWOG-S0003, SWOG-S0023, SWOG-S0126, SWOG-S0435, SWOG-S0220, SWOG-S0222, SWOG-S0327, SWOG-S0310, SWOG-S0339, SWOG-S0342, SWOG-S0341, SWOG-S0509, SWOG-S0429, or SWOG-S0124~PATIENT CHARACTERISTICS: Not specified~PRIOR CONCURRENT THERAPY: Not specified",,,t,t,t
6057112,NCT00761410,,ALL,45 Years,75 Years,f,,"Inclusion Criteria:~* Male or female subjects, aged between 45 and 75 years inclusive.~* Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained.~* Subjects who are able to achieve a pre-operative passive range of motion of equal to or greater than 110º.~* Subjects who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.~* Subjects who present with idiopathic osteoarthritis that in the opinion of the clinical investigator requires a primary total knee arthroplasty.~* Subjects who in the opinion of the Clinical Investigator are considered to be suitable for treatment with the P.F.C.® Sigma RPF knee, according to the indications specified in the package insert leaflet.~Exclusion Criteria:~* Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.~* Women who are pregnant.~* Subjects who are known drug or alcohol abusers or with psychological disorders that could effect follow-up care or treatment outcomes.~* Subjects who have participated in a clinical study with an investigational product in the last month (30 days).~* Subjects who are currently involved in any personal injury litigation claims.~* Subjects with a known history of poor compliance to medical treatment.~* Subjects who have a pre-operative limb deformity of equal to or greater than 10° varus or 15° valgus as defined using the anatomical axis.~* Subjects who have morbid obesity i.e. BMI ≥40.",,,t,f,t
6159230,NCT01353391,,FEMALE,18 Years,45 Years,f,,"Inclusion Criteria:~1. Women who are between of 18-45 years of age.~2. (i). Women diagnosed with type 2 diabetes prior to pregnancy, OR (ii). Women with undiagnosed type 2 diabetes diagnosed prior to 20 weeks gestation, defined as women presenting with gestational diabetes before 20 weeks gestation with various combinations, as per Canadian Diabetes Association, including:~   * 2 fasting glucose ≥ 7.0 mmol/L, or~  * 2 HbA1c of ≥0.065 (6.5%) performed in a laboratory using a method that is standardized to the Diabetes Control and Complications Trial (DCCT) assay, or~  * 1 fasting glucose ≥7.0 mmol/L and 1 HbA1c ≥ 0.065 (6.5%) performed in a laboratory using a method that is standardized to the DCCT assay, or~  * 1 fasting glucose ≥ 7.0 mmol/L and 1 two hour (2 hr) ≥ 11.1 on a 75 g Oral Glucose Tolerance Test (OGTT), or~  * 1 HbA1C ≥0.065 (6.5%) performed in a laboratory using a method that is standardized to the DCCT assay and 1 two hour (2 hr) ≥ 11.1 on a 75 g OGTT.~3. Pregnancy gestation between 6+0-22+6 weeks.~4. Live singleton fetus.~Exclusion Criteria:~1. Women who are not on insulin. Women who are on oral hypoglycemic agents will be taken off at the start of the trial and started on insulin prior to randomization.~2. Diabetes diagnosed after 20 weeks gestation.~3. Type 1 diabetes.~4. Known intolerance to metformin.~5. Contraindications to metformin use which include:~(i). Renal insufficiency (defined as serum creatinine of greater than 130 µmol/L or creatinine clearance \<60 ml/min) , (ii). Moderate to severe liver dysfunction (defined as liver enzymes (aspartate aminotransferase (AST) and alanine aminotransferase (ALT)) greater than 3 times the upper limit of normal), (iii). Shock or sepsis, and (iv.) Previous hypersensitivity to metformin.~f. Women with significant gastrointestinal problems such as severe vomiting requiring IV fluids or hospitalization, or active Crohn's or colitis.~g. Previous participation in the trial. h. Women who have a fetus with a known potentially lethal anomaly will be excluded. Information regarding congenital anomalies diagnosed after randomization will be recorded.~i. Known higher order pregnancies (twins, triplets, etc). These women will be excluded as they have a higher rate of adverse outcomes and we want to avoid any inequalities if they are unequally distributed between the groups.~j. Presence of acute or chronic metabolic acidosis, including diabetic ketoacidosis.~k. History of diabetic ketoacidosis or history of lactic acidosis. l. Presence of excessive alcohol intake, acute or chronic. m. Presence of congestive heart failure or history of congestive heart failure.",,,t,f,f
6159231,NCT04426500,,ALL,18 Years,,f,,Inclusion Criteria:~* Age 18 years or older~* Undergoing Robotic Assisted Laparoscopic Partial Nephrectomy or Robotic Assisted Laparoscopic Prostatectomy~* Ability to understand and the willingness to sign a written informed consent.~Exclusion Criteria:~* Prior Partial Nephrectomy or Subtotal Prostatectomy Surgery (organ specific)~* Conversion to open surgery~* History of chronic pain~* History of opiate or alcohol dependence~* Allergies to local anesthetic~* Retroperitoneal surgery~* Single Port Surgery,,,t,f,t
6159232,NCT01181791,,ALL,,6 Months,f,,"Inclusion Criteria:~* Preterm newborns admitted to the neonatal intensive care units with a birth weight 700-1500 g and who survive more than 3 days~Exclusion Criteria:~* Chromosomal anomalies.~* Major congenital anomalies (complex cardiac anomalies, congenital hydrocephalus, renal dysplasia)~* Congenital (e.g. jejunal atresia) and acquired (e.g. GI perforation) gastrointestinal pathology precluding oral feed and/or requiring major surgical or medical intervention~* Parental refusal~* Prior enrollment into a conflicting clinical trial",,,f,t,f
6159233,NCT02737891,,ALL,18 Years,70 Years,f,,"Inclusion Criteria:~1. Males and females~2. Confirmed diagnosis of T2DM~3. 18-70 years of age~4. HbA1c ≥7.0%~Exclusion Criteria:~1. Hypersensitivity to tesofensine/metoprolol~2. Heart failure class II or greater according to the New York Heart Association (NYHA) or decompensated heart failure~3. History of myocardial infarction or stroke within 12 months prior to enrolment~4. History of coronary revascularisation or angioplasty in the last 12 months prior to enrolment~5. Patients reporting angina in the last 6 months prior to enrolment~6. Treatment with insulin and/or other injectable anti-diabetic medications, or TZDs~7. Any clinically significant cardiac arrhythmia",,,t,f,t
6159234,NCT03338218,,ALL,18 Years,,f,,Inclusion:~* Male or female adult patients ≥18 years of age. Women of child bearing potential must test negative on standard pregnancy test (urine or serum) (as soon as possible during emergency care)~* Patients with blunt or penetrating trauma suffering from estimated blood loss of ≥ 500 ml~* Initial surgery deemed necessary within 24 hrs after trauma~* Deferred signed written informed consent form or as locally required~* No signs of intracranial or cerebral hemorrhage~* Administration of less than 15 ml/kg body weight colloid between trauma injury and hospital admission.~Exclusion:~* Hypersensitivity to the active substances or to any of the other excipients of the Investigational Products~* Body weight ≥ 140 kg~* Patients expected to die within 24h after traumatic injury~* Sepsis~* Burns~* Renal impairment (AKIN stage ≥ 1 or chronic) or acute and/or chronic Renal Replacement Therapy~* Critically ill patients (typically admitted to the intensive care unit)~* Hyperhydration~* Pulmonary edema~* Dehydration~* Hyperkalemia~* Severe hypernatremia~* Severe hyperchloremia~* Severely impaired hepatic function~* Congestive heart failure~* Severe coagulopathy~* Organ transplant patients~* Metabolic alkalosis~* Simultaneous participation in another interventional clinical trial (drugs or medical devices studies),,,t,f,t
6159235,NCT00141518,,ALL,18 Years,99 Years,f,,Inclusion Criteria:~- Advanced idiopathic Parkinson's disease~Exclusion Criteria:~- Other diseases which might influence compliance or participation in the study,,,t,f,t
6159236,NCT01562691,,ALL,20 Years,55 Years,f,,"Inclusion Criteria:~* patients who underwent septoplasty for septal deviation and chronic hypertrophic rhinitis~Exclusion Criteria:~* patients with comorbidities of coronary heart disease, arrhythmia, chronic obstructive lung diseases, and with past history of any nasal surgery were excluded.",,,t,f,f
6260252,NCT00486356,,ALL,18 Years,120 Years,f,,"Inclusion Criteria:~* Pathologically confirmed cancer, meeting 1 of the following criteria:~  * Disease that has progressed on standard therapy~ * Locally advanced but unresectable primary or recurrent solid tumor~ * Metastatic disease, including previously untreated metastatic disease for which study regimen represents reasonable initial chemotherapy with palliative intent (e.g., metastatic gastric cancer, hepatobiliary cancer, or cancer for which no effective standard therapy exists)~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Absolute neutrophil count ≥ 2,000/mm³~* Platelet count ≥ 100,000/mm³~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* alanine aminotransferase (ALT) \& aspartate aminotransferase (AST) ≤ 2.5 times ULN~* Creatinine ≤ 1.6 mg/dL~* Left ventricular ejection fraction ≥ 50%~* Fertile patients must use effective contraception~* Recovered from prior therapy~* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) or immunotherapy~* At least 2 weeks since prior radiotherapy~* At least 8 weeks since prior strontium therapy~* At least 4 weeks since prior and no concurrent sorivudine or brivudine~Exclusion Criteria:~* No other potentially curative treatment options available (e.g., surgery, radiotherapy, chemoradiotherapy, or combination chemotherapy)~* No leukemia or lymphoma~* No primary central nervous system (CNS) malignancies or CNS metastases~* No other medical illness that would preclude study treatment~* No active infection requiring IV antibiotic therapy unless the infection has resolved~* No history of allergy to platinum compounds, mannitol, or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy~* No history of unexpectedly severe intolerance to fluorouracil~* Not pregnant or nursing/negative pregnancy test~* No prior doxorubicin at cumulative doses \> 300 mg/m²~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No concurrent cimetidine",,,t,f,t
6159237,NCT04587518,,ALL,18 Years,,t,,Inclusion Criteria:~-diagnosis of borderline personality disorder (BPD)~Exclusion Criteria:~* diagnosed psychological conditions that would be better addressed by alternative treatments~* previously received more than 5 sessions of cognitive behavioral therapy in the past 5 years~* concurrent psychotherapy~* medication instability,,,t,f,t
6260253,NCT06451237,,ALL,18 Years,,f,,"Inclusion Criteria:~* Adult patients (≥ 18 years) with moderate to severe facial acne, as per the Investigator Global Assessment (IGA) scale~Exclusion Criteria:~* patients on systemic acne medications in the past 3 months or topicals in the last month, pregnant or breastfeeding females, those with evidence of endocrine disturbances or using medications for comorbidities",,,t,f,t
6159238,NCT01155128,,ALL,18 Years,,f,,"Inclusion Criteria:~* Individuals who have hypertension diagnosed with Glomerular Filtration Rate from 15 to 59 ml/min./1.73m2 characterized, therefore, in stages 3 or 4 chronic kidney disease enrolled in Basic Health Units (BHU) in the urban area of Pelotas , RS.~Exclusion Criteria:~* Ia) Subjects diagnosed with diabetes mellitus; b) Patients with severe physical disability (lower limb amputation without prosthesis, orthopedic diseases that worsen with exercise); c) Individuals who have had acute myocardial infarction in the last six months; d) Subjects with hypertension at rest uncontrolled (systolic\> 180 mmHg and / or diastolic pressure\> 110 mmHg); e) Patients with angina at rest (unstable) or triggered by exercise; f) Individuals with congestive heart failure (\> class II New York Heart Association; Table X); g) Patients with cardiac arrhythmias (\> Lown class II,\> 30 premature beats per minute); h) Individuals with peripheral vascular disease or moderate to severe; i) Subjects with prior renal transplant or dialysis.",,,t,f,t
6159239,NCT06242652,,ALL,18 Years,,f,,"Inclusion Criteria:~1. Female and male patients at least 18 years of age at the time of screening.~2. Participant with a clinical diagnosis of ankylosing spondylitis (AS) and meeting the modified New York criteria for AS.~3. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score \>= 4 and a Patient's Assessment of Total Back Pain score \>= 4 based on a 0 - 10 numeric rating scale (NRS) at the Screening and Baseline visits.~4. If entering the study on concomitant NSAIDs for AS, participant must be on stable dose(s) for at least 2 weeks prior to the Baseline visit.~Exclusion Criteria:~1. Patients with other uncontrolled active inflammatory diseases.~2. Clinical laboratory tests and other tests that reveal abnormalities with clinical significance~3. Patients who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening.~4. History of cancer.~5. Known or suspected history of immunosuppression.",,,t,f,t
6159240,NCT03068754,,ALL,18 Years,75 Years,f,,"Inclusion Criteria:~1. Is 18-75 years of age at Screening~2. Has ALS symptom onset within 2 years prior to Screening~3. Has forced vital capacity (FVC) no higher than 60% at screening~4. If taking riluzole, is on a stable dose for 4 weeks before Screening~Exclusion Criteria:~1. Has tracheostomy, diaphragm pacing, or an ongoing need for assisted ventilation of any type~2. Has used any medication within a time period not allowed per protocol~3. Has history of Type 1 or Type 2 diabetes mellitus, or any clinically significant infection~4. Used edaravone less than 1 week before Screening~5. Received any stem cell replacement therapy~6. Used steroids within a time period not allowed per protocol",,,t,f,t
6159241,NCT00873600,PROBABILITY_SAMPLE,ALL,65 Years,,f,Primary care clinic,"DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma, including one of the following:~  * Breast cancer (female), meeting the following criteria:~    * Stage I-III (T1-4, N0-3, M0) disease~   * Has undergone complete surgical removal of invasive cancer by mastectomy or lumpectomy~   * Has undergone either sentinel lymph node dissection or axillary lymph node dissection with adequate TNM staging~ * Colon cancer (male or female), meeting the following criteria:~    * Stage I-III (T1-3, any N, M0) disease~   * Has undergone appropriate surgical resection with TNM staging~* Newly diagnosed disease~* Scheduled to receive chemotherapy~  * Agrees to receive chemotherapy AND is able to receive chemotherapy within 3 months after surgery~* No distant metastases~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Menopausal status not specified~* Life expectancy ≥ 6 months~* Fluent in English~* Not living in a nursing home~* No end-stage disease~* No severe dementia~* No other clinically active malignancy within the past 5 years or within 3 months after diagnosis of current malignancy~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior chemotherapy for the malignancy~* More than 1 year since prior treatment on an inpatient/outpatient geriatric evaluation and management unit",,,f,f,t
6159242,NCT05257291,,ALL,40 Years,50 Years,f,,"Inclusion Criteria:~* Caucasian race;~* Age 40-50;~* Signed written informed consent~* Normal weight;~* Blood pressure: PAD \>90 mmHg and PAS \>140 mmHg;~* Blood pressure in the above mentioned range from at least 1 years~* Fasting blood sugar \< 100 mg/dL;~* Total cholesterol \< 200 mg/dL and triglycerides \< 150 mg/dL;~* Intake of antihypertensive therapies (except nitrates, statins and β-blockers);~* Non-smoking;~* No night shift workers (at least in the last 3 months before recruitment);~* With a regular sleep/wake rhythm;~* No pregnant/nursing women.~Exclusion Criteria:~* Blood pressure: PAD \<90 mmHg and PAS \<140 mmHg~* Heart disease of any kind;~* Autoimmune or rheumatological or vascular diseases other than essential hypertension;~* Anti-hypertensive therapies with nitrates, statins or β-blockers;~* Pregnancy/nursing;~* \< 40 or \> 50 years;~* Worker with night shifts (for a period of less than 3 months before recruitment);~* Continuous irregular sleep/wake rhythm.",,,t,f,f
6159243,NCT01586052,,ALL,6 Months,3 Years,f,,"Inclusion Criteria:~* Cerebral Palsy~* Abnormal Muscle Tone~* GMFCS (Gross Motor Functional Classification System): II to IV~* Age: 6 months \~ 3 years~* Abnormal Brain MRI compatible to clinical features and non-progressive~* Willing to Comply with All Study Procedure~Exclusion Criteria:~* Known Genetic Disorder~* Baseline Erythropoietin level \> 45 mU/mL~* Presence of Drug Hypersensitivity Related to the Study Remedy~* Previous Erythropoietin Treatment before 3 months~* Coagulopathy:~Family History, Unknown Cerebral Infarction, Thromboembolic Events History~* Intractable Seizure Disorder~* Poor Cooperation of Guardian including Inactive Attitude for Rehabilitation~* Uncontrolled Hypertension~* Liver Dysfunction~* Renal Dysfunction~* Absolute Neutrophil Count \< 500/dL~* Intracerebral or Intraventricular Hemorrhage~* Malignancy",,,f,t,f
6159244,NCT03183154,NON_PROBABILITY_SAMPLE,MALE,18 Years,,f,naïve HIV-infected MSM,Inclusion Criteria:~* naïve HIV-infected MSM~Exclusion Criteria:~* none,men who have sex with men (MSM),t,t,f,t
6159245,NCT05707052,,ALL,4 Years,15 Years,f,,"Inclusion Criteria:~* Children diagnosed with spastic diplegic cerebral palsy~* Children with score of GMFCS \[2\] \[3\] \[4\] levels(2, 16).~* Signed consent form from parents/guardians.~Exclusion Criteria:~* Children with visual impairments~* Children with major auditory impairments~* Children with previous orthopedic surgery and Botulium toxin-A injection at least for 6 months~* Children having pharmacological intervention for the inhibition of spasticity~* Contractures~* Uncontrolled seizures~* Focal spasticity",,,f,t,f
6159246,NCT00143650,,ALL,18 Years,64 Years,t,,"Inclusion Criteria:~* All in local area, nasal histamine responsive, grass allergic, from study KLINIR.~Exclusion Criteria:~* Pregnancy, house dust allergy, hyper-responding air ways, disease, disabled",,,t,f,f
6159247,NCT00744250,,ALL,18 Years,,f,,"Inclusion Criteria:~* Documented pancreatic enzyme insufficiency as determined by spot fecal elastase-1 (\<75 mcg/g) at the time of screening~* Required daily exogenous enzyme supplementation with commercially available pancreatic enzymes~* ≥ 18 years of age~* Male and female subjects~* Able to swallow capsules~* Clinically stable with no evidence of an acute medical conditions~Exclusion Criteria:~* History of fibrosing colonopathy in cystic fibrosis subjects~* Current diagnosis or a history of distal intestinal obstruction syndrome (DIOS) in the past 4 months~* Known contraindications, sensitivity or hypersensitivity to porcine pancreatic enzymes, benzocaine or similar products~* Women with a positive serum beta-hCG at the time of screening or the day of the study (due to radiation exposure)~* Liver disease~* ALT or AST ≥ 3 time the upper limit of normal~* Bilirubin ≥ 3 times the upper limit of normal~* Acute pancreatitis or acute exacerbation of chronic pancreatitis within 90 days~* Use of medications which affect with intestinal transit (example, narcotics, erythromycin, metoclopramide etc.)~* Subjects receiving treatment with antacids, H2 receptor blockers, or proton pump inhibitors and unable to discontinue these within 72 hr prior to the study day~* Diabetes mellitus~* A medical condition which the investigator deems significant enough to interfere with the ability of the subject to participate in the intubation study or interfere with the assessment of enzyme bioavailability~* Small bowel disease (i.e. celiac disease)~* Lactose intolerance~* History of gastric resection",,,t,f,t
6159248,NCT04256291,NON_PROBABILITY_SAMPLE,ALL,20 Years,,f,Patients who has received ceramic-on-ceramic total hip replacement after the year of 2013 at National Taiwan University Hospital Yunlin Branch.,Inclusion criteria:~Patients who has received ceramic-on-ceramic total hip replacement after the year of 2013.~Exclusion criteria:~1. Patients who are unable or unwilling to return for follow-up~2. Patients who have deep periprosthetic joint infection~3. Patients who are diagnosed skeletal dysplasia~4. Patients who suffer from mental disorders,,,t,f,t
6260254,NCT02195037,NON_PROBABILITY_SAMPLE,ALL,,1 Minute,f,Healthy full term infants delivered by vaginal birth with an estimated gestational age of 37+1 to 41+6 weeks corrected gestational age,Inclusion Criteria:~* Healthy full term infants~* Delivered by vaginal birth~* Estimated gestational age of 37+0to 41+6 weeks corrected gestational age~Exclusion Criteria:~* Multiples~* Known fetal anomalies (including cardiac defects).~* Instrumentation during delivery (forceps or vacuum)~* Non-reducible nuchal cord during delivery.~* Any maternal or neonatal indication requiring immediate cord clamping.,,,f,t,f
6159249,NCT02189291,,FEMALE,21 Years,85 Years,f,,Inclusion Criteria:~* Women undergoing minimally invasive sacrocolpopexy~* Sacrocolpopexy with or without concomitant procedures~* Patients having the first start surgery of the day to standardize hospital time.~Exclusion Criteria:~* Elevated post void residual (PVR)~* Mobility problems~* Neurological conditions~* Intra-operative cystotomy or urinary tract injury,,,t,f,t
6159250,NCT03278054,,ALL,18 Years,60 Years,t,,"Inclusion Criteria:~* Patient willing to participate in the study.~* Age greater than 18 years.~* No history of antibiotic use prior to treatment.~* Mature permanent mandibular molar having apical periodontitis requiring primary root canal treatment.~* There must be a radiographic evidence of periapical radiolucency and a diagnosis of pulpal necrosis, as confirmed by negative response to cold and electrical tests; and absence of bleeding on entering the pulp chamber.~Exclusion Criteria:~* Root canal retreatment.~* Failure to obtain authorization from patients.~* The presence of a difficult canal anatomy, internal or external resorption and immature teeth.~* Accident or complication during treatment like calcified canals, inability to achieve apical patency in any canals.~* Immuno-compromised, diabetic, pregnant and hypertensive patients.~* Periodontally compromised teeth.",,,t,f,f
6159251,NCT00455000,,ALL,50 Years,85 Years,f,,"Inclusion Criteria:~* Male or Females of non-childbearing potential, age 50-85~* Diagnosis of probable Alzheimer's disease, consistent with criteria from both: 1) National Institute of Neurological and Communicable Disease and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA); and 2)Diagnostic and Statistical Manual of Mental Disorders (DSM IV)~* Mini-mental status exam score of 16-26 inclusive~* Rosen-Modified Hachinski Ischemia Score \< or = 4~Exclusion Criteria:~* Diagnosis or history of other dementia or neurodegenerative disorders~* Diagnosis or history of clinically significant cerebrovascular disease~* Specific findings on magnetic resonance imaging (MRI): cortical infarct, micro hemorrhage, multiple white matter lacunes, extensive white matter abnormalities~* History of autoimmune disorders~* History of allergic or anaphylactic reactions",,,t,f,t
6159252,NCT03015454,,ALL,18 Years,,f,,Inclusion Criteria:~* All adult patients admitted to the participating units will be eligible.~Exclusion Criteria:~* All patients younger than 18 years of age will be excluded.,,,t,f,t
6263720,NCT01209793,,ALL,18 Years,65 Years,t,,"Inclusion Criteria:~* Healthy men and women between the ages of 18 and 65; women must be postmenopausal or surgically sterile~* Body Mass Index (BMI) between 18.0 and 30.0 kg/m2, inclusive~* Normal vital signs after resting in a sitting position for 5 minutes:~* Normal standard 12-lead ECG~* Willing and able to comply with clinic visits and study-related procedures~* Provide signed informed consent~* Able to understand and complete study-related questionnaires~Exclusion Criteria:~* Current or prior history of smoking~* Any illness or condition that would adversely affect the subject's participation in this study~* Hospitalization within 60 days of the screening visit~* Any clinically significant abnormalities observed during the screening visit~* History of or positive human immunodeficiency virus (HIV) screen result at the screening visit~* History of positive blood test for hepatitis B/hepatitis C or positive hepatitis screen result at the screening visit~* History of positive drug screen result for drug or alcohol abuse within a year prior to the screening visit~* Known sensitivity to any of the components of the Investigational Product formulation~* Participation in any clinical research study evaluating another investigational drug or therapy within 30 days or at least 5 half-lives (whichever is longer), of the investigational drug prior to the screening visit~* Any condition that would place the subject at risk, interfere with participation in the study~* History of a parasitic infection or recent (within the previous 6 months) travel to a parasitic endemic area~* Live/attenuated vaccinations within 12 weeks of screening or during the study~* Any subjects with planned elective surgery~* Sexually active men who are unwilling to utilize adequate contraception",,,t,f,t
6057113,NCT05551520,,ALL,12 Years,80 Years,t,,"Inclusion Criteria:~1. Age 12-80~2. Primary English speaking or fluent in English~Exclusion Criteria:~1. Documentation of a known special education diagnosis other than a 504 designation.~2. History of concussion less than 6 months to the study participation~3. Known physical (e.g., visual impairment not fixable by usual means, such as glasses) or psychological impairment (ADHD, LDD, etc.) that would affect their ability to perform the test.",,,t,t,t
6159253,NCT00000454,,ALL,21 Years,,f,,"Inclusion Criteria:~* Meets criteria for alcohol dependence within the past three months, and criteria for nicotine dependence.~* Smoking at least 10 or more cigarettes per day for the past year.~* Seeking treatment for both alcohol and nicotine dependence.~* Minimum 1 week of alcohol abstinence and substance abuse day treatment attendance.~* Willing to provide names of two individuals who can help locate the subject at follow-up.~* Willing to provide name of one individual who can provide collateral information about alcohol and tobacco use.~Exclusion Criteria:~* Other substance use disorder meeting criteria for dependence.~* Acute medical or psychiatric disorder requiring inpatient treatment.~* Taking medications known to influence alcohol urges (naltrexone, disulfiram).~* Medical problems that would contraindicate nicotine patch use.~* Allergy or hypersensitivity to nicotine or to adhesives used in transdermal delivery systems.~* Use of other nicotine products such as cigars, pipes, or smokeless tobacco.~* Severe generalized skin disorder.~* Myocardial infarction within 3 months prior to study entry.~* Unstable angina.~* Pregnant or lactating females, or females who are not practicing a medically accepted form of contraception.~* Impaired vision or hearing which would interfere with using a hand-held computer.~* Reading ability below fifth grade level.~* Lack of reliable transportation to the treatment site, or living more than 1 hour from treatment site.~* Homeless or unstable residence.~* Plan for future admission to residential treatment.",,,t,f,t
6159254,NCT00084227,,ALL,18 Years,,f,,"Inclusion Criteria:~* Written informed consent of the subject or a legally authorized representative~* Females and males \>= 18 years of age with uncomplicated, symptomatic malaria as indicated by the presence of both of the following: a.) Blood smears positive for Plasmodium falciparum asexual parasitemia between 1000 - 40,000 parasites/mL; b.) Fever or history of fever (\>= 38.5 C/101.2 F rectal or tympanic; \>= 37.5 C/99.5 F axillary or \>= 38 C/100.4 F oral) within the prior 24 hours~* Serum glucose \>= 60 mg/dL (by fingerstick or peripheral blood collection)~* Positive rapid diagnostic test (Binax NOW ICT) positive for P. falciparum~* Subjects must be willing to be treated in the inpatient setting for a minimum of three days or more until parasitemia has cleared and the Investigator deems the subject fit for discharge~* Women of childbearing potential (that is, women who have not been surgically sterilized or are not clearly post-menopausal), must have a negative urine gonadotropin prior to entry into the study and must agree to use adequate contraception during the entire study and for one month after the last study visit~Exclusion Criteria:~* Severe or complicated malaria including subjects with any of the following: a.) Impaired consciousness (e.g. obtundation, unarousable coma, delirium, stupor), seizures (any seizure within a 24 hour prior to enrollment) or abnormal neurologic exam suggestive of severe or complicated malaria b.) Hemoglobinuria c.) Jaundice d.) Respiratory distress (respiratory rate â‰¥ 30 breaths/minute) e.) Persistent vomiting f.) Hematuria, as reported by the patient~* Pregnant or breast-feeding women~* History of allergy to or hypersensitivity to azithromycin or any macrolide, atovaquone, proguanil or chloroquine~* Concomitant administration of rifampin or rifabutin and metoclopramide~* History of epilepsy or psoriasis~* History of treatment with any antimalarial drug (chloroquine, quinine, mefloquine, atovaquone/proguanil, sulfadoxine/pyrimethamine, artemisinin compounds) or antibacterial with known antimalarial activity (macrolides, doxycycline, clindamycin) within 2 weeks prior to enrollment into the study~* Known or suspected cardiovascular, hepatic or renal abnormality that in the opinion of the Investigator would place the subject at increased risk to participate in the study. The following findings are specific exclusions: a.) Known or suspected creatinine clearance \<30 mL/min b.) ALT and/or AST \> 3 x upper limit of normal~* Inability to swallow oral medication in tablet or capsule form~* Treatment with other investigational drugs within 30 days prior to enrollment into the study~* Alcohol and/or any other drug abuse~* Requirement to use medication during the study that might interfere with the evaluation of the study drug~* Specific systemic diseases or other medical conditions that would interfere with the evaluation of the therapeutic response or safety of the study drug~* Inability to comprehend and/or unwillingness follow to the study protocol~* Prior participation in this study",,,t,f,t
6159255,NCT03681054,,FEMALE,,,t,,Inclusion Criteria:~- Gestational diabetes at enrollment~Exclusion Criteria:~* Gestational weeks exceed 28+6~* Multiple pregnancy~* Food allergies or restrictions (other than lactose intolerance)~* Mother's or father's ethnic background other than Caucasian~* Type 1 or type 2 diabetes~* Medication which affects glucose metabolism~* Cholesterol medication~* Drug or alcohol abuse~* Psychiatric illness which affects participation in the study~* Factors hampering communication (e.g. lack of Finnish skills),,,t,t,t
6159256,NCT03905850,,ALL,18 Years,45 Years,t,,"Inclusion Criteria:~* Male or female, aged 18-45 years (both inclusive) at the time of signing informed consent.~* Body mass index (BMI) between 18.5 and 24.9 kg/m\^2 (both inclusive).~* Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator.~Exclusion Criteria:~* Participation in any clinical trial of an approved or non-approved investigational medicinal product within 45 days or 5 times the half-life of the previous investigational medicinal product, whichever is longer, before screening.~* Body weight above 100.0 kg~* Subject with any known history of growth hormone deficiency as declared by the subject.~* Subject who is non-naïve to growth hormone treatment as declared by the subject.",,,t,f,f
6159257,NCT03155854,,ALL,18 Years,,f,,Inclusion Criteria:~* Potential candidates for the study will be selected based upon clinical diagnosis of trigger finger with co-existing pretendinous cord. All potential subjects will have either failed non operative treatment or elected surgical treatment.~Exclusion Criteria:~* \<18 years of age,,,t,f,t
6260255,NCT02962583,,ALL,18 Years,55 Years,t,,"Inclusion Criteria:~* Aged 18 to 55 years~* BMI between 27.0 and 39.9 kg/m2~* Sedentary to moderate active (less than 30 minutes of physical activity, 3 times per week)~* Willingness to complete questionnaires, records, and diaries associated with the study and to complete all study visits~* Willingness to discontinue consumption of fermented foods or probiotics (e.g. yoghourts, with live, active cultures or supplements), laxatives, prebiotics and any substance for body weight control~* Willingness and ability to provide informed consent in French~* Willingness to receive random assignment to probiotic or placebo supplementation~* Committed to losing weight over the 12-week study period~Exclusion Criteria:~* Smokers~* Use of another investigational product within three months of the pre-baseline period.~* Known to be pregnant or breast-feeding or planning on becoming pregnant in the next 18 months.~  * Women of child-bearing potential not using effective contraception which include:~ * Hormonal contraceptives including combined oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormonal implants~ * Intrauterine devices (IUD) or Intrauterine system (IUS)~ * Tubal ligation~ * Vasectomy of partner~ * Double barrier method (use of physical barrier by both partners, e.g. male condom and diaphragm, male condom and cervical cap)~* Positive pregnancy test in women of child-bearing potential~* Menopausal women~* Allergic to milk, soy, or yeast~* Weight gain or loss of at least 10 lbs in previous three months~* Inflammatory bowel syndrome, celiac disease, short bowel syndrome, or any other malabsorptive syndrome~* Uncontrolled angina within the past six months~* Insulin-dependent diabetes (oral medications are not exclusionary)~* Serious and/or unstable medical conditions (e.g. cardiovascular, renal, lung, psychiatric illness, bleeding disorders, etc.)~* Cancer treatment (radiation, chemotherapy, surgery) within past six months or any other treatment or condition known to weaken the immune system (such as systemic corticosteroids or HIVIAIDS).~* Any physical condition deemed likely to significantly interfere with individuals' ability to participate in a nutritional intervention.~* Currently or at any point during the study participating in Weight Watcher's or another weight loss program or taking a medication for weight loss.~* Under antibiotics or treatments (medication or nutritional program) affecting body weight Intake and/or energy expenditure~* History of drug or alcohol (\> 9 drinks weekly) abuse~* Abnormal thyroid hormone levels~* Immune-compromised conditions~* Participant experiencing nausea, fever, vomiting, bloody diarrhoea or severe abdominal pain",,,t,f,f
6159258,NCT04147091,,ALL,20 Years,30 Years,t,,"Inclusion Criteria:~-initial approximal enamel lesions on premolar and molar teeth~Exclusion Criteria:~* distal surface of the last tooth in arch, overlapping teeth~* fillings on approximal surfaces of teeth of interest~* ongoing orthodontic therapy with braces or other appliances",,,t,f,f
6260256,NCT06450132,,ALL,21 Years,30 Years,t,,"Inclusion Criteria:~* best corrected visual acuity of 20/25 or better in each eye~* nearsighted~* current contact lens wearer~* normal binocular vision (to be determined by an examiner at the first study visit)~Exclusion Criteria:~* eye diseases (including lazy eye or eye turn)~* pregnant, nursing, or planning a pregnancy in the next 12 months~* history of refractive surgery (e.g., LASIK)~* history of myopia control treatment~* sensitivity to anesthetics or preservative in eye drops~* difficulty with pupillary dilation",,,t,f,f
6263721,NCT03145493,,ALL,18 Years,,f,,"Inclusion Criteria:~* Unilateral primary total knee arthroplasty~Exclusion Criteria:~* TKA revision~* Bilateral TKA~* Patients that refuse transfusions~* Contraindication to tranexamic acid use: allergy, thromboembolic history~* Coagulopathy~* Kidney failure",,,t,f,t
6159259,NCT00886418,,ALL,18 Years,,f,,"Inclusion Criteria:~* patients scheduled for a surgical procedure which not require a myorelaxation~Exclusion Criteria:~* age less than 18 years,~* ASA III and above,~* pregnant woman~* combined general and regional anesthesia,~* history of prolonged myorelaxation due to a decrease in cholinesterase,~* patient with a known lack in cholinesterase,~* history of cerebral or psychiatric central,~* allergy to latex, propofol, remifentanil, morphine, muscle relaxant or any of the excipients,~* known hypersensitivity to remifentanil or to an other derivative of fentanyl,~* presence of a pacemaker,~* psychotropic or agonist-antagonist morphine treatment,~* planned post-operative sedation.",,,t,f,t
6159260,NCT02394600,,ALL,18 Years,65 Years,f,,"Inclusion Criteria:~1. Participant demonstrates understanding and has provided an appropriately signed and dated informed consent.~2. Male or Female, 18 to 65 years of age, at time of the Screening visit.~3. Participant has a history of at least moderate allergic rhinoconjunctivitis due to hypersensitivity to birch pollen for a minimum of 2 years.~4. Participant responds to the birch pollen and timothy grass pollen through a standard skin prick test administered at the Screening visit. A positive test will be defined as a wheal diameter at least 5mm or larger than the negative control (normal saline) wheal. A historical skin-prick test performed within three-hundred sixty-five (365) days or one (1) year at the site will be accepted in lieu of performing a new skin prick test.~5. Participant understands and is willing, able and likely to comply with study procedures and restrictions.~6. Participant, if female, has a negative urine pregnancy test at Visit 1 and is willing to use a medically acceptable form of birth control. Acceptable methods of birth control for this study include:~   * oral, patch, or intra-vaginal hormonal contraceptives~  * Norplant System®~  * Depo-Provera®~  * IUD~  * double barrier method~  * abstinence~  * surgically sterile females (hysterectomy or tubal ligation)~  * \> 1 year post-menopausal females~  * same sex partner~  * partner vasectomy (\> 3 months)~7. Participant is healthy as determined by pre-study medical history, physical examination and vital signs.~8. Participant is able to read, comprehend, and record all information in English.~9. Participant has a serum specific IgE level to both birch and timothy grass of ≥0.7 ku/L.~Exclusion Criteria:~1. Has significant current nasal or ocular symptoms that the study doctor associates with perennial allergic or non-allergic rhinitis.~2. Female participant who is pregnant or lactating.~3. Has a history of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study. This includes a clinically relevant medical or surgical history or presence of other respiratory disease (exceptions made for asthma and allergic rhinitis as defined in further exclusion criteria), or gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, immunological, dermatological, connective tissue diseases or disorders, or a history of malignancy within the past 5 years, with the exception of non-melanoma skin cancer.~4. Has any significant abnormalities found during physical exam as determined by the investigator.~5. Has a current medical history of significant pulmonary disease and/or active asthma requiring daily drug therapy. Mild, intermittent asthma is permitted (managed with short acting beta-agonist less than 3 times per week). Isolated exercise-induced bronchospasm is also permitted.~6. Has received an investigational drug within the last thirty (30) days.~7. Has had use of immunotherapy containing grass or birch within the last 3 years.~8. Has significant nasal polyps, nasal septal perforation, or nasal tract malformations as noted on physical exam.~9. Administration of adrenaline (epinephrine) is contraindicated (e.g. participants with acute or chronic symptomatic coronary heart disease or concomitant beta-blocker therapy).~10. Is unlikely to cooperate with the requirements of the study including having the ability to communicate with the investigator appropriately.",,,t,f,t
6057114,NCT00356512,,ALL,18 Years,,f,,"* INCLUSION CRITERIA~Adult hypoparathyroid patients, as defined by low or inappropriately normal PTH levels despite hypocalcemia, who are on a stable treatment regimen of calcitriol and calcium supplementation, and who are willing to participate in the study will be eligible.~Adult PHP1B patients as defined by the clinical syndrome of elevated PTH and phosphorus and confirmed by methylation analysis of the GNAS gene.~EXCLUSION CRITERIA~Renal insufficiency as evidenced by a creatinine clearance of less than 50 ml/min~Medically unstable patients~Uncontrolled comorbid conditions, e.g., diabetes, coronary artery disease, congestive heart failure, or cerebrovascular disease.~Digitalis therapy~Patients on diuretic therapy, especially thiazides~Pregnant and lactating women~Patients whose hypoparathyroidism is caused by severe calcium-sensing receptor defects. These patients begin to have marked symptoms of hypercalcemia when the serum calcium is in the mid-normal range.~Patients under 18 years of age~Patients with history of any bone cancer, skeletal metastases or previous radiotherapy to the skeleton, unexplained elevations of serum alkaline phosphatase",,,t,f,t
6159261,NCT00733733,,ALL,18 Years,,f,,"Inclusion Criteria:~* Non-heart-beating-donors (Maastricht III/IV)~* Female patients of childbearing age agree to maintain effective birth control practice during the study.~Exclusion Criteria:~* Pregnant or lactating women at the time of randomization.~* Patients and donors are ABO incompatible.~* Women having had \>3 pregnancies (including abortions if no consistent data on PRA or anti-donor antibodies are available).~* Patients with hypersensibility to rabbit proteins, previous treatment with rabbit IgG, or known intolerance to any component of basal immunosuppression.~* Patients with leukocytes \<3,000/mm3 and/or platelets \<50,000/mm3 before initiation of transplant.~* Patients, who are HIV positive.~* Patients subjected to previous transplants or candidates for multiple transplants (e.g. SKP).~* Patients, who are unlikely to comply with the visit schedule in the protocol and patients who cannot communicate reliably with the investigator.~* Patients with pulmonary oedema or with other signs of overhydration.",,,t,f,t
6159262,NCT02676700,,FEMALE,18 Years,,f,,Inclusion Criteria:~* ICIQ-SF ≥ 12~* Urinary stress incontinence~* Ability to contract pelvic floor muscles~* Normal bladder capacity and normal flow during micturition with at least one micturition of \> 350 ml~Exclusion Criteria:~* Urgency urinary incontinence~* Cognitive problems~* Physical inability to perform Kaatsu program~* Inability to understand and read Danish,,,t,f,t
6159263,NCT06264518,PROBABILITY_SAMPLE,ALL,18 Years,,f,Quantity of participants in traumatic brain injury study who sustain participation until study completion,"Inclusion Criteria:~* Patient has been diagnosed with traumatic brain injury~* Patient has self-identified as planning to enroll in an observational clinical trial~* Patient is a minimum of 18 years or older~Exclusion Criteria:~* Pregnant or nursing patients~* Inability to perform regular electronic reporting~* Patient does not understand, sign, and return consent form",,,t,f,t
6159264,NCT01926691,NON_PROBABILITY_SAMPLE,ALL,50 Years,,f,Patients admitted to the Department of Emergency Medicine at the Tel-Aviv Sourasky Medical Center (TASMC) within three-days of their first-ever acute ischemic stroke or transient ischemic attack (TIA) symptoms onset.,"Inclusion Criteria:~* Age ≥ 50 years~* Israeli residents~* Acute stroke that occurred within the last 3 days as defined by:~* acute focal neurological deficit, with a total score on the NIH Stroke Scale (NIHSS) \<17~* Written informed consent by patient prior to study participation~* Willingness to participate in follow-up~Exclusion Criteria:~* patients presenting with a primary hemorrhagic stroke (intracerebral or subarachnoid)~* history of any preceding cerebral vascular event (excluding TIA)~* imminent death or unconscious state~* patients unlikely to be released from hospital following the qualifying stroke, or have a severe disability after the~* qualifying stroke which makes follow-up unlikely~* known malignant disease or other chronic disease with poor prognosis (predicted survival less than two-years)~* stroke resulting from trauma or invasive procedure~* patients with a prestroke history consistent with dementia, or cognitive impairment before the stroke~* severe aphasia.",,,t,f,t
6159265,NCT03762291,,ALL,18 Years,,f,,"Inclusion Criteria:~1. Any patient, greater than or equal to 18 yrs old regardless of sex, with a diagnosis of Myeloma after receiving at least two lines of conventional therapy which can include an autologous HSCT. If a patient has received an autologous or syngeneic SCT they must be greater than 90 days post-transplant~2. Patients with life expectancy greater than or equal to 6 weeks.~3. Pulse oximetry of greater than 90% on room air in patients who previously received radiation therapy to the chest. This is not required in patients who have not received radiation therapy to the chest in the past.~4. Patients with a Karnofsky score of greater than or equal to 50~5. Patients with bilirubin less than or equal to 2x upper limit of normal and Hgb greater than or equal to 7.0 (transfusion allowed).~6. AST less than or equal to 3x upper limit of normal.~7. ANC greater than 1000 at the time of vaccination and an ALC greater than 500.~8. Patients with a creatinine less than or equal to 2x upper limit of normal for age.~9. Patients should have been off other investigational therapy for one month prior to entry in this study.~10. Patients should be off anti-bacterial therapy for 14 days prior to vaccination~11. Patients should have been off conventional therapy for at least 1 week prior to entry in this study except immunomodulator drugs~12. Informed consent explained to, understood by and signed by patient. Patient given copy of informed consent.~13. Due to unknown effects of this therapy on a fetus, pregnant women are excluded from this research. The male partner should use a condom. Females of child-bearing potential must be willing to utilize one of the more effective birth control methods during the study unless female has had a hysterectomy or tubal ligation.~14. Ability to swallow medications~Exclusion Criteria~1. Severe intercurrent infection.~2. Patients receiving greater than 0.5 mg/kg/day (prednisone equivalent) of systemic corticosteroids~3. Pregnant or breast feeding.~4. Grade II or higher nausea, vomiting or diarrhea.~5. History of allergy to prior vaccination with a Salmonella vaccine~6. HIV infection~7. Unable to tolerate Salmonella directed antibiotics~8. Household contacts who are immunocompromised, pregnant or under 2 years of age.",,,t,f,t
6159266,NCT00501033,,FEMALE,18 Years,50 Years,t,,Inclusion Criteria:~* Term pregnancy~* Parturients candidates for mechanical induction of labor~Exclusion Criteria:~* Suspected amnionitis~* Vaginal discharge~* Pre induction pyrexia~* Immunocompromised parturients,,,t,f,f
6159267,NCT05896891,PROBABILITY_SAMPLE,ALL,18 Months,,f,Every male or female patient \> 16 years pertaining to IRCCS San Raffaele Hospital in Milan,Inclusion Criteria:~* EoE diagnosis proven histologically with clinical activity~* Age \> 16 years~Exclusion Criteria:~* Not signed informed consent~* No definite EoE diagnosis,,,t,t,t
6159268,NCT01794091,,ALL,40 Years,75 Years,f,,"For PHASE I (Prospective Cohort Study to determine prognostic value of fibrotic index)~Inclusion Criteria:~* Diabetes mellitus, type II~* Age \>= 40 years~* UKPDS 10 year Risk Score \> 15%~* Low risk stress test (defined explicitily in our protocol)~Exclusion Criteria:~* suspected or confirmed myocarditis or infiltrative disease (including hemochromatosis, sarcoid, or amyloid)~* history of prior MI or coronary revascularization (by Q waves on electrocardiogram in 2 contiguous leads or by clinical history)~* clinical HF (with prior hospital admission for HF or documentation of reduced LV ejection fraction after index CMR)~* metallic hazards~* hematocrit \< 30% (within 1 year of nuclear stress test) or history of active bleeding (within 3 months of stress test)~* estimated GFR (by Modified Diet in Renal Disease) \< 45 ml/min/1.73m2 (within 2 weeks of planned CMR)~* pregnancy~* severe non-cardiac illness that or prognosis (e.g., end stage liver disease, malignancy, advanced HIV/AIDS)~For PHASE 2:~Inclusion Criteria:~* Included in Phase I~* Systolic blood pressure \> 140 mmHg on two occasions (at the initial nuclear stress test and at the index cardiac MRI)~Exclusion criteria:~1. Concomitant cytochrome P450 (CYP3A4) inhibitors or inducers;~2. Concomitant potassium supplementation or potassium sparing diuretics;~3. Concomitant use of both ACE inhibitor and ARB therapy (at any dose);~4. Renal dysfunction (GFR \< 50 ml/min or serum creatinine \> 1.5 mg/dL (as assessed at time of index CMR);~5. Any urine microalbuminuria (as assessed at time of index CMR);~6. Baseline (pre-therapy) serum potassium \> 5.0 mEq/L;~7. Lack of reliable telephone contact number for relaying results or the need to discontinue drug therapy;~8. Age \> 75 years (given the tendency toward renal insufficiency not captured by GFR, dehydration and/or concomitant illness)~9. Women able to become pregnant (given the undefined risk of eplerenone therapy in pregnant women and newborns).",,,t,f,t
6263722,NCT02322593,,ALL,20 Years,,f,,Key Inclusion Criteria:~* Patients who are diagnosed as gastric cancer.~* No prior treatment for gastric cancer.~* Negative or unknown for HER2 testing.~* ECOG performance status of 0 or 1.~Key Exclusion Criteria:~* Unmanageable diarrhea.~* Current peripheral sensory neuropathy or paresthesia.~* Pregnant or lactating female.,,,t,f,t
6159269,NCT03123718,,ALL,18 Years,80 Years,f,,"Inclusion Criteria:~* Aged ≥18 years \<80~* Newly diagnosed, histologically confirmed DLBCL~* High-risk of CNS recurrence at diagnosis:~  1. Age-adjusted IPI (aaIPI) ≥2 or IPI ≥4 with extranodal involvement of \>1 site plus serum lactate dehydrogenase (LDH) \> normal OR~ 2. Involvement of high-risk locations: bone marrow, nasal or paranasal sinuses, testis, epidural disease (paravertebral or vertebra), breast, adrenal or kidney~* Estimated life expectancy of more than 90 days~* Performance status (ECOG) ≤ 2~* Written informed consent~Exclusion Criteria:~* Psychiatric or mental disorder which make the patient unable to give an informed consent and/or adhere to the protocol~* DLBCL or following subtypes:~  1. Primary mediastinal large B-cell lymphoma~ 2. Grey zone lymphoma)~ 3. Primary cutaneous DLBCL~* Previous immunochemotherapeutic treatment for DLBCL other than short-term use of corticosteroids (≤ 8 days before randomization)~* Previous radiotherapy~* CNS involvement of DLBCL at diagnosis~* HIV positive~* Any contraindication for application of RCHOP or high dose methotrexate~* Any of following laboratory results~  1. Absolute neutrophil count \< 1,500 cells/mm3 (1.5 x 109/L),~ 2. Platelet count \< 100,000/mm3 (100 x 109/L), or \< 75,000 /mm3 in patients with bone marrow involvement,~ 3. Serum aspartate transaminase or serum alanine transaminase ≥3.0 x upper limit of normal (ULN),~ 4. Serum total bilirubin \> 2 x ULN (with the exception of hemolytic anemia),~* Serum creatinine \>2.0 x ULN or creatinine clearance \<50 mL/min~* Active cancer except curable basal cell carcinoma, cervical cancer in situ, and/or papillary thyroid cancer during the last five years~* Ejection fraction \< 45% on echocardiography~* Uncontrolled active hepatitis~* Pregnancy or breast-feeding~* Men and women of reproductive potential no agreeing to use an acceptable method of birth control during treatment",,,t,f,t
6159270,NCT00506454,,ALL,18 Years,,f,,"Inclusion Criteria:~1. On hemodialysis for ≥ 3 months.~2. Provided written and dated informed consent.~3. Meets the following lab parameters on Screening labs:~   * Serum albumin \> 2.5 g/dL;~  * Serum total cholesterol \> 95 mg/dL;~  * Serum High-Density Lipoprotein (HDL) \> 20 mg/dL;~  * Serum hemoglobin ≥ 11 g/dL;~  * Serum transaminases \< 2x the upper limit of normal.~4. Has had a dialysis adequacy level (KT/V) greater than 1.3 for 2 months prior to screening.~5. Has a vitality score of ≤ 16 at time of screening.~Exclusion Criteria:~1. Currently participating in or has participated in an investigational drug or medical device study within 30 days or five half-lives, whichever is longer, prior to enrollment in this study.~2. Pregnant, breast-feeding or female of childbearing potential who does not agree to remain abstinent or to use an acceptable contraceptive regimen (oral contraceptive, double-barrier method, or abstention from sexual relations) during the study period.~3. Has any of the following laboratory abnormalities when screened:~   * Serum haptoglobin below the lower limit of normal;~  * Lactate dehydrogenase (LDH) \> 300 U/L;~  * Low-Density Lipoprotein (LDL) \> 190 mg/dL;~  * Fasting (8 hours, water only) triglyceride level \> 300 mg/dL;~  * Serum phospholipid level \> 500 mg/dL.~4. Has an EAA level \< 0.6 Endotoxin Activity (EA) at screening.~5. Has prolonged heart wave (QT) interval (as defined by corrected QT (QTc) \> 460 msec in males and \> 470 msec in females) on screening electrocardiogram (ECG).~6. Has a history of allergic reaction to eggs (or egg products), soybeans, Intralipid, or any component of LIPIDOSE.~7. Has had a recent hospitalization (within the last 30 days) or has other acute illness.~8. Deemed not medically or psychiatrically stable for the study (in opinion of investigator or the subject's primary nephrologist).~9. Currently on any of the following medications: (a) medications known to cause QT prolongation; (b) parenteral nutrition supplements (e.g., Intralipid); (c)amphotericin; (d) liposomal amphotericin; (e) amphotericin B lipid complex; or (f) coumadin.~10. Has known preexisting systolic dysfunction (as defined by previous echocardiogram with ejection fraction (EF) \< 35%).~11. Currently receiving one of the following prohibited concomitant medications; parenteral nutrition supplements containing lipid emulsion (e.g., Intralipid), amphotericin, liposomal amphotericin, or amphotericin B lipid complex.~12. Has a known active hemolytic disease; immune hemolytic anemias, hemoglobinopathies (sickle cell anemia and thalassemia major) or is known or believed to suffer from hereditary spherocytosis or S.E. Asian elliptocytosis.~13. Has a known bone marrow disorder of inadequate red cell production (e.g., aplastic anemia, myelodysplasia).~14. Has known current alcohol or drug abuse.",,,t,f,t
6159271,NCT01552018,,ALL,18 Years,80 Years,f,,"Inclusion Criteria:~* Patients \> 18, \< 80 years old, with type 2 diabetes mellitus and angiographically proven coronary artery disease.~* HbA1c \> 6.5% and under treatment with either metformin and/or glimepiride.~Exclusion Criteria:~* Allergy or hypersensitivity to any of the drug's components.~* Heart failure in NYHA class III or IV.~* Severe liver failure, moderate or severe kidney failure~* Malignant disease.~* Active infectious disease.~* Acute coronary syndrome in the last 3 months.~* Pregnancy or breastfeeding.",,,t,f,t
6159272,NCT02407652,,ALL,23 Years,65 Years,f,,"Inclusion Criteria:~* History of ≥ 1 depressive episode(s)~* Currently in stable full or partial remission (≥ 6 months)~Exclusion Criteria:~* Major depressive disorder (MDD; current)~* Bipolar disorder (current and/or previous)~* Psychotic disorder (current and/or previous)~* Neurological impairments (current and/or previous)~* Excessive substance abuse (current and/or previous)~* No other comorbid disorders (current)~* No ongoing psychotherapeutic treatment (maintenance treatment is allowed, but with a frequency less than once / 3 weeks)~* Use of antidepressant medication is allowed if kept at a constant level",,,t,f,t
6057115,NCT01772550,,ALL,18 Years,,f,,"Inclusion Criteria:~* Must be at least 18 years old at the time of enrollment,~* Must meet the investigational site's standard criteria for multi-detector Computed Tomography (CT),~* Per institutional protocol, the ordered scan must require a flow rate of 5.0-7.0 mL/sec (inclusive) for Visipaque 320 or 5.0-7.5 mL/sec (inclusive) for Omnipaque350 warmed to 35°C,~* The planned catheter insertion site must be located in the antecubital area,~* Must require any of the following multi-detector CT procedures: CT angiogram,CT pancreas,CT liver, CT kidney, Cardiac CT,~* Must be willing and able to provide informed consent,~* Must be able to read, write, and follow instructions in English,~* Must be able to accommodate a 20 G x 1.00 inch IV catheter,~Exclusion Criteria:~* Preexisting IV catheter or contrast-compatible port in place suitable for power injection with the intent to be used for contrast enhanced CT,~* Subjects who have reported an adverse reaction that precludes use of iodine-based contrast media,~* Subjects who have had a prior extravasation event involving solutions considered irritants or vesicants.",,,t,f,t
6159273,NCT00239252,,ALL,20 Years,,f,,"Inclusion Criteria:~* Hepatitis C patients (high titer, genotype1)~Exclusion Criteria:~* Patients with autoimmune disorder~* Patients with negative HBs antigen~* Patients with hepatic cirrhosis, hepatic failure and hepatic cancer~* Patients with depression or psychoneurotic disorder",,,t,f,t
6159274,NCT00566124,,MALE,20 Years,50 Years,t,,Inclusion Criteria:~* Male~* BMI 20 - 50 kg/m2~* Blood pressure \< 140/90 mmHg~* signed informed consent~* Caucasien~Exclusion Criteria:~* Diabetes or other disease~* Alcohol or drug abuse~* Smoking~* Use of prescription drugs,,,t,f,f
